

0000950170-24-12562210-Q Eledon Pharmaceuticals, Inc. 2024111220421112170028170028 0 0000950170-24-125622 10-Q 73 20240930 20241112 20241112 Eledon Pharmaceuticals, Inc. 0001404281 2834 00000000 DE 1231 10-Q 34 001-36620 241449584 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 Novus Therapeutics, Inc. 20170511 Tokai Pharmaceuticals Inc 20070622 10-Q 1 eldn-20240930.htm 10-Q 10-Q 0001404281-12-31falseQ3http://www.edelon.com/20240930#CommonStockWarrantsMemberhttp://www.edelon.com/20240930#CommonStockWarrantsMember00014042812023-09-300001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2024-01-012024-09-300001404281eldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMember2023-04-280001404281eldn:SecuritiesPurchaseAgreementSecondClosingMemberus-gaap:PrivatePlacementMember2024-07-082024-07-080001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001404281eldn:SecuritiesPurchaseAgreementInitialClosingMemberus-gaap:PrivatePlacementMember2023-05-052023-05-0500014042812024-03-310001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2023-03-310001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2024-05-0900014042812023-04-012023-06-300001404281us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281srt:RestatementAdjustmentMember2023-09-300001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2024-06-300001404281us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001404281srt:RestatementAdjustmentMember2023-01-012023-09-300001404281eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:SeriesX1NonVotingConvertiblePreferredStockMembereldn:ConversionAgreementMember2023-05-162023-05-160001404281eldn:PreFundedWarrantsMember2024-09-300001404281us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2024-10-012024-10-010001404281us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001404281us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2024-09-300001404281eldn:TwoThousandTwentyLongTermIncentivePlanMember2024-09-300001404281us-gaap:CommonStockMembereldn:AllOtherWarrantsMember2023-12-310001404281us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember2023-12-310001404281us-gaap:SubsequentEventMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2024-10-292024-10-290001404281us-gaap:CommonStockMember2024-04-012024-06-300001404281srt:ScenarioPreviouslyReportedMember2023-01-012023-09-300001404281us-gaap:WarrantMemberus-gaap:SubsequentEventMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2024-10-290001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2024-03-310001404281eldn:PreFundedWarrantsMember2024-01-012024-09-300001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2017-12-310001404281eldn:CommonStockWarrantsMember2024-01-012024-09-300001404281srt:BoardOfDirectorsChairmanMemberus-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-09-3000014042812022-12-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2017-01-012017-12-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2023-07-012023-09-300001404281eldn:CommonStockWarrantsMember2024-09-300001404281us-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281eldn:TwoThousandTwentyLongTermIncentivePlanMember2024-07-102024-07-100001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023-01-012023-09-300001404281eldn:CormorantGlobalHealthcareMasterFundLpMemberus-gaap:CommonStockMembereldn:SeriesX1NonVotingConvertiblePreferredStockMembereldn:ConversionAgreementMember2023-05-162023-05-160001404281us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2022-12-310001404281us-gaap:RetainedEarningsMember2023-04-012023-06-300001404281eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2024-01-012024-09-300001404281us-gaap:StockCompensationPlanMember2023-01-012023-09-300001404281us-gaap:CommonStockMemberus-gaap:SubsequentEventMembereldn:UnderwritingAgreementMembereldn:LeerinkPartnersLlcMember2024-10-290001404281us-gaap:RetainedEarningsMember2023-07-012023-09-300001404281srt:RestatementAdjustmentMember2023-04-012023-06-300001404281us-gaap:AccountingStandardsUpdate202309Member2024-09-300001404281eldn:SecuritiesPurchaseAgreementInitialClosingMemberus-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2023-05-050001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2024-09-300001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2021-01-012021-12-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2024-06-300001404281us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001404281us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-09-3000014042812023-01-012023-03-310001404281us-gaap:CommonStockMembereldn:PreFundedWarrantsMember2024-09-300001404281srt:MA2024-09-040001404281us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2023-04-012023-06-300001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2024-01-012024-09-300001404281eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2024-09-3000014042812024-09-300001404281eldn:OticPharmaIncMember2024-01-012024-09-300001404281us-gaap:CommonStockMember2024-06-300001404281eldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2023-04-280001404281srt:RestatementAdjustmentMember2023-06-300001404281eldn:AnelixisTherapeuticsIncorporationMember2020-09-142020-09-140001404281us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2023-11-060001404281us-gaap:CommonStockMember2023-03-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2024-03-310001404281us-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281srt:ScenarioPreviouslyReportedMember2022-12-310001404281us-gaap:PreferredStockMember2023-01-012023-09-300001404281us-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2024-09-300001404281us-gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember2023-12-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023-09-300001404281us-gaap:CommonStockMember2024-01-012024-03-310001404281srt:ScenarioPreviouslyReportedMember2023-01-012023-03-3100014042812023-07-012023-09-300001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2023-07-140001404281srt:ScenarioPreviouslyReportedMember2023-06-300001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2024-07-110001404281eldn:AnelixisTherapeuticsLlcAndOticPharmaLtdMember2024-01-012024-09-300001404281srt:RestatementAdjustmentMember2023-07-012023-09-300001404281us-gaap:AdditionalPaidInCapitalMember2022-12-310001404281us-gaap:CommonStockMembereldn:AllOtherWarrantsMember2024-09-300001404281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281us-gaap:SubsequentEventMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2024-10-010001404281eldn:GuggenheimSecuritiesLlcMembereldn:EquityDistributionAgreementMember2024-09-200001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281srt:ScenarioPreviouslyReportedMember2023-03-310001404281srt:ScenarioPreviouslyReportedMember2023-07-012023-09-300001404281us-gaap:CommonStockMember2022-12-310001404281srt:CA2024-04-190001404281us-gaap:AdditionalPaidInCapitalMember2024-03-310001404281us-gaap:CommonStockMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2024-09-300001404281us-gaap:CommonStockMember2023-06-300001404281eldn:SecuritiesPurchaseAgreementSecondClosingMembereldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMember2023-04-280001404281eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:ConversionAgreementMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2023-05-162023-05-160001404281us-gaap:CommonStockMembereldn:PreFundedWarrantsMember2023-12-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2018-01-012018-12-310001404281eldn:PreferredStockWarrantsMember2023-12-310001404281us-gaap:RetainedEarningsMember2024-09-300001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2023-03-310001404281eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2023-04-280001404281eldn:TimeBasedAndPerformanceBasedVestingRequirementsMember2023-05-012023-05-010001404281eldn:PreferredStockWarrantsMember2024-01-012024-09-300001404281us-gaap:CommonStockMember2023-09-300001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2023-09-300001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310001404281srt:CA2024-04-190001404281eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMember2023-04-282023-04-280001404281eldn:CormorantGlobalHealthcareMasterFundLpMemberus-gaap:CommonStockMembereldn:SeriesXNonVotingConvertiblePreferredStockMembereldn:ConversionAgreementMember2023-05-162023-05-160001404281us-gaap:CommonStockMembereldn:PreFundedWarrantsMember2024-01-012024-09-300001404281eldn:SecuritiesPurchaseAgreementInitialClosingMembereldn:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember2023-05-050001404281us-gaap:AdditionalPaidInCapitalMember2024-09-300001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2023-12-310001404281us-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2024-09-300001404281us-gaap:CommonStockMember2023-12-310001404281us-gaap:AccountingStandardsUpdate202307Member2024-09-300001404281eldn:AccreditedInvestorMembereldn:CommonStockWarrantsMembersrt:MaximumMember2023-04-282023-04-280001404281eldn:CommonStockWarrantsMember2023-12-310001404281us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281us-gaap:RetainedEarningsMember2024-04-012024-06-300001404281us-gaap:CommonStockMember2024-07-012024-09-300001404281eldn:SecuritiesPurchaseAgreementInitialClosingMembereldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMember2023-04-280001404281us-gaap:GeneralAndAdministrativeExpenseMember2024-07-012024-09-300001404281us-gaap:RetainedEarningsMember2024-06-300001404281eldn:CommonAndPreferredWarrantsOutstandingMember2023-01-012023-09-300001404281us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001404281us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-3100014042812024-11-080001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281eldn:SecuritiesPurchaseAgreementSecondClosingMemberus-gaap:PrivatePlacementMember2024-07-080001404281eldn:CommonStockWarrantsMember2024-01-012024-09-300001404281srt:CA2022-08-122022-08-120001404281us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2023-06-3000014042812024-01-012024-03-310001404281us-gaap:AdditionalPaidInCapitalMember2024-06-300001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2024-01-300001404281us-gaap:CommonStockMembersrt:MaximumMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2024-01-012024-09-300001404281us-gaap:CommonStockMembersrt:MinimumMembereldn:SeriesXNonVotingConvertiblePreferredStockMember2024-01-012024-09-300001404281srt:ScenarioPreviouslyReportedMember2023-04-012023-06-300001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2023-06-300001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMembereldn:OneBillionAggregateNetSalesMember2024-09-300001404281us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001404281eldn:SeriesXConvertiblePreferredStockMember2024-09-300001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2024-05-070001404281eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMembersrt:MaximumMember2024-05-062024-05-060001404281us-gaap:CommonStockMember2023-07-012023-09-300001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2023-07-100001404281eldn:GuggenheimSecuritiesLlcMembereldn:EquityDistributionAgreementMembersrt:MaximumMember2024-09-202024-09-2000014042812023-03-310001404281us-gaap:EmployeeStockOptionMembersrt:BoardOfDirectorsChairmanMember2024-01-012024-09-300001404281us-gaap:StockCompensationPlanMember2024-01-012024-09-300001404281us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001404281srt:ScenarioPreviouslyReportedMember2023-09-300001404281us-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClosingMember2024-09-302024-09-300001404281eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMembersrt:MaximumMember2023-04-282023-04-2800014042812024-04-012024-06-300001404281srt:MaximumMember2023-01-012023-12-310001404281eldn:SeriesXConvertiblePreferredStockMember2023-12-310001404281srt:MA2024-09-042024-09-040001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2023-09-300001404281us-gaap:CommonStockMember2024-03-310001404281eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMembersrt:MinimumMember2024-05-062024-05-060001404281srt:MinimumMember2023-01-012023-12-3100014042812024-01-012024-09-300001404281us-gaap:RetainedEarningsMembersrt:RestatementAdjustmentMember2023-09-300001404281us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001404281us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001404281us-gaap:RetainedEarningsMembersrt:RestatementAdjustmentMember2023-07-012023-09-300001404281eldn:SeriesXOnePreferredStockMember2024-09-300001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2022-12-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2024-09-300001404281eldn:TwoThousandFourteenStockIncentivePlanMember2024-09-300001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2022-01-012022-12-310001404281eldn:PreFundedWarrantsMember2023-01-012023-09-300001404281us-gaap:RetainedEarningsMember2022-12-310001404281us-gaap:AdditionalPaidInCapitalMember2023-09-3000014042812023-12-310001404281us-gaap:RetainedEarningsMember2023-03-310001404281us-gaap:RetainedEarningsMember2023-09-3000014042812023-01-012023-09-300001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2023-06-300001404281eldn:PreFundedWarrantsMember2023-07-012023-09-300001404281us-gaap:WarrantMember2024-09-300001404281us-gaap:AdditionalPaidInCapitalMember2023-03-

310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMembereldn:OneBillionAggregateNetSalesMember2024-01-012024-09-3000014042812023-01-012023-12-310001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2022-12-3100014042812024-06-300001404281us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001404281us-gaap:AdditionalPaidInCapitalMember2023-06-300001404281us-gaap:RetainedEarningsMember2024-01-012024-03-310001404281us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001404281us-gaap:EmployeeStockOptionMembersrt:BoardOfDirectorsChairmanMembersrt:MinimumMember2024-01-012024-09-300001404281us-gaap:RetainedEarningsMember2023-06-300001404281srt:MinimumMember2024-01-012024-09-300001404281us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001404281us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001404281us-gaap:AdditionalPaidInCapitalMember2023-12-310001404281eldn:PreferredStockWarrantsMember2024-09-300001404281us-gaap:RetainedEarningsMember2023-12-310001404281eldn:PreFundedWarrantsMember2024-07-012024-09-300001404281eldn:TwoThousandFourteenEmployeeStockPurchasePlanMember2024-09-300001404281us-gaap:RetainedEarningsMember2023-01-012023-03-310001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023-01-012023-12-310001404281eldn:SecuritiesPurchaseAgreementMembereldn:ArmisticeCapitalMasterFundLtdMember2023-11-020001404281eldn:AccreditedInvestorMembereldn:CommonStockWarrantsMember2023-04-282023-04-280001404281us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2023-03-310001404281us-gaap:RetainedEarningsMembersrt:RestatementAdjustmentMember2023-06-300001404281eldn:TimeBasedVestingRequirementsMember2023-05-012023-05-010001404281eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2018-12-3100014042812024-07-012024-09-300001404281us-gaap:PreferredStockMember2024-01-012024-09-300001404281srt:MaximumMember2024-01-012024-09-300001404281eldn:CommonAndPreferredWarrantsOutstandingMember2024-01-012024-09-300001404281us-gaap:CommonStockMember2023-04-012023-06-300001404281us-gaap:RetainedEarningsMembersrt:RestatementAdjustmentMember2023-04-012023-06-300001404281eldn:PerformanceBasedVestingRequirementsMember2024-06-132024-06-130001404281eldn:SeriesX1NonVotingConvertiblePreferredStockMember2023-04-012023-06-3000014042812023-06-300001404281us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-09-300001404281eldn:AccreditedInvestorMembereldn:SecuritiesPurchaseAgreementMemberus-gaap:PrivatePlacementMember2024-05-062024-05-060001404281eldn:SeriesXNonVotingConvertiblePreferredStockMember2023-12-310001404281us-gaap:RetainedEarningsMember2024-03-310001404281eldn:AccreditedInvestorMembereldn:SecuritiesPurchaseAgreementMemberus-gaap:PrivatePlacementMember2024-05-060001404281us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-30xbrli:pureiso4217:USDxbrli:sharesrtr:sgftxbrli:shareseldn:Milestoneiso4217:USD Ã A Ã UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Ã FORM 10-Q (2) 10-Q (2) Ã QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR Ã TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36620 Ã ELEDON PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Ã Delaware Ã 20-1000967 (State or other jurisdiction of incorporation or organization) Ã (I.R.S. Employer Identification No.) Ã Ã 19800 MacArthur Blvd., Suite 250Irvine, California Ã 92612 (Address of principal executive offices) Ã (Zip Code) Ã Ã (949) 238-8090 RegistrantÃs telephone number, including area code Ã Securities registered pursuant to Section 12(b) of the Act: Ã Title of each class Ã Trading Symbol(s) Ã Name of each exchange on which registered Common Stock, \$0.001 par value Ã ELDN Ã NasdaqÃ Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Ã Yes Ã No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Ã232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Ã Yes Ã No Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of Ãcelarge accelerated filer,Ãcẽ accelerated filer,Ãcẽ smaller reporting company,Ãcẽ andÃcẽemerging growth companyÃcẽ in Rule 12b-2 of the Exchange Act. Ã Large accelerated filer Ã Accelerated filer Ã Ã Ã Non-accelerated filer Ã Smaller reporting company Ã Ã Ã Emerging growth company Ã Ã If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Ã Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Ã Yes Ã No As of November 8, 2024 there were 59,739,275 shares of the RegistrantÃs common stock outstanding. Ã Ã Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains Ãcẽforward-looking statementsÃcẽ as defined by the Private Securities Litigation Reform Act of 1995, which statements involve substantial risks and uncertainties. Any statements other than statements of historical or current fact in this Quarterly Report on Form 10-Q are forward looking statements. In some instances, you can identify forward-looking statements by the use of words such as Ãcẽbelieves,Ãcẽ Ãcẽanticipates,Ãcẽ Ãcẽplans,Ãcẽ Ãcẽexpects,Ãcẽ Ãcẽestimates,Ãcẽ Ãcẽintends,Ãcẽ Ãcẽpredicts,Ãcẽ Ãcẽprojects,Ãcẽ Ãcẽtargets,Ãcẽ Ãcẽcould,Ãcẽ Ãcẽmay,Ãcẽ Ãcẽwill,Ãcẽ and similar expressions, although not all forward-looking statements include such identifying words. Forward-looking statements include, but are not limited to statements regarding: Ãcẽour product development plans, expectations for and the timing of commencement, enrollment, completion, data, and release of results of clinical trials for our product candidates; Ãcẽour estimates regarding our liquidity, expenses, capital requirements and needs for additional financing; Ãcẽour strategies with respect to our preclinical and clinical development programs, including our expectations regarding the production of clinical quantities of our product candidates; Ãcẽour plans, strategy and timing to obtain and maintain regulatory approvals of our product candidates; Ãcẽour expectations regarding competitive conditions for our product candidates; Ãcẽour review of strategic alternatives and the outcome of such review; and Ãcẽour expectations about our future financial performance or condition. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including the factors listed under ÃcẽRisk Factor SummaryÃcẽ below. These risks and uncertainties, as well as other risks and uncertainties that could cause the CompanyÃcẽs actual results to differ significantly from the forward-looking statements contained herein, are described in greater detail in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. Forward-looking statements contained in this Quarterly Report on Form 10-Q are based on our current beliefs, assumptions, expectations, estimates and projections, which may be impacted by known or unknown factors. Any forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not as of any future date, and the Company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise. You are therefore cautioned not to place undue reliance on the forward-looking statements included in this Quarterly Report on Form 10-Q. The market data and certain other statistical information used in this Quarterly Report are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on our good faith estimates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Ã 2 Ã RISK FACTOR SUMMARY The following summarizes the principal factors that make an investment in the Company speculative or risky, all of which are more fully described in Part II, Item 1A, Risk Factors in this Quarterly Report on Form 10-Q. This summary should be read in conjunction with the Risk Factors section and should not be relied upon as an exhaustive summary of the material risks facing our business. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. ÃcẽOur short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability. ÃcẽWe have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability. ÃcẽWe will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. ÃcẽIssuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities as well as shares and warrants issued or issuable in connection with our recent private placement transactions, could result in significant dilution and could cause our stock price to fall. ÃcẽOur product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed. ÃcẽUnfavorable global economic conditions could have a material adverse effect on our business. ÃcẽAdverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance. ÃcẽDrug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the U.S. Food and Drug Administration (FDA) or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development, formulation and commercialization of our product candidates. ÃcẽThe results of nonclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials, and there is a risk that additional nonclinical and/or clinical safety studies will be required by the FDA or similar regulatory authorities outside the United States or that subsequent studies will not match results seen in prior studies. ÃcẽDelays or difficulties in the enrollment of patients in clinical trials could delay or prevent our receipt of necessary regulatory approvals and increase expenses for the development of our product candidates. ÃcẽIf serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates. ÃcẽOur future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future. ÃcẽIf we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired. ÃcẽLegislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain. ÃcẽOur internal computer systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer security breaches, disruptions, or incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or 3 Ã confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations. ÃcẽEven if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success. ÃcẽIf our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the product could be compromised. ÃcẽWe face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do. ÃcẽThe insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. ÃcẽOur reliance on third parties for the manufacture of our product candidates for nonclinical and clinical trials, and for eventual commercialization, increases the risk that we will not have sufficient quantities of our product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts. ÃcẽWe depend on contract research organizations (ÃcẽCROsÃcẽ) and other contracted third parties to perform nonclinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control. ÃcẽIf we are unable to obtain and maintain intellectual property protection for our technology and products or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. ÃcẽPublic health crises, including pandemics or epidemics, could adversely affect our business. ÃcẽOur stock price could be volatile, and the market price of our common stock may drop unexpectedly. ÃcẽIf we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. ÃcẽProvisions in our corporate charter and under Delaware law could make an acquisition of the Company more difficult and may prevent attempts by our stockholders to replace or remove our current management. Ã 4 Ã ELEDON PHARMACEUTICALS, INC. FORM 10-Q FOR THE QUARTER ENDED SEPTEMBER 30, 2024 Table of Contents Ã Page Ã Ã PART I. FINANCIAL INFORMATION Ã Ã Ã Item 1. Condensed Consolidated Financial Statements - Unaudited Ã 6 Ã Ã Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (As Restated) Ã 6 Ã Ã Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2024 and 2023 (As Restated) Ã 7 Ã Ã Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2024 and 2023 (As Restated) Ã 8 Ã Ã Condensed Consolidated Statements of StockholdersÃcẽ Equity (Deficit) for the Three and Nine Months Ended September 30, 2024 and 2023 (As Restated) Ã 9 Ã Ã Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 (As Restated) Ã 11 Ã Ã Notes to Condensed Consolidated Financial Statements Ã 12 Ã Ã Item 2. ManagementÃcẽs Discussion and Analysis of Financial Condition and Results of Operations Ã 29 Ã Ã Item 3. Quantitative and Qualitative Disclosures About Market Risk Ã 41 Ã Ã Item 4. Controls and Procedures Ã 41 Ã Ã PART II. OTHER INFORMATION Ã Ã Ã Item 1. Legal Proceedings Ã 43 Ã Ã Item 1A. Risk Factors Ã 43 Ã Ã Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Ã 65 Ã Ã Item 3. Defaults Upon Senior Securities Ã 65 Ã Ã Item 4. Mine Safety Disclosures Ã 65 Ã Ã Item 5. Other Information Ã 65 Ã Ã Item 6. Exhibits Ã 66 Ã Ã Item 7. Signatures Ã 68 Ã PART I Ãcẽ FINANCIAL INFORMATION Item 1. Financial Statements ELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited) Ã Ã September 30, 2024 Ã Ã December 31, 2023 Ã Ã Ã (As Restated) Ã ASSETS Ã Ã Ã Ã Current assets: Ã Ã Ã Ã Cash and cash equivalents Ã \$ 6,751 Ã Ã \$ 4,612 Ã Short-term investments Ã 71,440 Ã Ã 46,490 Ã Prepaid expenses and other current assets Ã 3,318 Ã Ã 5,027 Ã Total current assets Ã 81,509 Ã Ã 56,129 Ã Operating lease asset, net Ã 471 Ã Ã 365 Ã In-process research and development Ã 32,386 Ã Ã 32,386 Ã Other assets Ã 210 Ã Ã 186 Ã Total assets Ã \$ 114,576 Ã Ã \$ 89,066 Ã LIABILITIES AND STOCKHOLDERSÃcẽ EQUITY Ã Ã Ã Ã Current liabilities: Ã Ã Ã Ã Accounts payable Ã \$ 5,860 Ã Ã \$ 967 Ã Current operating lease liabilities Ã 186 Ã Ã 383 Ã Accrued expenses and other liabilities Ã 6,443 Ã Ã 2,545 Ã Total current liabilities Ã 12,489 Ã Ã 3,895 Ã Deferred tax liabilities Ã 1,752 Ã Ã 1,752 Ã Non-current operating lease liabilities Ã 315 Ã Ã Ãcẽ Warrant liabilities Ã 23,962 Ã Ã 76,211 Ã Total liabilities Ã 38,518 Ã Ã 81,858 Ã Ã Ã Ã Ã Commitments and contingenciesÃ (Note 7) Ã Ã Ã Ã Ãcẽ StockholdersÃcẽ equity: Ã Ã Ã Ã Preferred stock, \$0.001Ã par value, 5,000,000Ã shares authorized at September 30, Ã Ã Ã 2024 and December 31, 2023: Ã Ã Ã Ã Series X1Ã non-voting convertible preferred stock, \$0.001Ã par value, Ã Ã Ã 515,000Ã shares designated; 110,086Ã shares issued and outstanding Ã Ã Ã at September 30, 2024 and December 31, 2023 Ã Ã Ã Ãcẽ Ã Ã Ãcẽ Series X non-voting convertible preferred stock, \$0.001Ã par value, Ã Ã Ã 10,000Ã shares designated; 4,422Ã shares issued and outstanding Ã Ã Ã at September 30, 2024 and December 31, 2023 Ã Ã Ã Ãcẽ Ã Ã Ãcẽ Common stock, \$0.001Ã par value, 200,000,000Ã shares authorized at September 30, Ã Ã Ã 2024 and December 31, 2023; 41,183,102Ã and 24,213,130Ã shares issued and Ã Ã Ã outstanding at September 30, 2024 and December 31, 2023, respectively Ã Ã Ã 41 Ã Ã 24 Ã Additional paid-in capital Ã 386,884 Ã Ã 326,586 Ã Accumulated other comprehensive income Ã 102 Ã Ã Ãcẽ Ã Accumulated deficit Ã (310,969) Ã Ã (319,402) Ã Total stockholdersÃcẽ equity Ã 76,058 Ã Ã 7,208 Ã Total liabilities and stockholdersÃcẽ equity Ã \$ 114,576 Ã Ã \$ 89,066 Ã See accompanying notes to unaudited condensed consolidated financial statements. 6 Ã ELEDON PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In

[illegible]

and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.Risks and UncertaintiesAs of September 30, 2024 and December 31, 2023, all of the Company's long-lived assets were located in the United States. The Company's products will require approval from the U.S. Food and Drug Administration (FDA) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company's business in the future. In 14 addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process. The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing. The Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages all its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all. In-Process Research and DevelopmentThe fair values of in-process research and development (IPR&D) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (R&D) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods. Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets. Research and Development ExpensesResearch and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed. The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company's accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company's prior period accrued estimates for clinical trial activities during the three and nine months ended September 30, 2024. 15 Recently Adopted Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future financial position, results of operations or cash flows. Warrant LiabilitiesThe Company accounts for issued warrants either as a liability or equity in accordance with ASC 815-40, Derivatives and Hedging. Contracts in Entity's Own Equity (ASC 815-40a). Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the condensed consolidated statements of operations and comprehensive loss as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. Note 3. Short-Term InvestmentsThe objectives of the Company's investment policy are to preserve principal, meet the Company's liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized. The following is a summary of short-term investments, which were classified as available-for-sale securities as of September 30, 2024 and December 31, 2023 (in thousands): September 30, 2024 December 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Amortized Cost Fair Value U.S. government securities \$ 67,745 \$ 105 \$ (3) \$ 67,847 \$ 33,213 \$ 33,213 U.S. government agency securities \$ 3,593 \$ \$ \$ \$ 3,593 \$ 13,277 \$ 13,277 Total short-term investments \$ 71,338 \$ 105 \$ (3) \$ 71,440 \$ 46,490 \$ 46,490 All of the Company's available-for-sale securities have a stated maturity of less than one year. 16 Note 4. Fair Value MeasurementsFinancial assets and liabilities are recorded at fair value. The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: Level 1: Quoted market prices (unadjusted) in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs. Financial AssetsThe following table summarizes the Company's financial asset instruments measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands). Included within cash and cash equivalents on the unaudited condensed consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions. As of September 30, 2024 and December 31, 2023, the Company's financial assets are categorized as follows: September 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents \$ 5,741 \$ \$ \$ 5,741 Total cash equivalents \$ 5,741 \$ \$ \$ 5,741 Short-term investments \$ 67,847 \$ \$ \$ 67,847 U.S. government securities \$ 3,593 \$ \$ \$ 3,593 Total short-term investments \$ 71,440 \$ \$ \$ 71,440 Total financial assets \$ 77,181 \$ \$ \$ 77,181 December 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents \$ 4,246 \$ \$ \$ 4,246 Total cash equivalents \$ 4,246 \$ \$ \$ 4,246 Short-term investments \$ 33,213 \$ \$ \$ 33,213 U.S. government securities \$ 4,246 \$ \$ \$ 4,246 Total financial assets \$ 46,490 \$ \$ \$ 46,490 Warrant LiabilitiesThe following table summarizes the Company's warrant liabilities (see Note 8) measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands) and was based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. As of September 30, 2024 and December 31, 2023, the Company's warrant liabilities are categorized as follows: September 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Total Warrant liabilities \$ 23,962 \$ \$ \$ 23,962 December 31, 2023 Level 1 Level 2 Level 3 Total Warrant liabilities \$ 76,211 \$ \$ \$ 76,211 The following table provides a roll-forward of the aggregate fair value of the warrant liability categorized with Level 3 inputs: As of December 31, 2023 Balance as of December 31, 2023 Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds \$ (51,829) Settlement of warrant liability \$ (420) Balance as of September 30, 2024 \$ 23,962 The change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes the reversal of \$58.7 million in warrant liabilities associated with the Subsequent Closing Warrants (as defined in Note 8), which expired during the quarter ended September 30, 2024. Note 5. Prepaid Expenses and Other Current AssetsPrepaid expenses and other current assets consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): As of September 30, 2024 December 31, 2023 Prepaid clinical \$ 2,526 \$ 4,128 Prepaid insurance \$ 87 \$ 624 Prepaid other \$ 263 \$ 185 Other current assets \$ 442 \$ 90 Total prepaid expenses and other current assets \$ 3,318 \$ 5,027 Note 6. Accrued Expenses and Other LiabilitiesAccrued expenses and other liabilities consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands): As of September 30, 2024 December 31, 2023 Accrued compensation and related expenses \$ 2,062 \$ 2,003 Accrued clinical \$ 3,798 \$ 451 Accrued professional services \$ 475 \$ 47 Accrued other \$ 108 \$ 44 Total accrued expenses and other liabilities \$ 6,443 \$ 2,545 Note 7. Commitments and ContingenciesOperating LeasesThe Company leases office space under various operating leases. Total rent expense for all operating leases in the accompanying condensed consolidated statements of operations and comprehensive income was \$0.1 million for each of the three months ended September 30, 2024 and 2023 and \$0.3 million for each of the nine months ended September 30, 2024 and 2023. On April 19, 2024, the Company entered into a 38-month operating lease for 5,817 square feet of office space in Irvine, California, that expires on June 30, 2027 (the Irvine Lease Agreement). On April 19, 2024, in conjunction with the Irvine Lease Agreement, the Company terminated an existing operating lease for 5,197 square feet of office space in Irvine, California, that was set to expire on December 31, 2024. On April 19, 2024, the effective date of the Irvine Lease Agreement, the Company recognized additional net ROU assets and lease liabilities in the amount of \$0.5 million. On September 4, 2024, the Company entered into a 36-month operating lease for 6,138 square feet of office space in Burlington, Massachusetts, that expires on November 21, 2027 (the Burlington Lease Agreement). The existing lease will expire on November 20, 2024. The Company will recognize additional net ROU assets and lease liabilities for the Burlington Lease Agreement beginning November 21, 2024. The Company determines if a contract contains a lease at inception. Our office leases have a remaining term of approximately 3 years and do not include options to extend the leases for additional periods. Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have no outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management's judgment. Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate components. We have elected the short-term lease recognition exemption for all applicable classes of underlying assets. Short-term disclosures include only those leases with a term greater than one month and 12 months or less, and expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less, that do not include an option to purchase the underlying asset that we are reasonably certain to exercise, are not recorded on the condensed consolidated balance sheet. The components of lease expense were as follows (in thousands): As of For the Nine Months Ended September 30, 2024 2023 Operating lease cost (a) \$ 306 \$ 300 (a) Includes variable operating lease expenses, which are immaterial 19 Other information related to leases was as follows (in thousands, except lease term and discount rate): As of For the Nine Months Ended September 30, 2024 2023 Supplemental Cash Flows Information As of As of Cash paid for amounts included in the measurement of lease liabilities: As of As of Operating cash flows from operating leases \$ 272 \$ 279 Weighted-average remaining lease term As of As of Operating leases 2.56A years 1.20A years Discount rate As of As of Operating leases 9.60 % 9.60 % All noncancelable operating leases have remaining terms of less than one year. Future payments for these noncancelable operating leases for the remainder of the current fiscal year are as follows (in thousands): As of September 30, 2024 2024 (remainder of) \$ 83 2025 \$ 191 2026 \$ 197 2027 \$ 100 Total minimum lease payments \$ 571 Less imputed interest \$ (70) Present value of lease liabilities \$ 501 Less current portion of operating lease liabilities \$ (186) Non-current operating lease liabilities \$ 315 Grants and LicensesALS Therapy Development Foundation, Inc. License AgreementIn May 2015, Anelixis executed a License Agreement (the Agreement), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. (ALS TDF) for certain patents and know-how of ALS TDF. This Agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDF, subject to the achievement of certain milestones and other conditions. The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was \$1.0 million each. During 2018 and 2017, Anelixis issued \$1.0 million worth of its common stock in lieu of making a

cash payment. There were no milestones achieved during the nine months ended September 30, 2024 or 2023.The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total \$6.0 million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to \$2.5 million in additional milestone payments.In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of \$0.1 million beginning on the earlier of January 1, 2022, the Company’s first sublicense, or change in control, as defined in the Agreement. The Company has made a \$0.1 million annual license maintenance fee each year since 2022.Furthermore, the Company is required to pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching \$500.0 million in aggregate net sales, the Company will be required to pay ALS TDI a one-time milestone payment of \$15.0 million. Upon the first calendar year of reaching \$1.0 billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of \$30.0 million. 20 A Lonza Sales AG Inc. License AgreementIn September 2018, Anelixis executed a License Agreement (the “Lonza Agreement”), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. (“Lonza”) for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee.eGenesis, Inc. Collaboration AgreementIn September 2022, and subsequently amended in January 2023, Eledon executed a non-exclusive collaborative research agreement with eGenesis, Inc. (the “eGenesis Agreement”), under which eGenesis will gain access to tegoprubart for eGenesis’ ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party.Legal MattersThe Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company’s results of operations, financial condition or cash flows.IndemnificationsIn the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. No amounts associated with such indemnifications have been recorded to date.ContingenciesFrom time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not aware of any contingent liabilities requiring accrual at September 30, 2024. Note 8. Stockholders’ Equity Preferred StockThe Company has 5,000,000 authorized shares of preferred stock with a par value of \$0.001 per share:Series X1 non-voting convertible preferred stock, 515,000 shares designated; 110,086 shares issued and outstanding, respectively, at each of September 30, 2024 and December 31, 2023; and Series X non-voting convertible preferred stock, 10,000 shares designated; 4,422 shares issued and outstanding, respectively, at each of September 30, 2024 and December 31, 2023.Each share of the Series X1 or X non-voting convertible preferred stock (the “Preferred Stock”) is convertible into 55,556 shares of common stock, at the option of the holder at any time, subject to certain limitations, including, that the holder will be prohibited from converting the Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at 9.99% or 9.9% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock or Series X1 Preferred Stock, respectively. The holder of the Preferred Stock is entitled to receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to-common-stock basis and without regard to any beneficial ownership limitations) to and in the same form as dividends actually paid on shares of the common stock. No other dividends will be paid on shares of the Preferred Stock. In the event of any liquidation, 21 A dissolution or winding up, the holder of the Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Preferred Stock were fully converted to common stock, which amounts shall be paid pari passu with all holders of common stock. Shares of the Preferred Stock will generally have no voting rights, except as required by law and except that consent of a majority of the holders of either series of outstanding Preferred Stock will be required to amend the terms of such series.2023 Securities Purchase AgreementOn April 28, 2023, the Company entered into the 2023 Securities Purchase Agreement with certain investors, pursuant to which the Company agreed to issue and sell to the investors in the 2023 Private Placement (i) in an initial closing, (a) an aggregate of 15,151,518 shares (the “Shares”) of the Company’s common stock, \$0.001 par value per share, or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”), and (b) common stock warrants exercisable into an aggregate of 15,151,518 shares of common stock (or Pre-Funded Warrants in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”); (ii) in the Second Closing, upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 20,202,024 shares of common stock (or Pre-Funded Warrants); and (iii) in the Third Closing, upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 25,252,530 shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the 2023 Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of \$3.00 per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of \$0.001 per share. The Pre-Funded Warrants and Common Warrants are subject to specified beneficial ownership limitations, which are generally set at 9.99% of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.On May 5, 2023, the initial closing occurred and the Company received \$35.0 million, or net proceeds of approximately \$33.0 million after deducting offering costs, in exchange for 8,730,168 shares of common stock and Pre-Funded Warrants to purchase 6,421,350 shares of common stock. On July 8, 2024, the Second Closing occurred and the Company received gross proceeds of \$2.1 million, or net proceeds of approximately \$2.0 million after deducting offering costs, in exchange for 909,088 shares of common stock. On September 30, 2024 and October 1, 2024, the Third Closing occurred and the Company received gross proceeds of \$4.0 million, or net proceeds of approximately \$3.8 million after deducting offering costs, in exchange for 1,727,400 shares of common stock.In connection with the 2023 Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (the “2023 Registration Statement”) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2023 Registration Statement became effective on June 2, 2023.In August 2024, the Company concluded that the Common Warrants, and the potential issuance of Pre-Funded Warrants in lieu of additional shares of common stock in the Second and Third Closings (the “Subsequent Closing Warrants”) do not meet the conditions to be classified as equity instruments under ASC 815-40 and must instead be recorded as liabilities on the Company’s consolidated balance sheets at their fair value and remeasured at fair value for each subsequent reporting period. The valuation of the Common Warrants and the Subsequent Closing Warrants is adjusted to fair value (Level 3) at each balance sheet date until the Common Warrants and the Subsequent Closing Warrants are settled or expired. 22 A The following table presents the assumptions used in the Black-Scholes option pricing model to determine the fair value of warrants as of September 30, 2024 as follows: A September 30, 2024 A December 31, 2023 A Risk-free interest rate A 3.58% A 3.84% A 3.88% A Expected volatility A 93.46% - 98.39% A A 89.08% - 94.28% A Expected term (in years) A 3.75 A - 5.25 A A 4.5 A - 6.0 A Share price A \$ 2.49 A - \$ 1.80 A 2024 Securities Purchase AgreementOn May 6, 2024, the Company entered into a Securities Purchase Agreement (the “2024 Securities Purchase Agreement”) with certain institutional and accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the “2024 Private Placement”) an aggregate of 13,110,484 shares (the “2024 Shares”) of the Company’s common stock, \$0.001 par value per share at a price of \$2.37 per share, and pre-funded warrants (the “2024 Pre-Funded Warrants”) at a price of \$2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of common stock at an exercise price of \$0.001 per share. The 2024 Pre-Funded Warrants were issued in lieu of shares of common stock and are exercisable immediately and until exercised in full. The 2024 Pre-Funded Warrants are subject to specified beneficial ownership limitations (equal to 4.99% or 9.99% as determined by holder of each such warrant) of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted.The 2024 Pre-Funded Warrants were classified as a component of permanent stockholders’ equity within additional paid-in-capital. The 2024 Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company’s common stock and meet the equity classification criteria. In addition, the 2024 Pre-Funded Warrants do not provide any guarantee of value or return.The 2024 Private Placement resulted in gross proceeds to the Company of \$50.0 million, or net proceeds of approximately \$48.1 million after deducting offering costs. The Company intends to use the net proceeds from the 2024 Private Placement to fund pre-commercial activities for its products and general corporate purposes.In connection with the 2024 Private Placement, the Company filed on May 24, 2024, a registration statement on Form S-3 (the “2024 Registration Statement”) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2024 Registration Statement became effective on June 5, 2024.2024 Equity Distribution AgreementOn September 20, 2024, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Guggenheim Securities, LLC (the “Guggenheim Securities”) to sell shares of the Company’s common stock, par value \$0.001 per share (the “Common Stock”), having aggregate sales proceeds of up to \$75.0 million, from time to time, through an “at market” equity offering program under which Guggenheim Securities will act as sales agent. In connection with the Sales Agreement, the Company filed on September 20, 2024 a registration statement on Form S-3 containing a prospectus and prospectus supplement (the “ATM Registration Statement”) with the SEC. The ATM Registration Statement became effective on October 2, 2024. The Company has not sold any shares under the Sales Agreement. 2023 Conversion Agreement of Non-Voting Convertible Preferred StockOn May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) 1,782 shares of Series X Non-Voting Convertible Preferred Stock for 99,000 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting Convertible Preferred Stock, and (ii) 7,883,586 shares of Series X1 Non-Voting Convertible Preferred Stock for 437,977 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X1 Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023. 23 A Exercise of Pre-Funded Warrants from 2023 Securities Purchase Agreement On July 10, 2023, Armistice Capital Master Fund Ltd. (the “Exercising Stockholder”) exercised Pre-Funded Warrants to purchase 501,197 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On July 14, 2023, the Company issued 501,197 shares of common stock to the Exercising Stockholder in accordance with such exercise. On November 2, 2023, the Exercising Stockholder exercised Pre-Funded Warrants to purchase 653,000 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On November 6, 2023, the Company issued 653,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.On January 30, 2024, the Exercising Stockholder exercised Pre-Funded Warrants to purchase 600,000 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On January 30, 2024, the Company issued 600,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.On May 7, 2024, the Exercising Stockholder exercised Pre-Funded Warrants to purchase 583,000 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On May 9, 2024, the Company issued 583,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.On July 11, 2024, the Exercising Stockholder exercised Pre-Funded Warrants to purchase 240,000 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On July 11, 2024, the Company issued 240,000 shares of common stock to the Exercising Stockholder in accordance with such exercise. Common Stock WarrantsAs of September 30, 2024, there were 28,121,237 warrants exercisable into common stock (after rounding for fractional shares and subject to beneficial ownership limitations).The following table shows the warrants to purchase common stock activity: A Roll-Forward of Warrant Activity A Common Stock Warrants A Pre-Funded Warrants A All Other Warrants A Total A Balance as of December 31, 2023 A 15,151,518 A 5,776,270 A 636,514 A 21,564,302 A Issued A A 7,989,516 A A 7,989,516 A Exercised A A 1,423,000 A A 1,423,000) Cancelled/Expired A A A A (9,581) A (9,581) Balance as of September 30, 2024 A 15,151,518 A A 12,342,786 A A 626,933 A A 28,121,237 A Preferred Stock WarrantsAs of September 30, 2024, there were 50,207,419 warrants exercisable into Series X1 Non-Voting Convertible Preferred Stock, which are convertible into 2,789,301 shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion limitations). A Roll-Forward of Series X1 Non-Voting Convertible Preferred Warrant Activity A Total A Balance as of December 31, 2023 A 50,207,419 A Issued A A A A Exercised A A A A Balance as of September 30, 2024 A 50,207,419 A A 24 A Note 9. Stock-based CompensationThe Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. For stock options granted to the Company’s board of directors (the “Board”), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination. The expected dividend assumption was based on the Company’s history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.Restricted Stock Units (“RSUs”) are measured and recognized based on the quoted market price of our common stock on the date of grant.On July 10, 2024, the Company held its Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2020 Long Term Incentive Plan (the “2020 Plan”). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company’s common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional 3,500,000 shares so that the new aggregate share limit under the 2020 Plan is 17,960,000 shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 28, 2034.On May 1, 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements, totaling 7,381,857 stock options, with 1,476,372 of the granted stock options subject to the Company’s customary time-based vesting schedule. The remaining 5,905,485 stock options granted are subject to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the Second and Third Closings of the 2023 Private Placement as specified in the 2023 Securities Purchase Agreement. In December 2023, the Company amended the performance-based vesting requirements with its named executive officers and other employees that upon the Second Closing and Third Closing, a full or prorated amount of each closing installment shall vest based on the percentage of funding received relative to the total funding opportunity represented by the investors’ Second Closing and Third Closing subscription amounts. On June 13, 2024, the performance-based vesting requirement based on the milestones applicable to the Second Closing were satisfied, and 1,980,952 stock options were issued. The 2014 Plan was closed to new grants following the initial approval of the 2020 Plan, and therefore, there were no shares

[illegible]

graft failure. Historical studies have reported average eGFRs generally in the low 50 30 Å mL/min/1.73m2 range during the first year after kidney transplant using current standard of care immunosuppression. An eGFR of 50 mL/min/1.73m2 or below indicates chronic kidney disease. We reported interim safety and efficacy results from the Phase 1b clinical trial in March 2023, and provided updated data in November 2023 and June 2024. At the time of the June 2024 update, which reported data as of April 3, 2024, results from the 13 participants in the Phase 1b trial support tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Data from historical studies using standard of care, calcineurin inhibitor-based, immunosuppression therapy typically report aggregate mean estimated glomerular filtration rates (eGFRs) of approximately 50 mL/min/1.73m2 during the first year after kidney transplant. In the ongoing Phase 1b trial, as of April 3, 2024, mean eGFR was above 60 mL/min/1.73m2 at each reported time points after day 30, with an overall mean eGFR of 70.5 mL/min/1.73m2 for all the reported time points after day 30 post-transplant. Two participants completed 12 months on therapy post-transplant, and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one-year post-transplant. The interim results demonstrated that tegoprubart is generally safe and well tolerated in patients undergoing de novo kidney transplantation. As of April 3, 2024, three subjects have discontinued the study due to hair loss and fatigue, viral infection, and rejection, respectively. There have been no cases of hyperglycemia, new onset diabetes, or tremor, all of which are side effects often associated with standard of care immunosuppression therapy. There have been no cases of graft loss or death. In July 2022, we received Investigational New Drug (IND) application clearance from the FDA for our controlled, Phase 2 BESTOW trial of tegoprubart for the prevention of transplant rejection in persons receiving a kidney transplant. The BESTOW study is a multi-center, two-arm, active comparator, head-to-head superiority clinical study, and will enroll approximately 120 participants undergoing kidney transplantation in the U.S. and other countries to evaluate the safety, pharmacokinetics, and efficacy of tegoprubart compared to the calcineurin inhibitor tacrolimus. The study’s primary objective is to assess graft function as measured by estimated eGFR at 12 months post-transplant in participants treated with tegoprubart compared to tacrolimus. Secondary objectives will include assessment of graft survival, biopsy-proven acute rejection, and the incidence of new onset diabetes mellitus after transplant. The BESTOW study is running in parallel to the ongoing Phase 1b clinical trial of tegoprubart in kidney transplantation. The first subject in the BESTOW study was dosed in August 2023. On September 4, 2024, we announced the completion of enrollment in the BESTOW study. In October 2023, we enrolled the first participant in a Phase 2 open-label extension (OLE) study which is designed to evaluate the long-term safety, pharmacokinetics, and efficacy of tegoprubart in participants who have completed one year of treatment in either the ongoing Phase 1b study or the Phase 2 BESTOW study. Clinical Development of Tegoprubart for the Prevention of Allograft Rejection in Xenotransplantation While inhibition of CD40L has shown it may play an important role in immunosuppression in allograft kidney transplantation, this mechanism of action may also play a role in the prevention of xenotransplant rejection (i.e., transplanting an organ from an animal to a human). In January 2023, we entered into a non-exclusive collaborative research agreement with eGenesis, Inc., (“eGenesis”), under which eGenesis gained access to tegoprubart for preclinical and clinical xenotransplantation studies in support of eGenesis’s kidney, heart and islet cell xenotransplantation programs. Clinical Development of Tegoprubart for the Prevention of Allograft Rejection in Islet Cell Transplantation (“ICT”) Type 1 diabetes (“T1D”) is a T cell mediated autoimmune disease with progressive loss of insulin producing pancreatic beta cells and affects approximately 2 million persons in the United States. Approximately 33% of people with T1D report impaired awareness of hypoglycemia regardless of continuous glucose monitoring or automated insulin usage. Approximately 12% of people with T1D experience recurrent severe hypoglycemic events annually, putting them at higher risk for adverse outcomes. Approximately 5% to 8% of adults with T1D experience diabetic ketoacidosis annually, often as a result of poor glycemic control. ICT is gaining attention as a therapeutic option for T1D because it can restore physiological insulin secretion, minimize the risk of hypoglycemic unawareness, and reduce the risk of death due to severe hypoglycemia. The advances made in this field over the past decade have improved patient outcomes, and the procedure has been evolving from an experimental treatment to a clinical treatment option. A number of issues are believed to continue to hamper the overall success of ICT and to need to be addressed in order for there to be widespread clinical acceptance. These include the acute loss of transplanted islets with current immunosuppressive treatments, particularly those with CNI-based therapies, due to islet cell toxicity and alloreactive immunologic responses to transplanted islets. Over time, the progressive loss of islet cells and decline in islet cell function 31 Å can lead to the need for multiple transplants in order for T1D patients to have optimal response to blood glucose levels and possibly achieve insulin independence. Tegoprubart seeks to address the challenges associated with current ICT immunosuppressive regimens using CNI-based therapies, by replacing the CNIs with tegoprubart to prevent rejection and protect the transplanted cells. We believe that tegoprubart may unlock the ICT market by potentially improving islet cell graft survival and reduce the side effects associated with standard of care regimens. Historical studies in nonhuman primate models of ICT have demonstrated that treatment with anti-CD40L antibodies induces long term islet cell function and graft survival, even as a monotherapy. Tegoprubart has shown pre-clinical, proof-of-concept efficacy in a non-human primate model of T1D, where animals undergoing ICT maintained glucose control and sustained levels of C-peptide with chronic tegoprubart treatment for up to a year. Compared to combination immunosuppressive therapy including CNIs, tegoprubart monotherapy was more effective in preventing long term islet cell rejection, associated with better graft function, and showed an improved safety profile. In 2022, the FDA granted orphan designation to tegoprubart for the prevention of allograft rejection in pancreatic islet cell transplantation. In January 2024, we announced that tegoprubart would be utilized in an investigator-initiated trial, conducted at the University of Chicago Medicine’s Transplantation Institute. This pilot study is assessing the safety of using a monoclonal antibody against CD40 ligand to achieve a calcineurin inhibitor-free immunosuppression regimen in patients with T1D mellitus undergoing islet cell transplantation. The Company is not funding this trial but is providing tegoprubart for use in the study. On October 29, 2024, positive data were reported for the first three islet transplant recipients in the study, potentially demonstrating the first human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy without the use of tacrolimus. The first two subjects achieved insulin independence and normal hemoglobin A1C (HbA1c) levels, a measure of average blood glucose, post-transplant. The third subject, decreased insulin use by more than 60% three days following the procedure and continues on insulin independence trajectory typically observed one-to-two months post-transplant. Subjects in the study received islet transplants combined with induction therapy and for chronic maintenance therapy, mycophenolate mofetil plus tegoprubart given every third week by intravenous infusion. The first two subjects achieved insulin independence and presented stable islet graft function at approximately three months and six months post-transplant, respectively. Islet engraftment, measured by graft function standardized to the number of islets infused, was three to five times higher than three comparable subjects who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart is less toxic to transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or hypoglycemic episodes. After initial islet transplant, the first participant reduced insulin requirements by over 60% and normalized blood glucose control. The first patient then achieved insulin independence within approximately a week after the second islet transplantation procedure. Clinical Development of Tegoprubart for ALS ALS is a progressive, paralytic disorder characterized by degeneration of motor neurons in the brain and spinal cord. In the U.S., the incidence is estimated at approximately 5,000 cases per year with a prevalence of approximately 30,000 cases overall. Despite 3 approved drugs, in most cases, death from respiratory failure occurs between 3 to 5 years from diagnosis, with 50% of patients living at least 3 years from diagnosis and only 20% of patients living at least 5 years from diagnosis. While the exact pathogenic mechanism of ALS is still not fully understood, there is strong evidence indicating that neuroinflammation plays an important role in the disease’s pathogenesis. Neuroinflammation in ALS is characterized by the infiltration of lymphocytes and macrophages into the central nervous system, and the activation of microglia and reactive astrocytes. Reactive astrocytes and microglia as well as infiltrating lymphocytes, dendritic cells, monocytes, macrophages and immune complexes have been identified in cerebrospinal fluid and neural tissues in both animal models of ALS and at autopsy in ALS patients. Tegoprubart is designed to block CD40L binding to CD40, thereby potentially inhibiting neuroinflammatory pathways leading to disease progression in ALS. In vitro proof-of-concept studies have shown that tegoprubart binds to CD40L in human cells and blocks CD40L binding on antigen presenting cells and activated T cells. The potential for therapeutic benefit of CD40L blockage in treating ALS has been demonstrated in a SOD1 mouse model of ALS, where a murine anti-CD40L antibody, MR1, prolonged survival and delayed the onset of neurological disease progression. These pathophysiological manifestations are believed to be due to reduced immune cell infiltration of macrophages into skeletal muscle and their destroying denervated nerves. The plasticity of the nervous system to repair itself in the absence of this 32 Å immune cell attack is believed to result in improved neuromuscular junction occupancy and improved muscle function. Blocking CD40L signaling also prevents pro-inflammatory polarization of lymphocytes, reduced neuroinflammation and improved motor neuron survival in rodent ALS models. In 2018, the FDA granted orphan drug designation to tegoprubart for ALS. In 2019, we completed a single ascending dose Phase 1 study of tegoprubart in healthy volunteers and people with ALS. In this study, the doses of tegoprubart studied were well tolerated in healthy adult subjects and adults with ALS. Tegoprubart demonstrated low anti-drug antibody responses that were not dose related, linear dose proportionality across the dose ranges, and a half-life of up to 26 days. In October 2020, we initiated a Phase 2a, open-label, multi-center study to evaluate the safety and tolerability of multiple doses of tegoprubart in adult subjects with ALS. Fifty-four subjects with ALS were enrolled into the study in the United States and Canada at 13 ALS treatment sites. Ascending doses of tegoprubart were administered as IV infusions to four sequentially enrolling cohorts. The first two cohorts consisted of nine participants, and the last two cohorts of 18 participants each. All enrolled subjects received six infusions of tegoprubart over a 12 week period. Blood samples for target engagement, and exploratory biomarkers for inflammation and neurodegeneration were taken and analyzed. Participant-focused clinical outcomes were also assessed. In May 2022, we completed the Phase 2a study and released positive topline results. Tegoprubart successfully met the primary endpoints of safety and tolerability. Fifty of the fifty-four subjects completed all six study infusions, and adverse events were typical of an ALS patient population. Tegoprubart was well-tolerated, and no drug-related serious adverse events were observed. No new safety signals emerged. Anti-drug antibodies (ADAs) were present in less than 5 percent of samples. All ADAs were of low titer and did not impact tegoprubart drug levels. Tegoprubart target engagement was demonstrated in all dose cohorts with increasing target engagement in a dose-dependent manner, plateauing at the 4 and 8 mg / kg dosing levels using CD40L and CXCL13 biomarkers related to T cell and B cell function, respectively. Tegoprubart exposure decreased inflammatory biomarker levels, in a dose dependent manner, in 20 of 32 pro-inflammatory proteins. Pro-inflammatory biomarkers reduced included biomarkers also associated with IgA nephropathy and kidney transplant rejection, such as IgA, IgE, IgM, C3, CXCL9, and CXCL10. We are seeking to further progress ALS clinical development and plan to work with key stakeholders on potential next steps to do so. However, we will be unable to continue our clinical development of tegoprubart for people with ALS without additional financing specific for our ALS program, and we can provide no assurances that we will be able to obtain financing on acceptable terms or at all. Clinical Development of Tegoprubart for IgA Nephropathy In January 2023, the Company announced the deprioritization of its IgAN program and all IgAN clinical development activities were discontinued in 2023. IgAN is the leading cause of chronic glomerulonephritis, a state of inflammation producing damage to the filtering part of the kidney. Disease manifestation and clinical presentation involves renal dysfunction characterized by proteinuria with a slow relentless course. Approximately 30%-40% of persons living with IgAN ultimately reach end stage renal disease (ESRD). The standard of care for ESRD is dialysis or kidney transplant, which represents a significant economic burden as well as a major impact on a patient’s quality of life. With an estimated prevalence of approximately 150,000 persons in the United States, IgAN is one of the most common autoimmune glomerulonephropathies. In the United States, oral budesonide Tarpeyo was approved for use in IgAN by the FDA in December 2021 and Kinpeygo received conditional approval by the European Medicines Agency (EMA) in July 2022. In August 2022, we received IND clearance from the FDA to evaluate tegoprubart for the treatment of IgAN. The Phase 2 global study was a 96-week open-label, dose ranging trial, and included both a high dose and a low dose cohort. The primary endpoint was change in urinary protein:creatinine ratio at week twenty-four. Secondary endpoints included change in estimated Glomerular Filtration Rate (eGFR) at week 96 as well as safety and tolerability. The first subject was dosed in May 2022. In January 2023, we announced the deprioritization of our IgAN program to focus resources on our kidney transplantation programs. We reported interim safety data from the Phase 2 high dose cohort in March 2023. All IgAN clinical development activities were discontinued in 2023. Financing Activities 2023 Securities Purchase Agreement On April 28, 2023, we entered into a Securities Purchase Agreement (the “2023 Securities Purchase Agreement”) with certain institutional and accredited investors, pursuant to which we agreed to issue and sell to the investors in a private 33 Å placement (the “2023 Private Placement”) (i) in an initial closing, (a) an aggregate of 15,151,518 shares (the “Shares”) of our common stock, \$0.001 par value per share, or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”), and (b) common stock warrants exercisable into an aggregate of 15,151,518 shares of common stock (or Pre-Funded Warrants in lieu thereof) (the “Common Warrants”) and, together with the Pre-Funded Warrants, the “Warrants”; (ii) in a second closing (the “Second Closing”), upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 20,202,024 shares of common stock (or Pre-Funded Warrants); and (iii) in a third closing (the “Third Closing”), upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 25,252,530 shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the 2023 Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of \$3.00 per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of \$0.001 per share. The Pre-Funded Warrants and Common Warrants are subject to specified beneficial ownership limitations, which are generally set at 9.99% of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder. On May 5, 2023, the initial closing occurred and we received gross proceeds of \$35.0 million, or net proceeds of approximately \$33.0 million after deducting underwriting discounts and commissions and offering expenses, in exchange for 8,730,168 shares of common stock and Pre-Funded Warrants to purchase 6,421,350 shares of common stock. On July 8, 2024, the Second Closing occurred and the Company received gross proceeds of \$2.1 million, or net proceeds of approximately \$2.0 million after deducting underwriting discounts and commissions and offering expenses, in exchange for 909,088 shares of common stock. On September 30, 2024 and October 1, 2024, the Third Closing occurred and the Company received gross proceeds of \$4.0 million, or net proceeds of approximately \$3.8 million after deducting underwriting discounts and commissions and offering expenses, in exchange for 1,727,400 shares of common stock. In connection with the 2023 Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (the “2023 Registration Statement”) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2023 Registration Statement became effective on June 2, 2023. 2024 Securities Purchase Agreement On May 6, 2024, we entered into a Securities Purchase Agreement (the “2024 Securities Purchase Agreement”) with certain institutional and accredited investors, pursuant to which we agreed to issue and sell to the investors in a private placement (the “2024 Private Placement”) an aggregate of 13,110,484 shares (the “2024 Shares”) of our common stock, \$0.001 par value per share at a price of \$2.37 per share, and pre-funded warrants (the “2024 Pre-Funded Warrants”) at a price of \$2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of common stock at an exercise price of \$0.001 per share. The 2024 Pre-Funded Warrants were issued in lieu of shares of common stock and are exercisable immediately and until exercised in full. The 2024 Pre-Funded Warrants are subject to specified beneficial ownership limitations (equal to 4.99% or 9.99% as determined by holder of each such warrant) of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted. The 2024 Private Placement resulted in gross proceeds to the Company of \$50.0 million, or net proceeds of approximately \$48.1 million after deducting offering costs. We intend to use the net proceeds from the 2024 Private Placement to fund pre-commercial activities for its products and general corporate purposes. In connection with the 2024 Private Placement, on May 24, 2024, we filed a registration statement on Form S-3 (the “2024 Registration Statement”) with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2024 Registration Statement became effective on June 5, 2024. 34 Å 2024 Equity Distribution Agreement On September 20, 2024, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Guggenheim Securities, LLC (the “Guggenheim Securities”) to sell shares of the Company’s common stock, par value \$0.001 per share (the “Common Stock”), having aggregate sales proceeds of up to \$75.0 million, from time to time, through an “at the market” equity offering program under which Guggenheim Securities will act as sales agent. In connection with the Sales Agreement, we filed a registration statement on Form S-3 containing a prospectus and prospectus supplement (the “ATM Registration Statement”) with the SEC. The ATM Registration Statement became effective on October 2, 2024. The Company has not sold any shares under the Sales Agreement. 2024 Underwriting Agreement On October 29, 2024, we entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners, LLC,

as representative of the several underwriters named therein (the “Underwriters”) in connection with the underwritten offering, issuance and sale by the Company (the “Offering”) of 18,356,173 shares of the Company’s common stock, par value \$0.001 per share, at an offering price of \$3.65 per share, and pre-funded warrants at a price of \$3.649 per pre-funded warrant, which are exercisable to purchase 4,931,507 shares of the Company’s common stock at an exercise price of \$0.001 per share. The Offering closed on October 30, 2024 and resulted in gross proceeds of \$85 million, or net proceeds of approximately \$79.5 million after deducting underwriting discounts and commissions and offering expenses. We currently plan to use the net proceeds from the 2024 Offering to advance our pipeline and for working capital and general corporate purposes. The Offering is being made pursuant to our registration statement on Form S-3 (File No. 333-282260), previously filed with the SEC on September 20, 2024 and declared effective by the SEC on October 2, 2024 and a prospectus supplement relating to the Offering dated October 29, 2024. A holder of the pre-funded warrants (together with its affiliates) may not exercise any portion of a pre-funded warrant to the extent that the that, after giving effect to such exercise, the holder (together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates) would beneficially own in excess of 4.99% (or, at the holder’s option upon issuance, 9.99%) of the number of shares of the our common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon exercise of such warrant. Market Trends and Uncertainties The global economy, including the financial and credit markets, has recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, elevated interest rates and uncertainty about economic stability. Likewise, the current conflicts in Ukraine and the Middle East have created extreme volatility in the global capital markets and global economic consequences, including disruptions of the global supply chain and energy markets. A severe or prolonged economic downturn or continued volatility in the financial and credit markets could negatively impact our ability to obtain necessary debt or equity financing in a timely manner or on favorable terms, if at all. The severity and duration of any such impacts cannot be predicted. Any such failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies or cause us to delay our clinical development plans, research and development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above. Any of these actions could materially harm our business. Any of the foregoing items could materially affect our business, possibly to a significant degree. The severity and duration of any such impacts cannot be predicted. See Item 1A, “Risk Factors” for additional information. CRITICAL ACCOUNTING ESTIMATES Our management’s discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities as of the date of the financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and 35 A liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. In Part II, Item 7 of our Amended Form 10-K, we disclosed our critical accounting estimates, which are those estimates made in accordance with GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operation. There have been no significant changes in our critical accounting estimates during the nine months ended September 30, 2024, as compared to those disclosed in the Amended Form 10-K. RESULTS OF OPERATIONS Comparison of the Three Months Ended September 30, 2024 and 2023 The following table provides comparative unaudited results of operations for the three months ended September 30, 2024 and 2023 (in thousands): A A A For the Three Months Ended September 30, A A A A A 2024 A A 2023 A A \$ Variance A A A A A (As Restated) A A A A Operating expenses: A A A A A Research and development A \$ 16,520 A A \$ 7,931 A A \$ 8,589 A General and administrative A A 3,990 A A 3,267 A A 723 A Total operating expenses A 20,510 A A 11,198 A A 9,312 A Loss from operations A (20,510) A (11,198) A (9,312) Other income, net A 1,042 A A 849 A A 193 A Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds A 96,439 A A 443 A A 95,996 A Net income (loss) A \$ 76,971 A A \$ (9,906) A \$ 86,877 A Unrealized gain on available-for-sale securities, net A 102 A A 102 A A 102 A Comprehensive income (loss) A \$ 77,073 A A \$ (9,906) A \$ 86,979 A Research and Development Expenses Research and development expenses increased \$8.6 million to \$16.5 million for the three months ended September 30, 2024, as compared to \$7.9 million for the three months ended September 30, 2023. The increase was primarily driven by a \$7.8 million rise in clinical development expenses with external contract research organizations, a \$0.5 million increase in employee compensation and benefits, a \$0.2 million increase in expenses related to the production of clinical trial materials, and a \$0.1 million increase in non-cash stock-based compensation expenses. General and Administrative Expenses General and administrative expenses increased \$0.7 million to \$4.0 million for the three months ended September 30, 2024, compared to \$3.3 million for the three months ended September 30, 2023. The increase was primarily due to a \$0.5 million rise in professional services and a \$0.2 million increase in general operating expenses. Other Income, Net The change in other income, net, was primarily due to an increase in interest income, driven by higher balances of cash equivalents and short-term investments for the three months ended September 30, 2024. Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds For the three months ended September 30, 2024, the fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds increased by \$96.0 million to \$96.4 million. The change was primarily due to the reversal of \$94.5 million in warrant liabilities associated with the Subsequent Closing Warrants, which expired during the quarter ended September 30, 2024. A 36 A Comparison of the Nine Months Ended September 30, 2024 and 2023 The following table provides comparative unaudited results of operations for the nine months ended September 30, 2024, and 2023 (in thousands): A A A For the Nine Months Ended September 30, A A A A A 2024 A A 2023 A A \$ Variance A A A A A (As Restated) A A A A Operating expenses: A A A A A Research and development A \$ 34,036 A A \$ 23,245 A A \$ 10,791 A General and administrative A A 11,845 A A 9,417 A A 2,428 A Total operating expenses A 45,881 A A 32,662 A A 13,219 A Loss from operations A (45,881) A (32,662) A (13,219) Other income, net A 2,485 A A 1,962 A A 523 A Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds A 51,829 A A (55,738) A 107,567 A Net income (loss) A \$ 8,433 A A \$ (86,438) A A \$ 94,871 A Unrealized gain on available-for-sale securities, net A 102 A A 102 A A 102 A Comprehensive income (loss) A \$ 8,535 A A \$ (86,438) A A \$ 94,973 A Research and Development Expenses Research and development expenses increased \$10.8 million to \$34.0 million for the nine months ended September 30, 2024, as compared to \$23.2 million for the nine months ended September 30, 2023. The increase was primarily driven by an \$8.2 million rise in clinical development expenses with external contract research organizations, a \$1.1 million increase in employee compensation and benefits, a \$1.1 million increase in expenses related to the production of clinical trial materials, and a \$0.4 million increase in non-cash stock-based compensation expenses. General and Administrative Expenses General and administrative expenses increased \$2.4 million to \$11.8 million for the nine months ended September 30, 2024, as compared to \$9.4 million for the nine months ended September 30, 2023. The increase was primarily driven by a \$1.3 million rise in non-cash stock-based compensation expenses, a \$0.7 million increase in professional fees, a \$0.2 million increase in employee compensation and benefits, and a \$0.2 million increase in general operating costs. Other Income, Net The change in other income, net, was primarily due to an increase in interest income, driven by higher interest rates and higher balances of cash equivalents and short-term investments for the nine months ended September 30, 2024 and 2023. Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds For the nine months ended September 30, 2024, the fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds increased by \$107.6 million to \$51.8 million. The change was primarily due to the reversal of \$58.7 million in warrant liabilities associated with the Subsequent Closing Warrants, which expired during the quarter ended September 30, 2024. This is compared to a \$55.7 million increase in fair value of the Common Warrants and the Subsequent Closing Warrants since issuance for the nine months ended September 30, 2023. LIQUIDITY AND CAPITAL RESOURCES Sources of Liquidity As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of \$78.2 million, working capital of \$69.0 million and an accumulated deficit of \$311.0 million. We do not have any approved products for commercial sale and have never generated revenue from product sales and have incurred significant net losses since our inception and expect to continue to incur net operating losses for the foreseeable future. We do not expect to receive any revenue from any product candidates that we develop unless and until we obtain 37 A regulatory approval and commercialize our product candidates or enter into collaborative arrangements with third parties. We currently have no credit facility or committed sources of capital. To date, our operations have been financed primarily by net proceeds from the sale of preferred and common stock, and the sale of warrants. Additionally, in view of our expectation to incur significant losses for the foreseeable future we will be required to raise additional capital resources in the future in order to fund our operations, although the availability of, and our access to, such resources is not assured. 2023 Securities Purchase Agreement On July 8, 2024, the Second Closing occurred and we received gross proceeds of \$2.1 million, or net proceeds of approximately \$2.0 million after deducting underwriting discounts and commissions and offering expenses, in exchange for 909,088 shares of common stock. On September 30, 2024 and October 1, 2024, the Third Closing occurred and the Company received gross proceeds of \$4.0 million, or net proceeds of approximately \$3.8 million after deducting underwriting discounts and commissions and offering expenses, in exchange for 1,727,400 shares of common stock. 2024 Securities Purchase Agreement On May 6, 2024, we entered into the 2024 Securities Purchase Agreement and issued 13,110,484 shares of common stock at a price of \$2.37 per share and pre-funded warrants which are exercisable to purchase 7,989,516 shares of common stock at a price of \$2.369 per underlying share. We received net proceeds of \$48.1 million from the offering, after deducting underwriting discounts and commissions and offering expenses. 2024 Underwriting Agreement On October 29, 2024, we entered into the 2024 Underwriting Agreement and issued 18,356,173 shares of common stock at a price of \$3.65 per share and pre-funded warrants which are exercisable to purchase 4,931,507 shares of common stock at a price of \$3.649 per underlying share. We received net proceeds of \$79.5 million from the offering, after deducting underwriting discounts and commissions and other offering expenses. Based on our liquidity estimates and our current resources, we have concluded that we have sufficient cash resources to meet our anticipated cash needs through at least the next 12 months from the date of this report and for the foreseeable future. We have based this estimate on assumptions that may prove to be incorrect, and we could utilize our available resources sooner than we currently expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. Further, from time to time, our operating plans may change, and we may need additional funds to meet operational needs for clinical studies sooner than planned or to fund additional clinical studies. For example, we do not currently have sufficient liquidity to fund the continued clinical development of tegoprubart for people with ALS without additional financing. We will continue to monitor our liquidity position in light of various financing alternatives and may pursue additional financing or other alternatives to allow us to continue our product development. However, there can be no assurance such financing or other alternatives will be available to us on acceptable terms, or at all, which could force us to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. Material Cash Requirements Our primary use of cash is to fund operating expenses, which consist of clinical research and development expenses, manufacturing expenses, legal and compliance expenses, compensation and related expenses, and general overhead costs. Cash used to fund operating expenses is impacted by the timing of when we pay or prepay these expenses. As of September 30, 2024, there have been no changes in our material cash requirements from known contractual and other obligations, including commitments for capital expenditures, as disclosed under “Liquidity and Capital Resources.” Material Cash Requirements In Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Amended Form 10-K. We expect our expenses to increase in connection with our ongoing activities, particularly as we expand our clinical program with tegoprubart, continue the research and development of, and seek marketing approval for, our product candidates. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. 38 A We will continue to require additional financing in order to advance our drug product through clinical development, to manufacture, obtain regulatory approval for and to commercialize our product candidates, to develop, acquire or in-license other potential product candidates, and to fund operations for the foreseeable future. Therefore, we will seek to raise additional capital through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. Our ability to raise substantial additional capital will depend on many factors, including: A the initiation, progress, timing, costs and results of our ongoing and future clinical trials of tegoprubart, including as such activities may be adversely impacted by global events or macroeconomic conditions; A the impact of global macroeconomic trends and uncertainties, which continue to experience extreme volatility and disruptions, including diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, rising interest rates and uncertainty about economic stability; A the number and scope of indications we decide to pursue for tegoprubart development; A the cost, timing and outcome of regulatory review of any biologics license application, or BLA, we may submit for tegoprubart; A the costs and timing of manufacturing for tegoprubart, if approved; A the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; A our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of tegoprubart; A the costs associated with being a public company; A the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; A the extent to which we acquire or in-license other product candidates and technologies; and A the cost associated with commercializing tegoprubart, if approved for commercial sale. Conditions in the financial and credit markets may also limit the availability of funding or increase the cost of funding. As a result of any of the foregoing factors, adequate additional funding may not be available to us on acceptable terms on a timely basis, or at all. The severity and duration of any such impacts cannot be predicted. Any such failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies or cause us to delay our clinical development plans, research and development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above. Any of these actions could materially harm our business. The issuance of shares of common stock in the 2023 Private Placement, the 2024 Private Placement and the 2024 Underwriting Agreement diluted the ownership interests of our existing stockholders, and to the extent that we raise additional capital through the sale of additional equity or convertible debt securities in the future, our stockholders’ ownership interests may be further diluted, and the terms of these securities may also include liquidation or other preferences that adversely affect our stockholders’ rights. Debt financing, if available, would result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. Please see the section of this Quarterly Report titled “Risk Factors” for additional risks associated with our substantial capital requirements and the challenges we may face in raising capital. 39 A Cash Flows The following table provides a summary of our net cash flow activity for the nine months ended September 30, 2024 and 2023 (in thousands): A A For the Nine Months Ended September 30, A A A 2024 A A 2023 A A \$ (As Restated) A Net cash used in operating activities A \$ (28,284) A \$ (30,396) Net cash used in investing activities A (22,932) A (55,363) Net cash provided by financing activities A 53,355 A A 33,017 A Net change in cash and cash equivalents A \$ 2,139 A A \$ (52,742) Operating Activities For the nine months ended September 30, 2024, operating activities used \$28.3 million in cash, primarily reflecting our net income of \$8.4 million. Operating activities included adjustments for certain non-cash charges, including \$51.8 million due to changes in warrant liabilities and fair value of financial instruments issued in excess of proceeds, and \$1.9 million from accretion of investment discounts. These were partially offset by \$6.5 million in stock-based compensation, and \$0.3 million in operating lease amortization. Net operating assets and liabilities changed by \$10.2 million, driven by an \$8.8 million increase in accounts payable and accrued expenses, a \$1.7 million decrease in prepaid expenses and other assets, and a \$0.2 million increase in operating lease liabilities. For the nine months ended September 30, 2023, operating activities used \$30.4 million in cash, primarily reflecting our net loss of \$86.4 million. Operating activities included adjustments for certain non-cash charges including \$55.7 million due to changes in warrant liabilities and fair value of financial instruments issued in excess of proceeds, \$4.8 million in stock-based compensation, and \$0.3 million in operating lease amortization, partially offset by \$0.6 million in accretion of investment discounts. Net operating assets and liabilities changed by \$4.2 million, driven by a \$3.6 million decrease in accounts payable and accrued expenses, a \$0.3 million increase in operating lease liabilities, and a \$0.4 million increase in prepaid expenses

and other assets. Investing Activities Net cash used in investing activities for the nine months ended September 30, 2024 was \$22.9 million. This consisted of \$83.4 million used to purchase available-for-sale short-term investments, partially offset by \$60.4 million in proceeds from maturity of available-for-sale short-term investments. Net cash used in investing activities for the nine months ended September 30, 2023 was \$55.4 million. This consisted of \$60.4 million used to purchase available-for-sale short-term investments, partially offset by \$5.0 million in proceeds from maturity of available-for-sale short-term investments. Financing Activities Net cash provided by financing activities for the nine months ended September 30, 2024, consisted of the following: \$48.1 million in net proceeds from the 2024 Private Placement, involving the sale of 13.1 million shares of common stock and 8.0 million pre-funded warrants to purchase common stock; \$2.0 million in net proceeds from the Second Closing, involving the sale of 909,088 shares of common stock; and \$3.3 million in net proceeds from the Third Closing, involving the sale of 1.5 million shares of common stock. Net cash provided by financing activities for the nine months ended September 30, 2023, consisted of the 2023 Private Placement, totaling \$33.0 million in net proceeds from the sale of 8.7 million shares of common stock and 6.4 million pre-funded warrants to purchase common stock. 40 A Item 3. Quantitative and Qualitative Disclosures About Market Risk Per AS229.305 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in AS229.10(f)(1) of Regulation S-K, is not required to provide the disclosure required by this Item. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As of September 30, 2024, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on this evaluation, management concluded that our disclosure controls and procedures were not effective, at the reasonable assurance level, as of September 30, 2024 due to the material weakness in our internal control over financial reporting described below. Material Weakness in Internal Control over Financial Reporting In the course of preparing the Company’s unaudited condensed consolidated financial statements as of and for the three and six months ended June 30, 2024, our management concluded that the Common Warrants and Subsequent Closing Warrants do not meet the conditions to be classified as equity instruments under ASC 815-40, “Derivatives and Hedging - Contracts in Entity’s Own Equity,” and must instead be recorded as liabilities on the Company’s condensed consolidated balance sheet at their fair value and remeasured at fair value for each subsequent reporting period. In light of this determination, on August 13, 2024, management and the audit committee of our Board of Directors together concluded that our previously issued (i) audited consolidated financial statements as of and for the fiscal year ended December 31, 2023 included in our Annual Report on Form 10-K filed with the SEC on March 28, 2023 and (ii) unaudited condensed consolidated financial statements as of and for (a) the three months ended March 31, 2024 included in our Quarterly Report on Form 10-Q filed with the SEC on May 15, 2024, (b) the three and nine months ended September 30, 2023 included in our Quarterly Report on Form 10-Q filed with the SEC on November 9, 2023 and (c) the three and six months ended June 30, 2023 included in our Quarterly Report on Form 10-Q filed with the SEC on August 10, 2023 (together, the “Impacted Reports”) were each materially misstated. As a result, our management, including our principal executive officer and principal financial officer, determined that there existed a material weakness in our internal control over financial reporting related to our accounting for equity instruments for the periods covered by each of the Impacted Reports. A material weakness is a deficiency, or a combination of deficiencies, in the internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected in a timely basis. Specifically, our management determined that we did not maintain effective controls to timely identify and account for complex derivative type financial instruments. This material weakness resulted in the material misstatement of each of the Impacted Reports and, if not remediated, could result in further material misstatements to our annual or interim consolidated financial statements that would not be prevented or detected. Due to this material weakness, our management re-assessed the effectiveness of the Company’s internal control over financial reporting and concluded that our internal control over financial reporting was not effective as of December 31, 2023. Remediation of Material Weakness Management has implemented remediation steps to address the material weakness described above and to improve our internal control over financial reporting. While we have processes to properly identify and evaluate the appropriate accounting technical pronouncements and other literature for all significant or unusual transactions, we are improving these processes to ensure that the nuances of such transactions are effectively evaluated in the context of the increasingly complex 41 A accounting standards. Specifically, we have increased our access to accounting literature and research materials, and have consulted with more third-party professionals regarding complex accounting matters than we have done previously. Changes in Internal Control Over Financial Reporting Other than as described above, there have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) of the Exchange Act) during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 42 A PART II “OTHER INFORMATION” Item 1. Legal Proceedings Neither we nor any of our subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time-to-time party to legal proceedings that arise in the ordinary course of our business. Item 1A. Risk Factors An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this Quarterly Report on Form 10-Q and in our other public filings. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described in our public filings when evaluating our business. Risks Related to Our Operations Our short operating history and shifts in our business strategy may make it difficult to evaluate the success of our business to date and to assess our future viability. We are a clinical stage biopharmaceutical company. Our ongoing operations to date have been limited to organizing and staffing the Company, business planning, raising capital, acquiring and developing technology, identifying potential product candidates and pursuing nonclinical and clinical trials. We have not yet demonstrated our ability to successfully manufacture drug product in large enough quantities and with stability to support additional clinical trials, execute pivotal clinical trials, obtain marketing approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. It can take many years to develop a new medicine from the time it is discovered to when it is available for treating patients. Consequently, any predictions made about our future success or viability based on our short operating history to date may not be as accurate as they could be if we had a longer operating history. In addition, as a result of the acquisition of Anelixis and our decision to discontinue our Company funding of the islet cell transplantation program and the IgAN program, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or previously projected by our management. In addition, as an early-stage business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. To successfully market any of our current or future product candidates, we will need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. We have incurred significant operating losses since our inception and expect that we will continue to incur losses over the next several years and may never achieve or maintain profitability. We have incurred significant annual net operating losses in every year since our inception. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we continue to incur significant research and development and other general and administrative expenses related to our ongoing operations. If tegoprubart or any future product candidates we develop are not successfully developed and approved, we may never generate any revenue from sales of products. The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of \$78.2 million, working capital of \$69.0 million and an accumulated deficit of \$311.0 million. We have not generated any revenues from product sales, have not completed the development of any product candidate and may never have a product candidate approved for commercialization. We expect it will be several years, if ever, before we have a product candidate ready for commercialization. We have financed our operations to date primarily through the sale of preferred and common stock, and the sale of warrants and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials. Our net losses may fluctuate significantly from quarter to quarter and year to year and will depend, in part, on the rate at which we incur expenses and our ability to generate revenue. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. 43 A We anticipate that we will continue to incur significant expenses as we: “conduct nonclinical and clinical development of our product candidates or any future product candidate; “seek to identify and acquire additional product candidates; “acquire or in-license other products and technologies; “enter into collaboration arrangements with regards to product discovery or development; “develop manufacturing processes; “seek marketing approvals for any of our product candidates that successfully complete clinical trials; “establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval; “maintain, expand, and protect our intellectual property portfolio; “hire additional personnel; “add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization efforts; and “operate as a public company. To become and remain profitable, we must develop and eventually commercialize a product or products with significant market potential. This will require us to be successful in a range of challenging activities, including completing clinical trials of our product candidates, obtaining marketing approval for these product candidates and manufacturing, marketing and selling those products for which we obtain marketing approval. We may never succeed in these activities, including if we do not have available financial resources to allow us to pursue clinical trials and other clinical development activities, and, even if we are successful, we may never generate revenues that are significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of the Company, could impair our ability to raise capital, maintain our nonclinical and clinical development efforts, and expand our business or continue our operations and may require us to raise additional capital that may dilute the ownership interest of common stockholders. A decline in the value of the Company could also cause stockholders to lose all or part of their investment. We will require additional funding to be able to complete the development of our lead drug candidate. If we are unable to raise capital, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. As of September 30, 2024, there were 41,183,102 shares of our common stock outstanding. In connection with the closing of the 2024 Private Placement on May 9, 2024, we issued 13,110,484 shares of our common stock and pre-funded warrants to purchase 7,989,516 shares of common stock to the investors therein. In connection with the completion of the Second Closing on July 8 2024, we issued 909,088 shares of our common stock and with the completion of the Third Closing on September 30, 2024 and October 1, 2024, we issued 1,727,400 shares of our common stock to the investors therein. In connection with the closing of the 2024 Underwriting Agreement on October 29, 2024, we issued 18,356,173 shares of our common stock and pre-funded warrants to purchase 4,931,507 shares of our common stock to the investors therein. In view of our expectation to incur significant losses for the foreseeable future, we will be required to raise additional capital resources in the future in order to fund our operations. We also provide no assurance that other funding will be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our objectives. If we are unable to raise such capital, or if we are unable to do so on acceptable terms, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. For example, we are currently unable to continue our clinical development of tegoprubart for people with ALS without additional financing, and we can provide no assurances that we will be able to obtain financing on acceptable terms or at all. Our funding needs may fluctuate significantly based on a number of factors, such as: “the scope, progress, results and costs of formulation development and manufacture of drug product to support nonclinical and clinical development of our product candidates; “the extent to which we enter into additional collaboration arrangements regarding product discovery or development, or acquire or in-license products or technologies; 44 A “our ability to establish additional collaborations with favorable terms, if at all; “the costs, timing, and outcome of regulatory review of our product candidates; “the costs of future commercialization activities, including product sales, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; “revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval; and “the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims. Identifying potential product candidates and conducting formulation development, nonclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Even if we generate positive clinical data or are able to successfully commercialize one or more of our product candidates, additional financing may not be available to us on acceptable terms, or at all. In addition to the dilution of our current stockholders’ ownership as a result of the 2023 Private Placement, the 2024 Private Placement and the 2024 Underwriting Agreement, we currently have a significant number of securities outstanding that are exercisable for our common stock, which could result in significant additional dilution and downward pressure on our stock price. Future issuances of our common stock, including common stock that may be issuable pursuant to outstanding warrants or other convertible securities, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. As of September 30, 2024, there were 41,183,102 shares of our common stock outstanding. In connection with the closing of the 2024 Private Placement on May 9, 2024, we issued 13,110,484 shares of our common stock and pre-funded warrants to purchase 7,989,516 shares of common stock to the investors therein. In connection with the completion of the Second Closing on July 8 2024, we issued 909,088 shares of our common stock and the completion of the Third Closing on September 30, 2024 and October 1, 2024, we issued 1,727,400 shares of our common stock to the investors therein. In connection with the closing of the 2024 Underwriting Agreement on October 29, 2024, we issued 18,356,173 shares of our common stock and pre-funded warrants to purchase 4,931,507 shares of our common stock to the investors therein. The issuance of shares of common stock in the 2023 Private Placement, the 2024 Private Placement and the 2024 Underwriting Agreement diluted the ownership interests of our existing stockholders. The issuance of shares of common stock upon exercise of pre-funded warrants or common warrants issued in the initial closing of the 2023 Private Placement, the pre-funded warrants issued in the 2024 Private Placement and the pre-funded warrants issued in the 2024 Underwriting Agreement would result in significant additional dilution to our current stockholders, which could adversely affect the price of our common stock and the terms on which we could raise additional capital. If we sell additional shares of common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of our common stock. Our product candidates are in the early stages of clinical development and may not be successfully developed. If we are unable to successfully develop and commercialize these or any other product candidate, or if we experience significant delays in doing so, our business will be materially harmed. We currently do not have any products that have gained regulatory approval. We have invested substantially all of our efforts and financial resources in the development of our lead drug candidate tegoprubart, including funding nonclinical studies, clinical trials, drug formulation and the manufacturing of clinical trial materials. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of one or more drug candidates. As a result, our business is substantially depending on our ability to successfully complete the development of and obtain approval for one of our potential future additional product candidates. 45 A We have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the pharmaceutical area. For example, to execute our business plan, we will need to successfully: “obtain additional financing in order to advance our drug product through clinical development, and to manufacture, obtain regulatory approval for and commercialize our product candidates; “execute formulation, manufacturing, clinical, and nonclinical development activities; “manufacture

drug product at commercial scale; we establish and confirm commercially acceptable stability (shelf-life) of our drug products; we in-license or acquire other product candidates and advance them through clinical development; we obtain required regulatory approvals for the development and commercialization of tegoprobart or other product candidates; we maintain, leverage, and expand our intellectual property portfolio; we build and maintain robust sales, distribution and marketing capabilities, either on our own or in collaboration with strategic partners; we gain market acceptance for any approved and marketed drug products; we obtain and maintain adequate product pricing and reimbursement; we develop and maintain any strategic relationships we elect to enter; and we manage our spending as costs and expenses increase due to product manufacturing, nonclinical development, clinical trials, regulatory approvals, post-marketing commitments, and commercialization. If we are unsuccessful in accomplishing these objectives, we may not be able to successfully develop and commercialize our or other product candidates, and our business will suffer. Public health crises, including pandemics or epidemics could adversely affect our business. Our business and operations, including but not limited to ongoing or planned research and development activities may be impacted by public health crises. For example, our business was adversely affected by the COVID-19 pandemic, which also caused significant disruption in the operations of third parties upon whom we rely. Other future public health crises, including any future pandemics or epidemics could have a similar impact on our business. We have experienced, and may in the future experience disruptions as a result of the COVID-19 pandemic or from another public health crisis, including any future pandemic or epidemic, that could severely impact our operations and development activities, including, but not limited to: delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; delays in manufacturing of our drug candidates due to increased competition for manufacturing capacity as a result of the pandemic; limitations in employee resources that would otherwise be focused on the conduct of our development activities, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; refusal of the FDA to accept data from clinical trials in affected geographies; delays in procuring drug substance and/or in manufacturing drug product due to limitations in employee resources or forced furloughs at our contract manufacturing organizations; delays in initiation of future clinical trials, including delays in receiving authorization from local regulatory authorities to initiate such clinical trials; and delays or disturbances in enrollment and trial execution, for example, because clinical trial sites may be unable to operate normally, or patients may elect to forego visits to medical facilities or undertake voluntary medical procedures. 46 Any of the foregoing factors, or other effects of any public health crisis, including any future pandemic or epidemic, could materially affect our business, possibly to a significant degree. The severity and duration of any such impacts cannot be predicted. Unfavorable global economic conditions could adversely affect our business, financial condition and results of operations. The global economy, including the financial and credit markets, continues to experience extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, increases in inflation rates, rising interest rates and uncertainty about economic stability. Likewise, the current conflicts in Ukraine and the Middle East have created extreme volatility in the global capital markets and global economic consequences, including disruptions of the global supply chain and energy markets. A severe or prolonged economic downturn or continued volatility in the financial and credit markets could negatively impact our ability to obtain necessary debt or equity financing in a timely manner or on favorable terms, if at all. The severity and duration of any such impacts cannot be predicted. Any such failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies or cause us to delay our clinical development plans, research and development programs or commercialization efforts, out-license intellectual property rights to our product candidates or sell unsecured assets, or a combination of the above. Any of these actions could materially harm our business. For example, we do not currently have sufficient liquidity to fund the continued clinical development of tegoprobart for people with ALS without additional financing, notwithstanding the positive topline results of our Phase 2a study of tegoprobart for adult subjects with ALS. In addition, if we are unable to raise capital, we will be forced to significantly alter our business strategy, substantially curtail our current operations, or liquidate and cease operations altogether. In addition, inflation has recently increased throughout the U.S. economy. As a result of inflation, we have experienced and may continue to experience cost increases, including costs of clinical trials and research and development of our product candidates, production costs, the price of labor, administration and other costs of doing business. Although we may continue to take measures to mitigate the impact of this inflation, if these measures are not effective, our business, financial condition, results of operations and liquidity could be materially adversely affected. Further, in an inflationary environment, cost increases may outpace our expectations, causing us to use our cash and other liquid assets faster than forecasted. If this happens, we may need to raise more capital to fund our operations than expected, and such capital may not be available in sufficient amounts or on reasonable terms, if at all. Adverse conditions in the financial markets, including bank failures, could adversely affect our liquidity and financial performance. We currently maintain domestic cash deposits, for short term operating requirements, in Federal Deposit Insurance Corporation (FDIC) insured banks, which exceed the FDIC insurance limits. Our additional cash and cash equivalents are held in accounts managed by third-party financial institutions and consist of primarily of cash invested in money market funds and government bonds. Bank failures, events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, or concerns or rumors about such events, may lead to widespread demands for customer withdrawals and liquidity constraints that may result in market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank failed and was taken into receivership by the FDIC. At that time, we maintained deposits amounting to approximately 78% of our total cash at Silicon Valley Bank. On March 26, 2023, the assets, deposits and loans of Silicon Valley Bank were acquired by First-Citizens Bank & Trust Company. In response to the failure of Silicon Valley Bank, we diversified our cash deposits into money market funds, U.S. treasuries and U.S. government agency securities and, as of the date of this report, our total cash maintained in FDIC insured banking accounts is less than 3% of our total cash and cash equivalents and short-term investments. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the U.S. or any applicable foreign government in the future or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a future failure or liquidity crisis. Additionally, our cash investments outside of FDIC insured bank accounts are subject to general credit, liquidity, market, and interest rate risks. If the carrying value of an investment exceeds the fair value, and the decline in fair value is deemed to be other-than-temporary, we are required to write down the value of the investment, which could materially harm our results of operations and financial condition and could limit our access to liquidity. 47 A Drug development involves a lengthy and expensive process with an uncertain outcome, including failure to demonstrate safety and efficacy to the satisfaction of the FDA or similar regulatory authorities outside the United States. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the formulation and commercialization of our product candidates. Given the early stage of development for our product candidates, the risk of failure is high. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct nonclinical trials, and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Formulation and device development, nonclinical and clinical testing are all expensive activities, difficult to design and implement, and can take years to complete. Failure can occur at any time during the development program, including during the clinical trial process. Further, the results of nonclinical studies and early clinical trials of our product candidates, as well as earlier generation formulations may not be predictive of the results of later-stage clinical trials. Interim results of a clinical trial do not necessarily predict final results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in nonclinical and clinical trials have nonetheless failed to obtain marketing approval of their products. There is a risk that additional nonclinical and/or clinical safety studies will be required by the FDA or similar regulatory authorities outside the United States and/or that subsequent studies will not match results seen in prior studies. It is impossible to predict when or if any of our product candidates will prove effective, safe and well-tolerated in humans or will receive regulatory approval. We may experience delays in our clinical trials, and we do not know whether planned clinical trials will begin or enroll subjects on time, need to be redesigned or be completed on schedule, if at all. There can be no assurance that the FDA or equivalent foreign regulatory bodies will approve investigational new drug applications and allow us to start clinical trials for any of our product candidates in the future, including for islet cell transplant. Once a clinical trial has commenced, there is also no assurance that the FDA or equivalent foreign regulatory body will not put any of our product candidates on clinical hold. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates. Clinical trials may be delayed, suspended or prematurely terminated for a variety of reasons, such as: delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we want to execute; delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory authority regarding the scope or design of a clinical trial; delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; delays in completing formulation development and manufacturing as a prerequisite to commencing clinical work; inability, delay, or failure in identifying and maintaining a sufficient number of trial sites, many of which may already be engaged in other clinical programs; delay or failure in recruiting and enrolling suitable subjects to participate in a trial; delay or failure in having subjects complete a trial or return for post-treatment follow-up; clinical sites and investigators deviating from trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial; lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays, requirements to conduct additional clinical trials and increased expenses associated with the services of our contract research organizations (CROs) and other third parties; clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials at a higher rate than we anticipate; we may experience delays or difficulties in the enrollment of patients that our product candidates are designed to target; 48 A our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; we may have difficulty partnering with experienced CROs and study sites that can identify patients that our product candidates are designed to target and run our clinical trials effectively; regulators or IRBs may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; the cost of clinical trials of our product candidates may be greater than we anticipate; the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; or there may be changes in governmental regulations or administrative actions. In addition, our development and commercialization activities could be harmed or delayed by a shutdown of the U.S. government, including the FDA. For example, a prolonged shutdown may significantly delay the FDA's ability to timely review and process any submissions we may file or cause other regulatory delays, which could materially and adversely affect our business. If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive, or if there are safety concerns, we may: be delayed in obtaining marketing approval for our product candidates; not obtain marketing approval at all; obtain approval for indications or patient populations that are not as broad as intended or desired; obtain approval with labeling that includes significant use or distribution restrictions or safety warnings that would reduce the potential market for our products or inhibit our ability to successfully commercialize our products; be subject to additional post-marketing restrictions and/or testing requirements; or have the product removed from the market after obtaining marketing approval. Our product development costs will also increase if we experience delays in testing or marketing approvals. We do not know whether any of our nonclinical studies or clinical trials will need to be restructured or will be completed on schedule, or at all. Significant nonclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or may allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented and expenses for the development of our product candidates could increase. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to demonstrate safety and efficacy. We do not know whether the ongoing or planned clinical trials will enroll subjects in a timely fashion, require redesign of essential trial elements or be completed on its projected schedule. In addition, competitors may have ongoing clinical trials for product candidates that treat related or the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors' product candidates. Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Patient enrollment is affected by other factors including: the eligibility criteria for the study in question; the perceived risks and benefits of the product candidate under study; the efforts to facilitate timely enrollment in clinical trials; 49 A the inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs, including some that may be for the same disease indication; the patient referral practices of physicians; the proximity and availability of clinical trial sites for prospective patients; ambiguous or negative interim results of our clinical trials, or results that are inconsistent with earlier results; feedback from regulatory authorities, IRBs, ethics committees (ECs), or data safety monitoring boards, or results from earlier stage or concurrent nonclinical and clinical trials, that might require modifications to the protocol; decisions by regulatory authorities, IRBs, ECs, or the Company, or recommendations by data safety monitoring boards, to suspend or terminate clinical trials at any time for safety issues or for any other reason; and unacceptable risk-benefit profile or unforeseen safety issues or adverse effects. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing. Our ability to conduct clinical trials in some jurisdictions outside of the United States may be adversely affected. We currently have clinical trial sites in regions outside the United States, including Asia, the European Union and the United Kingdom, and we will continue to conduct future clinical trials in these markets. Our ability to conduct clinical trials at sites located outside the United States is subject to numerous risks unique to conducting business in jurisdictions outside the United States, including: difficulty in establishing or managing relationships with qualified CROs, physicians and clinical trial sites; different local standards for the conduct of clinical trials; difficulty in complying with various and complex import laws and regulations when shipping drugs to certain countries; the potential burden of complying with a variety of laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatments; lack of consistency in standard of care from country to country; diminished protection of intellectual property in some countries; instability in economic or political conditions, including inflation, recession and actual or anticipated military conflicts, social upheaval or political uncertainty; foreign exchange fluctuations; cultural differences in medical practice and clinical research; and changes in country or regional regulatory requirements. The ongoing conflict in Ukraine and the resulting imposition of economic and other sanctions by the United States, European Union and many other nations on Russia, individuals in Russia, Russian businesses and the Russian central bank, or any escalation of tensions in the region, could have a broader impact that expands into other countries. The ongoing conflict in the Middle East could have similar impacts. Although the length and impact of any military action and expansion of the conflict into other countries are highly unpredictable, if either conflict spreads or has effects on additional countries, we may experience disruptions or delays in our plans to conduct clinical trial activities in affected regions outside the United States. If serious adverse events or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates. If our product candidates are associated with undesirable effects in nonclinical or clinical trials or have characteristics that are unexpected, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more so A acceptable from a risk-benefit perspective. Any occurrences of clinically significant adverse events with our product candidates may harm our business, financial condition and prospects significantly. Tegoprobart is an early-stage product candidate, and the side effect profile in humans has not been fully established. Currently unknown, drug-related side effects may be identified through ongoing and future clinical trials and, as such, these possible drug-related side effects could affect patient recruitment, the ability of enrolled subjects to complete the trial, or result in potential product liability

claims. Our future success depends on our ability to retain executives and key employees and to attract, retain and motivate qualified personnel in the future. We are highly dependent on the product development, clinical and business development expertise of the principal members of our management, scientific and clinical team. Although we have entered into employment agreements with our executives and key employees, each of them may terminate their employment with us at any time. We do not maintain adequate insurance for any of our executives or other employees. Our recent decision to discontinue the islet cell transplantation program and IGAN program and uncertainties regarding our financial condition may increase the likelihood that employees depart in the foreseeable future. Recruiting and retaining qualified scientific, clinical, manufacturing, sales and marketing personnel is critical to our success. Due to the small size of the Company and the limited number of employees, each of our executives and key employees serves in a critical role. The loss of the services of our executive officers or other key employees could impede the achievement of our development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating drug product, nonclinical development, clinical development, regulatory strategy, and commercial strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to provide services to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.

Risks Related to Regulatory Approval of Our Product Candidates and Other Compliance Matters

If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, or the approvals may be for a narrow indication, we may not be able to commercialize our product candidates, and our ability to generate revenue may be materially impaired. Our product candidates must be approved by the FDA pursuant to a new drug application in the United States and by other regulatory authorities outside the United States prior to commercialization in the respective regions. The process of obtaining marketing approvals, both in the United States and outside the United States, is expensive and takes several years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any country. We have no experience in filing and supporting the applications necessary to gain marketing approvals for our products and may engage third-party consultants to assist in this process. Securing marketing approval requires the submission of extensive nonclinical and clinical data, and other supporting information to regulatory authorities for each therapeutic indication to establish the product candidate's safety and efficacy. Securing marketing approval also requires the submission of information about the product formulation and manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional nonclinical, clinical or other data. In addition, varying interpretations of the data obtained from nonclinical and clinical trials could delay, limit or prevent marketing approval of a product candidate. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may also cause delays in or prevent the approval of an application. Any marketing approval we ultimately obtain may be for fewer or more limited indications than requested or subject to restrictions or post-approval commitments that render the approved product not commercially viable or its market potential significantly impaired. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. In order to market and sell our products in the EU and other international jurisdictions outside of the United States, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and may require additional nonclinical, clinical or health outcome data. In addition, the time required to obtain approval may differ substantially amongst international jurisdictions. The regulatory approval process outside the United States generally includes all the risks associated with obtaining FDA approval. In addition to regulatory approval, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved. Our product candidates and the activities associated with their development and commercialization, including their testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation that are specific to those defined by regulatory authorities in the countries where the product is approved. In the United States and other countries that follow the International Conference on Harmonization, these requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities, requirements regarding the distribution of samples to physicians and recordkeeping. The FDA, or other regulatory authorities, may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers' communications regarding use of their products and if we promote our products beyond their approved indications, we may be subject to enforcement action for off-label promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: restrictions on such products, manufacturers, or manufacturing processes; restrictions on the labeling or marketing of a product; restrictions on product distribution or use; requirements to conduct post-marketing studies or clinical trials; warning or untitled letters; withdrawal of the products from the market; refusal to approve pending applications or supplements to approved applications that we submit; recall of products; fines, restitution or disgorgement of profits or revenues; suspension or withdrawal of marketing approvals; refusal to permit the import or export of our products; product seizure; or injunctions or the imposition of civil or criminal penalties. Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU's requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Legislation regulating the pharmaceutical and healthcare industries may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes intended to contain healthcare costs and modify the regulation of drug and biologic products. These and other regulatory changes could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. For example, on August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022, which, among other things, includes policies that are designed to have a direct impact on drug prices and reduce drug spending by the federal government, which shall take effect in 2023. The Inflation Reduction Act requires drug manufacturers to pay rebates to Medicare if they increase prices faster than inflation for certain drugs used by Medicare beneficiaries. The mechanics of the rebate calculation would mimic those of the Medicaid rebate, but the expansion of inflation-based rebates may further complicate pricing strategies. The Inflation Reduction Act of 2022 or other similar legislation could have the effect of reducing the prices we can charge and reimbursement we receive for our products, thereby reducing our profitability. We expect that additional state and federal healthcare reform measures and regulations will be adopted in the future. Any of these measures and regulations could limit the amounts that federal and state governments will pay for healthcare products and services, result in reduced demand for our product candidates or additional pricing pressures and affect our product development, testing, marketing approvals and post-market activities. Laws, restrictions, and other regulatory measures are also imposed by healthcare laws and regulations in international jurisdictions and in those jurisdictions we face the same issues as in the United States regarding difficulty and cost for us to obtain marketing approval and commercialization of our product candidates and which may affect the prices we may obtain. In some countries, particularly the countries of the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially. Our business operations and relationships with healthcare providers, physicians, third-party payers, and customers will be subject to applicable anti-kickback, fraud and abuse and other broadly applicable healthcare laws, which could expose us to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm and diminished profits and future earnings. Healthcare providers, physicians and third-party payers will play a primary role in the recommendation and prescription of any product candidates for which we receive marketing approval. Our current and future arrangements may expose us to broadly applicable fraud and abuse and other healthcare laws that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute the products for which we receive marketing approval. Even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, federal and state healthcare laws are and will be applicable to our business. Such laws include, but are not limited to federal false claims, false statements and civil monetary penalties laws, including the federal civil False Claims Act (FCA), the federal Anti-Kickback Statute, the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), patient data privacy and security regulation, including, in the United States, HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (HITECH), the federal transparency requirements under the Physician Payments Sunshine Act, and analogous state, local or foreign law. Pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, that person or entity may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Laws, restrictions, and other regulatory measures are also imposed by anti-kickback, fraud and abuse, and other healthcare laws and regulations in international jurisdictions, and in those jurisdictions we face the same issues as in the United States regarding exposure to criminal sanctions, civil penalties, program exclusion, contractual damages, reputational harm, and diminished profits and future earnings. We depend on our information systems and those of our third-party collaborators, service providers, contractors or consultants. Our information systems, or those of our third-party collaborators, service providers, contractors or consultants, may fail or suffer cybersecurity incidents, which could result in a material disruption of our development programs or loss of data or compromise the privacy, security, integrity or confidentiality of sensitive information related to our business and have a material adverse effect on our reputation, business, financial condition or results of operations. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. Our information systems and infrastructure, and those of our current or future third-party collaborators, service providers, contractors and consultants are vulnerable to damage from cybersecurity incidents, including computer viruses, denial-of-service attacks, hacking, phishing and other social engineering attacks, unauthorized access or use resulting from malware, as well as disruptions due to natural disasters, terrorism, war, mistakes or technical errors, including due to software updates and telecommunication and electrical failures. We may also experience cybersecurity incidents stemming from persons inside our organizations (including employees or contractors), or other persons with access to information systems inside our organization. Attacks on information systems are increasing in their frequency, levels of persistence, sophistication and intensity, and they are being conducted by increasingly sophisticated and organized foreign governments, groups and individuals with a wide range of motives and expertise. In addition to extracting or accessing sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the security, confidentiality, integrity and availability of information. The prevalent use of mobile devices that access sensitive information also increases the risk of data security incidents which could lead to the loss of confidential information or other intellectual property. Information system disruptions, even if inadvertent, may limit or disable our access or important third parties' access to our systems. While to our knowledge we have not experienced any material information system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations or the operations of third-party collaborators, service providers, contractors or consultants, it could result in a material disruption of our development programs and significant reputational, financial, legal, regulatory, business or operational harm. The costs to us to mitigate, investigate and respond to potential security incidents, breaches, disruptions, network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any real or perceived security breach affects our information systems (or those of our third-party collaborators, service providers, contractors or consultants), or results in the loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information or damage to our data or applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could be found to have violated applicable U.S. and international privacy, data protection and other laws, which could subject us to litigation and governmental investigations and proceedings by federal, state and local regulatory entities in the U.S. and by international regulatory entities, resulting in exposure to material civil and/or criminal liability, and the further development of our product candidates could be delayed. Such a breach may require notification to governmental agencies, the media or individuals pursuant to various foreign, domestic (federal and state) privacy and security laws, if applicable, including HIPAA, as amended by HITECH, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. In addition, our liability insurance may not be sufficient in type or amount to cover us against claims related to cybersecurity incidents. Any failure or perceived failure by us or any third-party collaborators, service providers, contractors or consultants to comply with our privacy, confidentiality, data security or similar obligations, or any data security incidents or other security breaches that result in the accidental, unlawful or unauthorized access to, use of, release of, processing of, or

transfer of sensitive information, including personally identifiable information, may result in negative publicity, harm to our reputation, governmental investigations, enforcement actions, regulatory fines, litigation or public statements against us, could cause third parties to lose trust in us or could result in claims by third parties, including those that assert that we have breached our privacy, confidentiality, data security or similar obligations, any of which could have a material adverse effect on our reputation, business, financial condition or results of operations. To the extent we maintain individually identifiable health information, we could be subject to fines and penalties (including civil and criminal) under HIPAA for any failure by us or our business associates to comply with HIPAA's requirements. Moreover, data security incidents and other security breaches can be difficult to detect, and any delay in identifying them may lead to increased harm. While we have implemented data security measures intended to protect our information, data, information systems, applications and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or cybersecurity incidents. European data collection is governed by restrictive regulations governing the collection, use, processing and cross-border transfer of personal information. We may collect, process, use or transfer personal information from individuals located in the European Economic Area in connection with our business, including in connection with conducting clinical trials in the EEA. Additionally, if any of our product candidates are approved, we may seek to commercialize those products in the European Economic Area. The collection and use of personal health data in the European Economic Area is governed by the provisions of the General Data Protection Regulation ((EU) 2016/679) (the "GDPR"), along with other European Union and country-specific laws and regulations. The United Kingdom and Switzerland have also adopted data protection laws and regulations. These legislative acts (together with regulations and guidelines) impose requirements relating to having legal bases for processing personal data relating to identifiable individuals and transferring such data outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their personal data, keeping personal data secure, having data processing agreements with third parties who process personal data, responding to individuals' requests to exercise their rights in respect of their personal data, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers or corporate representatives, conducting data protection impact assessments and record-keeping. The GDPR imposes additional responsibilities and liabilities in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European Economic Area and other states in the European Economic Area may result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, financial condition and results of operations. European data protection authorities may interpret the GDPR and national laws differently and may impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. 55 A If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business. We may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our nonclinical or clinical development or production efforts. Our failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. Risks Related to the Commercialization of Our Product Candidates Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success. If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payers and others in the medical community. In addition, physicians, patients and third-party payers may prefer other novel products to ours. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: the efficacy and safety and potential advantages and disadvantages compared to alternative treatments; the ability to offer our products for sale at competitive prices; the convenience and ease of administration compared to alternative treatments; the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; the strength of our marketing and distribution support; the availability of third-party coverage and adequate reimbursement, including patient cost-sharing programs such as copays and deductibles; the ability to develop or partner with third-party collaborators to develop companion diagnostics; the prevalence and severity of any side effects; and any restrictions on the use of our products together with other medications. If our current product candidates, or a future product candidate receives marketing approval and we, or others, later discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the product could be compromised. Clinical trials are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent beneficial effect of a product candidate that is greater than the actual positive effect in a broader patient population or alternatively fail to identify undesirable side effects. If, following approval of a product candidate, we, or others, discover that the product is less effective than previously believed or causes undesirable side effects that were not previously identified, any of the following events could occur: regulatory authorities may withdraw their approval of the product or seize the product; the product may be required to be recalled or changes may be required to the way the product is administered; additional restrictions may be imposed on the marketing of, or the manufacturing processes for, the product; regulatory authorities may require the addition of labeling statements, such as a black box warning or a contraindication; the creation of a Medication Guide outlining the risks of the previously unidentified side effects for distribution to patients; additional restrictions may be imposed on the distribution or use of the product via a Risk Evaluation and Mitigation Strategy; we could be sued and held liable for harm caused to patients; the product may become less competitive; and 56 A Our reputation may suffer. Any of these events could have a material and adverse effect on our operations and business. The commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired. We currently have no marketing or sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues. We currently do not have a marketing or sales team for the marketing, sales and distribution of any of our product candidates that are able to obtain regulatory approval. In order to commercialize any product candidates, we must build on a territory-by-territory basis marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we intend to establish an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming, will require significant attention of our executive officers to manage and may nonetheless fail to effectively market and sell our product candidates. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our products that we obtain approval to market. With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses. We face substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than we do. The development and commercialization of new drug products is highly competitive. We face competition with respect to our current product candidates and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Specifically, there are a number of companies developing competing anti-CD40 and anti-CD40L therapeutics in clinical trials for transplant, autoimmune or central nervous system indications, including: Novartis, Sanofi, UCB, Amgen (post-acquisition of Horizon Therapeutics), Bristol Myers Squibb, and Kiniksa. All of these companies are larger than Eleodon and have significantly greater resources to develop their drug candidates. If approved, we expect that tegoprobart will face competition from numerous FDA-approved therapeutics for the prevention of transplant rejection, including PROGRAF®, ASTAGRAF XL®, ENVARSUS XR®, NULOJIX®, CELLCEPT®, MYFORTIC®, and numerous other branded and generic immunosuppressive agents. Multiple companies are working on islet cell and kidney transplant solutions that may ultimately potentially negate the need for immunosuppressive agents in these indications altogether. We expect that tegoprobart will face competition from FDA-approved therapeutics for the treatment of ALS including RADICAVA®, RELYVRIO®, RILUZOLE, and numerous other branded and generic immunosuppressive agents. Multiple pharmaceutical and biotechnology companies, including but not limited to Biogen, Ionis Pharmaceuticals, Alexion Pharmaceuticals, Orion Pharma, Orphazyme, AZ Therapeutics, Voyager Therapeutics, Apic Bio, Brainstorm Cell Therapeutics, and Cytokinetics, are also working on competing ALS pharmaceutical, gene therapy and cell therapy approaches. 57 A Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. In addition, our ability to compete may be affected in many cases by insurers or other third-party payers seeking to encourage the use of generic products. Generic products are currently available, with additional generic products expected to become available over the coming years, potentially creating pricing pressure. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic products. Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, conducting nonclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. The insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue. The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS, as CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payers tend to follow CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS. Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of our product candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In general, the prices of medicines under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for medicines but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts by governmental and third-party payers, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. Increased expense is incurred to cover costs of health outcome focused research used to generate data necessary to justify the value of our products in order to secure reimbursement. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market. 58 A In addition, many private payers contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our products. Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates or products that we may develop; injury to our reputation and significant negative media attention; withdrawal of clinical trial participants; significant costs to defend the related litigation; substantial monetary awards to trial participants or patients; loss of revenue; reduced resources of our management to pursue our business strategy; and the inability to commercialize any products that we may develop. We currently hold \$10.0 million in product liability insurance coverage in the aggregate, with a per incident limit of \$10.0 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Risks Related to Our Dependence on Third Parties We contract with third parties for the manufacture of our product candidates for nonclinical and clinical trials and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products at an acceptable cost and quality, which could delay, prevent or impair our development or commercialization efforts. We have utilized, and intend to continue utilizing, third parties to formulate, manufacture, package, and distribute clinical supplies of our drug candidates. We have no experience in manufacturing and do not have any manufacturing facilities. Currently, we rely on third parties for the manufacturing of drug substance and drug product for nonclinical and clinical activities. Our manufacturing vendors utilize proprietary cell culture media, cell lines, buffers, manufacturing equipment, manufacturing supplies, and storage buffers for the manufacturing of tegoprobart and other product candidates. These materials are custom-made and available from only a limited number of sources. Although we believe that our third-party suppliers maintain a significant supply of these materials and equipment on hand, any sustained disruption in this supply, could adversely affect our operations. We do not have any long-term agreements in place with our current suppliers. If we are required to change manufacturers, we may experience delays associated with finding an alternate manufacturer that is properly qualified to produce supplies of our products and product candidates in accordance with regulatory requirements and our specifications. Any delays or difficulties in obtaining or in manufacturing, packaging or distributing approved product candidates could negatively impact our clinical trials. We expect to rely on third-party

manufacturers or third-party collaborators for the manufacture of commercial supply of any other product candidates for which our collaborators or we obtain marketing approval. Despite drug substance and product risk management, this reliance on third parties presents a risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. For example, these third parties experienced disruptions in their operations in conjunction with the COVID-19 pandemic. Any delay or performance failure on the part of our existing or future manufacturers of drug substance or drug products could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply. If suppliers cannot supply us with our requirements, we may be required to identify alternative manufacturers, which would lead us to incur added costs and delays in identifying and qualifying any such replacement. Formulations and devices used in early studies are not final formulations and devices for commercialization. Additional changes may be required by the FDA or other regulatory authorities on specifications and storage conditions. These may require additional studies and may result in a delay in our clinical trials and commercialization activities. 59 Â We also expect to rely on other third parties to label, store, and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: â€reliance on the third party for regulatory compliance and quality assurance; â€the possible breach of the manufacturing agreement by the third party; â€the possible misappropriation of our proprietary information, including our trade secrets and know-how; and â€the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. The third parties we rely on for manufacturing and packaging are also subject to regulatory review, and any regulatory compliance problems with these third parties could significantly delay or disrupt our clinical or commercialization activities. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. Additionally, macro-economic conditions may adversely affect these third parties, causing them to suffer liquidity or operational problems. If a key third-party vendor becomes insolvent or is forced to lay off workers assisting with our projects, our results and development timing could suffer. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. We depend on CROs and other contracted third parties to perform nonclinical and clinical testing and certain other research and development activities. As a result, the outcomes of the activities performed by these organizations will be, to a certain extent, beyond our control. The nature of outsourcing a substantial portion of our business will require that we rely on CROs and other contractors to assist us with research and development, clinical testing activities, patient enrollment, data collection, and regulatory submissions to the FDA or other regulatory bodies. As a result, our success will depend partially on the success of these third parties in performing their responsibilities. Although we intend to pre-qualify our CROs and other contractors and we believe that the contractors selected will be fully capable of performing their contractual obligations, we cannot directly control the adequacy and timeliness of the resources and expertise that they apply to these activities. Additionally, macro-economic conditions may affect our development partners and vendors, which could adversely affect their ability to timely perform their tasks. If our contractors do not perform their obligations in an adequate and timely manner, the pace of clinical development, regulatory approval and commercialization of our drug candidates could be significantly delayed, and our prospects could be adversely affected. Risks Related to Our Intellectual Property If we are unable to obtain and maintain intellectual property protection for our technology and products or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired. Our success depends in large part on our ability to obtain and maintain patent protection in relevant countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications 60 Â in the United States and internationally that are related to our novel technologies and product candidates. This patent portfolio includes issued patents and pending patent applications covering pharmaceutical compositions and methods of use. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We may choose not to seek patent protection for certain innovations and may choose not to pursue patent protection in certain jurisdictions, and under the laws of certain jurisdictions, patents or other intellectual property rights may be unavailable or limited in scope. It is also possible that we will fail to identify patentable aspects of our discovery and nonclinical development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, India and China do not allow patents for methods of treating the human body. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the EU, the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The risks described pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license, and any failure to obtain, maintain and enforce these rights could have a material adverse effect on our business. In some cases, we may not have control over the prosecution, maintenance or enforcement of the patents that we license, and our licensors may fail to take the steps that we believe are necessary or desirable in order to obtain, maintain and enforce the licensed patents. Any inability on our part to protect adequately our intellectual property may have a material adverse effect on our business, operating results and financial position. The USPTO and various non-U.S. governmental patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In certain situations, non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. In addition, we have acquired rights to tegoprubart and other product candidates through a license agreement with The ALS Therapy Development Institute, and may in the future enter into other license agreements with third parties for other intellectual property rights or assets. These license agreements may impose various diligence, milestone payment, royalty, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the license, in which event we would not be able to develop or market products covered by the license. Additionally, the milestone and other payments associated with these licenses will make it less profitable for us to develop our drug candidates than if we had developed the licensed technology internally. In some cases, patent prosecution of our licensed technology may be controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we may control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. If disputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. 61 Â We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful. Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference or derivation proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third partyâ€™s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneysâ€™ fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Because competition in our industry is intense, competitors may infringe or otherwise violate our issued patents, patents of our licensors or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours is invalid or unenforceable, in whole or in part, construe the patentâ€™s claims narrowly, or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. We may also elect to enter into license agreements in order to settle patent infringement claims or to resolve disputes prior to litigation, and any such license agreements may require us to pay royalties and other fees that could be significant. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure. We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms. A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. If we were not able to obtain a license or are not able to obtain a license on commercially reasonable terms, our business could be harmed, possibly materially. If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Any NDAs or similar agreements entered into by the Company may not be with all relevant parties, or adequately protect the confidentiality of our trade secrets. Moreover, to the extent we enter into such agreements, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate them, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. 62 Â We may be subject to claims of misappropriation of trade secrets from former employers of Company personnel. Many of our employees and certain of our directors were previously employed at or affiliated with research foundations or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees and directors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees or directors have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employeeâ€™s or directorâ€™s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. Risks Related to Our Common Stock We expect our stock price to be volatile, and the market price of our common stock may drop unexpectedly. The market price of our common stock could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biopharmaceutical, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include: â€uncertainties regarding our financial condition and our ability to raise sufficient capital to fund our ongoing operations; â€our ability to obtain regulatory approvals for our product candidates or other product candidates, and delays or failures to obtain such approvals; â€failure of any of our product candidates, if approved, to achieve commercial success; â€issues in manufacturing our approved products, if any, or product candidates; â€the results of our current and any future clinical trials of our product candidates; â€the entry into, or termination of, key agreements, including key commercial partner agreements; â€the initiation of, material developments in, or conclusion of litigation to enforce or defend any of our intellectual property rights or defend against the intellectual property rights of others; â€announcements by commercial partners or competitors of new commercial products, clinical progress, or the lack thereof, significant contracts, commercial relationships, or capital commitments; â€the introduction of technological innovations or new therapies that compete with our potential products; â€the loss of key employees; â€changes in estimates or recommendations by securities analysts, if any, who cover our common stock; â€general and industry-specific economic conditions that may affect our research and development expenditures; â€changes in the structure of healthcare payment systems; â€period-to-period fluctuations in our financial results; and â€future issuances of shares of common stock. Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock. In the past, following periods of volatility in the market price of a companyâ€™s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. 63 Â If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed. Ensuring that we will have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with GAAP. As described in Part 1, Item 4 of this report, we have identified a material weakness in our internal control over financial reporting. If we are unable to remediate the material weaknesses or otherwise successfully maintain internal controls over financial reporting, the accuracy and timing of our financial reporting, and our stock price, may be adversely affected and we may be unable to maintain compliance with the applicable stock exchange listing requirements. Additionally, as we become a larger company, we will become subject to Section 404(b) of the Sarbanes-Oxley Act, which requires our independent auditors to document and test our internal controls. These additional requirements are costly, and our auditors may identify control deficiencies. Implementing any changes to our internal controls may distract the officers and employees of the Company, entail substantial costs to modify its existing processes and take significant time to complete. These changes may not,

however, be effective in maintaining the adequacy of the internal controls of the Company, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase operating costs and harm the business. In addition, investors’ perceptions that the internal controls of the Company are inadequate or that we are unable to produce accurate financial statements on a timely basis may harm the stock price of the Company. Provisions in our corporate charter documents and under Delaware law could make an acquisition of the Company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. Provisions in our corporate charter and bylaws may discourage, delay or prevent a merger, acquisition or other change in control of the Company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our Board is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by stockholders to replace or remove the current management by making it more difficult for stockholders to replace members of our Board. Among other things, these provisions: • establish a classified Board such that not all members of the Board are elected at one time; • allow the authorized number of our directors to be changed only by resolution of our Board; • limit the manner in which stockholders can remove directors from our Board; • establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our Board; • require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; • limit who may call stockholder meetings; • authorize our Board to issue preferred stock without stockholder approval, which could be used to institute a poison pill that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board; and • require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal certain provisions of the Company’s charter or bylaws. We do not expect to pay any cash dividends in the foreseeable future. We expect to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be the sole source of gain, if any, for any stockholders for the foreseeable future. 64

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Not applicable. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Insider Trading Arrangements During the nine months ended September 30, 2024, none of our officers or directors adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or constituted a non-Rule 10b5-1 trading arrangement. 65

Item 6. Exhibits. A Exhibit Number A Description A A 2.1 A Agreement and Plan of Merger, dated September 14, 2020, by and among Novus Therapeutics, Inc., Nautilus Merger Sub 1, Inc., Nautilus Merger Sub 2, LLC and Anelixis Therapeutics, Inc. (filed with the SEC as Exhibit 2.1 to the Company’s Current Report on Form 8-K filed on September 15, 2020). A A 3.1 A Restated Certificate of Incorporation of Novus Therapeutics, Inc., a Delaware corporation, dated September 22, 2014 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on September 26, 2014). A A 3.2 A Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a reverse stock-split), filed with the Secretary of the State of Delaware on May 9, 2017 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on May 15, 2017). A A 3.3 A Certificate of Amendment to Certificate of Incorporation of Novus Therapeutics, Inc. (effecting, among other things a change in the corporation’s name to Novus Therapeutics, Inc.), filed with the Secretary of the State of Delaware on May 9, 2017 (filed with the SEC as Exhibit 3.2 on the Company’s Current Report on Form 8-K filed on May 15, 2017). A A 3.4 A Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a reverse stock-split) effective as of October 5, 2020 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on October 6, 2020). A A 3.5 A Certificate of Amendment to the Restated Certificate of Incorporation of Novus Therapeutics, Inc., (effecting, among other things a change in the corporation’s name to Eledon Pharmaceuticals, Inc.) effective as of January 5, 2021 (filed with the SEC as Exhibit 3.1 on the Company’s Current Report on Form 8-K filed on January 5, 2021). A A 3.6 A Certificate of Designations of Series X Convertible Preferred Stock (filed with the SEC as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 19, 2020). A A 3.7 A Certificate of Designations of Series X1 Convertible Preferred Stock (filed with the SEC as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on September 15, 2020). A A 3.8 A Amended and Restated Bylaws of Eledon Pharmaceuticals, Inc. (filed with the SEC as Exhibit 3.2 to the Company’s Current Report on Form 8-K filed on January 5, 2021). A A 4.1 A Form of Pre-Funded Warrant to Purchase Common Stock (filed with the SEC as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 7, 2024). A A 10.1 A Open Market Sale Agreement, dated September 20, 2024, by and between Eledon Pharmaceuticals, Inc. and Guggenheim Securities, LLC (incorporated by reference to Exhibit 1.2 to the Company’s registration statement on Form S-3, filed on September 20, 2024). A A 10.2 A Eledon Pharmaceuticals, Inc. 2020 Long Term Incentive Plan, as amended (filed with the SEC as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 10, 2024) A A 31.1* A Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A 31.2* A Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A A 32.1** A Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A A 101.INS A INLINE XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document A A 101.SCH A INLINE XBRL Taxonomy Extension Schema With Embedded Linkbase Documents A A 104 A Cover Page formatted as INLINE XBRL and contained in Exhibit 101 A * A Filed herewith. 66

** A Furnished herewith. A Management contract or compensatory plan or arrangement. 67

A SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. A Eledon Pharmaceuticals, Inc. A A A Date: November 12, 2024 A By: A /s/ David-Alexandre C. Gros, M.D. A A A David-Alexandre C. Gros, M.D. A A A Chief Executive Officer A and Director (Principal Executive Officer) Date: November 12, 2024 A By: A /s/ Paul Little A A A Paul Little A A A Chief Financial Officer (Principal Financial and Accounting Officer) 68 EX-31.1 2 eldn-ex31.1.htm EX-31.1 EX-31.1 Exhibit 31.1 CERTIFICATIONS I, David-Alexandre C. Gros, M.D., certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 12, 2024 By: A /s/ David-Alexandre C. Gros, M.D. A A David-Alexandre C. Gros, M.D. A Chief Executive Officer (Principal Executive Officer) A EX-31.2 5 eldn-ex31.2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATIONS I, Paul Little, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. Date: November 12, 2024 By: A /s/ Paul Little A A Paul Little A Chief Financial Officer (Principal Financial and Accounting Officer) A EX-32.1 4 eldn-ex32.1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David-Alexandre C. Gros, M.D., Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 12, 2024 By: A /s/ David-Alexandre C. Gros, M.D. A A David-Alexandre C. Gros, M.D. A Chief Executive Officer (Principal Executive Officer) A EX-32.2 5 eldn-ex32.2.htm EX-32.2 EX-32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report on Form 10-Q of Eledon Pharmaceuticals, Inc. (the “Company”) for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Paul Little, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge: (1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Date: November 12, 2024 By: A /s/ Paul Little A A Paul Little A Chief Financial Officer (Principal Financial and Accounting Officer) A EX-101.SCH 6 eldn-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (loss) link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 100060 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Going Concern and Management’s Plans link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Short-Term Investments link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Accrued Expenses and Other Liabilities link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Net Income/Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Short-Term Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Accrued Expenses and Other Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) 2 link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Net Income/Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements (Tables) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Description of Business - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Going Concern and Management’s Plans - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Short-Term Investments - Summary of Short-term Investments Classified as Available-for-sale Securities (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) link:presentationLink link:calculationLink

link:definitionLink 995755 - Disclosure - Fair Value Measurements - Summary of Warrant Liabilities Measured at Fair value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Fair Value Measurements - Schedule of Aggregate Fair Value of Warrant Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Components of Lease Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Stockholders' Equity - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stockholders Equity - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stockholders' Equity - Schedule of Warrant Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stockholders' Equity - Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Net Income/Loss Per Share - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Net Income/Loss Per Share - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Net Income/Loss Per Share - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Detail) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Cash Flows (Details) link:presentationLink link:calculationLink link:definitionLink Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Proceeds from maturities of available-for-sale short-term investments Statement [Line Items] Statement [Line Items] New aggregate share limit Share Based Compensation Arrangement By Share Based Payment Award Total Number Of Shares Authorized Share based compensation arrangement by share based payment award total number of shares authorized. Entity Addresses, Address Type [Axis] Plan Name [Domain] Plan Name Pre-funded Warrants [Member] Pre-funded Warrants [Member] Pre-funded warrants, Series X1 Non-voting Convertible Preferred Stock [Member] Series X1 non-voting convertible preferred stock. Series X1 Non Voting Convertible Preferred Stock [Member] Series X1 Preferred Stock [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Fair Value, Recurring and Nonrecurring [Table] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member] Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member] Anelixis Therapeutics, LLC and Otic Pharma, Ltd. Shares, Outstanding Ending Balance, Shares Beginning Balance, Shares Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Accounts payable, accrued expenses and other liabilities Accounts payable, accrued expenses and other liabilities Accounts payable, accrued expenses and other liabilities. Error Corrections and Prior Period Adjustments Restatement [Line Items] 2024 (remainder of) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stock, Class of Stock [Table] Schedule Of Stock By Class [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Summary of Warrant Liabilities Measured at Fair value on a Recurring Basis Deferred tax liabilities Deferred Income Tax Liabilities, Net Deferred Income Tax Liabilities, Net, Total Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Information [Table] Description of business. Description Of Business [Table] Description Of Business [Table] Equity [Text Block] Stockholders' Equity Description of business. Description Of Business [Line Items] Description Of Business [Line Items] Title and Position [Axis] Title of Individual Class of Warrant or Right [Axis] Sale of Stock [Domain] Sale of Stock Cash and Cash Equivalents [Domain] 2014 Employee Stock Purchase Plan [Member] Two thousand fourteen employee stock purchase plan. Two Thousand Fourteen Employee Stock Purchase Plan [Member] Other Commitments [Line Items] Other Commitments [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract] Entity Central Index Key Entity Central Index Key Debt Securities, Available-for-Sale [Line Items] Warrants [Member] Warrant liabilities [Member] Warrant [Member] Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Securities purchase agreement - Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, Minimum Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Business Description and Basis of Presentation [Text Block] Description of Business Preferred Stock Preferred Stock [Member] Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares Issuance Of Common Stock In Connection With Conversion Of X Non-voting Convertible Preferred Stock Shares Issuance of common stock in connection with conversion of x non-voting convertible preferred stock shares. Income Statement [Abstract] Entity Address, State or Province Entity Address, State or Province Prepaid clinical expense. Prepaid Clinical Expense Prepaid clinical Revision of Prior Period [Axis] Class of Warrant or Right [Table] Class Of Warrant Or Right [Table] Biotechnology value fund exchanging stockholders. Biotechnology Value Fund Exchanging Stockholders [Member] BVF Exchanging Stockholders [Member] Increased number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Class of warrant or right number of warrants or rights cancelled or expired. Class Of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired Cancelled/Expired Cover [Abstract] Subsequent Event [Line Items] Basic net income (loss) per common share Net loss per share, basic Earnings Per Share, Basic, Total Underwriting agreement [Member] Underwriting Agreement [Member] Underwriting agreement. Prior Period Adjustment [Abstract] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Operating Expenses [Abstract] Operating expenses Investments, Debt and Equity Securities [Abstract] Total stock-based compensation Share-Based Payment Arrangement, Expense Stock-based compensation Conversion Agreement [Member] Conversion agreement. Retained Earnings (Accumulated Deficit) Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Warrants beneficial ownership limitation percentage Warrants Beneficial Ownership Limitation Percentage Warrants beneficial ownership limitation percentage. Plan Name [Axis] Plan Name Regulatory milestone payments obligation. Regulatory Milestone Payments Obligation Development and regulatory milestone payments Cash cash equivalents and restricted cash maturity period. Cash Cash Equivalents And Restricted Cash Maturity Period Cash, cash equivalents and restricted cash, maturity period Assets, Current [Abstract] Current assets: Common stock, number of shares reserved for issuance Common Stock, Capital Shares Reserved for Future Issuance Liquidity and financial condition. Liquidity And Financial Condition Policy [Text Block] Liquidity and Financial Condition Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Prepaid Expenses and Other Current Assets Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net cash used in Operating Activities Net cash used in Operating Activities Stock Issued Common stock issued in lieu of making a cash payment Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Lessee, Operating Lease, Term of Contract Operating lease, term of contract Class of Warrant Subject to Specified Beneficial Ownership Limitations Percentage Class of Warrant Subject to Specified Beneficial Ownership Limitations Percentage Class of warrant subject to specified beneficial ownership limitations percentage. Cash flows used in operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Fair Value, Recurring [Member] Fair Value, Recurring [Member] Vesting [Axis] Common stock par value Common Stock, Par or Stated Value Per Share Common stock, par value Stock Options Outstanding [Member] Issuance Of Common Stock In Connection With Exercise Of Pre-funded Warrants, Value Issuance of common stock in connection with exercise of pre-funded warrants, Value Issuance of common stock in connection with exercise of pre-funded warrants, value Series X Non-Voting Convertible Preferred Stock [Member] Series X non-voting convertible preferred stock. Series X Non Voting Convertible Preferred Stock [Member] Statement of Cash Flows [Abstract] Counterparty Name [Axis] Counterparty Name Schedule of warrant activity. Schedule Of Warrant Activity Table [Text Block] Schedule of Warrant Activity At the market offering program. At Market Offering Program [Member] ATM Program [Member] Office of chief scientist of Israeli ministry of economy and industry. Office Of Chief Scientist Of Israeli Ministry Of Economy And Industry [Member] Office of Chief Scientist of Israeli Ministry of Economy and Industry [Member] Antidilutive Securities, Name [Domain] Common stock warrants to purchase common common stock shares Common stock warrants exercisable Class of Warrant or Right, Number of Securities Called by Warrants or Rights Entity [Domain] Entity Area of office space. Area Of Office Space Area of office space Net income (losses) excluding gain of change in fair value of warrant Net Income (Losses) Excluding Gain Of Change In Fair Value Of Warrant Net income (losses) excluding gain of change in fair value of warrant. Equity Components [Axis] Additional Paid-In Capital [Member] Biotechnology Value Fund LP, Biotechnology Value Fund II LP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC and Cormorant Global Healthcare Master Fund LP, Biotechnology Value Fund L P Biotechnology Value Fund I L P P Biotechnology Value Trading Fund O S L P M S I B V F S P V L L C and Cormorant Global Healthcare Master Fund L P [Member] BVF Exchanging Stockholders, Series X Exchanging Stockholders [Member] Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share Subsequent Event Type [Axis] Common stock options [Member] Equity Option [Member] Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Armistice Capital Master Fund Ltd [Member] Armistice Capital Master Fund Ltd [Member] Armistice Capital Master Fund Ltd. Securities purchase agreement two thousand twenty four. Securities Purchase Agreement 2024 [Member] 2024 Securities Purchase Agreement Amendment Flag Amendment Flag Warrants Exchanged for Series X1 Preferred Stock. Warrants Exchanged For Series X1 Preferred Stock [Member] Warrants Exchanged for Series X1 Preferred Stock [Member] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent, Total Text Block [Abstract] Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Offering price common stock Stock price per share Sale of Stock, Price Per Share Net income (loss) Net income (loss) Net loss and comprehensive loss Research and Development [Member] Research and Development Expense [Member] Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement General and Administrative Expense General and administrative General and Administrative Expense, Total Fee due for milestones achieved. Fee Due For Milestones Achieved Fee due for milestones achieved Securities Purchase Agreement Initial Closing [Member] Securities Purchase Agreement Initial Closing [Member] Securities purchase agreement initial closing. Other income, net Other income, net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Operating cash flows from operating leases Operating Lease, Payments U.S. Government Agency Securities [Member] US Government Corporations and Agencies Securities [Member] All Other Warrants [Member] All Other Warrants [Member] All other warrants. Class of warrant or right number of warrants or rights issued. Class Of Warrant Or Right Number Of Warrants Or Rights Issued Issued Payables and Accruals [Abstract] Annual license maintenance fee. Annual License Maintenance Fee Annual License Maintenance Fee Net proceeds after deducting offering costs Proceeds from issuances of common stock and pre-funded warrants, net Proceeds from Issuance of Common Stock And Pre Funded Warrants Net Proceeds from issuance of common stock and pre funded warrants net. Short-term investments Short-Term Investments Short-Term Investments, Total Stock options issued Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Operating Lease, Expense Rental expense Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total prepaid expenses and other current assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, Maximum Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Class of Stock [Domain] Class of Stock Other comprehensive income Other Comprehensive Income (Loss), Net of Tax Other comprehensive income (Loss), Net of Tax, Total Expected life assumption using simplified method, description Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term, Simplified Method Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Purchase of available-for-sale short-term investments Payments to Acquire Debt Securities, Available-for-Sale Preferred Stock, Par or Stated Value Per Share Preferred stock, par value Private placement two thousand twenty four. Private Placement 2024 [Member] 2024 Private Placement Antidilutive Securities [Axis] Accredited Investor [Member] Accredited Investor [Member] Accredited Investor. Entity Interactive Data Current Entity Interactive Data Current Class of warrant or right number of warrants or rights assumed and replaced. Class Of Warrant Or Right Number Of Warrants Or Rights Assumed And Replaced Assumed and replaced Lease Expiration Date Lease expiration date Accounting Standards Update [Domain] Document Quarterly Report Document Quarterly Report Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total Statistical Measurement [Axis] Statistical Measurement Operating Lease, Cost Operating lease cost Stockholders' Equity, Policy [Policy Text Block] Warrant Liabilities Total financial assets Assets, Fair Value Disclosure Related and Nonrelated Parties [Domain] Schedule of Future Payments Under Noncancelable Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Gross proceeds Proceeds from Issuance of Private Placement Research and Development Expense, Policy [Policy Text Block] Research and Development Expenses Securities Purchase Agreement Third Closing [Member] Securities purchase agreement third closing. Statement of Income Location, Balance [Axis] Income Statement Location Cash and Cash Equivalents [Axis] Assets Total assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term (in years) Time-based and Performance-based Vesting Requirements [Member] Time-based and Performance-based Vesting Requirements [Member] Time-based and performance-based vesting requirements. Preferred stock warrants. Preferred Stock Warrants [Member] Preferred Stock Warrants [Member] Aggregate net sales achievement. Aggregate Net Sales Achievement Reaching of aggregate net sales Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Entity Address, City or Town Entity Address, City or Town Revision of Prior Period, Adjustment [Member] Restatement Impact [Member] Accumulated Other Comprehensive Income [Member] AOCI Attributable to Parent [Member] Equity [Abstract] Common stock exchanged for X and X1 non-voting convertible preferred stock Common Stock Exchanged For X And X One Non-voting Convertible Preferred Stock Common stock exchanged for X and X1 non-voting convertible preferred stock. Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Stock-Based Compensation

Expense Recognized Share Price Revision of Prior Period [Domain] Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes reversal Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds Includes Reversal Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes reversal. Private Placement [Member] Private Placement Warrants [Member] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Prepaid Expense and Other Assets, Current [Abstract] Operating leases Operating Lease, Weighted Average Discount Rate, Percent Schedule of accrued expenses and other liabilities. Schedule Of Accrued Expenses And Other Liabilities Table [Text Block] Schedule of Accrued Expenses and Other Liabilities Fair Value Disclosures [Abstract] Unrealized gain on available-for-sale securities Unrealized Gain on Available-for-Sale Securities Unrealized gain on available-for-sale securities. Accretion on investment discounts Accretion on investment discounts Accretion on Investment Discounts Accretion on Investment Discounts Public float minimum balance to be maintained Public Float Minimum Balance To Be Maintained Public float minimum balance to be maintained Lessee operating lease remaining term of contract. Lessee Operating Lease Remaining Term Of Contract Remaining term of office lease Accounting Standards Update 2023-09 [Member] Accounting Standards Update 2023-09 [Member] Liabilities, Current [Abstract] Current liabilities: Securities purchase agreement second closing. Securities Purchase Agreement Second Closing [Member] Securities Purchase Agreement Second Closing [Member] Document Type Document Type Leerink Partners LLC [Member] Leerink partners LLC. Accounting Standards Update [Axis] U.S. Government Securities [Member] US Government Agencies Debt Securities [Member] Workers' Compensation Liability, Current Accrued compensation and related expenses Title of 12(b) Security Title of 12(b) Security Series X One Preferred Stock. Series X One Preferred Stock [Member] Series X1 Preferred Stock [Member] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Lease, Cost [Table Text Block] Components of Lease Expense Statement of Stockholders' Equity [Abstract] Balance as of September 30, 2024 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance as of December 31, 2023 Document Fiscal Period Focus Document Fiscal Period Focus Research and Development Expense Research and development Research and Development Expense, Total Irvine, California [Member] CALIFORNIA Equity distribution agreement. Equity Distribution Agreement [Member] Equity Distribution Agreement [Member] Stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Business Acquisition, Effective Date of Acquisition Date of acquisition MASSACHUSETTS Burlington, Massachusetts [Member] Address Type [Domain] Consolidation, Policy [Policy Text Block] Principles of Consolidation Subsequent Event Type [Domain] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted Error Correction [Table] Performance-based Vesting Requirements [Member] Performance-based Vesting Requirements [Member] Performance-based vesting requirements. Warrant exercise price Warrant exercise price per share Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Former Address [Member] Class of Warrant or Right [Line Items] Class Of Warrant Or Right [Line Items] Sale of Stock [Axis] Sale of Stock Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Category of Item Purchased [Axis] Category of Item Purchased Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Statement of Comprehensive Income [Abstract] Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Other Commitments [Table] Other Commitments [Table] Anelixis Therapeutics, Incorporation. Anelixis Therapeutics Incorporation [Member] Anelixis [Member] Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Shares Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares. Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares Accounting Standards Update 2023-07 [Member] Accounting Standards Update 2023-07 [Member] Debt Securities, Available-for-Sale [Table] Other Accrued Liabilities, Current Accrued other Entity Address, Address Line Two Entity Address, Address Line Two Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERSâ€™ EQUITY Document Period End Date Document Period End Date Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash paid for amounts included in the measurement of lease liabilities: Cash paid for amounts included in measurement of lease liabilities. Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Total Antidilutive securities excluded from computation of diluted earnings per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Noncash activities: Noncash Activities [Abstract] Noncash activities. Trading Symbol Trading Symbol Equity, Attributable to Parent Ending Balance Beginning Balance Total stockholdersâ€™ equity Total stockholders' equity Guarantor Obligations, Current Carrying Value Indemnification obligations amount Earnings Per Share, Diluted, Convertible Security, Method [Extensible Enumeration] Unrealized gain on available-for-sale securities, net Unrealized gain (loss) on available-for-sale securities, net OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Warrant to purchase common stock Class of Warrant or Right, Outstanding Ending Balance Beginning Balance Warrants available for exercise Conversion of Stock, Shares Issued Conversion of stock, shares issued In-Process Research and Development In Process Research and Development, Policy [Policy Text Block] Goodwill Goodwill Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Risks and Uncertainties Risks and Uncertainties [Policy Text Block] Risks and uncertainties. Change in accounting principle, accounting standards update, adopted Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Geographical [Axis] Geographical Unrealized Losses Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Guggenheim Securities LLC [Member] Guggenheim Securities LLC. Use of Estimates, Policy [Policy Text Block] Use of Estimates Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Value Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value. Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents Class of Stock [Line Items] Class Of Stock [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, Minimum Common and Preferred Warrants Outstanding [Member] Common And Preferred Warrants Outstanding [Member] Common and preferred warrants outstanding. Weighted-average remaining lease term. Weighted-Average Remaining Lease Term [Abstract] Weighted-average remaining lease term Security Exchange Name Security Exchange Name Counterparty Name [Domain] Counterparty Name Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree Operating Expenses Total operating expenses Accrued severance current. Accrued Severance Current Accrued severance Class of Stock [Axis] Class of Stock Legal Entity [Axis] Legal Entity 2020 Long Term Incentive Plan [Member] Two thousand twenty long term incentive plan. Two Thousand Twenty Long Term Incentive Plan [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Lessee, Operating Lease, Liability, to be Paid, Year Three 2027 Conversion of Stock, Shares Converted Conversion of stock, shares converted Error Correction [Text Block] Restatement of Previously Issued Consolidated Financial Statements Subsequent Event [Member] Subsequent event Maximum [Member] Maximum [Member] Total liabilities and stockholders' equity Liabilities and Equity Number of pre-funded warrants exercised for common stock Number of Pre-funded Warrants Exercised for Common Stock Number of pre-funded warrants exercised for common stock. Operating Lease, Right-of-Use Asset Operating lease asset, net ROU assets and lease liabilities Supplemental Cash Flow Information [Abstract] Supplemental Cash Flows Information Basic net income (loss) per common share Net loss per share, diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Liabilities Total liabilities Total liabilities Fair Value Hierarchy and NAV [Domain] Assets, Current Total current assets Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Stock Issued During Period, Shares, New Issues Common stock number of shares issued Increase decrease in operating lease asset and liability due to new lease. Increase Decrease in Operating Lease Asset and Liability Due To New Lease Increase in operating lease asset and liability due to new lease Vesting period of stock options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Entity Filer Category Entity Filer Category Net proceeds after deducting offering costs Proceeds from Issuance of Private Placement, Net of Offering Costs Proceeds from issuance of private placement, net of offering costs. Working capital. Working Capital Working capital Net income (loss) attributable to common shares - basic Net income (loss) attributable to common shares - diluted Net Income (Loss) Available to Common Stockholders, Diluted Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Common stock warrants. Common Stock Warrants [Member] Common Stock Warrants [Member] Current Fiscal Year End Date Current Fiscal Year End Date Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less imputed interest Discount rate. Discount Rate [Abstract] Discount rate Related and Nonrelated Parties [Axis] Net proceeds after deducting offering costs Proceeds From Issuance Of Net Of Offering Costs Proceeds from issuance of net of offering costs. Entity Registrant Name Entity Registrant Name Allocated undistributed earnings allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted, Total Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Net Income/Loss Per Share Earnings Per Share [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Money Market Funds [Member] Money Market Funds [Member] Weighted-average number of shares outstanding, Basic Basic weighted-average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Vesting [Domain] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, Maximum Common Stock, Shares Authorized Common stock, shares authorized Proceeds from Issuance of Common Stock Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Value Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value. Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Number of days after registration settlement Number of Days After Registration Settlement Number of days after registration settlement. Financial Instrument [Axis] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-term Purchase Commitment, Category of Item Purchased General and Administrative [Member] General and Administrative Expense [Member] Share-Based Payment Arrangement [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Time-based Vesting Requirements [Member] Time-based Vesting Requirements [Member] Time-based vesting requirements. Potentially dilutive common shares: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Common warrants issued Proceeds from issuance of pre-funded warrants Proceeds from Issuance of Warrants Fair Value Debt Securities, Available-for-Sale Debt Securities, Available-for-Sale, Total Accounting Policies [Abstract] Undistributed earnings allocated to participating securities Undistributed earnings allocated to participating securities Undistributed Earnings (Loss) Allocated to Participating Securities, Basic Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total Stockholders' equity: Equity, Attributable to Parent [Abstract] Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental disclosure of non-cash investing and financing activities Statement [Table] Statement [Table] Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Subsequent Event [Table] Accrued Liabilities and Other Liabilities [Abstract] Preferred Stock, Shares Authorized Preferred stock, shares authorized Securities Act File Number Entity File Number Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net change in cash and cash equivalents Earnings Per Share [Abstract] Class of Warrant Subject to Specified Beneficial Ownership Limitations Permitted Percentage Class of Warrant Subject to Specified Beneficial Ownership Limitations permitted percentage. Statement of Financial Position [Abstract] Operating Income (Loss) Loss from operations Issuance Of Common Stock In Connection With Exercise Of Pre-funded Warrants Shares Issuance of common stock in connection with exercise of pre-funded warrants, Shares Issuance of common stock in connection with exercise of pre-funded warrants, shares. Shares Issued, Price Per Share Shares price per share Entity Shell Company Entity Shell Company Accrued Professional Fees, Current Accrued professional services Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] ASSETS Schedule of Error Corrections and Prior Period Adjustments [Table Text Block] Summary of Impact of Correction of Misstatements Settlement of warrant liability Settlement of Warrant Liability Settlement of warrant liability. Class of Warrant or Right [Domain] Entity Current Reporting Status Entity Current Reporting Status Net income (loss) attributable to common shares - basic Net income (loss) attributable to common shares - basic Net Income (Loss) Available to Common Stockholders, Basic Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Aggregate Fair Values of Warrant Liability Subsequent Events [Abstract] Previously Reported [Member] As Previously Reported [Member] Geographical [Domain] Geographical Document Fiscal Year Focus Document Fiscal Year Focus Cash and cash equivalents and short-term investments Cash, Cash Equivalents, and Short-Term Investments Cash, Cash Equivalents, and Short-Term Investments, Total In-process research and development. In Process research and development. In Process Research And Development In-process research and development Preferred Stock, Value, Issued Preferred stock, value Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Other information related to leases. Other Information Related To Leases Table [Text Block] Schedule of Other Information Related to Leases Business Acquisition [Axis] Business Acquisition City Area Code City Area Code Grodd proceeds Proceeds From Issuance Offering Proceeds from issuance offering Debt outstanding Debt, Long-Term and Short-Term, Combined Amount, Total Liabilities, Current Total current liabilities Jefferies Limited Liability Company. Jefferies Limited Liability Company [Member] Jefferies LLC [Member] Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. Change in Fair Value of Warrant Liabilities and Fair Value of Financial Instruments Issued In Excess Of Proceeds Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. Change in Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds, Net Of Tax Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax. Antidilutive Security, Excluded EPS Calculation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] BVF Exchanging Stockholders [Member] Biotechnology Value Fund LP, Biotechnology Value Fund II LP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC. Biotechnology Value Fund I LP Biotechnology Value Fund I LP Biotechnology Value Trading Fund O S L P M S I B V F S P V L L C

[Member] Minimum [Member] Minimum [Member] Unrealized gain on available-for-sale short term investments Unrealized Gain (Loss) on Investments Common Stock [Member] Common Stock [Member] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Settlement of warrant liability into common stock due to exercise Settlement Of Warrant Liability Into Common Stock Due To Exercise Settlement of warrant liability into common stock due to exercise. Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Equity distribution agreement maximum value of common shares issuable. Equity Distribution Agreement Maximum Value Of Common Shares Issuable Equity distribution agreement maximum value of common shares issuable Statement of Income Location, Balance [Domain] Income Statement Location Lessee, Operating Lease, Liability, to be Paid, Year One 2025 Other Assets, Noncurrent Other assets Other Assets, Noncurrent, Total Other Prepaid Expense, Current Prepaid other Other Assets, Current Other current assets Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding U.S. Government Agency Securities [Member] US Government Agencies Short-Term Debt Securities [Member] Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Title and Position [Domain] Title of Individual Table Text Block Supplement [Abstract] Warrants and Rights Outstanding Warrant liabilities Balance as of December 31, 2023 Balance as of June 30, 2024 Warrant liabilities Royalty Guarantees, Commitments, Amount Amount of one-time milestone payment Common stock, \$0.001 par value, 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 41,183,102 and 24,213,130 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Shares Issuance of common stock in connection with conversion of X non-voting convertible preferred stock shares. Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Prepaid Insurance Prepaid insurance Potentially dilutive common shares, Common stock warrants Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities Total cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash and Cash Equivalent [Table] Financial Instruments Measured At Fair Value On A Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Amortization of operating lease asset. Amortization Of Operating Lease Asset Amortization of operating lease asset Proceeds from issuance of common stock with exercise of pre-funded warrants. Proceeds From Issuance Of Common Stock With Exercise Of Pre-funded Warrants Proceeds from issuance of common stock with exercise of pre-funded warrants Operating Lease, Liability Present value of lease liabilities Cormorant Global Healthcare Master Fund LP [Member] Cormorant Global Healthcare Master Fund LP [Member] Cormorant global healthcare master fund lp. Summary of Short-term Investments Classified as Available-for-sale Securities Debt Securities, Available-for-Sale [Table Text Block] Going Concern and Management's Plans Substantial Doubt about Going Concern [Text Block] Measurement Frequency [Axis] Commitments and contingencies (Note 7) Commitments and Contingencies Weighted-average number of common shares outstanding, diluted Weighted-average number of shares outstanding, Diluted Weighted-average common shares outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Lessee, Operating Lease, Liability, to be Paid Total minimum lease payments Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions Ownership interest percentage Entity Small Business Entity Small Business One billion aggregate net sales. One Billion Aggregate Net Sales [Member] Achievement of 1 Billion Aggregate Sales [Member] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] U.S. Treasuries [Member] US Treasury Securities [Member] Total short-term investments Total short-term investments Investments, Fair Value Disclosure ALS therapy development foundation, Inc. license agreement. A L S Therapy Development Foundation Inc License Agreement [Member] ALS Therapy Development Foundation, Inc. License Agreement [Member] Accrued clinical current. Accrued Clinical Current Accrued clinical Securities Purchase Agreement Second and Third Closing [Member] Securities Purchase Agreement Second And Third Closing [Member] Securities purchase agreement second and third closing. Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Accrued Expenses and Other Liabilities Contingent liabilities Contingent liability. Contingent Liability Measurement Frequency [Domain] Number of milestones achieved. Number Of Milestones Achieved Number of Milestones Achieved Fair Value, Inputs, Level 3 [Member] Fair Value Inputs, Level 3 [Member] Operating leases Operating Lease, Weighted Average Remaining Lease Term Subsequent Events [Text Block] Subsequent Events Share-Based Payment Arrangement [Member] Stock Options Outstanding and Other Equity Awards [Member] Gain (Loss) on Termination of Lease Gain on lease termination Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Liabilities, Fair Value Disclosure, Total Liabilities, Fair Value Disclosure Liabilities measured at fair value XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 08, 2024 Document Information [Line Items] A A Document Type 10-Q A Amendment Flag false A Document Period End Date Sep. 30, 2024 A Document Fiscal Year Focus 2024 A Document Fiscal Period Focus Q3 A Trading Symbol ELDN A Entity Registrant Name ELEDON PHARMACEUTICALS, INC. A Entity Central Index Key 0001404281 A Entity Current Reporting Status Yes A Current Fiscal Year End Date --12-31 A Entity Filer category Non-accelerated Filer A Entity Small Business true A Entity Shell Company false A Entity Emerging Growth Company false A Entity Common Stock, Shares Outstanding A 59,739,275 Entity File Number 001-36620 A Entity Tax Identification Number 20-1000967 A Entity Address, Address Line One 19800 MacArthur Blvd A Entity Address, Address Line Two Suite 250 A Entity Address, City or Town Irvine A Entity Address, State or Province CA A Entity Address, Postal Zip Code 92612 A City Area Code (949) A Local Phone Number 238-8090 A Document Quarterly Report true A Document Transition Report false A Entity Incorporation, State or Country Code DE A Title of 12(b) Security Common Stock, \$0.001 par value A Security Exchange Name NASDAQ A Entity Interactive Data Current Yes A X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItem Type Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItem Type Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateTimeItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItem Type Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Address Line 2 such as Street or Suite number + References No definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItem Type Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItem Type Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItem Type Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItem Type Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItem Type Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company (SRC). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItem Type Balance Type: na Period Type: duration X - Definition The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItem Type Balance Type: na Period Type: duration X - Definition Local phone number for entity. + References No definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normlizedStringItem Type Balance Type: na Period Type: duration X - Definition Title of a 12(b) registered security. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItem Type Balance Type: na Period Type: duration X - Definition Name of the Exchange on which a security is registered. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItem Type Balance Type: na Period Type: duration X - Definition Trading symbol of an instrument as listed on an exchange. + References No definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItem Type Balance Type: na Period Type: duration XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: A A Cash and cash equivalents \$ 6,751 \$ 4,612 Short-term investments 71,440 46,490 Prepaid expenses and other current assets 3,318 5,027 Total current assets 81,509 56,129 Operating lease asset, net 471 365 In-process research and development 32,386 32,386 Other assets 210 186 Total assets 114,576 89,066 Current liabilities: A A Accounts payable 5,860 967 Current operating lease liabilities 186 383 Accrued expenses and other liabilities 6,443 2,545 Total current liabilities 12,489 3,895 Deferred tax liabilities 1,752 1,752 Non-current operating lease liabilities 315 A Warrant liabilities 23,962 76,211 Total liabilities 38,518 81,858 Commitments and contingencies (Note 7) Stockholders' equity: A A Common stock, \$0.001 par value, 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 41,183,102 and 24,213,130 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 41 24 Additional paid-in capital 386,884 326,586 Accumulated other comprehensive loss 102 A Accumulated deficit (310,969) (319,402) Total stockholders' equity 76,058 7,208 Total liabilities and stockholders' equity 114,576 89,066 Series X1 Non-voting Convertible Preferred Stock [Member] A A Stockholders' equity: A A Preferred stock, value Series X Non-voting Convertible Preferred Stock [Member] A A Stockholders' equity: A A Preferred stock, value X - Definition In-process research and development. + References No definition available. + Details Name: eldn_InProcessResearchAndDevelopment Namespace Prefix: eldn_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 599 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit

Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 2: <https://asc.fasb.org/1943274/2147482790/220-10-45-14>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-14> + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7> + Details Name: us-gaap AssetsCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap AssetsCurrentAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommitmentsAndContingencies Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Accounting Standards Codification -Section 45- Paragraph 6- Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-50-1-Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3- Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3-Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25-Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3- Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3-Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-50-1-Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3- Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3-Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28-Reference 15: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481968/946-830-55-12-Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1- Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-50-1-Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-50-1-Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7-Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7-Reference 29: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1:

-URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap ShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 10 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - \$ / shares Sep. 30, 2024 Dec. 31, 2023 Preferred stock, par value \$ 0.001 \$ 0.001 Preferred stock, shares authorized 5,000,000 5,000,000 Common stock, par value \$ 0.001 \$ 0.001 Common stock, shares authorized 200,000,000 200,000,000 Common stock, shares issued 41,183,102 24,213,130 Common stock, shares outstanding 41,183,102 24,213,130 Series X1 Non-voting Convertible Preferred Stock [Member] A A Preferred stock, par value \$ 0.001 \$ 0.001 Preferred stock, shares authorized 515,000 515,000 Preferred stock, shares issued 110,086 110,086 Preferred stock, shares outstanding 110,086 110,086 Series X Non-voting Convertible Preferred Stock [Member] A A Preferred stock, par value \$ 0.001 \$ 0.001 Preferred stock, shares authorized 10,000 10,000 Preferred stock, shares issued 4,422 4,422 Preferred stock, shares outstanding 4,422 4,422 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1> + Details Name: us-gaap PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13> + Details Name: us-gaap PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - Details Name: us-gaap StatementClassOfStockAxis=eldn_SeriesX1NonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementClassOfStockAxis=eldn_SeriesXConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 11 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations - USD \$(\$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Operating expenses A A A Research and development \$ 16,520 \$ 7,931 \$ 34,036 \$ 23,245 General and administrative 3,990 3,267 11,845 9,417 Total operating expenses 20,510 11,198 45,881 32,662 Loss from operations (20,510) (11,198) (45,881) (32,662) Other income, net 1,042 849 2,485 1,962 Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds 96,439 443 51,829 (55,738) Net income (loss) 76,971 (9,906) 8,433 (86,438) Net income (loss) attributable to common shares - basic \$ 54,429 \$ (9,906) \$ 5,551 \$ (86,438) Basic net income (loss) per common share \$ 1.05 \$ (0.33) \$ 0.13 \$ (3.79) Weighted-average number of shares outstanding, Basic 51,945,920 29,974,400 41,443,409 22,813,085 Net income (loss) attributable to common shares - diluted \$ (17,504) \$ (9,906) \$ (61,086) \$ (86,438) Basic net income (loss) per common share \$ (0.32) \$ (0.33) \$ (1.42) \$ (3.79) Weighted-average number of shares outstanding, Diluted 55,478,342 29,974,400 43,106,746 22,813,085 X - DefinitionChange in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. + ReferencesNo definition available. + Details Name: eldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds Namespace Prefix: eldn_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/214746176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-12>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI

<https://asc.fasb.org/1943274/2147483443/250-10-50-1-Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-10-Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2-Reference> 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1-Reference> 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1-Reference> 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-7-Details> Name: us-gaap EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6-Reference> 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-2-Reference> 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1-Reference> 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2-Reference> 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3-Reference> 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15-Reference> 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference> 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1-Reference> 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11-Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11-Reference> 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7-Reference> 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-2-Reference> 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B-Reference> 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4-Reference> 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1-Reference> 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2-Reference> 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -Sub

-Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph \(b\)\(3\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI)
https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIte
Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringIteType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2:> <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3:>
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4:> [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(i\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5:> [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(ee\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6:> [http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph \(c\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7:> <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: credit Period Type: duration X - DefinitionAmount of income \(expense\) related to nonoperating activities, classified as other. + ReferencesReference 1:](https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1:)
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(9\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI) https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writt
off of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI>
<https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4:> <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit \(EPU\), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1:](https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesIteType Balance Type: na Period Type: duration X - DefinitionNumber of \[basic\] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1:](https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesIteType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesIteType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Income \(loss\) - USD \(\\$\) \\$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income \[Abstract\] 1:](https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesIteType Balance Type: na Period Type: duration XML 12 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Income (loss) - USD ($) $ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] 1:)
[http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(24\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 120 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(26\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 120 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 4:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(20\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 7:> <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI> https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryIteType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5:> [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17:> <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/214747750/944-220-S99-1Reference 20:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:> [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI)

Balance at Sep. 30, 2023 35,597 \$ 24 324,876 A (289,303) A Ending Balance, Shares at Sep. 30, 2023 A 23,545,130 A A 110,086 4,422 Beginning Balance at Mar. 31, 2023 74,792 \$ 14 288,415 A (213,637) A Beginning Balance, Shares at Mar. 31, 2023 A 13,776,788 A A 117,970 6,204 Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares A 8,730,168 A A A Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value 33,017 \$ 9 933,008 A A A Issuance of common stock in connection with conversion of X non-voting convertible preferred stock, Shares A 99,000 A A A (1,782) Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Shares A 43,977 A A A (7,884) A Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value (1) A (1) A A A Stock-based compensation 1,720 A 1,720 A A A Net loss and comprehensive loss (65,760) A A (65,760) A Ending Balance at Jun. 30, 2023 43,768 \$ 23 323,142 A (279,397) A Ending Balance, Shares at Jun. 30, 2023 A 23,043,933 A A 110,086 4,422 Issuance of common stock in connection with exercise of pre-funded warrants, Shares A 501,197 A A A Issuance of common stock in connection with exercise of pre-funded warrants, Value 1 \$ 1 A A A Stock-based compensation 1,734 A 1,734 A A A Net loss and comprehensive loss (9,906) A (9,906) A Ending Balance at Sep. 30, 2023 35,597 \$ 24 324,876 A (289,303) A Ending Balance, Shares at Sep. 30, 2023 A 23,545,130 A A 110,086 4,422 Beginning Balance at Dec. 31, 2023 7,208 \$ 24 326,586 A (319,402) A Beginning Balance, Shares at Dec. 31, 2023 A 24,213,130 A A 110,086 4,422 Issuance of common stock in connection with exercise of pre-funded warrants, Shares A 600,000 A A A Issuance of common stock in connection with exercise of pre-funded warrants, Value 1 \$ 1 A A A Stock-based compensation 1,694 A 1,694 A A A Net loss and comprehensive loss (23,631) A A (23,631) A Ending Balance at Mar. 31, 2024 (14,728) \$ 25 328,280 A (343,033) A Ending Balance, Shares at Mar. 31, 2024 A 24,813,130 A A 110,086 4,422 Beginning Balance at Dec. 31, 2023 7,208 \$ 24 326,586 A (319,402) A Beginning Balance, Shares at Dec. 31, 2023 A 24,213,130 A A 110,086 4,422 Net loss and comprehensive loss 8,433 A A A A Ending Balance at Sep. 30, 2024 76,058 \$ 41 386,884 \$ 102 (310,969) A Ending Balance, Shares at Sep. 30, 2024 A 41,183,102 A A 110,086 4,422 Beginning Balance at Mar. 31, 2024 (14,728) \$ 25 328,280 A (343,033) A Beginning Balance, Shares at Mar. 31, 2024 A 24,813,130 A A 110,086 4,422 Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares A 13,110,484 A A A Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value 48,070 \$ 13 48,057 A A A Issuance of common stock in connection with exercise of pre-funded warrants, Shares A 583,000 A A A Issuance of common stock in connection with exercise of pre-funded warrants, Value 1 \$ 1 A A A Stock-based compensation 3,063 A 3,063 A A A Net loss and comprehensive loss (44,907) A A (44,907) A Ending Balance at Jun. 30, 2024 (8,501) \$ 39 379,400 A (387,940) A Ending Balance, Shares at Jun. 30, 2024 A 38,506,614 A A 110,086 4,422 Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Shares A 2,436,488 A A A A Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value 5,703 \$ 2 5,701 A A A Issuance of common stock in connection with exercise of pre-funded warrants, Shares A 240,000 A A A A Stock-based compensation 1,783 A 1,783 A A A Other comprehensive income 102 A 102 A A Net loss and comprehensive loss 76,971 A A 76,971 A Ending Balance at Sep. 30, 2024 \$ 76,058 41 \$ 386,884 \$ 102 (310,969) A Ending Balance, Shares at Sep. 30, 2024 A 41,183,102 A A 110,086 4,422 X - DefinitionIssuance of common stock in connection with conversion of X non-voting convertible preferred stock shares. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares Namespace Prefix: eldn_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionIssuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue Namespace Prefix: eldn_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock in connection with conversion of x non-voting convertible preferred stock shares. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares Namespace Prefix: eldn_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionIssuance of common stock in connection with exercise of pre-funded warrants, shares. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares Namespace Prefix: eldn_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionIssuance of common stock in connection with exercise of pre-funded warrants, value + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue Namespace Prefix: eldn_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares Namespace Prefix: eldn_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionIssuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value. + ReferencesNo definition available. + Details Name: eldn_IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue Namespace Prefix: eldn_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12> + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7](http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 23: [Reference 25: \[Reference 27: \\[Reference 29: \\\[Reference 31: \\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\\\(SX 210.13-02\\\\(a\\\\)\\\\(5\\\\)\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: <a href=\\\\)Reference 34: \\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \\\\\(a\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A\\\\]\\\\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28\\\\)Reference 36: \\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \\\\\(SX 210.5-03\\\\\(21\\\\\)\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \\\\(a\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B\\\\)Reference 10: \\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \\\\\(b\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B\\\\]\\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\(SX 210.9-04\\\\(23\\\\)\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1\\\\)Reference 12: \\\\[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \\\\\(b\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A\\\\]\\\\(http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15\\\\) + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionAmount of equity \\\\(deficit\\\\) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\(SX 210.5-02\\\\\(29\\\\\)\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\]\\\\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\(SX 210.5-02\\\\(29\\\\)\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\)Reference 2: \\\\[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\\(SX 210.5-02\\\\\(29\\\\\)\\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\]\\\\(http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \\\\(SX 210.5-02\\\\(29\\\\)\\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1\\\\)\\\]\\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\\(SX 210.13-02\\\(a\\\)\\\(4\\\)\\\(iii\\\)\\\(B\\\)\\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: <a href=\\\)\\]\\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \\(SX 210.13-02\\(a\\)\\(4\\)\\(i\\)\\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: <a href=\\)\]\(http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: <a href=\)](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: <a href=)

standards Codification -Section S99 -Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7))-Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R7.htm IDEBA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD (\$) as in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Cash flows used in operating activities: \$ 76,971 \$ (9,906) \$ 8,433 \$ (86,348) Adjustments to reconcile net income (loss) to net cash used in operating activities: \$ \$ \$ \$ Gain on lease termination \$ (10) \$ Amortization of operating lease asset \$ 271 \$ Accretion on investment discounts \$ (1,916) \$ (579) Stock-based compensation 1,783 1,734 6,540 4,835 Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds (96,439) (443) (51,829) 55,738 Changes in operating assets and liabilities: \$ \$ \$ \$ Prepaid expenses and other assets \$ 1,685 \$ (356) Accounts payable, accrued expenses and other liabilities \$ 8,791 \$ (3,609) Operating lease liabilities \$ (249) \$ (267) Net cash used in operating activities \$ (28,284) \$ (30,396) Cash flows from investing activities: \$ \$ \$ \$ Purchase of available-for-sale short-term investments \$ (83,350) \$ (60,363) Proceeds from maturities of available-for-sale short-term investments \$ 60,418 \$ 5,000 Net cash used in investing activities \$ (22,932) \$ (55,363) Cash flows from financing activities: \$ \$ \$ \$ Proceeds from issuances of common stock and pre-funded warrants, net \$ 53,355 \$ 33,017 Net cash provided by financing activities \$ 53,355 \$ 33,017 Net change in cash and cash equivalents \$ 2,139 \$ (52,742) Cash and cash equivalents at beginning of period \$ 4,612 \$ 56,409 Cash and cash equivalents at end of period \$ 6,751 \$ 3,667 6,751 3,667 Noncash activities: \$ \$ \$ \$ Common stock exchanged for X and X1 non-voting convertible preferred stock \$ 1 \$ Unrealized gain on available-for-sale securities \$ 102 \$ Increase in operating lease asset and liability due to new lease \$ 377 \$ Settlement of warrant liability into common stock due to exercise \$ 420 \$ X - DefinitionAccounts payable, accrued expenses and other liabilities. + ReferencesNo definition available. + Details Name: eldn AccountsPayableAccruedExpensesAndOtherLiabilities Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAccretion on Investment Discounts + ReferencesNo definition available. + Details Name: eldn AccretionOnInvestmentDiscounts Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmortization of operating lease asset. + ReferencesNo definition available. + Details Name: eldn AmortizationOfOperatingLeaseAsset Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionChange in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. + ReferencesNo definition available. + Details Name: eldn ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCommon stock exchanged for X and X1 non-voting convertible preferred stock + ReferencesNo definition available. + Details Name: eldn CommonStockExchangedForXAndX1NonVotingConvertiblePreferredStock Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in operating lease asset and liability due to new lease. + ReferencesNo definition available. + Details Name: eldn IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNoncash activities. + ReferencesNo definition available. + Details Name: eldn NoncashActivitiesAbstract Namespace Prefix: eldn_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionProceeds from issuance of common stock and pre-funded warrants net. + ReferencesNo definition available. + Details Name: eldn ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsNet Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSettlement of warrant liability into common stock due to exercise. + ReferencesNo definition available. + Details Name: eldn SettlementOfWarrantLiabilityIntoCommonStockDueToExercise Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionUnrealized gain on available-for-sale securities. + ReferencesNo definition available. + Details Name: eldn UnrealizedGainOnAvailableForSaleSecurities Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap GainLossOnTerminationOfLease Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/20

Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 15 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Á Á Á Á Á Á Net Income (Loss) \$ 76,971 \$ (44,907) \$ (23,631) \$ (9,906) \$ (65,760) \$ (10,772) \$ 8,433 \$ (86,438) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(v)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 9 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Á Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmndtFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmndtFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph 4 + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 17 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Á Description of Business Note 1. Description of BusinessEledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its immunology expertise in targeting the CD40 Ligand (á€œCD40Lá€) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (á€œALSá€). The Companyá€™s lead compound in development is tegoprobart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms á€œEledon,á€ á€œceour,á€ á€œceus,á€ á€œceus,á€ á€œceus,á€ or the á€œCompanyá€ refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis. On September 14, 2020, Eledon acquired Anelixis Therapeutics, Inc. (á€œAnelixisá€), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.Restatement of Previously Issued Financial StatementsDuring the preparation of the Companyá€™s Condensed Consolidated Financial Statements for the fiscal quarter ended June 30, 2024, the Company determined that the Common Warrants and the Subsequent Closing Warrants (each as defined in Note 8) do not meet the conditions to be classified as equity instruments under ASC 815-40, á€œDerivatives and Hedging á€ Contracts in Entityá€™s Own Equity,á€ (á€œASC 815-40á€) and must instead be recorded as liabilities on the Companyá€™s consolidated balance sheet at their fair value and remeasured at fair value for each subsequent reporting period. As a result, the Company determined that a correction was necessary with respect to the Companyá€™s reporting and recording of the fair value of the Common Warrants and the Subsequent Closing Warrants. Certain prior period financial statements and financial information are presented herein as restated. See Note 12 for further

information. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - Definition The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1:

[illegible]

cess terminated earlier by either party. Legal Matters The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company's results of operations, financial condition or cash flows. Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company's exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations. No amounts associated with such indemnifications have been recorded to date. Contingencies From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not aware of any contingent liabilities requiring accrual at September 30, 2024. X - References No definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition The entire disclosure for commitments and contingencies. + References Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContentReference> 2:

us-gaap_ DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] A Stock-Based Compensation Note 9. Stock-based Compensation The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term. For stock options granted to the Company's board of directors (the Board), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination. The expected dividend assumption was based on the Company's history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation. Restricted Stock Units (RSUs) are measured and recognized based on the quoted market price of our common stock on the date of grant. On July 10, 2024, the Company held its Annual Meeting of Stockholders (the Annual Meeting). At the Annual Meeting, the Company's stockholders approved an amendment to the Company's 2020 Long Term Incentive Plan (the 2020 Plan). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company's common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional 3,500,000 shares so that the new aggregate share limit under the 2020 Plan is 17,960,000 shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 28, 2034. On May 1, 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements, totaling 7,381,857 stock options, with 1,476,372 of the granted stock options subject to the Company's customary time-based vesting schedule. The remaining 5,905,485 stock options granted are subject to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the Second and Third Closings of the 2023 Private Placement as specified in the 2023 Securities Purchase Agreement. In December 2023, the Company amended the performance-based vesting requirements with its named executive officers and other employees that upon the Second Closing and Third Closing, a full or prorated amount of each closing installment shall vest based on the percentage of funding received relative to the total funding opportunity represented by the investors' Second Closing and Third Closing subscription amounts. On June 13, 2024, the performance-based vesting requirement based on the milestones applicable to the Second Closing were satisfied, and 1,980,952 stock options were issued. The 2014 Plan was closed to new grants following the initial approval of the 2020 Plan, and therefore, there were no shares reserved for issuance under the 2014 Plan as of September 30, 2024. The number of shares reserved for issuance under the 2020 Plan and ESPP was 6,388,742 and 24,077 shares, respectively, as of September 30, 2024. Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
General and administrative	\$ 1,395	\$ 4,143
Research and development	\$ 4,988	\$ 14,362
Total stock-based compensation	\$ 6,383	\$ 18,505

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,472,694	40,177,333

For the Three Months Ended September 30, 2024, the Company's net income (loss) was \$ 76,971 (a decrease of \$ 8,433 from \$ 86,438 in the prior period). The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive.

	For the Three Months Ended September 30, 2024	For the Nine Months Ended September 30, 2024
Preferred Stock	6,361,567	6,361,567
Stock options outstanding and other equity awards	16,543,376	15,238,434
Common and preferred warrants outstanding	18,567,751	18,577,332
Total	41,	

regulation S-X requirements as set forth by the Securities and Exchange Commission (“SEC”) for interitem financial information and reflect all adjustments and disclosures, which are, in the opinion of management, of a normal and recurring nature, and considered necessary for a fair presentation of the financial information contained herein. Pursuant to these rules and regulations, the unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of results of operations and comprehensive loss, financial position, and cash flows in conformity with GAAP. The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and accompanying notes of Eledon for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed by the Company with the SEC on March 28, 2024, as amended on each of April 26, 2024 and August 19, 2024 (together, the “Amended Form 10-K”). The results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024 are not necessarily indicative of results expected for the full fiscal year or any other future period.

Principles of Consolidation Principles of ConsolidationEledon, a Delaware corporation, owns 100% of the issued and outstanding common stock or other ownership interest in Anelix Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel (the “Otic Entities”). Otic owns 100% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc. The functional currency of the Company’s foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company’s foreign subsidiary are not significant to the condensed consolidated financial statements. All significant intercompany accounts and transactions among the entities have been eliminated from the condensed consolidated financial statements. Liquidity and Financial Condition Liquidity and Financial ConditionThe accompanying unaudited condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of the Company’s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. The Company recorded net income of \$77.0 million and \$8.4 million for the three and nine months ended September 30, 2024, respectively. These results include a \$96.4 million gain related to changes in the fair value of warrant liabilities and the fair value of financial instruments issued in excess of proceeds, recorded in the third quarter ended September 30, 2024. Excluding this gain, the Company would have recorded net losses of \$19.5 million and \$43.4 million for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of \$78.2 million, working capital of \$69.0 million and an accumulated deficit of \$311.0 million. On October 29, 2024, the Company entered into an underwriting agreement with Leerink Partners, LLC, as representative of the several underwriters named therein in connection with the underwritten offering, issuance and sale by the Company (the “Offering”) of 18,356,173 shares of the Company’s common stock, par value \$0.001 per share, at an offering price of \$3.65 per share, and pre-funded warrants at a price of \$3.649 per pre-funded warrant, which are exercisable to purchase 4,931,507 shares of the Company’s common stock at an exercise price of \$0.001 per share. The Offering resulted in gross proceeds to the Company of \$85.0 million, or net proceeds of approximately \$79.5 million after deducting underwriting discounts and commissions and offering expenses. See Note 11.

Subsequent Events for additional information. The Company currently plans to use the net proceeds from the Offering to advance our pipeline and for working capital and general corporate purposes.Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. In order to continue these activities, the Company will need to raise additional funds through public or private debt and equity financings or strategic collaboration and licensing arrangements. The Company’s ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company’s common stock, which itself is subject to a number of risks and uncertainties, as well as uncertainty as to whether the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. If the Company issues equity or convertible debt securities to raise additional funding, its existing stockholders may experience dilution, it may incur significant financing costs, and the new equity or convertible debt securities may have rights, preferences and privileges senior to those of its existing stockholders. If the Company issues debt securities to raise additional funding, it would incur additional debt service obligations, it could become subject to additional restrictions limiting its ability to operate its business, and it may be required to further encumber its assets.At the time of issuance of the condensed consolidated financial statements for the three and nine months ended September 30, 2024, the Company’s management performed an analysis and concluded that the Company had sufficient cash resources to meet its anticipated cash needs through at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements. Use of EstimatesUse of EstimatesThe preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to stock-based compensation expense, warrant liabilities, the fair value of right-of-use assets and liabilities, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements. Concentration of Credit RiskConcentration of Credit RiskFinancial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk. Cash and Cash EquivalentsCash and Cash EquivalentsThe Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments. Risks and UncertaintiesRisks and UncertaintiesAs of September 30, 2024 and December 31, 2023, all of the Company’s long-lived assets were located in the United States.The Company’s products will require approval from the U.S. Food and Drug Administration (the “FDA”) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company’s business in the future. In addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.The Company’s facilities and equipment, including those of the Company’s suppliers and vendors, may be affected by natural or man-made disasters. The Company’s administrative office is based in Irvine, California and the Company manages all its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company’s facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.

In-Process Research and DevelopmentIn-Process Research and DevelopmentThe fair values of in-process research and development (the “IPRD”) projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development (the “R&D”) efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors’ products could result in partial or full impairment of the related intangible assets. Research and Development ExpensesResearch and DevelopmentExpensesResearch and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company’s accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company’s prior period accrued estimates for clinical trial activities during the three and nine months ended September 30, 2024. Recently Adopted Accounting PronouncementsRecently Adopted Accounting PronouncementsIn December 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (the “ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements. Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company’s present or future financial position, results of operations or cash flows. Warrant LiabilitiesWarrant LiabilitiesThe Company accounts for issued warrants either as a liability or equity in accordance with ASC 815-40, Derivatives and Hedging. Contracts in Entity’s Own Equity (ASC 815-40). Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the condensed consolidated statements of operations and comprehensive loss as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date. X - DefinitionLiquidity and financial condition. + ReferencesNo definition available. + Details Name: eldn_LiquidityAndFinancialConditionPolicyTextBlock Namespace Prefix: eldn_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionRisks and uncertainties. + ReferencesNo definition available. + Details Name: eldn_RisksAndUncertaintiesPolicyTextBlock Namespace Prefix: eldn_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity’s use of its cash and cash equivalents, (2) whether the entity’s cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147

of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets. + ReferencesNo definition available. + Details Name: us-gaap InProcessResearchAndDevelopmentPolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1) + Details Name: us-gaap ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1) + Details Name: us-gaap StockholdersEquityPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8) + Details Name: us-gaap UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Short-Term Investments (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] A Summary of Short-term Investments Classified as Available-for-sale Securities The following is a summary of short-term investments, which were classified as available-for-sale securities as of September 30, 2024 and December 31, 2023 (in thousands): A A September 30, 2024 A A December 31, 2023 A A Amortized Cost A A Unrealized Gains A A Unrealized Losses A A Fair Value A A Amortized Cost A A Fair Value A U.S. government securities A \$ 67,745 A A \$ 105 A A (3) A A \$ 67,847 A A \$ 33,213 A A \$ 33,213 A U.S. government agency securities A A 3,593 A A A A A A A A 3,593 A A A A 13,277 A A A 13,277 A Total short-term investments A \$ 71,338 A A \$ 105 A A (3) A A \$ 71,440 A A \$ 46,490 A A \$ 46,490 X - DefinitionTabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for-sale). + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)

Interest expense for finance lease, amortization right-of-use asset for finance lease, operating lease cost, short-term lease cost and sublease income. +

ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 4-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6> + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 35 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity (Tables) 9 Months Ended Sep. 30, 2024 Class Of Stock [Line Items] A Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted The following table presents the assumptions used in the Black-Scholes option pricing model to determine the fair value of warrants as of September 30, 2024 as follows: A A September 30, 2024 A A December 31, 2023 A Risk-free interest rate A 3.58% A A 3.84% - 3.88% A Expected volatility A 93.46% - 98.39% A A 89.08% - 94.28% A Expected term (in years) A 3.75A - 5.25 A A 4.5A - 6.0 A Share price A \$ 2.49 A A \$ 1.80 A Common Stock Warrants [Member] A Class Of Stock [Line Items] A Schedule of Warrant Activity The following table shows the warrants to purchase common stock activity:A A Roll-Forward of Warrant Activity A A Common Stock Warrants A A Pre-funded Warrants A A All Other Warrants A A Total A Balance as of December 31, 2023 A A 15,151,518 A A 15,151,518 A A 5,776,270 A A 6,366,514 A A 21,564,302 A Issued A A A A A 7,989,516 A A A A A 7,989,516 A Exercised A A A A A (1,423,000) A A A A A (1,423,000) Cancelled/Expired A A A A A A A A A A A (9,581) A A A A A (9,581) Balance as of September 30, 2024 A A 15,151,518 A A 12,342,786 A A 6,266,933 A A 28,121,237 A Preferred Stock Warrants [Member] A Class Of Stock [Line Items] A Schedule of Warrant Activity As of September 30, 2024, there were 50,207,419 warrants exercisable into Series X1 Non-Voting Convertible Preferred Stock, which are convertible into 2,789,301 shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion limitations). A A A Roll-Forward of Series X1 Non-Voting Convertible Preferred Warrant Activity A A Total A Balance as of December 31, 2023 A A 50,207,419 A Issued A A A A A Exercised A A A A A A Balance as of September 30, 2024 A A 50,207,419 A X - DefinitionSchedule of warrant activity. + ReferencesNo definition available. + Details Name: eldn ScheduleOfWarrantActivityTableTextBlock Namespace Prefix: eldn Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(d\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 3-Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1-Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(d\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.4-08(d))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(e\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (e)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(f\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (f)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(27\)\(b\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27)(b))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 2-Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 14:

The acquire, in YYYY-MM-DD format. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-7>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-25-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479328/805-10-25-2)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 25 -Paragraph 6 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-6> + Details Name: us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_BusinessAcquisitionAxis=eldn AnelixisTherapeuticsIncorporationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML d4 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Going Concern and Management's Plans - Additional Information (Detail) - USD (\$) \$ / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Oct. 01, 2024 Sep. 30, 2024 Jul. 08, 2024 May 06, 2024 May 05, 2023 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Apr. 28, 2023 Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Net income (loss) A A A A A \$ 76,971 \$ (44,907) \$ (23,631) \$ (9,906) \$ (65,760) \$ (10,772) \$ 8,433 \$ (86,438) A Net cash used in Operating Activities A A A A A A A A A A 28,284 30,396 A Accumulated deficit A A A A A \$ (310,969) A A (310,969) A A (289,303) A (310,969) \$ (289,303) \$ (319,402) A Cash and cash equivalents and short-term investments A \$ 78,200 A A A \$ 78,200 A A A A A Common stock, shares issued A 41,183,102 A A 41,183,102 A A A A 41,183,102 A 24,213,130 A Common stock, par value A \$ 0.001 A A A A \$ 0.001 A A A A \$ 0.001 A A A Accredited Investor [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Warrant exercise price A A A A A A A A A A A \$ 3 Accredited Investor [Member] | Private Placement [Member] | Pre-funded Warrants [Member] A A A A A A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Warrant exercise price A A A A A A A A A A A \$ 0.001 Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common warrants issued A A A A A \$ 35,000 A A A A A A A A A A A Securities Purchase Agreement Initial Closing [Member] | Private Placement [Member] | Pre-funded Warrants [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A A A 6,421,350 A A A A A A A A A A A Securities Purchase Agreement Initial Closing [Member] | Accredited Investor [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A A A A A A A A A A A 15,151,518 Common stock, par value A A A A A A A A A A A \$ 0.001 Common stock warrants to purchase common stock shares A A A A A A A A A A A 15,151,518 Securities Purchase Agreement Second Closing [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A 909,088 A A A A A A A A A A A Proceeds from Issuance of Common Stock A \$ 2,100 A A A A A A A A A A A Net proceeds after deducting offering costs A \$ 2,000 A A A A A A A A A A A Securities Purchase Agreement Second Closing [Member] | Accredited Investor [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A A A A A A A A A A A 20,202,024 Securities Purchase Agreement Third Closing [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A 1,727,400 A A A 1,727,400 A A A A 1,727,400 A A A Proceeds from Issuance of Common Stock A \$ 4,000 A A A A A A A A A A A Net proceeds after deducting offering costs A \$ 3,800 A A A A A A A A A A A Securities Purchase Agreement Third Closing [Member] | Private Placement [Member] | Subsequent Event [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued 1,727,400 A A A A A A A A A A A Proceeds from Issuance of Common Stock \$ 4,000 A A A A A A A A A A A Net proceeds after deducting offering costs A \$ 3,800 A A A A A A A A A A A Securities Purchase Agreement Third Closing [Member] | Accredited Investor [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A A A A A A A A A A A 25,252,530 Securities Purchase Agreement [Member] | Accredited Investor [Member] | Private Placement [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock, shares issued A A 13,110,484 A A A A A A A A A A A Common stock, par value A \$ 0.001 A A A A A A A A A A A Stock price per share A A \$ 2.37 A A A A A A A A A Gross proceeds A A \$ 50,000 A A A A A A A A A A A Net proceeds after deducting offering costs A A \$ 48,100 A A A A A A A A A A A Securities Purchase Agreement [Member] | Accredited Investor [Member] | Private Placement [Member] | Pre-funded Warrants [Member] A A A A A A A A A A A Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] A A A A A A A A A A A Common stock warrants to purchase common stock shares A A 7,989,516 A A A A A A A A A A A Stock price per share A A \$ 2.369 A A A A A A A A A A A Warrant exercise price A A \$ 0.001 A A A A A A A A A A X - DefinitionProceeds from issuance of private placement, net of offering costs. + ReferencesNo definition available. + Details Name: eldn_ProceedsFromIssuanceOfPrivatePlacementNetOfOfferingCosts Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) + Details Name: us-gaap_CashCashEquivalentsAndShortTermInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dt-type:perShareItemBalance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3> + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1) + Details Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1:

[Sub-Topic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 7 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483499/205-20-50-Reference 34:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 230 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 28 - Publisher FASB - URI](#)

[https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1A - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef - Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section 45 - Paragraph 1B - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:](#)

[http://fasb.org/us-gaap/role/ref/legacyRef - Topic 942 - SubTopic 220 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.9-04\(22\)\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 14 - Subparagraph \(a\) - SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 14 - Subparagraph \(a\) - SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price \(usually issued together with corporate debt\). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Name Accounting Standards Codification -Section 45 -Paragraph 14 - Subparagraph \(a\) - SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of accumulated undistributed earnings \(deficit\). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 210 - SubTopic 10 - Name Accounting Standards Codification -Section S99 - Paragraph 1 - Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef - Topic 852 - SubTopic 10 - Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 40 - Name Accounting Standards Codification -Section 65 -Paragraph 2 - Subparagraph \(g\)\(2\)\(i\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 40 - Name Accounting Standards Codification -Section 65 -Paragraph 2 - Subparagraph \(h\)\(2\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 20 - Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef - Topic 944 - SubTopic 210 - Name Accounting Standards Codification -Section S99 - Paragraph 1 - Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef - Topic 946 - SubTopic 210 - Name Accounting Standards Codification -Section S99 - Paragraph 1 - Subparagraph \(SX 210.6-04\(17\)\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef - Topic 505 - SubTopic 10 - Name Accounting Standards Codification -Section S99 - Paragraph 1 - Subparagraph \(SX 210.3-04\) - Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Balance Type: na Period Type: instant X - Details Name: srt>TitleOfIndividualAxis=eldn_AccreditedInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=eldn_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementThirdClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Additional Information \(Detail\) - USD \(\\$ \\$ \) / shares in Units, \\$ in Thousands 3 Months Ended 9 Months Ended Oct. 29, 2024 Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Á Á Cash, cash equivalents and restricted cash, maturity period Á Á Á Á Á three months or less Á Á Net income \(loss\) Á \\$ 76,971 \\$ \(44,907\) \\$ \(23,631\) \\$ \(9,906\) \\$ \(65,760\) \\$ \(10,772\) \\$ 8,433 \\$ \(86,438\) Á Net income \(losses\) excluding gain of change in fair value of warrant Á \(19,500\) Á Á Á \(43,400\) Á Á Cash and cash equivalents and short-term investments Á 78,200 Á Á Á 78,200 Á Á Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds Á 96,439 Á Á 443 Á Á 51,829 \(55,738\) Á Working capital Á 69,000 Á Á Á 69,000 Á Á Accumulated deficit Á \\$ \(310,969\) Á Á \\$ \(289,303\) Á Á \\$ \(310,969\) \\$ \(289,303\) \\$ \(319,402\) Common stock, shares issued Á 41,183,102 Á Á Á 41,183,102 Á Á 24,213,130 Common stock, par value Á \\$ 0.001 Á Á Á \\$ 0.001 Á Á \\$ 0.001 Accounting Standards Update 2023-09 \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Change in accounting principle, accounting standards update, adopted Á true Á Á Á Á true Á Á Accounting Standards Update 2023-07 \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Change in accounting principle, accounting standards update, adopted Á true Á Á Á Á true Á Á Anelixis Therapeutics, LLC and Otic Pharma, Ltd. Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Ownership interest percentage Á Á Á Á Á 100.00% Á Á Leerink Partners LLC \[Member\] | Subsequent event | Underwriting agreement \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Proceeds From Issuance Offering \\$ 85,000 Á Á Á Á Á Á Á Á Net proceeds after deducting offering costs \\$ 79,500 Á Á Á Á Á Warrants \[Member\] | Leerink Partners LLC \[Member\] | Subsequent event | Underwriting agreement \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Warrant exercise price \\$ 3.649 Á Á Á Á Á Á Á Á Common Stock \[Member\] | Leerink Partners LLC \[Member\] | Subsequent event | Underwriting agreement \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Common stock, shares issued 18,356,173 Á Á Á Á Á Á Á Á Common stock, par value \\$ 0.001 Á Á Á Á Á Á Á Á Offering price common stock 3.65 Á Á Á Á Á Á Á Á Warrant exercise price \\$ 0.001 Á Á Á Á Á Á Á Á Common stock warrants exercisable 4,931,507 Á Á Á Á Á Á Á Á Otic Pharma, Inc. \[Member\] Á Á Á Á Á Á Á Á Summary Of Significant Accounting Policies \[Line Items\] Á Á Á Á Á Á Á Á Ownership interest percentage Á Á Á Á Á 100.00% Á Á X - DefinitionCash cash equivalents and restricted cash maturity period. + ReferencesNo definition available. + Details Name: eldn_CashCashEquivalentsAndRestrictedCashMaturityPeriod Namespace Prefix: eldn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionChange in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. + ReferencesNo definition available. + Details Name: eldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet income \(losses\) excluding gain of change in fair value of warrant. + ReferencesNo definition available. + Details Name: eldn_NetIncomeLossesExcludingGainOfChangeInFairValueOfWarrant Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from issuance of net of offering costs. + ReferencesNo definition available. + Details Name: eldn_ProceedsFromIssuanceOfNetOfOfferingCosts Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance offering + ReferencesNo definition available. + Details Name: eldn_ProceedsFromIssuanceOffering Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSummary of significant accounting policies. + ReferencesNo definition available. + Details Name: eldn_SummaryOfSignificantAccountingPoliciesLineItems Namespace Prefix: eldn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWorking capital. + ReferencesNo definition available. + Details Name: eldn_WorkingCapital Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year \(or the normal operating cycle if longer\) and may include trading securities, available-for-sale securities, or held-to-maturity securities \(if maturing within one year\), as applicable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef - Topic](#)

https://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 231 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/231-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -

<http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1> + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNamespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(aaa\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3) + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 43 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

	À Total cash equivalents \$ 5,741	À 2,426 Total short-term investments 71,440	À 46,490 Total financial assets 77,181	À 50,736 Money Market Funds [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total cash equivalents 5,741	À 4,246 U.S. Government Securities [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total short-term investments 67,847	À 33,213 U.S. Government Agency Securities [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total short-term investments 3,593	À 13,277 Fair Value, Inputs, Level 1 [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total cash equivalents 5,741	À 4,246 Total financial assets 5,741	À 4,246 Fair Value, Inputs, Level 1 [Member] Money Market Funds [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total cash equivalents 5,741	À 4,246 Fair Value, Inputs, Level 2 [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total short-term investments 71,440	À 46,490 Total financial assets 71,440	À 46,490 Fair Value, Inputs, Level 2 [Member] U.S. Government Securities [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total short-term investments 67,847	À 33,213 Fair Value, Inputs, Level 2 [Member] U.S. Government Agency Securities [Member] À Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] À Total short-term investments 3,593	À 13,277 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/

Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_ClassOfStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Prepaid Expense and Other Assets, Current [Abstract] Á Á Prepaid clinical \$ 2,526 \$ 4,128 Prepaid insurance 87 624 Prepaid other 263 185 Other current assets 442 90 Total prepaid expenses and other current assets \$ 3,318 \$ 5,027 X - DefinitionPrepaid clinical expense. + ReferencesNo definition available. + Details Name: eldn_PrepaidClinicalExpense Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1 + Details Name: us-gaap_OtherPrepaidExpenseCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidInsurance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 48 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) - USD (\$) in Thousands Sep. 30, 2024 Dec. 31, 2023 Accrued Liabilities and Other Liabilities [Abstract] Á Á Accrued compensation and related expenses \$ 2,062 \$ 2,003 Accrued clinical 3,798 451 Accrued professional services 475 47 Accrued other 108 44 Total accrued expenses and other liabilities \$ 6,443 \$ 2,545 X - DefinitionAccrued clinical current. + ReferencesNo definition available. + Details Name: eldn_AccruedClinicalCurrent Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_WorkersCompensationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 49 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 40, 2024 ft² Apr. 19, 2024 USD (\$) ft² Aug. 12, 2022 Sep. 30, 2024 USD (\$) Sep. 30, 2023 USD (\$) Sep. 30, 2024 USD (\$) Milestone Sep. 30, 2023 USD (\$) Milestone Dec. 31, 2023 USD (\$) Dec. 31, 2022 USD (\$) ft² Dec. 31, 2021 USD (\$) Dec. 31, 2020 USD (\$) Dec. 31, 2018 USD (\$) Dec. 31, 2017 USD (\$) Other Commitments [Line Items] Á Á Á Á Á Á Á Á Rental expense Á Á Á \$ 100,000 \$ 100,000 \$ 300,000 \$ 300,000 Á Á Á Á Á Á Á Á ROU assets and lease liabilities Á Á Á 471,000 Á \$ 471,000 Á \$ 365,000 Á Á Á Á Remaining term of office lease Á Á Á Á 3 years Á Á Á Á Debt outstanding Á Á Á 0 Á \$ 0 Á Á Á Á Indemnification obligations amount Á Á Á 0 Á \$ 0 Á Á Á Á ALS Therapy Development Foundation, Inc. License Agreement [Member] Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Fee due for milestones achieved Á Á Á Á Á Á Á Á \$ 1,000,000.0 \$ 1,000,000.0 Common stock issued in lieu of making a cash payment Á Á Á Á Á Á Á Á \$ 1,000,000.0 \$ 1,000,000.0 Number of Milestones Achieved | Milestone Á Á Á Á 0 Á Á Á Á Remaining milestone payments for first licensed product Á Á Á 6,000,000.0 Á \$ 6,000,000.0 Á Á Á Á Annual License Maintenance Fee Á Á Á Á \$ 100,000 \$ 100,000 \$ 100,000 Á Á Á ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 500 Million Aggregate Sales [Member] Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Reaching of aggregate net sales Á Á Á Á 500,000,000.0 Á Á Á Á Amount of one-time milestone payment Á Á Á 15,000,000.0 Á 15,000,000.0 Á Á Á Á Á Á Á Á ALS Therapy Development Foundation, Inc. License Agreement [Member] | Achievement of 1 Billion Aggregate Sales [Member] Á Á Á Á Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Reaching of aggregate net sales Á Á Á Á 1,000,000,000.0 Á Á Á Á Amount of one-time milestone payment Á Á Á 30,000,000.0 Á \$ 30,000,000.0 Á Á Á Á Á Á Á Á Maximum [Member] Á Á Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Remaining term of office lease Á Á Á Á 1 year Á Á Á Á Á Á Á Á Maximum [Member] | ALS Therapy Development Foundation, Inc. License Agreement [Member] Á Á Á Á Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Development and regulatory milestone payments Á Á Á 2,500,000 Á \$ 2,500,000 Á Á Á Á Irvine, California [Member] Á Á Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Area of office space | ft² Á 5,817 Á Á Á Á 5,197 Á Á Á Á Operating lease, term of contract Á 38 months Á Á Á Á Á Á Á Á Lease expiration date Á Jun. 30, 2027 Dec. 31, 2024 Á Á Á Á Á Á Á Á ROU assets and lease liabilities Á \$ 500,000 Á Á Á Á Á Á Á Á Burlington, Massachusetts [Member] Á Á Á Á Á Á Á Á Á Á Other Commitments [Line Items] Á Á Á Á Á Á Á Á Á Á Area of office space | ft² Á 6,138 Á Á Á Á Á Á Á Á Á Á Operating lease, term of contract 36 months Á Á Á Á Á Á Á Á Lease expiration date Nov. 21, 2027 Á Á Á Á Á Á Á Á Á Á Á Á X - DefinitionAggregate net sales achievement. + ReferencesNo definition available. + Details Name: eldn_AggregateNetSalesAchievement Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAnnual license maintenance fee. + ReferencesNo definition available. + Details Name: eldn_AnnualLicenseMaintenanceFee Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionArea of office space. + ReferencesNo definition available. + Details Name: eldn_AreaOfOfficeSpace Namespace Prefix: eldn_ Data Type: dtr-types:arealtemType Balance Type: na Period Type: duration X - DefinitionFee due for milestones achieved. + ReferencesNo definition available. + Details Name: eldn_FeeDueForMilestonesAchieved Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLessee operating lease remaining term of contract. + ReferencesNo definition available. + Details Name: eldn_LesseeOperatingLeaseRemainingTermOfContract Namespace Prefix: eldn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of milestones achieved. + ReferencesNo definition available. + Details Name: eldn_NumberOfMilestonesAchieved Namespace Prefix: eldn_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionRegulatory milestone payments obligation. + ReferencesNo definition available. + Details Name: eldn_RegulatoryMilestonePaymentsObligation Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRemaining milestone payments for first licensed product. + ReferencesNo definition available. + Details Name: eldn_RemainingMilestonePaymentsForFirstLicensedProduct Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRepresents the aggregate of total long-term debt, including current maturities and short-term debt. + ReferencesNo definition available. + Details Name: us-gaap_DebtLongtermAndShorttermCombinedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4 + Details Name: us-gaap_GuaranteeObligationsCurrentCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYmNdThHmMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount the entity has committed to make for future royalty guarantees. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1 + Details Name: us-gaap_RoyaltyGuaranteesCommitmentsAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_ALSTherapyDevelopmentFoundationIncLicenseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_FiveHundredMillionAggregateNetSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=eldn_OneBillionAggregateNetSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name:

srt StatementGeographicalAxis=stpr_CA NameSpace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt StatementGeographicalAxis=stpr_MA NameSpace Prefix: Data Type: na Balance Type: Period Type: XML S0 R43.htm IDEA: XBRL DOCUMENT V3.24.3 Commitments and Contingencies - Components of Lease Expense (Detail) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Commitments and Contingencies Disclosure [Abstract] A A Operating lease cost \$ 306 \$ 300 X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:numericalItemType Balance Type: debit Period Type: duration XML 51 R44.htm IDEA: XBRL DOCUMENT V3.24.3 Commitments and Contingencies - Schedule of Other Information Related to Leases (Detail) - USD (\$) \$ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash paid for amounts included in the measurement of lease liabilities: A A Operating cash flows from operating leases \$ 272 \$ 279 Weighted-average remaining lease term A A Operating leases 2 years 6 months 21 days 1 year 2 months 12 days Discount rate A A Operating leases 9.60% 2.48% X - DefinitionCash paid for amounts included in measurement of lease liabilities. + ReferencesNo definition available. + Details Name: eldn CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract Namespace Prefix: eldn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDiscount rate. + ReferencesNo definition available. + Details Name: eldn DiscountRateAbstract Namespace Prefix: eldn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average remaining lease term. + ReferencesNo definition available. + Details Name: eldn WeightedAverageRemainingLeaseTermAbstract Namespace Prefix: eldn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 5-Subparagraph (c)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:numericalItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(4)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in "PnYmNdThHnMnS" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55-Paragraph 53-Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 4-Subparagraph (g)(3)-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageRemainingLeaseTermI Namespace Prefix: us-gaap_ Data Type: xbrli:durationalItemType Balance Type: na Period Type: instant XML 52 R45.htm IDEA: XBRL DOCUMENT V3.24.3 Commitments and Contingencies - Schedule of Future Payments Under Noncancelable Operating Leases (Detail) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Commitments and Contingencies Disclosure [Abstract] A A 2024 (remainder of) \$ 83 A 2025 191 A 2026 197 A 2027 100 A Total minimum lease payments 571 A Less imputed interest (70) A Present value of lease liabilities 501 A Less current portion of operating lease liabilities (186) \$ (383) Non-current operating lease liabilities \$ 315 A X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50-Paragraph 6-Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R46.htm IDEA: XBRL DOCUMENT V3.24.3 Stockholders' Equity - Additional Information (Detail) - USD (\$) 9 Months Ended Oct. 01, 2024 Sep. 30, 2024 Sep. 20, 2024 Jul. 08, 2024 May 06, 2024 May 16, 2023 May 05, 2023 Apr. 28, 2023 Apr. 28, 2023 Jul. 11, 2024 May 09, 2024 May 07, 2024 Jan. 30, 2024 Dec. 31, 2023 Nov. 06, 2023 Nov. 02, 2023 Jul. 14, 2023 Jul. 10, 2023 Class Of Stock [Line Items] A A A A A A A A A A A A A A A A Debt outstanding \$ 0 A A A A A A A A A A A A Common stock, shares issued A 41,183,102 A A A A A A A A A A A A A A A A 24,213,130 A A A A A A A A A A A A Common stock par value \$ 0.001 A A A A A A A A A A A A \$ 0.001 A A A A A A A A A A Net proceeds after deducting offering costs A A A A A A A A A A A A A A A A Preferred stock, shares authorized A 5,000,000 A A A A A A A A A A A A A A A A A 5,000,000 A A A A A A A A A A Preferred stock, par value \$ 0.001 A A A A A A A A A A A A A A A A Armistice Capital Master Fund Ltd [Member] | Securities Purchase Agreement [Member] A A A A A A A A A A A A A A A A Class Of Stock [Line Items] A A A A A A A A A A A A A A A A Number of pre-funded warrants exercised for common stock A A A A A A A A A A A A A A A A 240,000 A 583,000 600,000 A 653,000 A 501,197 Common stock, shares issued A A A A A A A A A A A A A A A A A 240,000 583,000 A 600,000 A 653,000 A 501,197 Warrant exercise price

[illegible]

SubTopic 10 - Topic 230 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Name Accounting Standards Codification - Section 45 - Paragraph 14 - Subparagraph (a) - SubTopic 10 - Topic 230 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> - Name Accounting Standards Codification - Section 45 - Paragraph 14 - Subparagraph (a) - SubTopic 10 - Topic 230 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap_ShareOfStockPricePerShare Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eldn_ArmisticeCapitalMasterFundLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=eldn_SeriesXOnePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=eldn_SeriesXNonVotingConvertiblePreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=eldn_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=eldn_PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=eldn_AccreditedInvestorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=eldn_CommonStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidarySaleOfStockAxis=eldn_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementInitialClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementSecondClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_SecuritiesPurchaseAgreementThirdClosingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypesAxis=eldn_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=eldn_GuggenheimSecuritiesLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_EquityDistributionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=eldn_CormorantGlobalHealthcareMasterFundLpMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=eldn_ConversionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: XML 54 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Equity - Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted (Details) - \$ / shares 9 Months Ended 12 Months Ended Sep. 30, 2024 Dec. 31, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A Risk-free interest rate 3.58% A Risk-free interest rate, Minimum A 3.84% Risk-free interest rate, Maximum A 3.88% Expected volatility, Minimum 93.46% 89.08% Expected volatility, Maximum 98.39% 94.28% Share Price \$ 2.49 \$ 1.8 Maximum [Member] A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A Expected term (in years) 5 years 3 months 6 years Minimum [Member] A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A Expected term (in years) 3 years 9 months 4 years 6 months X - Definition The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (f)(2)(iv) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The maximum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition The minimum risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 35 - Paragraph 1D - Publisher FASB - URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 35 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(1) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(2) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (a)(3) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(ii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(iv) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(v) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(vi) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(vii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(1)(viii) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> - Topic 718 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Subparagraph (c)(2)(i) - Publisher FASB - URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -

ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of warrants or rights outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=eldn PreferredStockWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Additional Information (Detail) - shares 9 Months Ended Jul. 10, 2024 Jun. 13, 2024 May 01, 2023 Sep. 30, 2024 Time-based and Performance-based Vesting Requirements [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Stock options granted A A 7,381,857 A Stock options issued A A 5,905,485 A Time-based Vesting Requirements [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Stock options issued A A 1,980,952 A 2014 Stock Incentive Plan [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Common stock, number of shares reserved for issuance A A 0 2020 Long Term Incentive Plan [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Common stock, number of shares reserved for issuance A A 6,388,742 Increased number of shares 3,500,000 A A New aggregate share limit 17,960,000 A A 2014 Employee Stock Purchase Plan [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Common stock, number of shares reserved for issuance A A 24,077 Employee Stock Option [Member] | Board of Directors [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Expected life assumption using simplified method, description A A For stock options granted to the Companyâ€™s board of directors (the â€œBoardâ€), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination. Employee Stock Option [Member] | Board of Directors [Member] | Minimum [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Vesting period of stock options granted A A 12 months Employee Stock Option [Member] | Board of Directors [Member] | Maximum [Member] A A A Share-based Compensation Arrangement by Share-based Payment Award [Line Items] A A A Vesting period of stock options granted A A 18 months X - DefinitionShare based compensation arrangement by share based payment award total number of shares authorized. + ReferencesNo definition available. + Details Name: eldn_ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized Namespace Prefix: eldn_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAggregate number of common shares reserved for future issuance. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMndTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionDiscloses use of the simplified method to calculate the expected term that stock option awards under the specified plan will exist before being exercised or terminated, the reason and justification for its use, and the periods for which the method was used if it was not used in all periods presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.D.2.Q6) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermSimplifiedMethod Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_VestingAxis=eldn TimeBasedAndPerformanceBasedVestingRequirementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=eldn TwoThousandAndFourteenStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=eldn TwoThousandAndTwentyLongTermIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=eldn TwoThousandAndFourteenEmployeeStockPurchasePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Schedule of Stock-Based Compensation Expense Recognized (Detail) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation \$ 1,783 \$ 1,734 \$ 6,540 \$ 4,835 Research and Development [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation 388 321 1,552 1,173 General and Administrative [Member] A A A Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] A A A Stock-based compensation \$ 1,395 \$ 1,413 \$ 4,988 \$ 3,662 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income/Loss Per Share - Additional Information (Detail) - \$ / shares 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] A A A Weighted-average number of shares outstanding, Basic 51,945,920 29,974,400 41,443,049 22,813,085 Pre-funded Warrants [Member] A A A Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] A A A Weighted-average number of shares outstanding, Basic 12,342,786 6,429,270 12,342,786 6,429,270 Warrant exercise price \$ 0.001 A \$ 0.001 A X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareBasicLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-

gaap_LossOfWarrantOrRightAxis=eldn PreFundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income/Class Per Share - Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) - USD (\$) / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Jun 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2023 Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] A A A A A A A A Net income (loss) \$ 76,971 \$ (44,907) \$ (23,631) \$ (9,906) \$ (65,760) \$ (10,772) \$ 8,433 \$ (86,438) Undistributed earnings allocated to participating securities (22,542) A A A A (2,882) A Net income (loss) attributable to common shares - basic 54,429 A A (9,906) A 5,551 (86,438) Allocated undistributed earnings allocated to participating securities 22,542 A A A A 2,882 A Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax (94,475) A A A A (69,519) A Net income (loss) attributable to common shares - basic \$ (17,504) A A \$ (9,906) A A \$ (61,086) \$ (86,438) Basic weighted-average common shares outstanding 51,945,920 A 29,974,400 A 41,443,049 22,813,085 Potentially dilutive common shares: A A A A A A Potentially dilutive common shares, Common stock warrants \$ 3,532,422 A A A \$ 1,663,697 A Earnings Per Share, Diluted, Convertible Security, Method [Extensible Enumeration] Common Stock Warrants [Member] A A A Common Stock Warrants [Member] A Weighted-average number of common shares outstanding, diluted 55,478,342 A 29,974,400 A 43,106,746 22,813,085 Net loss per share, basic \$ 1.05 A A \$ (0.33) A A \$ 0.13 \$ (3.79) Net loss per share, diluted \$ (0.32) A A \$ (0.33) A A \$ (1.42) \$ (3.79) X - DefinitionChange in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax, + ReferencesNo definition available. + Details Name: eldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsNetOfTax Namespace Prefix: eldn Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DilutiveSecuritiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units. + ReferencesNo definition available. + Details Name: us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147478524/942-220-599-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147478524/942-220-599-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI> [dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income \(loss\) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-7+Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483621/220-10-599-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147478524/942-220-599-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147478524/942-220-599-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147477250/944-220-599-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI> [Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: enum2:enumerationSetItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or more axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-7+Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: duration X - DefinitionIndicates method used to calculate diluted earnings per share (EPS) for dilutive convertible security, excluding methods for convertible preferred stock of employee stock option plan (ESOP) and share-based payment award. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI) [Details Name: us-gaap_EarningsPerShareDilutedLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482689/260-10-45-60B+Details Name: us-gaap_EarningsPerShareDilutedLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI) [https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI](https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 6-Publisher FASB-URI> [https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference](https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI)

Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147467176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 65 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 65 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-65Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 66 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfOutstandingSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 61 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Net Income/Loss Per Share - Summary of Common Share Equivalents were excluded because the Inclusion is Anti-dilutive (Detail) - shares 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Total 41,472,694 40,177,333 Preferred Stock [Member] Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Total 16,543,376 15,238,434 Stock Options Outstanding and Other Equity Awards [Member] Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Total 16,543,376 15,238,434 Common and Preferred Warrants Outstanding [Member] Á Á Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Á Á Total 18,567,751 18,577,332 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementOfEquityComponentsAxis=us-gaap PreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap StockCompensationPlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=eldn CommonAndPreferredWarrantsOutstandingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events - Additional Information (Details) - USD (\$) \$ / shares in Units, \$ in Millions Oct. 29, 2024 Sep. 30, 2024 Dec. 31, 2023 Subsequent Event [Line Items] Á Á Common stock, shares issued Á 41,183,102 24,213,130 Common stock, par value Á 0.001 \$ 0.001 Subsequent event [Leerink Partners LLC [Member] | Underwriting Agreement [Member] Á Á Subsequent Event [Line Items] Á Á Proceeds From Issuance Offering \$ 85.0 Á Á Net proceeds after deducting offering costs \$ 79.5 Á Á Subsequent event [Leerink Partners LLC [Member] | Underwriting Agreement [Member] | Common Stock [Member] Á Á Subsequent Event [Line Items] Á Á Common stock, shares issued 18,356,173 Á Á Common stock, par value \$ 0.001 Á Á Offering price common stock 3.65 Á Á Warrant exercise price \$ 0.001 Á Á Common stock warrants exercisable 4,931,507 Á Á Subsequent event [Leerink Partners LLC [Member] | Underwriting Agreement [Member] | Warrants [Member] Á Á Subsequent Event [Line Items] Á Á Warrant exercise price \$ 3.649 Á X - DefinitionProceeds from issuance of net of offering costs. + ReferencesNo definition available. + Details Name: eldn ProceedsFromIssuanceOfNetOfferingCosts Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from issuance offering + ReferencesNo definition available. + Details Name: eldn ProceedsFromIssuanceOffering Namespace Prefix: eldn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap SubsequentEventTypeAxis=us-gaap SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap BusinessAcquisitionAxis=eldn LeerinkPartnersLlcMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=eldn UnderwritingAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementOfEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementOfEquityComponentsAxis=us-gaap WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Balance Sheets (Details) - USD (\$) \$ in

Thousands Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2023 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2022 Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Warrant liabilities \$ 23,962 Á Á \$ 76,211 Á Á \$ 55,738 Á Á Á Total liabilities 38,518 Á Á 81,858 60,472 Á Á Á Common stock 41 Á Á 24 24 Á Á Á Additional paid-in capital 386,884 Á Á 326,586 324,876 Á Á Á Accumulated deficit (310,969) Á Á (319,402) (289,303) Á Á Á Total stockholders' equity \$ 76,058 \$ (8,501) \$ (14,728) \$ 7,208 35,597 \$ 43,768 \$ 74,792 \$ 84,183 Á Á Á As Previously Reported [Member] Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Total liabilities Á Á Á Á 4,734 Á Á Á Common stock Á Á Á Á 24 Á Á Á Additional paid-in capital Á Á Á Á 324,876 Á Á Á Accumulated deficit Á Á Á Á (233,565) Á Á Á Á Total stockholders' equity Á Á Á Á 91,335 99,949 \$ 74,792 \$ 84,183 Restatement Impact [Member] Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Warrant liabilities Á Á Á Á 55,738 Á Á Á Total liabilities Á Á Á Á 55,738 Á Á Á Accumulated deficit Á Á Á Á (55,738) Á Á Á Total stockholders' equity Á Á Á Á \$ (55,738) \$ (56,181) Á Á X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap CommonStockValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-7> + Details Name: us-gaap ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 15: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30> + Details Name: us-gaap Liabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480016/944-40-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2> + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt RestatementAxis=srt ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RestatementAxis=srt RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Restatement of Previously Issued Consolidated

0.03 \$ A \$ (1.42) \$ (3.79) As Previously Reported [Member] A A A A A A A A Error Corrections and Prior Period Adjustments Restatement [Line Items] A A A A A A A A Net loss and comprehensive loss A A \$ (10,349) (9,579) \$ (10,772) A \$ (30,700) Net loss per share, basic A A \$ (0.35) A A \$ (1.35) Net loss per share, diluted A A \$ (0.35) A A \$ (1.35) Restatement Impact [Member] A A A A A A A A Error Corrections and Prior Period Adjustments Restatement [Line Items] A A A A A A A A Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds A A \$ 443 A A \$ (55,738) Net loss and comprehensive loss A A \$ 443 \$ (56,181) A A \$ (55,738) Net loss per share, basic A A \$ 0.02 A A \$ (2.44) Net loss per share, diluted A A \$ 0.02 A A \$ (2.44) X - DefinitionChange in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. + ReferencesNo definition available. + Details Name: eldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1:

Section 45 - Paragraph 60B - Subparagraph (a) - Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: https://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt RestatementAxis=srt ScenarioPreviouslyReportedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt RestatementAxis=srt RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Miststatements - Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Beginning Balance \$ (8,501) \$ (14,728) \$ 7,208 \$ 43,768 \$ 74,792 \$ 84,183 \$ 7,208 \$ 84,183 Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value 5,703 48,070 Á Á 33,017 Á Á Á Issuance of common stock in connection with exercise of pre-funded warrants, Value Á 1 1 Á Á Á Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value Á Á Á Á (1) Á Á Stock-based compensation 1,783 3,063 1,694 1,734 1,720 1,381 Á Á Net loss and comprehensive loss 76,971 (44,907) (23,631) (9,906) (65,760) (10,772) 8,433 (86,438) Ending Balance 76,058 (8,501) (14,728) 35,597 43,768 74,792 76,058 35,597 Accumulated Deficit [Member] Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Beginning Balance (387,940) (343,033) (319,402) (279,397) (213,637) (202,865) (319,402) (202,865) Net loss and comprehensive loss 76,971 (44,907) (23,631) (9,906) (65,760) (10,772) Á Á Ending Balance \$ (310,969) \$ (387,940) \$ (343,033) (289,303) (279,397) (213,637) \$ (310,969) (289,303) Á Á Previously Reported [Member] Á Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Beginning Balance Á Á Á Á Á Á 99,949 74,792 84,183 Á 84,183 Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs, Value Á Á Á Á 33,017 Á Á Á Issuance of common stock in connection with exercise of pre-funded warrants, Value Á Á Á Á Á Á Á Á Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock, Value Á Á Á Á (1) Á Á Stock-based compensation Á Á Á 1,734 1,720 1,381 Á Á Net loss and comprehensive loss Á Á Á (10,349) (9,579) (10,772) Á (30,700) Ending Balance Á Á Á 91,335 99,949 74,792 Á 91,335 Á Á Previously Reported [Member] | Accumulated Deficit [Member] Á Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Beginning Balance Á Á Á (223,216) (213,637) (202,865) (202,865) Net loss and comprehensive loss Á Á (10,349) (9,579) (10,772) Á Á Ending Balance Á Á Á (233,565) (223,216) \$ (213,637) Á (233,565) Restatement Impact [Member] Á Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Beginning Balance Á Á Á Á Á Á Á Á (56,181) Á Á Á Net loss and comprehensive loss Á Á Á 443 (56,181) Á Á (55,738) Ending Balance Á Á Á (55,738) (56,181) Á Á (55,738) Restatement Impact [Member] | Accumulated Deficit [Member] Á Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Beginning Balance Á Á Á Á Á Á Á Á (56,181) Á Á Á Net loss and comprehensive loss Á Á Á 443 (56,181) Á Á Á (55,738) Á Á Ending Balance Á Á Á (55,738) \$ (56,181) Á Á Á (55,738) X - DefinitionIssuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value. + ReferencesNo definition available. + Details Name: eldn IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockValue Namespace Prefix: eldn Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock in connection with exercise of pre-funded warrants, value + ReferencesNo definition available. + Details Name: eldn IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue Namespace Prefix: eldn Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value. + ReferencesNo definition available. + Details Name: eldn IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue Namespace Prefix: eldn Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_ReportedEquityComponentsAxis=us-gaap_RetainedEarningsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Cash Flows (Details) - USD (\$) in Thousands 3 Months Ended 9 Months Ended Sep 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Net income (loss) \$ 76,971 \$ (44,907) \$ (23,631) \$ (9,906) \$ (65,760) \$ (10,772) \$ 8,433 \$ (86,438) Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds \$ (96,439) Á Á (443) Á Á (51,829) 55,738 Net cash used in operating activities Á Á Á Á Á Á \$ (28,284) (30,396) As Previously Reported [Member] Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Net income (loss) Á Á Á Á Á Á (10,349) (9,579) \$ (10,772) Á (30,700) Net cash used in operating activities Á Á Á Á Á Á (30,396) Restatement Impact [Member] Á Á Á Á Á Á Á Á Error Corrections and Prior Period Adjustments Restatement [Line Items] Á Á Á Á Á Á Á Á Net income (loss) Á Á Á Á Á Á 443 \$ (56,181) Á Á (55,738) Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds. + References No definition available. + Details Name: eldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds Namespace Prefix: eldn_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 + Details Name: us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/214748666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_RestatementAxis=srt_RestatementAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 67 Financial Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial Report.xlsx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~ VVZG=PZ.JZ8D;D* MTU*0;VYZ<5X&N(VY02Y?9A7;?> 8T=?Y%1L/O@N=QXCRHB#N8.S8#>KAME[7YAGE<90-11M*PD+>S-W8+C72P4X&1+@ , @Z1 Q 256 Q6!8*Y?B M2\$R,1!>APY=> <?"/IDN/I;F6G;JU=QEM(EYPPF8\$V~>MRMYEL<?<5< *J56 *P MOFH]M!5S Y9KF4Q9Z,RWRT ,2Q;B#D2XDU!=I=7GFYRN>B)V?I=W MP6#R 7#)1P E _=?>]M%>KG[VW>Z/L,1[2\$R<>=41 71% B.5' 86%6S+D4.22 MD 83 >LX=SFWJXPD6L QCG'ODRWSEPVSK> UJF M\$RQ=H!1?8?M!<@>I&K&KZZKT Y9P[M@QO@2> , ;:/I;=X QU!M:160K\$3!+ M!WP?D@9CC%OT~?%&6!MIK&QM0MQH#F 6/,H68WXW=>6FAHSU8N.L8T*? 5S M0.4 VJ0-8-R!15XQF;8VH<1.'CS< N!<Q=+<C&MNB!4\$!#!10 (M J)C'GGCK<? ,@4 -X? 8 >PO=VJR=W-H965T&UL MM9G0;<@V' , %8M!TTJ3->A A1M%6HBG=>A<6%1A-MVDV01, =>F<C.OZ4 YWU MSAZJ[AC FFFH>@>M+DMK41(GYO&F[H2]KEE, M (G-B0&O&G)UT827GLB#) J)= M FRGTTJNF@>4%6F9@M!M/O DM-B;C MVOUAP<C=>?RZ7! +059S1IEZR#>N> M<4>:(ASMUK&9E9G?V, /U#D20?DY;CJ 3EP3H'R4) 3ZJ02G+>KMVV<~O6~@>E0H0U511H+SB5%>[SX >J(07D1KQO6! M9&0L4A-7%>~K7!HXN6&6MY+>JZKBCP6%G'D*WDS1@>=>=18G,M!W6W1A!60; M?6194!P *!>AP9FCGQ;>1K(G)8&)&-(WYJ?36VR&W5~A;K.8V!<=<A)2OU5!>SN MNW00&Q 4-PJ043V'L.KP8%YY3#>9L4+>UD+P=>M05!>U58L!1B*1, BW5UD! M6N(E&J!>C=LNCF,BV+9&KJ!>M&WN,[I#8ZMKC?0=2+15%,FJ7AB@>=>N#MA M(A?+MMWK85~>@N\$S(5\$R) (7Q6&6%J25S3UY&KBKWPW?VNNQSUABC MW0~X1 C"50C'9X6@>L=>)]>3\J!>E6P0?(<W">>+<2&O1~\$ST1=(S%)N7H+MAZ M6O+Q">2B0A7B0B?N1 T M*25<41[LB!+=/2;L51? >85E3Q<H083C+5%0,632)GR4%>@>[SVJTUVL*XA!Y% M(ONL4~82,7,8E6I:CF96A6Z1X/O.T7G' 72B3/>X1"ZRUJQDPRFZ0L9<=>D M6?C=RZJH>V4RSK0XL1% ,J]?C.O9?0% ,%>H2P)]EX8- JZ7P<@>~d6*(5C1Y M=37@>[SHYLC<Q ,3.B!B700%=>6E MY06-7%?YIB<7P>69<=>Q+>TPF8?Y1XE!Y!>O ,@!A02P, \$ M% @>HAL6=>B+R+2X!<@ QP !>IX:~JW,WJ;XYR,NM;QG +O&S&6+10YDXRFE3* F,U\$ M#41%N9 M&F+>=>[DKM][RFPFNBUZV]TN(OZ[N]WC70)=PPJEW?(>O)XY&I!(221T)JX!>A69DM T9\$54CAJUT\$DSJG; *M&@>~C+>F? *H GCF 7F47(L<1N9RHQ?VWJ)ZM4+&#&A03=F=>@G5?]>U5% M7VZVQ (RU:#2~2+1'07 %CUS! M-2@>J!>K-E&GY!@>E/5?>O)X&1&5, OJCKW!>L Y M?RYJ\$ZON70!JH=?>W-R- MDQ53&)>77!>43Y6K!>JS6J7Q5FWFWX+D>O!>L=[:.O!>H&Y<32H RQJ+>TSB MY B P6\$L&K;H=P.6KRS<8PO?>S"(%GG9G)C"- *F#H~ BFX083?Y1K!& 9HQ6?V'D5T.MCP&@>Q19?2FLMUCL39(ILFNMLKQ MT @-W1'+>1,2FIH+BN2+OZ!" 15XGMN!>1"OC>RS<&6X;=YKJ\$<OCI MD+@>@LI<+1C,W' Q!K6E-FCGMBMR2Q3,&S&LND!>@>H-V MAOO\$LK(H)P08P&70!>V#O~S>T=+>C+=.C=PY B(AG2"/7P6 .AF;S \$S\$X M,@DM'4([U:~%70CCD/>=>UJ;O!1A<=>=>6 MJR*074&BV.J3Y4)J#[N# .:j8XIVi3, (T:8@>+>T'5=>,"OPEQ8O.~8 .MR8B,YG@>@>U(3W450~ MF;,\$A&LFN, =QB MT+V+G+G0601?6&V7" M.C5P?>8JGLG,B 42@EDEQ; MPCD70@FFG2?>T9MF. <=>E56P*~9/H*~D' .J.QW(=>~29C>H09>@>B-T MTU!H7M?>@1.U1ET+>S/E&T[NEE*XA7Q] IPc43;850*Y5 M C3%>XXK:MP UW 42%>5S;3N>VDUDFL L3~ZJMV3-MR?>EHWZ[VC>[M@>4;M6P, J M 9/5\$!>SOJ91~?>@1\$N;]=7SWJL[SOE<~O-OWK95-Y+EYON&K&R8E2O!>M +>=>@PK6!>OVQ6>ZGOMOP]UWJGO 51+ P04 * *B&Q963&0%># I. M#P & *AL+W=O6B71%133=N+3E&C437C3P!58!J[NMGWZV4!>: BOJLN+Q?99WY!>= M.T_E9+>+QD?*>001UD<6Z%2295MS<~S'F,H+GD+BGRRYB*G24!>R92J !IE3 M'D.OGTJIBRQJ]>

2BF(Y654AM)JLIC MEY?@#N1KA-Z91=1 A#9#E1C(VEV1 KJ9D81PRBVAJMGOCSPJ"[OS>15 M,+P(8(??&4V5@2S5D8FD,7X70-UR3>X/WZ, C9%+7B-SH1F/K, A6. MK:&%&2C=3N"/83% GU3#R21S+11M0/LR(69+ th-B5'L MK#OBX10.3E<MW1PLT1SLBR&WKH9-3X%&ECK.905:5%MGPO+&SN=&Z*=, M'ZG)E?>?BD01#V2/& (157IR2K) (&#F)K1\$;V=40?)*4.RGT3MTCEXC&AEO MKJ13K2B6JQ[9?7^9J.D3WGD%XC%&YAIMS?>C?NVT?T?>U.G>WZFF[K,L2.M.4)G'R">R3>3/Q0 B=M:VZ? W~4&4BK40AD9J\$KLMC57(8ID>V4SP1?>9D9?>W.M.VBSJH"Z):&A&FC A=I=JY+JA>".N.9VFI8>SSQD>K=L'M%>=>XW04Q1' MNEVIE;-K5-VHPIEKZ3LG49J:JZ]>WHY&=&6MHMEA;I? 40=>IIV92KNN)P"< M'B%#EV#G?>ADH,YQ"7N\$=YIRLXG5=KBUOT'5BRJH,>=(&4~&R&L1OPT;H.M.OBF,70J[4QYQNN~&Y+#+<@%M\$@%9M.3>JH9'W\$]> "K+IG\$K[JE7J4? MC"VMRI+&1\$J\$U>D?C] 79,0%Q2E&A=>NKL-JL*,\$AH^@U(MS"U6..)=JDU>U;"E8LD2B7J;#%PM/+ +6S5Y1,M/WPNNJ&TJ&B;ZP@O~M.M.CG2[5X1&1&P@VJRW:V H965T&ULK5&C,MLV\$P'K19%&A;HD3=MEX#M;47H&F";(TO9M'X%\$EEZ3M]=[W"EEFZ2%39,76Y&(XR,77^66 M,86)J6X.M4KM[SY,K+;NH\$]>?..FHN~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~3<? M0U<+G.CUQ653&P5.F\$75(PFR.TEC\$AHNFMDH0+&C&BPFPE@,"ULU#~?DCIU M>Q+Y[! 7E7 'ET 8,>EU'QKQMF&~7H29XD1U&M; E5TBCI !+U+&F6J5NF@8WH'B>>41IR..Z00R MS4=>9K1@1WJD;GR4^<(U-V)A&E;#VF0&8&E4B.OO3\$?IP0U?>4 K2NKG;G7V~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

[illegible]

!JKYFYOCG23+WKGS^4Y+!TKJAH MYSW!":~9@C5^YV(7F=38IX.3H#0'B'8:TK&;:X^VS2G2DVW52.8I MS9S5+B7LA SAZ(WM:Y^WYU)>@RC.R.TOW9.FGHH^MC/:#PPG\$AI!DGDUX MD2.52==M^N^QO.RR.KMAY3!3!OIVU16MS^4I!Z>UF4!OT 5T.M035=I.M.MS715N.YZ!+S+VB VY.VH>V5F10Q.S:~!((77.0ID MCTGS5^3WR!.MC2=L.8GR. 19707C?==>CMR@RLLO.BDFH.33%IX4.100^4^5Y:ZM4!+4.M#IOU!>O.8USF^64%/7!0V^D?B^*H+H>3%T8GC ==>X5CH7!M8%QOL!>.O.MBTE5Y W^Z= .3.6@.OJ6#~7T. LLEWKS%Y.22^2^ HCJG@W.WKFP^RUE.MBR MOV+>=13H76@<87C.F. @V\$P^U+UO.GL2Z. BJ9=5MGTYN@M!7RE7030!\$S@V>O!N^HC1Z+!V<W+7F Z(CZ\$C74T W%OA.&AOZK3 MFS@1CL1W2.LX&82^..W6.W.S1T94V\$018^U!8I.X)O>Q?P. #30.68G!M^U@4^8K<=3.1951QZ9F ZC<^>S#3M^MORDO!P787XZ!N^28C1Z^H!P4V+9J. MSRRMOQ?^ \$YCLN!S.P%K!K.J5F1CL!>O. @!+K+3CDYNG^! IFLCOS\$M.V! V2&Z4PDL^VKG\$F!>5=F5GIX TGL09T!4S!H!<+5JO00N^!^X. #*M2M.M^CO.12MLL1.W^X^ H=PE258A.FE.S!N4^K+B&R3ZPV M818R9!>==&RWI!Q592J!D\$+U.W+OX^4\$1.0!U (JL:FE31.6M^L1H^*11 9>=&PO=VIR.W:H9657!>M. M=2GHF=O@OMJ!*/%X>X^W=? NAGUO.9QW9=7!>+N^!<U^PZ2&TW10?M.CO.WPRD.N!>UO;UHKM:PH9M^D?7R!>ZEP.XZ2^&H!P?>O@B^OK25Z3.MS.JA!MS.4M.UO.GI.R2A^>N=6ZYQO!\$!&BFOOY13G/QW M.U.9LNI.1H^E7!>Z.T! #!# ^YK&9A@GLJIKNROZIOGER=989F^M/W.M!>W^K. 08Z1VU4G.V9W^NSCIR!>9G11O?<^&52! >@>DORR^KLPX.(J!MNI.Z2&AKI7S8OFOV.HN.DT9N? LE49#>Z>O?Z+>BZ.3WMAFEGCTFV479Q>CLSW^+AH+KFA. ^S!LZWZ^U!>9ONL.DIL23J.MG6UOIH?12I271LJAUAO.E!8QU3VY.M^1F^*QOBRRO<.95IWU8YA^725:~*G2ES^G-B^+? 96MS1.%M56&1I03 MXCF7<1M@:Y.7+DG/L127FYO2 8!+<^&9\$K.MYS5=UO&^P4A!<^<Z^TNCN 7%Y<M5U>?>?^C1 BWG\$V!>=TFV8.KU^*9>=6L!LTT+!DIRP4O?122VK7!>=M7M:= !LKNRU!>9=CCKS3D7W.B^TVI+>V!+!DGL15G&1LJ!ENRRN+>M!PEBOVA27C!>KJ!RDF234BUKLR8!>M3?>O C/LJH:(W17?7KH>+M^MZC?I MIFP0V!>16AJEHET:~!>X?J!> O.AP!<^>..NK.15G5.M.MLR5<=5.3PCYU!M^PO!1W^<Z.48-OC0Z!!LH.Z9ZG2N!^2ATKIE.Q.3B>+2.4SPUI:~#F36D+ MSS\$>7FH0.W!U!<^>.M3T.4V!N2 MKF5!4^B^OHJP= <^>O!>OOG6JL43L!>Y+T=^0.7\$SJIU/O!L.P!>M!>@UO!>1!>1P&24 26R!>O!<^>12BSC0~0927D?I>=U&^!T9N^&6086HZ2L6H!IM8.MP3B^M^M.SA85:OK^<^>A:FUH!<^>54W^8.8A? Q^H56=^TO M03^TSA.BA-IN25U/OPLU916V.4^F3FGFLN!>O!>1!>09PTU5.7M^>2.MJ5&F7&Z!8XVZP8^GV!E!O2E< 27>9Y>P=RD<ICL!TBH^5T5.&M0166GNITCYB.4LOKZ: <^>~(BMCBOJ!>^3EJOYR^<@M^9.T.OB7@9TIV4^\$K MIB3^>O>B8H(AAINBIO L^*P!>Z!>U+O@OEG758!79E:UYYN^XH<I&ED5 M\$S. &O!<^>C^&5^>U!>U^>O!>J<^>+M^> <^>26^R&^ADRT597L^>VNY^<+CWEL.M5MNIJ5L.4Z8V!>Z!A2.V!E\$<4!>QCD<^>W%G!4+MNE.B!&S52MA@L.MN948E^M^B.F9@Q!>@V!4.9%~*CBFUS_>L>EYF6^VC.G0!WPED!<^>M!<7B: M1JLW8RR>J6^O2F>V!>8<=E&9#17!+>^!>X55^>J!>DAS^2!>E!&M8OY^400!+>L2+BOZCMK6<R58OVS^F!>Z>4@>M^M!2%V1^Z>UO.2G5! M.WA15!>M^2!>M^>K9R#>=KIV:9!7966E!<YPLGJS.B!>A&E!28/OBS39P54V!\$2O A60P.O100^V\$6<=58V.O!V^>L^>M^>M5G8K.HPC>DL.M.ZYIF!>14A^O@!>94!>T.G.SIYIOL2TK+VUX^N^&6? QV.O= M^V32^AT 2IN!15B^>9<K^U2!>16>AD^>O!>THX4!D!LO^HTC.Z^>HSG\$S!W?>M3O=IN^6!>S^O!2T^>P!>DO.^!>1^>9E4!<5TR^Z>=X0^SSZ~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~>ZD3!>K!>I2ON2QEVZ!>L8M!>2FEZ!>T^>RS!>XN!>P^>C!>G!>J!>V2^>M^>P!>6!>F4!>U!>F4!>S!>O!>1HRN!>J!>L^>A!>S!>A!>K!>A!>O!>^>+?>66.8^>JXU!> %!>B^>=I2CSKF^>0SHO+^>F.U324E.%!>ZRS!>T+3VF^>M!>OGOFQ?>#W^>T!>N+^>E3ZMEZ>#>OY^>^>V!>4^>B^>FOSALP.5RVDRU!>7M!>S!>M5<3^>#E^K!>O!>E!>X!>Z^>O.CITABY^>4>=? 95Z.LD16=>+H(9!>#30PB^>E^>~&S.M080M^K2N^K!>^>O!>JEEB8^>Z!>J!>5U43^>P#S!>O^>UBF2!>G.6.21K^>A!>E!>K.M^>8^>9#>#^>H!>D!>B!>J5PQ.SD!>@!>T!>ZMUJTC>N^>#>#>E!>Y!>Z!>K!>Y965^>J M!>OH@>V^>7!>8!>DV=NOMV^>T!>Y=K^>S^>K^>Y!>K!>+!>V^>GXV^>G.S.V.NJ3

[illegible]

@.P47N.2
 M1=BR0XZK8MJKYJ1.>@.6HAJ M4B5M1+L4SUB6HJF6H6E MU1ZA.>@.V.2.MH1X>3U.2@OJ1N.>@.GMALU.0347U0A1USM0+40U0U1@.6HUH1.>+A5
 M4E3+4SVA6DYIM4TJO+76S1.4+SUZAFH01.>@ZIN:CFH0J.>@&JA.>@F4U1M1. MM1C5E23J.B6H0J.M5R2IM7BBI.4+SUWJM=-5.1>H0J.>@VHNQCFHYHIN.MH2
 =SN. /4I30&H+U24BU5M036J.BF10.BF14VCMYH05050.>@.IA7M.>=V1. /Z7L1ZR<QK1SA48U15<5-0S4>+U.5-5I.H0%.&C.HJDE42USM.M0S6%.CFEUGM.?
 1@1=&#.KRIC14+U604*.D43POQU1.WSBY8I=->H.U.014.M02@6I6I.M5.CAU6EUDW92Z6G.V06%CIJC6HJ.KFHYHJ.CVHJH6H6E.M0K48U14DZB6.MHEJ&.@K5%%4>B.K08%\$<
 .>@ZIN:CFH0J.M.>@&JA.>@F4U1M1C5E23J.B6H0J.M5R2IM7A2U1H.M=2VCSD0OAAT.K8N.M=-2&W.9.ZHHQXVFEN%<OC4.U04S1&USUFC76Y4U.1C4U04S1U.114.U044S2@6H5I.
 M.>@FJ251+42U&E.85I.75%T65.OHJHMSUEFHUJ.*B2GM4U.17ZL.>@.FHMJ.MJKYJ.>@.6HAJ.M4B5M1+L4SUB6HJF6H6E MU1ZA.1A7Y>NO.K.W>2+V>.*KM1HZ.ZH<+U.3U.105%1S4I
 I0@<ZGHC.K#>T4T1?UJCFHYH1.AVH1.>@6HJ?>0+1.M0U642U1H?H?>AF153+>1+>1542AGL.ZX41+>F.M>18>1U.02U4LU.0347
 MU304U04M0+40U0U1@.6HUH1.>+A54E3+4SVA6DYIM4TJO.1IYC.04GR13U.W.SFA64U14U.1C4U04S1U.9.IUS.&XWFRT6D#.M5.M13>A.&HOJB6HE&M14.U12U916+P15>GNL?&br/>
 UJWLXZ5+1N2.K7+>F.MZJ=-7U&5%9L1SA4UKH+5%1SA4U15%1M3>A.&HOJB6HE&M14.U12U916K5%5GI9U.M3Z&Z4&6%5.9IM2P.*Y5W6M7.C)
 MMN4U.02U4LU.0347U04P1.23CU7C.Z9A4UGU2ADY.HJF.M0K48U14DZB6.MHEJ&.@K5.CF.MHUJ.B&F52+4U&M035JHED.AEFDUQ.1A.E.%>8NVU
 -55I.H0%.&C.HJDE42USM.M0S6%.CFEUG2M%>2.2..YX%MIU>1%1H@1S4+U604C<18WG.2L.BXZJ>1JH%1J.BEDU1.5B5M0.M3>1.BFH0JBE4RRFEMOOE7R2?=>2IWF2WJ9K?UJVLZG.68?
 E1<+P1.LW44A.6H14+U604XHC.UB4&S8?CFHYH1.M1JY1.AFHJ1.1%90+4U.425)HE1.AFHU74JMU>B>@.&.&GL.%&M.19J9C.BFH1+JY1.CF6HJH.HJ5M0+4U14DJB6HE&.@K6G#5
 M1#6I.M4AQJ0BHM1SM135.E11301936KT5I.CMB2XWM7M1.CHKJKTS6S1.670JAOX.MM2S14U0.E17V.5U.5F.FEH1+M.M159C&C.G0Z6S0%CF6HJMFH0J.BYH>
 MJOFH1J1.B&H1U24HUS.M036J.BF10.BF14VCMYH05050.%3M5\$S.&FQ13FH6+>1%0(VRSLDY1J?ZL2@GY4.2.M1WZ5I&C<HJZC&Z.A>+W8=&UJSZP2%1B.%%>?115BS9KFY7EWO0#?+620G
 MLYS%2SGCLUPQY.ON.7IVR.0LXO&RPN6BU.@N0KFSY231+I2R7L90BN1SC.M0@H21P21H2I7F1E=51ST>.&#BL2.%R&21+3321C2.<1JLWHR.*DG<K025TIV0JDHWO5ZK1+C2G>4LEK.9SCER
 M9Y7%0%09T.IR.FOXY.G3AD.<WR&6P&2VE.4REE.LEV<6=&8GA0.M231M2N&E2.E.&=>Y2R6LUQ.83F7Y3R6IUDN8+FOY031+12P7LUS.594.7W>=>H.\$L9I&OG&5Y?/1LOD1+&#&1?>
 +1292GLUS.0G&5Y./0<@M2?=>1.19I7A?>OG.IR.MD1J.NY1>+OG.IR.DL3%ORYRXNOSPST1R1.MY26BRUDN83GJ5.MC.R1LMY1>S7.RJL.S&7@NDN.1J?
 1A/B0W6(6R1DLYORRYOY.S+FB&L19S<+>A12P6C.Y&N0CF&1.31>I2R9BNSR&C.NK0R2.M1Y>WGS17RBM2G.ZL%XA4IJO.R.M>+>?OC62+T1Y1>V.OJRAA??
 +>RG.<R/L11+>1RG&Y.MB5BEDM83KJOQ.UR#1LN1>+OG.IR.R.DL%1H0C14I27?1Y.&S87.MK#2SGCLUS.0G&5Y./1LHP1W6L1.M0W1H70K&E.2I@O&5+>S+U.L6A9&.
 YUOBM.PMLL.0AK=<PR.V.9I.7Y1+>1M.P1.VG1E.OV123PQMOR&C.FD&9W1XG1>FN+E>M2.CU19+>S.CJ.RJ5&S>Z>P&X1W8P.M.>XIM<IIR.L2UQ=K>R?1.VN+>^>1N6Y?R6LUG.83F?
 MY3R6IUDN8+FOY031+12P7LUS.R.DL%1PG.OD1B>=>7.TIEYTO.B1.H%1+>1RG&Y.B5BEDM8.M3K02SCLUS.0G&5Y./2ME1MKU10EME.#?Y2R6
 MLUC.83F7Y3R6IUDN8+FOY031+12P7LUS.5J.RDN52ELM83K%5.MC.R1LMY1>S7.IRY@.5E4E1%P=N=&V6IR<C.UCYW69FY4*6SR2P.ML5S.<@G+299+62YC.<5R.
 <8IE8=WINZINBP%G3S23%<NB.%Q11+>1.7&V.66.MW1Y.XY197&KJOJ.11J1.CBXS.Y1A52?>+>HJ6FW1.OE73&E1&PO=VIR.M.W.H65T9JASX.SIS9F>GXPA6:2
 M>LH12.1LKRUGS%NH8U@X12N.6M>2(UDRMM44VGL1VX&0O.&5&@&K5MGS.W1E.&1AKT8=9DWMM+Y>1OJDQ1L2QRQ@QNG.1J.BL1J5WEY9Y.M0BW%\$S90%>80.M2VGH/2C9
 LKYT5@YPAU21?1J1E1P=@M.TM199767A1M1CQUT0U1F35+8V1A08H41RT.1R+5.HOODL17H6X85R.1I?MCL@CND&+52WZMG@JBP.S0516E6KE.7P1D1B3CND1?>ZL&61.C90T9R3E1K.ML
 RH&S>1R2N.12J1E1F.W%=<+&S9JHET1.<@QO2U1F6.*07NU.1(16#.M.8B0Y&5\$S=5.T5WE+>@&P1E1(C5)39U1R1L1C.GY@.715>1.8R10Q@NL.MR.LH1R>RCTH1?
 ?ZINOG.>?TBSNV.<OPN1L5EY.1#>2W1T78&IT16=HOGU1AL.M8CC&5A5K14MHN14M1.WF<+&C>3P-89?2.SHGUR7DXM.N1%7K1IWKX4150X.M4AFCG3AX1?>LML0.L#
 I02LX5P1U?Y44A1RH2>+&K05QA4.%Y9I.2>3RA.M2W.%Y1>1U?CQ0%ZMBQZ+>+>ZKJOE1J1.7&Z>2&S7R=ZERXKXVE5PM.MNX.41TV05Q&EVH.<K?3Y?L6M1?J1VMP05?
 SB.01KPLBL1+11X%QG%&W&+WMB6&OYON1E=INNRRB&3.M1U19Q.9H3SRGZ.K=TY1RW%>@U24H1MJE1.OMZSW@>5>OCZ2GCM69G7.T1+>R?)
 M.T10.1U12.A1>=>6V1Y.U.2C61XK72FCGX0LX01.<?#1#@N14RW9&3.7MISN%VGRVZEZL146I.GDZU+HAU6&3=FL1LJ?E.WOE77ZIN1.N>13B?&M10RK1LU.Z/SH8.13>?>8YE65.X<#ZH?
 V2K7#A\$5?&B&BVYK.&PO=VIR.W.H65T9J&3IRU&M0Q8BL&6IYR.E>OP.F6BR>YF1E.H16253CHK1-870B.S%914GO.U5K@HJN2.M.MT42U?N1=?#BJ93X1@DM&5Y14M<1%61.WRA65?
 OD.R417Z1X.N4=M.W2C44?>#?7GTW6=DAHY2WPO=IKLL>5%>10M>10&1J?>1+>9A8+1G1.M1J5LU@.Y9.S1J.R>=>8H1JDR&C>=>88K.ODT651.9ZG.8W1>+>92H
 M&UXAT1N.1+11V&B4=+LQR&1%>2142A1Z0PZ1P2.107Z%=<#E8?7H0M>10&1J?>1+>@%N%NSCG.FB12JG15T1?P.B2V0U51JBZJ11).OOJ1Y1LR43.M0I(61.C.B2&51&2&ZH
 E1&W.S&M80J1SU1KWA0Z9R33Y1N.D1N87R&<22.M01SG>L>2?7.IH1C03R&P.WOW.ZX?7QSSCK1JW1L741155+>W.E1@.31M

~~R9.htm 995410 – Disclosure – Pay vs Performance Disclosure Sheet <http://xbrl.sec.gov/ecd/role/Prp>Disclosure Pay vs Performance Disclosure Notes 8 false false R9.htm 995445 – Disclosure – Insider Trading Arrangements Sheet <http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements> Insider Trading Arrangements Notes 9 false false R10.htm 995455 – Disclosure – Description of Business Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusiness Description of Business Notes 10 false false R11.htm 995475 – Disclosure – Summary of Significant Accounting Policies Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 11 false false R12.htm 995485 – Disclosure – Short-Term Investments Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestments> Short-Term Investments Notes 12 false false R13.htm 995495 – Disclosure – Fair Value Measurements Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurements> Fair Value Measurements Notes 13 false false R14.htm 995505 – Disclosure – Prepaid Expenses and Other Current Assets Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 14 false false R15.htm 995515 – Disclosure – Accrued Expenses and Other Liabilities Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherLiabilities Accrued Expenses and Other Liabilities Notes 15 false false R16.htm 995525 – Disclosure – Commitments and Contingencies Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 16 false false R17.htm 995535 – Disclosure – Stockholders' Equity Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity Stockholders' Equity Notes 17 false false R18.htm 995545 – Disclosure – Stock-based Compensation Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensation> Stock-based Compensation Notes 18 false false R19.htm 995555 – Disclosure – Net Income/Loss Per Share Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomelossPerShare> Net Income/Loss Per Share Notes 19 false false R20.htm 995565 – Disclosure – Subsequent Events Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 20 false false R21.htm 995575 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatements> Restatement of Previously Issued Consolidated Financial Statements Notes 21 false false R22.htm 995585 – Disclosure – Summary of Significant Accounting Policies (Policies) Sheet [http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies\(Policies\)](http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies(Policies)) Policies Notes 22 false false R23.htm 995605 – Disclosure – Short-Term Investments (Tables) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsTables> Short-Term Investments (Tables) Tables Notes 23 false false R24.htm 995615 – Disclosure – Fair Value Measurements (Tables) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables> Fair Value Measurements (Tables) Tables Notes 24 false false R25.htm 995625 – Disclosure – Prepaid Expenses and Other Current Assets (Tables) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables Notes 25 false false R26.htm 995635 – Disclosure – Accrued Expenses and Other Liabilities (Tables) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherLiabilitiesTables Accrued Expenses and Other Liabilities (Tables) Tables Notes 26 false false R27.htm 995645 – Disclosure – Commitments and Contingencies (Tables) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables Notes 27 false false R28.htm 995655 – Disclosure – Stockholders' Equity (Tables) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables Stockholders' Equity (Tables) Tables Notes 28 false false R29.htm 995675 – Disclosure – Stock-Based Compensation (Tables) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationTables> Stock-Based Compensation (Tables) Tables Notes 29 false false R30.htm 995685 – Disclosure – Net Income/Loss Per Share (Tables) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomelossPerShareTables> Net Income/Loss Per Share (Tables) Tables Notes 30 false false R31.htm 995695 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements (Tables) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatements> Restatement of Previously Issued Consolidated Financial Statements (Tables) Tables Notes 31 false false R32.htm 995705 – Disclosure – Description of Business – Additional Information (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureDescriptionOfBusinessAdditionalInformationDetail Description of Business – Additional Information (Detail) Details 32 false false R33.htm 995715 – Disclosure – Going Concern and Management's Plans – Additional Information (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail> Going Concern and Management's Plans – Additional Information (Detail) Details 33 false false R34.htm 995725 – Disclosure – Summary of Significant Accounting Policies – Additional Information (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies – Additional Information (Detail) Details 34 false false R35.htm 995735 – Disclosure – Short-Term Investments – Summary of Short-term Investments Classified as Available-for-sale Securities (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail> Short-Term Investments – Summary of Short-term Investments Classified as Available-for-sale Securities (Detail) Details 35 false false R36.htm 995745 – Disclosure – Fair Value Measurements – Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail> Fair Value Measurements – Schedule of Financial Instruments Measured At Fair Value On A Recurring Basis (Detail) Details 36 false false R37.htm 995755 – Disclosure – Fair Value Measurements – Summary of Warrant Liabilities Measured At Fair value on a Recurring Basis (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfWarrantLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails> Fair Value Measurements – Summary of Warrant Liabilities Measured At Fair value on a Recurring Basis (Details) Details 37 false false R38.htm 995765 – Disclosure – Fair Value Measurements – Schedule of Aggregate Fair Value of Warrant Liability (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails> Fair Value Measurements – Schedule of Aggregate Fair Value of Warrant Liability (Details) Details 38 false false R39.htm 995775 – Disclosure – Fair Value Measurements – Additional Information (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails> Fair Value Measurements – Additional Information (Details) Details 39 false false R40.htm 995785 – Disclosure – Prepaid Expenses and Other Current Assets – Prepaid Expenses and Other Current Assets (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsDetail Prepaid Expenses and Other Current Assets – Prepaid Expenses and Other Current Assets (Detail) Details 40 false false R41.htm 995795 – Disclosure – Accrued Expenses and Other Liabilities – Schedule of Accrued Expenses and Other Liabilities (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherLiabilitiesDetail Accrued Expenses and Other Liabilities – Schedule of Accrued Expenses and Other Liabilities (Detail) Details 41 false false R42.htm 995805 – Disclosure – Commitments and Contingencies – Additional Information (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies – Additional Information (Detail) Details 42 false false R43.htm 995815 – Disclosure – Commitments and Contingencies – Components of Lease Expense (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail Commitments and Contingencies – Components of Lease Expense (Detail) Details 43 false false R44.htm 995825 – Disclosure – Commitments and Contingencies – Schedule of Other Information Related to Leases (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail Commitments and Contingencies – Schedule of Other Information Related to Leases (Detail) Details 44 false false R45.htm 995835 – Disclosure – Commitments and Contingencies – Schedule of Future Payments Under Noncancelable Operating Leases (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail> Commitments and Contingencies – Schedule of Future Payments Under Noncancelable Operating Leases (Detail) Details 45 false false R46.htm 995845 – Disclosure – Stockholders' Equity – Additional Information (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail Stockholders' Equity – Additional Information (Detail) Details 46 false false R47.htm 995855 – Disclosure – Stockholders' Equity – Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDeta> Stockholders' Equity – Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted (Details) Details 47 false false R48.htm 995865 – Disclosure – Stockholders' Equity – Schedule of Warrant Activity (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail Stockholders' Equity – Schedule of Warrant Activity (Detail) Details 48 false false R49.htm 995875 – Disclosure – Stockholders' Equity – Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail) Sheet http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail Stockholders' Equity – Schedule of Series X1 Convertible Preferred Stock Warrant Activity (Detail) Details 49 false false R50.htm 995885 – Disclosure – Stock-Based Compensation – Additional Information (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail> Stock-Based Compensation – Additional Information (Detail) Details 50 false false R51.htm 995895 – Disclosure – Stock-Based Compensation – Schedule of Stock-Based Compensation Expense Recognized (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationExpenseRecognizedDetail> Stock-Based Compensation – Schedule of Stock-Based Compensation Expense Recognized (Detail) Details 51 false false R52.htm 995905 – Disclosure – Net Income/Loss Per Share – Additional Information (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomelossPerShareAdditionalInformationDetail> Net Income/Loss Per Share – Additional Information (Detail) Details 52 false false R53.htm 995915 – Disclosure – Net Income/Loss Per Share – Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomelossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail> Net Income/Loss Per Share – Schedule of Common Share Equivalents Included from Computation of Net Loss Per Share (Detail) Details 53 false false R54.htm 995925 – Disclosure – Net Income/Loss Per Share – Summary of Common Share Equivalents were excluded because the inclusion is Anti dilutive (Detail) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomelossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail> Net Income/Loss Per Share – Summary of Common Share Equivalents were excluded because the inclusion is Anti dilutive (Detail) Details 54 false false R55.htm 995935 – Disclosure – Subsequent Events – Additional Information (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails> Subsequent Events – Additional Information (Details) Details 55 false false R56.htm 995945 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Balance Sheets (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense> Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Balance Sheets (Details) Details 56 false false R57.htm 995955 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense> Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Details) Details 57 false false R58.htm 995965 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense> Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details) Details 58 false false R59.htm 995975 – Disclosure – Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Cash Flows (Details) Sheet <http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense> Restatement of Previously Issued Consolidated Financial Statements – Summary of Impact of Correction of Misstatements – Corrected Condensed Consolidated Statements of Cash Flows (Details) Details 59 false false All Reports Book All Reports eldn-20240930.htm eldn-20240930.xsd <http://fasb.org/us-gaap/2024> <http://xbrl.sec.gov/ecd/2024> <http://xbrl.sec.gov/ecd/2024> false false ISON 73 MetaLinks.json IDEA: XBRL DOCUMENT / "version": "2.2", "instance": / "elcldn-20240930.htm", / "nsprefix": "elcldn", "nsuri": "http://www.eledon.com/20240930", "dts": / "inline": / "local": / "elcldn-20240930.htm" / }, "schema": / "local": / "elcldn-20240930.xsd" / }, "remote": / "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldtd-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/arerole/esma-arerole-2018-11-21.xsd", "http://www.xbrl.org/ir/role/negated-2009-12-16.xsd", "http://www.xbrl.org/ir/role/net-2009-12-16.xsd", "http://www.xbrl.org/ir/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/doi/2024/doi-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" / } / }, "keyStandard": 190, "keyCustom": 50, "axisStandard": 25, "axisCustom": 0, "memberStandard": 29, "memberCustom": 33, "hidden": / "total": 12, "http://fasb.org/us-gaap/2024": 8, "http://xbrl.sec.gov/doi/2024": 4, / "contextCount": 250, "entityCount": 1, "segmentCount": 68, "elementCount": 560, "unitCount": 6, "baseTaxonomies": / "http://fasb.org/us-gaap/2024": 622, "http://xbrl.sec.gov/doi/2024": 30, "http://xbrl.sec.gov/ecd/2024": 4, / "report": / "R1": / "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 –~~

Document - Document and Entity Information - "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "R2": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", "longName": "100010-Statement-Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "R3": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "100020-Statement-Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "R4": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfOperations", "longName": "100030-Statement-Condensed Consolidated Statements of Operations", "shortName": "Condensed Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "R5": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "longName": "100040-Statement-Condensed Consolidated Statements of Comprehensive Income (loss)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true }, "R6": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "longName": "100050-Statement-Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C 9c07952e-1923-454b-991b-8827d5353f4f", "name": "us-gaap:StockholdersEquity", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 24188eb-13e7-47fe-94ac-cf087afa2348", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "R7": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100060-Statement-Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:GainLossOnTerminationOfLease", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:GainLossOnTerminationOfLease", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "R8": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-DisclosurePayPerformanceDisclosure", "longName": "995410-Disclosure-Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C 735ced6-c27f-4b4b-9662-44ba226d1fa8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "R11": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995475-Disclosure-Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "div": "body", "html": "table", "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "R12": { "role": "http://www.edelton.com/20240930/taxonomy/role/Role-DisclosureShortTermInvestments", "longName": "995485-Disclosure-Short Term Investments", "shortName": "Short Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsText

["/, "R23"/, "role": "http://www.edelon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsTables", "longName": "995605 - Disclosure - Short-Term Investments \(Tables\)", "shortName": "Short Term Investments \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R24"/, "role": "http://www.edelon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables", "longName": "995615 - Disclosure - Fair Value Measurements \(Tables\)", "shortName": "Fair Value Measurements \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:FairValueDislosuresTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:FairValueDislosuresTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R25"/, "role": "http://www.edelon.com/20240930/taxonomy/role/Role-DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "995625 - Disclosure - Prepaid Expenses and Other Current Assets \(Tables\)", "shortName": "Prepaid Expenses and Other Current Assets \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "eldn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "eldn:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R26"/, "role": "http://www.edelon.com/20240930/taxonomy/role/Role-DisclosureAccruedExpensesAndOtherLiabilitiesTables", "longName": "995635 - Disclosure - Accrued Expenses and Other Liabilities \(Tables\)", "shortName": "Accrued Expenses and Other Liabilities \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "eldn:ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R27"/, "role": "http://www.edelon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesTables", "longName": "995645 - Disclosure - Commitments and Contingencies \(Tables\)", "shortName": "Commitments and Contingencies \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R28"/, "role": "http://www.edelon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityTables", "longName": "995655 - Disclosure - Stockholders' Equity \(Tables\)", "shortName": "Stockholders' Equity \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "ix:continuation", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "ix:continuation", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R29"/, "role": "http://www.edelon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationTables", "longName": "995675 - Disclosure - Stock-Based Compensation \(Tables\)", "shortName": "Stock-Based Compensation \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R30"/, "role": "http://www.edelon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareTables", "longName": "995685 - Disclosure - Net Income/Loss Per Share \(Tables\)", "shortName": "Net Income/Loss Per Share \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:EarningsPerShareTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:EarningsPerShareTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R31"/, "role": "http://www.edelon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsTables", "longName": "995695 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements \(Tables\)", "shortName": "Restatement of Previously Issued Consolidated Financial Statements \(Tables\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:ErrorCorrectionTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "uniqueAnchor": "/contextRef": "C_30e9b269-2b6e-4bb1-b06f-0de43b6bf18", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": /div/, "us-gaap:ErrorCorrectionTableTextBlock", "div", "body", "html" | reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true, "unique": true |, "R32"/, "role": "http://www.edelon.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAdditionalInformationDetail", "longName": "995705 - Disclosure - Description of Business - Additional Information \(Detail\)", "shortName": "Description of Business - Additional Information \(Detail\)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": "/contextRef": "C_bebd40d9-e18](#)

Prepaid Expenses and Other Current Assets (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "eclدن.PrepaidClinicalExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div": "eclدن.PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "eclدن.PrepaidClinicalExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div": "eclدن.PrepaidExpensesAndOtherCurrentAssetsTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R41": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", "longName": "995795-Disclosure-Accrued Expenses and Other Liabilities-Schedule of Accrued Expenses and Other Liabilities (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:WorkersCompensationLiabilityCurrent", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "eclدن.ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:WorkersCompensationLiabilityCurrent", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "eclدن.ScheduleOfAccruedExpensesAndOtherLiabilitiesTableTextBlock", "div": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R42": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995805-Disclosure-Commitments and Contingencies-Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C 735ced66-c27f-4bab-9662-44ba226d1fa8", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 735ced66-c27f-4bab-9662-44ba226d1fa8", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "5", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R43": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail", "longName": "995815-Disclosure-Commitments and Contingencies-Components of Lease Expense (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:LeaseCostTableTextBlock", "div": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:LeaseCostTableTextBlock", "div": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R44": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail", "longName": "995825-Disclosure-Commitments and Contingencies-Schedule of Other Information Related to Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "eclدن.OtherInformationRelatedToLeasesTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "eclدن.OtherInformationRelatedToLeasesTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R45": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail", "longName": "995835-Disclosure-Commitments and Contingencies-Schedule of Future Payments Under Noncancelable Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R46": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "longName": "995845-Disclosure-Stockholders' Equity-Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "unitRef": "U USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C ced47b5-b6c3-4d50-8e5d-3d006c73ca1", "name": "eclدن.NumberOfPreFundedWarrantsExercisedForCommonStock", "unitRef": "U shares", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:CommitmentsAndContingenciesDisclosureTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R47": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDetail", "longName": "995855-Disclosure-Stockholders' Equity-Schedule of Assumptions Used in Black-Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U pure", "xsiNil": "false", "lang": "null", "decimals": "4", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C 30e9b269-2b6e-4bb1-b06f-0de43b6bf1f8", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "U pure", "xsiNil": "false", "lang": "null", "decimals": "4", "ancestors": { "span": "p", "td": "tr", "table": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div": "ix:continuation", "div": "body", "html": "reportCount": 1, "baseRef": "eclدن20240930.htm", "first": true, "unique": true }, "R48": { "role": "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail", "longName": "995865-Disclosure-Stockholders' Equity-Schedule of Warrant Activity (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C 02186185-0ebf-435a-b3c0-f9a51c68277", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U shares", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": { "span": "p", "td": "tr", "table": "eclدن.ScheduleOfWarrantActivityTableTextBlock", "

[http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsAdditionalInformationDetails](#), "longName": "995935 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "C_bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": "null", "decimals": "1NF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": null, "R56": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "longName": "995945 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Balance Sheets (Details)", "shortName": "Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "C_bbe2473b-f749-4ad7-a48f-d1955dd3b06d", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_8006081f3ba3-4fea-b7ba-16627a76cc18", "name": "us-gaap:WarrantsAndRightsOutstanding", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "div", "us-gaap:ErrorCorrectionTextBlock", "div", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "unique": true } }, "R57": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "longName": "995955 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "shortName": "Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Operations and Comprehensive Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "C_735ced6e-c27f-4bab-9662-44ba226df1fa", "name": "eldn-ChangeInFairValueOfWarrantLiabilitiesAndFairValueOffinancialInstrumentIssuesInExcessOfProceeds", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d6cd936b-b49d-43e7-9d09-e333c17f50a4", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": "null", "decimals": "2", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "div", "us-gaap:ErrorCorrectionTextBlock", "div", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "unique": true } }, "R58": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "longName": "995965 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details)", "shortName": "Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "C_6139ea66-ae9d-49e5-8180-e3f776cecf446", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_142108dc-0728-49d7-841a-3fbc81db1c1a", "name": "eldn:IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfferSuanceCostsValue", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "unique": true } }, "R59": { "role": "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "longName": "995975 - Disclosure - Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Cash Flows (Details)", "shortName": "Restatement of Previously Issued Consolidated Financial Statements - Summary of Impact of Correction of Misstatements - Corrected Condensed Consolidated Statements of Cash Flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "C_735ced6e-c27f-4bab-9662-44ba226df1fa", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_07f3ea60-4b60-4b22-9d57-6fad004a9250", "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "unitRef": "U_USD", "xsiNil": "false", "lang": "null", "decimals": "3", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html",], "reportCount": 1, "baseRef": "eldn-20240930.htm", "unique": true } }, "tag": { "eldn-ALSTherapyDevelopmentFoundationIncLicenseAgreementMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930/", "localname": "ALSTherapyDevelopmentFoundationIncLicenseAgreementMember", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", { "lang": "en-us", "role": "documentation", "ALSTherapyDevelopmentFoundationIncLicenseAgreement", { "label": "ALSTherapyDevelopmentFoundationIncLicenseAgreement[Member]", "auth-ref": ["us-gaap:AccountingPoliciesAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AccountingPoliciesAbstract", "lang": "en-us", "role": "label", "AccountingPoliciesAbstract", { "auth-ref": ["us-gaap:AccountingStandardsUpdate202307Member", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AccountingStandardsUpdate202307Member", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", { "lang": "en-us", "role": "label", "AccountingStandardsUpdate2023-07[Member]", "terseLabel": "Accounting Standards Update 2023-07 Segment Reporting (Topic 280). Improvements to Reportable Segment Disclosures.", "auth-ref": ["r191", "r192", "us-gaap:AccountingStandardsUpdate202309Member", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "AccountingStandardsUpdate202309Member", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", { "lang": "en-us", "role": "label", "AccountingStandardsUpdate2023-07[Member]", "terseLabel": "Accounting Standards Update 2023-07 Income Taxes (Topic 740). Improvements to Income Tax Disclosures.", "auth-ref": ["r351", "r352", "r353", "eldn-AccountsPayableAccruedExpensesAndOtherLiabilities", "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930/", "localname": "Accounts Payable Accrued Expenses And Other Liabilities", "credit": "debit", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", { "lang": "en-us", "role": "label", "Accounts payable, accrued expenses and other liabilities", "label": "Accounts payable, accrued expenses and other liabilities", "documentation": "Accounts payable, accrued expenses and other liabilities." }, "us-gaap-AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current Text Block", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureAccruedExpensesAndOtherLiabilities", { "lang": "en-us", "role": "label", "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure - Current [Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." }, "us-gaap-AccountsPayableCurrent", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "Accounts Payable Current", "credit": "debit", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", { "lang": "en-us", "role": "label", "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." }, "us-gaap-AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://www.eledon.com/20240930/", "localname": "Accredited Investor Member", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", { "lang": "en-us", "role": "label", "Accredited Investor [Member]", "label": "Aceredited Investor [Member]", "documentation": "Aceredited Investor." }, "us-gaap-AcrectionOnInvestmentDiscounts", { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930/", "localname": "Acrection On Investment Discounts", "credit": "debit", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets", { "lang": "en-us", "role": "label", "Acrection on investment discounts", "negatedLabel": "Acrection on investment discounts", "label": "Acrection on Investment Discounts", "documentation": "Acrection on Investment Discounts." }, "us-gaap-AccruedClinicalCurrent", { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930/", "localname": "Accrued Clinical Current", "credit": "debit", "presentation": false }, "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail", { "lang": "en-us", "role": "label", "Accrued clinical current", "label": "Accrued Clinical Current", "terseLabel": "Accrued clinical", "documentation": "Accrued clinical current." }, "us-gaap-AccruedLiabilitiesAndOtherLiabilities", { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024/", "localname": "Accrued Liabilities And Other Liabilities", "credit": "debit", "presentation": false }, "http://www.eledon.com/202

"Adjustment To Compensation:" } } }, "auth ref": { "r789" } }, "ecd AdjToNonPeeoNeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeeoNeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth ref": { "r789" } }, "ecd AdjToPeeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to PEO Compensation Footnote" } } }, "auth ref": { "r789" } } }, "us-gaap-AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth ref": { "r97", "r98", "r99", "r100", "r101", "r102", "r143", "r144", "r145", "r146", "r158", "r191", "r192", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r253", "r254", "r257", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r425", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r448", "r449", "r450", "r451", "r452", "r453", "r494", "r495", "r496", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567" } } }, "us-gaap-AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth ref": { "r40", "r41", "r308" } } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth ref": { "eldn-AggregateNetSalesAchievement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AggregateNetSalesAchievement", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Aggregate net sales achievement", "label": "Aggregate Net Sales Achievement", "terseLabel": "Reaching of aggregate net sales" } } }, "auth ref": { "eldn-AggtChngPnsnValInSummryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth ref": { "eldn-AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth ref": { "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth ref": { "eldn-AggtPnsnAdisSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdisSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth ref": { "eldn-AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth ref": { "eldn-AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth ref": { "eldn-AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth ref": { "eldn-AllOtherWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AllOtherWarrantsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityScheduleOfWarrantActivityDetail" }, "lang": { "en-us": { "role": { "terseLabel": "All Other Warrants [Member]", "label": "All Other Warrants [Member]", "documentation": "All other warrants." } } }, "auth ref": { "eldn-AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth ref": { "us-gaap-AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseRecognizedDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "totalLabel": "Total stock-based compensation", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth ref": { "doI-AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DocumentDocumentAndEntityInformation" }, "lang": { "en-us": { "role": { "label": "Amendment Flag", "verboseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth ref": { "eldn-AmortizationOfOperatingLeaseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AmortizationOfOperatingLeaseAsset", "crdr": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Amortization of operating lease asset", "label": "Amortization Of Operating Lease Asset", "terseLabel": "Amortization of operating lease asset" } } }, "auth ref": { "eldn-AnelixisTherapeuticsIncorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AnelixisTherapeuticsIncorporationMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureDescriptionOfBusinessAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Anelixis Therapeutics, Incorporation", "label": "Anelixis Therapeutics Incorporation [Member]", "terseLabel": "Anelixis [Member]" } } }, "auth ref": { "eldn-AnelixisTherapeuticsLlcAndOticPharmaLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AnelixisTherapeuticsLlcAndOticPharmaLtdMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]", "label": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd [Member]", "terseLabel": "Anelixis Therapeutics, LLC and Otic Pharma, Ltd." } } }, "auth ref": { "eldn-AnnualLicenseMaintenanceFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AnnualLicenseMaintenanceFee", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Annual license maintenance fee", "label": "Annual License Maintenance Fee", "terseLabel": "Annual License Maintenance Fee" } } }, "auth ref": { "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail" }, "lang": { "en-us": { "role": { "verboseLabel": "Total", "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share", "label": "Antidilutive Securities Excluded From Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth ref": { "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail" }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth ref": { "us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail" }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "us-gaap-AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail" }, "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth ref": { "eldn-AreaOfOfficeSpace": { "xbrltype": "areaItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "AreaOfOfficeSpace", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Area of office space", "label": "Area Of Office Space", "terseLabel": "Area of office space" } } }, "auth ref": { "eldn-ArmisticeCapitalMasterFundLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ArmisticeCapitalMasterFundLtdMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Armistice Capital Master Fund Ltd [Member]", "label": "Armistice Capital Master Fund Ltd [Member]", "documentation": "Armistice Capital Master Fund Ltd." } } }, "auth ref": { "us-gaap-ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } }, "auth ref": { "us-gaap-Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth ref": { "r81", "r88", "r109", "r136", "r186", "r187", "r188", "r226", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r373", "r375", "r426", "r536", "r613", "r687", "r688", "r716", "r737", "r896", "r897", "r946" } } }, "us-gaap-AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "auth ref": { "us-gaap-AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth ref": { "r104", "r115", "r136", "r226", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r373", "r375", "r426", "r536", "r613", "r687", "r688", "r716", "r737", "r896", "r897", "r946" } } }, "us-gaap-AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "auth ref": { "us-gaap-AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" }, "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } } }

auth ref: { "r402", "r403", "r704" } }, "eldn AtMarketOfferingProgramMember": { "xbrlytype": "domainItemType", "nsuri": "http://www.cledon.com/20240930", "localname": "AtMarketOfferingProgramMember", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "At the market offering program." } } }, "label": "At Market Offering Program [Member]", "terseLabel": "ATM Program [Member]" } } }, "auth ref: { "r1" } }, "us gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities Available for Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref: { "r199" } }, "us gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses", "negatedLabel": "Unrealized Losses", "label": "Debt Securities Available for Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref: { "r200" } }, "us gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities Available for Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref: { "r196", "r243", "r535" } }, "us gaap AvailableForSaleSecuritiesDebtSecurities": { "xbrlytype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities Available for Sale", "totalLabel": "Debt Securities Available for Sale, Total", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth ref: { "r197", "r243", "r402", "r530", "r704", "r708", "r870", "r932", "r933", "r934" } }, "ecd AwardExrePrice": { "xbrlytype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrePrice", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth ref: { "r811" } }, "ecd AwardGrantDateFairValue": { "xbrlytype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth ref: { "r812" } }, "ecd AwardTmgDisclLineItems": { "xbrlytype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDisclLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth ref: { "r807" } }, "ecd AwardTmgHwMnpiCnsdrdTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHwMnpiCnsdrdTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing_How MNPI Considered [Text Block]", "terseLabel": "Award Timing_How MNPI Considered" } } }, "auth ref: { "r807" } }, "ecd AwardTmgMethodTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth ref: { "r807" } }, "ecd AwardTmgMnpiCnsdrdFlag": { "xbrlytype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth ref: { "r807" } }, "ecd AwardTmgMnpiDisclTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDisclTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth ref: { "r807" } }, "ecd AwardTmgPredtrmndFlag": { "xbrlytype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth ref: { "r807" } }, "us gaap AwardTypeAxis": { "xbrlytype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth ref: { "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" } }, "ecd AwardUndrlygSecuritiesAmt": { "xbrlytype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth ref: { "r810" } }, "ecd AwardsCloseToMnpiDisclndName": { "xbrlytype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclndName", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth ref: { "r809" } }, "ecd AwardsCloseToMnpiDisclTable": { "xbrlytype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclTable", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth ref: { "r808" } }, "ecd AwardsCloseToMnpiDisclTableTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth ref: { "r808" } }, "us gaap BasisOfAccountingPolicyTextBlock": { "xbrlytype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth ref: { "r1" } }, "eldn BiotechnologyValueFundExchangingStockholdersMember": { "xbrlytype": "domainItemType", "nsuri": "http://www.cledon.com/20240930", "localname": "BiotechnologyValueFundExchangingStockholdersMember", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Biotechnology value fund exchanging stockholders." } } }, "label": "Biotechnology Value Fund Exchanging Stockholders [Member]", "terseLabel": "BVF Exchanging Stockholders [Member]" } } }, "auth ref: { "r1" } }, "eldn BiotechnologyValueFundLPBiotechnologyValueFundILPBiotechnologyValueTradingFundOSLPMSIBVFPVLLCAndCormorantGlobalHealthcareMasterFundLPMember": { "xbrlytype": "domainItemType", "nsuri": "http://www.cledon.com/20240930", "localname": "BiotechnologyValueFundLPBiotechnologyValueFundILPBiotechnologyValueTradingFundOSLPMSIBVFPVLLCAndCormorantGlobalHealthcareMasterFundLPMember", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Biotechnology Value Fund LP, Biotechnology Value Fund ILP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC and Cormorant Global Healthcare Master Fund LP." } } }, "label": "Biotechnology Value Fund LP, Biotechnology Value Fund ILP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC and Cormorant Global Healthcare Master Fund LP [Member]", "terseLabel": "BVF Exchanging Stockholders_Series X Exchanging Stockholders [Member]" } } }, "auth ref: { "r1" } }, "eldn BiotechnologyValueFundLPBiotechnologyValueFundILPBiotechnologyValueTradingFundOSLPMSIBVFPVLLCMember": { "xbrlytype": "domainItemType", "nsuri": "http://www.cledon.com/20240930", "localname": "BiotechnologyValueFundLPBiotechnologyValueFundILPBiotechnologyValueTradingFundOSLPMSIBVFPVLLCMember", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Biotechnology Value Fund LP, Biotechnology Value Fund ILP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC." } } }, "label": "Biotechnology Value Fund LP, Biotechnology Value Fund ILP, Biotechnology Value Trading Fund OS LP, MSI BVF SPV LLC [Member]" } } }, "auth ref: { "r1" }, "srt BoardOfDirectorsChairmanMember": { "xbrlytype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "BoardOfDirectorsChairmanMember", "presentation": { "http://www.cledon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail": { "lang": { "en-us": {

"CashCashEquivalentsAndRestrictedCashMaturityPeriod", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "documentation": "Cash cash equivalents and restricted cash maturity period.", "label": "Cash Cash Equivalents And Restricted Cash Maturity Period", "terseLabel": "Cash, cash equivalents and restricted cash, maturity period" } } }, "auth ref": { "1" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and short-term investments", "label": "Cash, Cash Equivalents, and Short-Term Investments", "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available for sale securities, or held to maturity securities (if maturing within one year), as applicable." } } }, "auth ref": { "r47": "1" }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureShortTermInvestments", "lang": { "en-us": { "role": { "terseLabel": "Short-Term Investments", "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]", "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities." } } }, "auth ref": { "r669": "1" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": { "r18": "r67", "r133": "1" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease) Including Exchange Rate Effect", "totalLabel": "Net change in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth ref": { "r2": "r67": "1" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "auth ref": { "1" }, "oldn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail", "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities.", "documentation": "Cash paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]" } } }, "auth ref": { "1" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Change in accounting principle, accounting standards update, adopted", "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]", "documentation": "Indicates (true false) whether accounting standards update was adopted." } } }, "auth ref": { "r4": "r95", "r102", "r142", "r191", "r227", "r228", "r229", "r234", "r235", "r257", "r351", "r354", "r355", "r364", "r365", "r367", "r377", "r378", "r390", "r391", "r424", "r425", "r436", "r448", "r449", "r494", "r495", "r566", "r557" } }, "oldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceeds", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails",
"http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense",
"http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds", "documentation": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds.", "label": "Change in Fair Value of Warrant Liabilities and Fair Value of Financial Instruments Issued in Excess of Proceeds", "terseLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds", "negatedLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax", "documentation": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax." } } }, "auth ref": { "1" }, "oldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsIncludesReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsIncludesReversal", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes reversal", "label": "Change In Fair Value Of Warrant Liabilities And Fair Value Of Financial Instruments Issued In Excess Of Proceeds Includes Reversal", "documentation": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes reversal." } } }, "auth ref": { "1" }, "oldn_ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ChangeInFairValueOfWarrantLiabilitiesAndFairValueOfFinancialInstrumentsIssuedInExcessOfProceedsNetOfTax", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax", "negatedLabel": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax", "documentation": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax." } } }, "auth ref": { "1" }, "ced_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth ref": { "r787": "1" }, "ced_ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "documentation": "Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax." } } }, "auth ref": { "r784": "1" }, "ced_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year over Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth ref": { "r782": "1" }, "doi_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "CityAreaCode", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth ref": { "1" }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables",
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical",
"http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Class of Stock (Domain)", "terseLabel": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth ref": { "r96": "r110", "r111", "r112", "r136", "r163", "r164", "r172", "r176", "r184", "r185", "r226", "r266", "r268", "r269", "r270", "r273", "r274", "r279", "r280", "r283", "r286", "r294", "r426", "r571", "r572", "r573", "r574", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r601", "r622", "r640", "r656", "r657", "r658", "r659", "r660", "r827", "r852", "r859" } }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "label": "Class of Stock (Line Items)", "terseLabel": "Class Of Stock (Line Items)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth ref": { "r110", "r111", "r112", "r184", "r270", "r280", "r281", "r283", "r286", "r292", "r294", "r571", "r572", "r573", "r574", "r695", "r827", "r852" } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth ref": { "r38": "1" }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Class of Warrant or Right (Domain)", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth ref": { "1" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail",
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price", "verboseLabel": "Warrant exercise price per share", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth ref": { "r295": "1" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail",

http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail } , "lang": "en-us" , "role": "label": "Class of Warrant or Right [Line Items]" , "terseLabel": "Class of Warrant or Right [Line Items]" , "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } , "auth_ref": [1] , "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" ("xbrltype": "sharesItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" , "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"] , "lang": "en-us" , "role": "verboseLabel": "Common stock warrants to purchase common stock shares" , "terseLabel": "Common stock warrants exercisable" , "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights" , "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } , "auth_ref": ["r295"] , "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" ("xbrltype": "sharesItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsAssumedAndReplaced" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "documentation": "Class of warrant or right number of warrants or rights assumed and replaced." , "label": "Class of Warrant Or Right Number Of Warrants Or Rights Assumed And Replaced" , "verboseLabel": "Assumed and replaced" } } , "auth_ref": [1] , "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" ("xbrltype": "sharesItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsCancelledOrExpired" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "documentation": "Class of warrant or right number of warrants or rights cancelled or expired." , "label": "Class of Warrant Or Right Number Of Warrants Or Rights Cancelled Or Expired" , "negatedLabel": "Cancelled/Expired" } } , "auth_ref": [1] , "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" ("xbrltype": "sharesItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsExercised" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "documentation": "Class of warrant or right number of warrants exercised." , "label": "Class of Warrant Or Right Number Of Warrants Or Rights Exercised" , "negatedLabel": "Exercised" } } , "auth_ref": [1] , "eldn_ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" ("xbrltype": "sharesItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantOrRightNumberOfWarrantsOrRightsIssued" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "documentation": "Class of warrant or right number of warrants or rights issued." , "label": "Class of Warrant Or Right Number Of Warrants Or Rights Issued" , "terseLabel": "Issued" } } , "auth_ref": [1] , "us-gaap_ClassOfWarrantOrRightOutstanding" ("xbrltype": "sharesItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ClassOfWarrantOrRightOutstanding" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "verboseLabel": "Warrant to purchase common stock" , "label": "Class of Warrant or Right, Outstanding" , "periodEndLabel": "Ending Balance" , "periodStartLabel": "Beginning Balance" , "terseLabel": "Warrants available for exercise" , "documentation": "Number of warrants or rights outstanding." } } , "auth_ref": [1] , "us-gaap_ClassOfWarrantOrRightTable" ("xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ClassOfWarrantOrRightTable" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "verboseLabel": "Warrant to purchase common stock" , "label": "Class of Warrant or Right, Outstanding" , "periodEndLabel": "Ending Balance" , "periodStartLabel": "Beginning Balance" , "terseLabel": "Warrants available for exercise" , "documentation": "Number of warrants or rights outstanding." } } , "auth_ref": [1] , "us-gaap_ClassOfWarrantOrRightTable" ("xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "ClassOfWarrantOrRightTable" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" , "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"] , "lang": "en-us" , "role": "label": "Class of Warrant or Right [Table]" , "terseLabel": "Class of Warrant or Right [Table]" , "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } , "auth_ref": ["r38"] , "eldn_ClassOfWarrantSubjectToSpecifiedBeneficialOwnershipLimitationsPercentage" ("xbrltype": "percentItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantSubjectToSpecifiedBeneficialOwnershipLimitationsPercentage" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"] , "lang": "en-us" , "role": "terseLabel": "Class of Warrant Subject to Specified Beneficial Ownership Limitations Percentage" , "label": "Class of Warrant Subject to Specified Beneficial Ownership Limitations Percentage" , "documentation": "Class of warrant subject to specified beneficial ownership limitations percentage." } } , "auth_ref": [1] , "eldn_ClassOfWarrantSubjectToSpecifiedBeneficialOwnershipLimitationsPermittedPercentage" ("xbrltype": "percentItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "ClassOfWarrantSubjectToSpecifiedBeneficialOwnershipLimitationsPermittedPercentage" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"] , "lang": "en-us" , "role": "terseLabel": "Class of Warrant Subject to Specified Beneficial Ownership Limitations Permitted Percentage" , "label": "Class of Warrant Subject to Specified Beneficial Ownership Limitations Permitted Percentage" , "documentation": "Class of warrant subject to specified beneficial ownership limitations permitted percentage." } } , "auth_ref": [1] , "ecd_CoSelectedMeasureAmt" ("xbrltype": "decimalItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "CoSelectedMeasureAmt" , "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": "en-us" , "role": "label": "Company Selected Measure Amount" , "terseLabel": "Company Selected Measure Amount" } } , "auth_ref": ["r788"] , "ecd_CoSelectedMeasureName" ("xbrltype": "normalizedStringItemType" , "nsuri": "http://xbrl.sec.gov/ecd/2024" , "localname": "CoSelectedMeasureName" , "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"] , "lang": "en-us" , "role": "label": "Company Selected Measure Name" , "terseLabel": "Company Selected Measure Name" } } , "auth_ref": ["r788"] , "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" ("xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail"] , "lang": "en-us" , "role": "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" , "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } , "auth_ref": ["r372"] , "us-gaap_CommitmentsAndContingencies" ("xbrltype": "monetaryItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "CommitmentsAndContingencies" , "crdr": "credit" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"] , "lang": "en-us" , "role": "terseLabel": "Commitments and contingencies (Note 2)" , "label": "Commitments and Contingencies" , "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } , "auth_ref": ["r54" , "r62" , "r539" , "r600"] , "us-gaap_CommitmentsAndContingenciesDisclosureAbstract" ("xbrltype": "stringItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "CommitmentsAndContingenciesDisclosureAbstract" , "lang": "en-us" , "role": "label": "Commitments and Contingencies Disclosure [Abstract]" } } , "auth_ref": [1] , "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" ("xbrltype": "textBlockItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "CommitmentsAndContingenciesDisclosureTextBlock" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"] , "lang": "en-us" , "role": "label": "Commitments and Contingencies Disclosure [Text Block]" , "terseLabel": "Commitments and Contingencies" , "documentation": "The entire disclosure for commitments and contingencies." } } , "auth_ref": ["r73" , "r259" , "r260" , "r663" , "r893" , "r895"] , "eldn_CommonAndPreferredWarrantsOutstandingMember" ("xbrltype": "domainItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "CommonAndPreferredWarrantsOutstandingMember" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail"] , "lang": "en-us" , "role": "terseLabel": "Common and Preferred Warrants Outstanding [Member]" , "label": "Common And Preferred Warrants Outstanding [Member]" , "documentation": "Common and preferred warrants outstanding." } } , "auth_ref": [1] , "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" ("xbrltype": "sharesItemType" , "nsuri": "http://fasb.org/us-gaap/2024" , "localname": "CommonStockCapitalSharesReservedForFutureIssuance" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"] , "lang": "en-us" , "role": "terseLabel": "Common stock, number of shares reserved for issuance" , "label": "Common Stock, Capital Shares Reserved for Future Issuance" , "documentation": "Aggregate number of common shares reserved for future issuance." } } , "auth_ref": ["r57"] , "eldn_CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" ("xbrltype": "monetaryItemType" , "nsuri": "http://www.eledon.com/20240930" , "localname": "CommonStockExchangedForXAndXOneNonVotingConvertiblePreferredStock" , "crdr": "credit" , "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"] , "lang": "en-us" , "role": "terseLabel": "Common stock exchanged


```

http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"/>
http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail"/>
http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables"/>
lang": "en-us", "role": "documentation", "Common stock warrants.", "label": "Common Stock Warrants [Member]", "terseLabel": "Common Stock Warrants [Member]" } } }, "auth_ref": [ ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrvpDisclosure"}, "lang": "en-us", "role": "label", "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r293" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrvpDisclosure"}, "lang": "en-us", "role": "label", "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r792" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrvpDisclosure"}, "lang": "en-us", "role": "label", "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r794" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrvpDisclosure"}, "lang": "en-us", "role": "label", "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r791" ] }, "us_gaap_ComprehensiveIncomeNetOffTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOffTax", "erdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLess"}, "lang": "en-us", "role": "label", "Comprehensive income (loss)", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r16", "r120", "r122", "r127", "r332", "r540", "r550" ] }, "us_gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"}, "lang": "en-us", "role": "label", "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r45", "r91" ] }, "us_gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"}, "lang": "en-us", "role": "label", "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the appropriate treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r44", "r682" ] }, "eldn_ContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ContingentLiability", "erdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Contingent liabilities", "documentation": "Contingent liability." } } }, "auth_ref": [ ] }, "eldn_ConversionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ConversionAgreementMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Conversion Agreement [Member]", "documentation": "Conversion agreement." } } }, "auth_ref": [ ] }, "eldn_ConversionOfPreferredStockConversionBlockerPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ConversionOfPreferredStockConversionBlockerPercent", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Conversion of preferred stock, conversion blocker, percent." } } }, "auth_ref": [ ] }, "us_gaap_ConversionOfStockSharesConverted": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Conversion of Stock Shares Converted", "terseLabel": "Conversion of stock, shares converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us_gaap_ConversionOfStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesIssued", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Conversion of Stock Shares Issued", "verboseLabel": "Conversion of stock, shares issued", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. 'Part noncash' refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r20", "r21", "r22" ] }, "us_gaap_ConvertiblePreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail"}, "lang": "en-us", "role": "label", "Preferred stock conversion to common stock [Member]", "label": "Convertible Preferred Stock [Member]", "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option." } } }, "auth_ref": [ "r270", "r280", "r283", "r732", "r733", "r734", "r735" ] }, "us_gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Shares of common stock issued upon conversion of each share of preferred stock", "documentation": "Number of shares issued for each share of convertible preferred stock that is converted." } } }, "auth_ref": [ "r13", "r34", "r56", "r77", "r289" ] }, "eldn_CormorantGlobalHealthcareMasterFundLPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "CormorantGlobalHealthcareMasterFundLPMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Cormorant Global Healthcare Master Fund LP [Member]", "label": "Cormorant Global Healthcare Master Fund LP [Member]", "documentation": "Cormorant global healthcare master fund lp." } } }, "auth_ref": [ ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "auth_ref": [ "r137", "r138", "r275", "r281", "r456", "r476", "r534", "r679", "r681" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": "en-us", "role": "label", "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [ ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"}, "lang": "en-us", "role": "label", "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format MM-DD." } } }, "auth_ref": [ ] }, "us_gaap_DebtLongTermAndShortTermCombinedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtLongTermAndShortTermCombinedAmount", "erdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"}, "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail"}, "lang": "en-us", "role": "label", "Debt outstanding", "label": "Debt, Long Term and Short Term, Combined Amount, Total", "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt." } } }, "auth_ref": [ ] }, "us_gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureShortTermInvestmentsSummaryOfShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"}, "lang": "en-us", "role": "label", "Debt Securities, Available for Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206" ] }, "us_gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureShortTermInvestmentsTables"}, "lang": "en-us", "role": "label", "Summary of Short Term Investments Classified as Available for Sale Securities", "label": "Debt Securities, Available for Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883" ] }, "us_gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"}, "lang": "en-us", "role": "label", "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Prepaid Expenses
```

Items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. } } }, "auth_ref": { "label": "DocumentInformationTable", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "document_information_table_documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": { "label": "DocumentPeriodEndDate", "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "document_period_end_date_verbose_label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the earliest event reported; for the EDGAR submission types of Form N-1A, the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { "label": "DocumentQuarterlyReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "document_quarterly_report": "Boolean flag that is true only for a form used as a quarterly report." } } }, "auth_ref": { "label": "DocumentTransitionReport", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "document_transition_report": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "label": "DocumentType", "xbrltype": "submissionTypeItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "document_type_verbose_label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": { "label": "DividendsOrOtherEarningsPaidOnEquityAwardsNotOtherwiseReflectedInTotalCompensationForCoveredYear", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecdd/2024", "localname": "DivdvsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRfctdnTtlCompFrCvrdYrMmber", "presentation": "http://xbrl.sec.gov/ecdd/rpt/disclosure", "lang": "en-us", "role": "label", "dividends_or_other_earnings_paid_on_equity_awards_not_others_reflected_in_total_compensation_for_covered_year_member": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards Not Otherwise Reflected in Total Compensation for Covered Year", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": "en-us", "role": "label", "earnings_per_share_abstract": "Earnings Per Share [Abstract]" } } }, "auth_ref": { "label": "us_gaap_earnings_per_share_basic", "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": "http://www.edclon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "lang": "en-us", "role": "label", "us_gaap_earnings_per_share_diluted": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "label": "us_gaap_earnings_per_share_diluted", "xbrltype": "perShareItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": "http://www.edclon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "lang": "en-us", "role": "label", "us_gaap_earnings_per_share_text_block": "Text Block Item Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": "http://www.edclon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "lang": "en-us", "role": "label", "employee_service_share_based_compensation_allocation_of_recognized_period_costs_line_items": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs Line Items", "presentation": "http://www.edclon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationExpenseRecognizedDetail", "lang": "en-us", "role": "label", "share_based_payment_arrangement_expensed_and_capitalized_amount_line_items": "Share-based Payment Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "label": "employee_stock_option_member", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": "http://www.edclon.com/20240930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail", "lang": "en-us", "role": "label", "employee_stock_option_verbose_label": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { "label": "dei_entity_address_line_1", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_address_line_one": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "label": "dei_entity_address_line_2", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_address_line_two": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { "label": "dei_entity_address_city_or_town", "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_address_city_or_town": "Name of the City or Town" } } }, "auth_ref": { "label": "dei_entity_postal_zip_code", "xbrltype": "normalizedStringItemType", "nsuri": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_postal_zip_code": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "label": "dei_entity_state_or_province", "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_address_state_or_province": "Name of the state or province" } } }, "auth_ref": { "label": "dei_entity_addresses_address_type_axis", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_addresses_address_type_axis": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": { "label": "dei_entity_central_index_key", "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_central_index_key": "Entity Central Index Key", "documentation": "A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "label": "dei_entity_common_stock_shares_outstanding", "xbrltype": "sharesItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_common_stock_shares_outstanding": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings. Instrument." } } }, "auth_ref": { "label": "dei_entity_current_reporting_status", "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_current_reporting_status": "Indicate Yes or No whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "label": "dei_entity_domain", "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": "en-us", "role": "label", "entity_domain": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "label": "dei_entity_emerging_growth_company", "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_emerging_growth_company": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "label": "dei_entity_file_number", "xbrltype": "fileNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_file_number": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "label": "dei_entity_filer_category", "xbrltype": "filerCategoryItem", "nsuri": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_filer_category": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "label": "dei_entity_incorporation_state_country_code", "xbrltype": "edgarStateCountryItem", "nsuri": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_incorporation_state_or_country_code": "Two character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "label": "dei_entity_interactive_data_current", "xbrltype": "yesNoItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": "http://www.edclon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "lang": "en-us", "role": "label", "entity_interactive_data_current": "Boolean

```
"http://www.eledon.com/20240930/taxonomy/role/Role_DocumentContentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)" } } }, "auth ref": { "r739" } }, { "doi_EntityTaxIdentificationNumber": { "xbrltype": "EmployerIdItem Type", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DocumentContentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } }, "auth ref": { "r739" } }, { "ced_EgtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EgtyAwrdsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments Footnote", "documentation": "Footnote" } } }, "auth ref": { "r780" } }, { "ced_EgtyAwrdsAdjsExclGValRprtInSummaryCompsnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EgtyAwrdsAdjsExclGValRprtInSummaryCompsnTblMember", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments Excluded Value Reported in Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments Excluded Value Reported in Compensation Table", "documentation": "Excluding Value Reported in the Compensation Table [Member]" } } }, "auth ref": { "r821" } }, { "ced_EgtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EgtyAwrdsAdjsMember", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9 digit value assigned by the IRS." } } }, "auth ref": { "r821" } }, { "ced_EgtyAwrdsInSummaryCompsnTblForApblMmber": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ced/2024", "localname": "EgtyAwrdsInSummaryCompsnTblForApblMmber", "presentation": { "http://xbrl.sec.gov/ced/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "documentation": "Footnote" } } }, "auth ref": { "r821" } }, { "us_gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640" } }, { "eldn_EquityDistributionAgreementMaximumValueOfCommonSharesIssuable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "EquityDistributionAgreementMaximumValueOfCommonSharesIssuable", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Equity distribution agreement maximum value of common shares issuable", "label": "Equity Distribution Agreement Maximum Value Of Common Shares Issuable", "terseLabel": "Equity distribution agreement maximum value of common shares issuable" } } }, "auth ref": { "r90", "r90", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r266", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r56
```

```
{ "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Aggregate Fair Values of Warrant Liability", "documentation": "Tabular disclosure of liabilities, including financial instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset." } }, "auth-ref": { "r30": "r31" } }, "us-gaap": { "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfWarrantLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails": { "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r407": "r408", "r409": "r410", "r411": "r412" } }, "us-gaap": { "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfWarrantLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails": { "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input." } } }, "auth-ref": { "r407": "r408", "r409": "r410", "r411": "r412", "r417" } } }, "us-gaap": { "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsTables": { "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Warrant Liabilities Measured at Fair Value on a Recurring Basis", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth-ref": { "r407": "r412", "r417" } } }, "us-gaap": { "FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Fair Value Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth-ref": { "r402": "r403", "r404": "r406", "r704": "r933", "r936" } } } }, "us-gaap": { "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Balance as of September 30, 2024", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodStartLabel": "Balance as of December 31, 2023", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth-ref": { "r407": "r417" } } } }, "us-gaap": { "FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail": { "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth-ref": { "r276": "r298", "r299": "r300", "r301": "r302", "r303": "r401", "r403", "r404", "r405", "r406", "r415", "r416", "r418", "r463", "r464", "r465", "r693", "r694", "r697", "r698", "r699", "r704", "r708" } } } }, "us-gaap": { "FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth-ref": { "r704": "r930", "r931": "r932", "r933", "r934", "r936" } } } }, "eldn": { "FeeDueForMilestonesAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "FeeDueForMilestonesAchieved", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "label": "Fee due for milestones achieved.", "label": "Fee Due For Milestones Achieved", "terseLabel": "Fee due for milestones achieved" } } }, "auth-ref": {} } } }, "us-gaap": { "FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Financial Instrument Axis", "documentation": "Information by type of financial instrument." } } }, "auth-ref": { "r195": "r196", "r197": "r198", "r199", "r200", "r201", "r202", "r203", "r242", "r244", "r245", "r246", "r277", "r292", "r388", "r423", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r548", "r690", "r704", "r706", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r717", "r838", "r839", "r840", "r841", "r842", "r843", "r844", "r893", "r894", "r895", "r896", "r920", "r932", "r933", "r934", "r935", "r936" } } } }, "eldn": { "FiveHundredMillionAggregateNetSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "FiveHundredMillionAggregateNetSalesMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "label": "Five hundred million aggregate net sales.", "label": "Five Hundred Million Aggregate Net Sales [Member]", "terseLabel": "Achievement of 500 Million Aggregate Sales [Member]" } } }, "auth-ref": {} } } }, "ecd": { "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth-ref": { "r751": "r761", "r772", "r804" } } } }, "ecd": { "ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth-ref": { "r751": "r761", "r772", "r804" } } } }, "ecd": { "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth-ref": { "r751": "r761", "r772", "r804" } } } }, "ecd": { "ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth-ref": { "r751": "r761", "r772", "r804" } } } }, "ecd": { "ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth-ref": { "r751": "r761", "r772", "r804" } } } }, "dei": { "FormerAddressMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "FormerAddressMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DocumentDocumentAndEntityInformation": { "lang": { "en-us": { "role": { "label": "Former Address [Member]", "documentation": "Former address for entity" } } }, "auth-ref": { "r742": "r764" } } } }, "ecd": { "FrValAsOfPrYrEndOfEqtyAwrdGrtndPrYrsFlvStngCndsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOfEqtyAwrdGrtndPrYrsFl
```

```

reported." } } }, "auth ref": [ "r256", "r258", "r408", "r412", "r417", "r553", "r555", "r625", "r675", "r707", "r957" ] }, "us-gaap-IncreaseDecreaseInOperatingCapitalAbstract" - { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "auth ref": [ ] }, "oldn-IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease" - { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IncreaseDecreaseInOperatingLeaseAssetAndLiabilityDueToNewLease", "credit": "presentation", { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease asset and liability due to new lease." }, "label": "Increase Decrease in Operating Lease Asset and Liability Due To New Lease", "terseLabel": "Increase in operating lease asset and liability due to new lease" } } }, "auth ref": [ ] }, "us-gaap-IncreaseDecreaseInOperatingLeaseLiability" - { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "credit": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth ref": [ "r833", "r851" ] }, "us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" - { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "credit": "presentation", { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth ref": [ "r5" ] }, "ecd-IndividualAxis" - { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PrpDisclosure", "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual." } } }, "auth ref": [ "r751", "r761", "r772", "r796", "r804", "r808", "r816" ] }, "ecd-InsiderTradingArrLineItems" - { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements." } } }, "auth ref": [ "r814" ] }, "ecd-InsiderTradingPoliciesProcLineItems" - { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures." } } }, "auth ref": [ "r743", "r820" ] }, "ecd-InsiderTrdPoliciesProcAdoptedFlag" - { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth ref": [ "r743", "r820" ] }, "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock" - { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth ref": [ "r743", "r820" ] }, "us-gaap-InvestmentsDebtAndEquitySecuritiesAbstract" - { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Investments Debt and Equity Securities [Abstract]", "terseLabel": "Investments Debt and Equity Securities" } } }, "auth ref": [ ] }, "us-gaap-InvestmentsFairValueDisclosure" - { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "credit": "debit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOffFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" }, "lang": { "en-us": { "role": { "terseLabel": "Total short term investments", "totalLabel": "Total short term investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } }, "auth ref": [ "r930", "r931", "r935" ] }, "oldn-IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares" - { "xbrltype": "sharesItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithConversionOfX1NonVotingConvertiblePreferredStockShares", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock Shares", "label": "Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Shares", "documentation": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock shares." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockValue" - { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockValue", "credit": "presentation", { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock Value", "label": "Issuance Of Common Stock In Connection With Conversion Of X1 Non-voting Convertible Preferred Stock Value", "documentation": "Issuance of common stock in connection with conversion of X1 non-voting convertible preferred stock value." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares" - { "xbrltype": "sharesItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithConversionOfXNonVotingConvertiblePreferredStockShares", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with conversion of X non-voting convertible preferred stock Shares", "label": "Issuance Of Common Stock In Connection With Conversion Of X Non-voting Convertible Preferred Stock Shares", "documentation": "Issuance of common stock in connection with conversion of x non-voting convertible preferred stock shares." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares" - { "xbrltype": "sharesItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsShares", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with exercise of pre-funded warrants shares." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue" - { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithExerciseOfPreFundedWarrantsValue", "credit": "presentation", { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of common stock in connection with exercise of pre-funded warrants Value", "label": "Issuance Of Common Stock In Connection With Exercise Of Pre-funded Warrants Value", "documentation": "Issuance of common stock in connection with exercise of pre-funded warrants value." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares" - { "xbrltype": "sharesItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsShares", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Shares", "documentation": "Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, shares." } } }, "auth ref": [ ] }, "oldn-IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue" - { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "IssuanceOfCommonStockInConnectionWithPrivateInvestmentInPublicEquityTransactionNetOfIssuanceCostsValue", "credit": "presentation", { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": { "en-us": { "role": { "label": "Issuance of Common Stock in Connection with Private Investment in Public Equity Transaction, Net of Issuance Costs, Value", "documentation": "Issuance of common stock in connection with private investment in public equity transaction, net of issuance costs, value." } } }, "auth ref": [ ] }, "oldn-JefferiesLimitedLiabilityCompanyMember" - { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "documentation": "Jefferies Limited Liability Company", "label": "Jefferies Limited Liability Company [Member]", "terseLabel": "Jefferies LLC [Member]" } } }, "auth ref": [ ] }, "us-gaap-LeaseCostTableTextBlock" - { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesTables", "lang": { "en-us": { "role": { "label": "Lease Cost [Table Text Block]", "terseLabel": "Components of Lease Expense", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth ref": [ "r940" ] }, "us-gaap-LeaseExpirationDate" - { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Lease Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth ref": [ ] }, "oldn-LeerinkPartnersLlcMember" - { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "LeerinkPartnersLlcMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Disc
```


lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": { "r447" } }, "eIdn_LesseeOperatingLeaseRemainingTermOfContract": { "xbrlyte":
"durationItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "LesseeOperatingLeaseRemainingTermOfContract", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-us": { "role": { "documentation": "Lessee
operating lease remaining term of contract.", "label": "Lessee Operating Lease Remaining Term Of Contract", "terseLabel": "Remaining term of office lease" } } }, "auth_ref": { } }, "us-
gaap_LesseeOperatingLeaseTermOfContract": { "xbrlyte": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "label": "Lessee Operating Lease
Term of Contract", "terseLabel": "Operating lease term of contract", "documentation": "Term of lessee's operating lease in PnYnMnDtnHnMns format, for example, PIY5M13D represents
reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r939" } }, "us-gaap_Liabilities": { "xbrlyte": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "Liabilities", "crdr": "credit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense"
"http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities",
"terseLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": {
"r12", "r49", "r50", "r51", "r52", "r53", "r54", "r55", "r136", "r226", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r374", "r375", "r376", "r426", "r599", "r685", "r737",
"r896", "r946", "r947" } } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrlyte": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-
us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity
attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r62", "r83", "r544", "r716", "r853", "r887", "r937" } } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrlyte":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel":
"LIABILITIES AND STOCKHOLDERS EQUITY (19 EQUI)" } } }, "auth_ref": { } }, "us-gaap_LiabilitiesCurrent": { "xbrlyte": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "
"LiabilitiesCurrent", "crdr": "credit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-us": { "role": { "role":
"label", "Liabilities Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following
twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r51", "r105", "r136", "r226", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r374", "r375",
"r376", "r426", "r716", "r896", "r946", "r947" } } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrlyte": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "
"LiabilitiesCurrentAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets"} } }, "lang": { "en-us": { "role": { "label":
"Liabilities Current [Abstract]", "terseLabel": "Current liabilities." } } }, "auth_ref": { } }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrlyte": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfWarrantLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails"} } }, "lang": { "en-us": { "role":
"totalLabel": "Liabilities Fair Value Disclosure Total", "label": "Liabilities Fair Value Disclosure", "terseLabel": "Liabilities measured at fair value", "documentation": "Fair value of financial
and nonfinancial obligations." } } }, "auth_ref": { "r403", "r930" } }, "eIdn_LiquidityAndFinancialConditionPolicyTextBlock": { "xbrlyte": "textBlockItemType", "nsuri":
"http://www.eledon.com/20240930", "localname": "LiquidityAndFinancialConditionPolicyTextBlock", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesPolicies"} } }, "lang": { "en-us": { "role": { "documentation": "Liquidity and financial
condition.", "label": "Liquidity And Financial Condition Policy [Text Block]", "terseLabel": "Liquidity and Financial Condition" } } }, "auth_ref": { } }, "dei_LocalPhoneNumber": { "xbrlyte":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DocumentDocumentAndEntityInformation"} } }, "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone
Number", "documentation": "Local phone number for entity." } } }, "auth_ref": { } }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrlyte": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "label": "Category of Item
Purchased [Axis]", "terseLabel": "Category of Item Purchased", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": { } },
"us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrlyte": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "
"LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "label": "Long Term Purchase
Commitment Category of Item Purchased [Domain]", "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased", "documentation": "General description of the goods or
services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": { } }, "stpr_MA": { "xbrlyte": "domainItemType", "nsuri":
"http://xbrl.sec.gov/stpr/2024", "localname": "MA", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "label": "MASSACHUSETTS",
"terseLabel": "Burlington, Massachusetts [Member]" } } }, "auth_ref": { } }, "srt_MaximumMember": { "xbrlyte": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "
"MaximumMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"} } },
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlacksholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet"
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "label": "Maximum [Member]", "label":
"Maximum [Member]" } } }, "auth_ref": { "r261", "r262", "r263", "r264", "r305", "r343", "r406", "r492", "r552", "r554", "r568", "r591", "r592", "r647", "r649", "r651", "r652", "r654", "r673",
"r674", "r689", "r695", "r702", "r708", "r709", "r713", "r714", "r726", "r898", "r948", "r949", "r950", "r951", "r952", "r953" } } }, "eed_MeasureAxis": { "xbrlyte": "stringItemType", "nsuri":
"http://xbrl.sec.gov/eed/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/eed/role/PvpDisclosure"} } }, "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel":
"Measure." } } }, "auth_ref": { "r788" } }, "eed_MeasureName": { "xbrlyte": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/eed/2024", "localname": "MeasureName", "presentation": {
"http://xbrl.sec.gov/eed/role/PvpDisclosure"} } }, "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": { "r788" } }, "srt_MinimumMember": { "xbrlyte":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"} } },
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlacksholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet"
"http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail"} } }, "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label":
"Minimum [Member]" } } }, "auth_ref": { "r261", "r262", "r263", "r264", "r305", "r343", "r406", "r492", "r552", "r554", "r568", "r591", "r592", "r647", "r649", "r651", "r652", "r654", "r673",
"r674", "r689", "r695", "r702", "r708", "r709", "r713", "r726", "r898", "r948", "r949", "r950", "r951", "r952", "r953" } } }, "eed_MnpDiscTimedForCompValFlag": { "xbrlyte": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/eed/2024", "localname": "MnpDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/eed/AwardTimingDisclosure"} } }, "lang": { "en-us": { "role": { "role":
"label", "MNPI Disclosure Timed for Compensation Val[Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": { "r907" } } }, "us-
gaap_MoneyMarketFundsMember": { "xbrlyte": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"} } },

"http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail"
"http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": / "en-us": / "role": / "totalLabel": "Net income (loss) attributable to common shares - basic", "terseLabel": "Net income (loss) attributable to common shares - diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }."auth ref": / "r129": "r162", "r165", "r166", "r167", "r168", "r171", "r176" } }
"eldn_NetIncomeLossesExcludingGainOfChangeInFairValueOfWarrant": / "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "NetIncomeLossesExcludingGainOfChangeInFairValueOfWarrant", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "terseLabel": "Net income (losses) excluding gain of change in fair value of warrant", "label": "Net Income (Losses) Excluding Gain Of Change In Fair Value Of Warrant", "documentation": "Net income (losses) excluding gain of change in fair value of warrant." } } }."auth ref": / "us-gaap-NewAccountingPronouncementsPolicyPolicyTextBlock": / "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "lang": / "en-us": / "role": / "terseLabel": "Recently Adopted Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }."auth ref": / "ced_NonGaapMeasureDescriptionTextBlock": / "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": / "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": / "en-us": / "role": / "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }."auth ref": / "r788": / "ced_NonNeosMember": / "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": / "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": / "en-us": / "role": / "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }."auth ref": / "r751": "r761", "r772", "r796", "r804" } }"ced_NonPeeNeoAvgCompActuallyPaidAmt": / "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt", "presentation": / "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": / "en-us": / "role": / "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }."auth ref": / "r779" } }"ced_NonPeeNeoAvgTotalCompAmt": / "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgTotalCompAmt", "presentation": / "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": / "en-us": / "role": / "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }."auth ref": / "r789" } }"ced_NonPeeNeoMember": / "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoMember", "presentation": / "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": / "en-us": / "role": / "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }."auth ref": / "r796" } }"ced_NonRule10b51ArrAdoptedFlag": / "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": / "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": / "en-us": / "role": / "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }."auth ref": / "r815" } }"ced_NonRule10b51ArrTrmndFlag": / "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": / "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": / "en-us": / "role": / "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }."auth ref": / "r815" } }"eldn_NoncashActivitiesAbstract": / "xbrltype": "stringItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "NoncashActivitiesAbstract", "presentation": /
"http://www.eledon.com/20240930", "localname": "NoncashActivitiesAbstract", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "lang": / "en-us": / "role": / "terseLabel": "Noncash activities", "label": "Noncash Activities [Abstract]", "documentation": "Noncash activities." } } }."auth ref": / "eldn_NumberOfDaysAfterRegistrationSettlement": / "xbrltype": "durationItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "NumberOfDaysAfterRegistrationSettlement", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "terseLabel": "Number of days after registration settlement", "label": "Number of Days After Registration Settlement", "documentation": "Number of days after registration settlement." } } }."auth ref": / "eldn_NumberOfMilestonesAchieved": / "xbrltype": "integerItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "NumberOfMilestonesAchieved", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "documentation": "Number of milestones achieved", "label": "Number Of Milestones Achieved", "terseLabel": "Number of Milestones Achieved" } } }."auth ref": / "eldn_NumberOfPreFundedWarrantsExercisedForCommonStock": / "xbrltype": "sharesItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "NumberOfPreFundedWarrantsExercisedForCommonStock", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "terseLabel": "Number of pre-funded warrants exercised for common stock", "label": "Number of Pre-funded Warrants Exercised For Common Stock", "documentation": "Number of pre-funded warrants exercised for common stock." } } }."auth ref": / "eldn_OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember": / "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "OfficeOfChiefScientistOfIsraeliMinistryOfEconomyAndIndustryMember", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "documentation": "Office of chief scientist of Israeli ministry of economy and industry", "label": "Office Of Chief Scientist Of Israeli Ministry Of Economy And Industry [Member]", "terseLabel": "Office of Chief Scientist of Israeli Ministry of Economy and Industry [Member]" } } }."auth ref": / "eldn_OneBillionAggregateNetSalesMember": / "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "OneBillionAggregateNetSalesMember", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "documentation": "One billion aggregate net sales", "label": "One Billion Aggregate Net Sales [Member]", "terseLabel": "Achievement of 1 Billion Aggregate Sales [Member]" } } }."auth ref": / "us-gaap-OperatingExpenses": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": / "en-us": / "role": / "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }."auth ref": / "us-gaap-OperatingExpensesAbstract": / "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations", "lang": / "en-us": / "role": / "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }."auth ref": / "us-gaap-OperatingIncomeLoss": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" }, "lang": / "en-us": / "role": / "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }."auth ref": / "r87": "r866", "r862", "r863", "r864", "r865", "r866" } }"us-gaap-OperatingLeaseCost": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesComponentsOfLeaseExpenseDetail" }, "lang": / "en-us": / "role": / "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right of use asset, calculated by amortization of remaining right of use asset and accretion of lease liability." } } }."auth ref": / "r443": "r715" } }"us-gaap-OperatingLeaseExpense": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "label": "Operating Lease, Expense", "terseLabel": "Rental expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }."auth ref": / "r938" } }"us-gaap-OperatingLeaseLiability": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail" }, "lang": / "en-us": / "role": / "label": "Operating Lease, Liability", "totalLabel": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }."auth ref": / "r441" } }"us-gaap-OperatingLeaseLiabilityCurrent": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": / "en-us": / "role": / "negatedLabel": "Less current portion of operating lease liabilities", "verboseLabel": "Current operating lease liabilities", "totalLabel": "Operating Lease, Liability, Current, Total", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }."auth ref": / "r441" } }"us-gaap-OperatingLeaseLiabilityNoncurrent": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFuturePaymentsUnderNoncancelableOperatingLeasesDetail"
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": / "en-us": / "role": / "terseLabel": "Non-current operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "totalLabel": "Operating Lease, Liability, Noncurrent, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }."auth ref": / "r441" } }"us-gaap-OperatingLeasePayments": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" }, "lang": / "en-us": / "role": / "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }."auth ref": / "r442": "r444" } }"us-gaap-OperatingLeaseRightOfUseAsset": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": / "en-us": / "role": / "label": "Operating Lease, Right of Use Asset", "verboseLabel": "Operating lease asset, net", "terseLabel": "ROU assets and lease liabilities", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }."auth ref": / "r440" } }"us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": / "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" }, "lang": / "en-us": / "role": / "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }."auth ref": / "r446": "r715" } }"us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm": / "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail" }, "lang": / "en-us": / "role": / "label": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }."auth ref": / "r445": "r715" } }"us-gaap-OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": / "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": / "en-us": / "role": / "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }."auth ref": / "us-gaap-OtherAccruedLiabilitiesCurrent": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureAccruedExpensesAndOtherLiabilitiesScheduleOfAccruedExpensesAndOtherLiabilitiesDetail" }, "lang": / "en-us": / "role": / "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }."auth ref": / "r50" } }"us-gaap-OtherAssetsCurrent": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail" }, "lang": / "en-us": / "role": / "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }."auth ref": / "r144": "r716" } }"us-gaap-OtherAssetsNoncurrent": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": / "en-us": / "role": / "label": "Other Assets, Noncurrent", "terseLabel": "Other assets", "totalLabel": "Other Assets, Noncurrent, Total", "documentation": "Amount of noncurrent assets classified as other." } } }."auth ref": / "r108" } }"us-gaap-OtherCommitmentsLineItems": / "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }."auth ref": / "us-gaap-OtherCommitmentsTable": / "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": /
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" }, "lang": / "en-us": / "role": / "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }."auth ref": / "us-gaap-OtherComprehensiveIncomeLossNetOfTax": / "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": / "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" }, "lang": / "en-us": / "role": / "terseLabel": "Other comprehensive income", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total", "documentation": "Amount of other comprehensive income (loss), net of tax, available to common shareholders, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }.

Amount after tax and reclassification adjustments of other comprehensive income (loss) } } } "auth-ref": { "r9", "r11", "r119", "r122", "r126", "r152", "r427", "r428", "r433", "r531", "r547", "r648", "r840" } }, "us-gaap-OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "lang": { "en-us": { "role": { "verboseLabel": "Unrealized gain on available-for-sale securities, net", "terseLabel": "Unrealized gain (loss) on available-for-sale securities, net", "label": "OCI Debt Securities Available for Sale Unrealized Holding Gain (Loss) before Adjustment and Tax", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } } }, "auth-ref": { "r16", "r117", "r225" } }, "eldn-OtherInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://www.eddon.com/20240930", "localname": "OtherInformationRelatedToLeasesTableTextBlock", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesTables": { "lang": { "en-us": { "role": { "documentation": "Other information related to leases.", "label": "Other Information Related To Leases Table [Text Block]", "terseLabel": "Schedule of Other Information Related to Leases" } } } }, "auth-ref": { "us-gaap-OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": { "lang": { "en-us": { "role": { "verboseLabel": "Other income, net", "terseLabel": "Other income, net", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense) Total", "documentation": "Amount of income (expense) related to nonoperating activities classified as other." } } } }, "auth-ref": { "r66" } }, "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Other Performance Measure Amount", "terseLabel": "Other Performance Measure Amount", "label": "Other Performance Measure Amount" } } } }, "auth-ref": { "r788" } }, "us-gaap-OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/Role-DisclosurePrepaidExpensesAndOtherCurrentAssetsPrepaidExpensesAndOtherCurrentAssetsDetail": { "lang": { "en-us": { "role": { "label": "Other Prepaid Expense Current", "terseLabel": "Prepaid other, documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } } }, "auth-ref": { "r845", "r890" } }, "eldn-OtherPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eddon.com/20240930", "localname": "OtherPharmaIncMember", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail": { "lang": { "en-us": { "role": { "documentation": "Otic Pharma, Inc.", "label": "Otic Pharma Inc [Member]", "terseLabel": "Otic Pharma, Inc. [Member]" } } } }, "auth-ref": { "ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } } }, "auth-ref": { "r740", "r759", "r770", "r802" } }, "ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } } }, "auth-ref": { "r752", "r762", "r773", "r805" } }, "ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Recovery Individual Name", "terseLabel": "Name" } } } }, "auth-ref": { "r752", "r762", "r773", "r805" } }, "ecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } } }, "auth-ref": { "r772" } }, "us-gaap-PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables And Accruals [Abstract]", "auth-ref": { "us-gaap-PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase of available-for-sale short-term investments", "label": "Payments to Acquire Debt Securities Available for Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } } }, "auth-ref": { "r17", "r130", "r194" } }, "ecd-PeerGroupIssuesFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuesFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Peer Group Issues, Footnote [Text Block]", "terseLabel": "Peer Group Issues, Footnote" } } } }, "auth-ref": { "r787" } }, "ecd-PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } } }, "auth-ref": { "r787" } }, "ecd-PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } } }, "auth-ref": { "r779" } }, "ecd-PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } } }, "auth-ref": { "r796" } }, "ecd-PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } } }, "auth-ref": { "r789" } }, "ecd-PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } } }, "auth-ref": { "r778" } }, "eldn-PerformanceBasedVestingRequirementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eddon.com/20240930", "localname": "PerformanceBasedVestingRequirementsMember", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail": { "lang": { "en-us": { "role": { "terseLabel": "Performance-based Vesting Requirements [Member]", "label": "Performance-based Vesting Requirements [Member]", "documentation": "Performance-based vesting requirements." } } } }, "auth-ref": { "us-gaap-PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail": { "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } } }, "auth-ref": { "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926" } }, "us-gaap-PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.eddon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail": { "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } } }, "auth-ref": { "r901", "r902", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926" } }, "ecd-PnsAdjsPrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsAdjsPrSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } } }, "auth-ref": { "r780" } }, "ecd-PnsAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } } }, "auth-ref": { "r824" } }, "ecd-PnsBnfAsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsBnfAsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } } }, "auth-ref": { "r779" } }, "eldn-PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eddon.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": { "http://www.eddon.com/202409

[illegible]

<http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense>
"http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "lang": { "en-us": { "role": { "label": "Revision of Prior Period Adjustment [Member]" } } } | "auth_ref": { "r130": "r140" | "r141" | "r154" | "r155" | "r181" | "r308" | "r390" | "r437" | "r828" | "r829" | "r830" | "r831" | "r832" | "r836" | "r837" | "r867" } | "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]" } } } | "auth_ref": { "r100": "r130" | "r140" | "r141" | "r143" | "r144" | "r147" | "r148" | "r149" | "r150" | "r153" | "r154" | "r155" | "r156" | "r157" | "r158" | "r181" | "r223" | "r233" | "r238" | "r358" | "r359" | "r361" | "r362" | "r370" | "r371" | "r394" | "r398" | "r399" | "r400" | "r435" | "r437" | "r452" | "r453" | "r558" | "r559" | "r560" | "r561" | "r562" | "r563" | "r564" | "r565" | "r566" | "r567" | "r569" | "r867" } | "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } } | "terseLabel": "Restatement Determination Date" } | "auth_ref": { "r745" | "r755" | "r766" | "r790" } | "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } } | "terseLabel": "Restatement Determination Date" } | "auth_ref": { "r746" | "r756" | "r767" | "r790" } | "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" | "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]" } } } | "terseLabel": "Restatement does not require Recovery" } | "auth_ref": { "r753" | "r763" | "r774" | "r806" } | "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]" } } } | "auth_ref": { "r100": "r130" | "r140" | "r141" | "r143" | "r144" | "r147" | "r148" | "r149" | "r150" | "r153" | "r154" | "r155" | "r156" | "r157" | "r158" | "r181" | "r223" | "r233" | "r238" | "r358" | "r359" | "r361" | "r362" | "r370" | "r371" | "r394" | "r398" | "r399" | "r400" | "r435" | "r437" | "r452" | "r453" | "r558" | "r559" | "r560" | "r561" | "r562" | "r563" | "r564" | "r565" | "r566" | "r567" | "r569" | "r867" } | "us-gaap-RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail" | "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Domain]" } } } | "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } | "auth_ref": { "r106" } | "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" | "http://www.eledon.com/20240930/taxonomy/role/Role-StatementCondensedConsolidatedBalanceSheets" | "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)" } } } | "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit). Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit). Beginning Balance", "periodEndLabel": "Retained Earnings (Accumulated Deficit). Ending Balance", "documentation": "Amount of accumulated undistributed earnings (deficit)." } | "auth_ref": { "r59" | "r79" | "r543" | "r562" | "r567" | "r575" | "r602" | "r716" } | "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense" | "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" | "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]" } } } | "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } | "auth_ref": { "r90" | "r139" | "r140" | "r141" | "r144" | "r152" | "r155" | "r157" | "r231" | "r237" | "r254" | "r349" | "r350" | "r357" | "r358" | "r359" | "r362" | "r370" | "r371" | "r380" | "r383" | "r384" | "r387" | "r398" | "r436" | "r438" | "r558" | "r560" | "r576" | "r986" } | "oldn-RisksAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "RisksAndUncertaintiesPolicyTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureSummaryOfSignificantAccountingPoliciesPolicies" | "lang": { "en-us": { "role": { "label": "Risks and Uncertainties" } } } | "label": "Risks and Uncertainties [Policy Text Block]", "documentation": "Risks and uncertainties." } | "auth_ref": { "us-gaap-RoyaltyGuaranteesCommitmentsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RoyaltyGuaranteesCommitmentsAmount", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" | "lang": { "en-us": { "role": { "label": "Royalty Guarantees. Commitments. Amount" } } } | "terseLabel": "Amount of one-time milestone payment", "documentation": "The amount the entity has committed to make for future royalty guarantees." } | "auth_ref": { "r497" } | "ecd-Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" | "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } } | "terseLabel": "Rule 10b5-1 Arrangement Adopted" } | "auth_ref": { "r815" } | "ecd-Rule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" | "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } } | "terseLabel": "Rule 10b5-1 Arrangement Terminated" } | "auth_ref": { "r815" } | "us-gaap-SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail" | "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail" | "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityScheduleOfWarrantActivityDetail" | "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]" } } } | "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } | "auth_ref": { "us-gaap-SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail" | "http://www.eledon.com/

"role": "label", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method Table", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two class method." }, { "role": "auth ref", "ref": "r26", "r28", "r163", "r164", "r172" }, { "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStockbasedCompensationExpenseRecognizedDetail", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Expensed and Capitalized, Amount Table", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs Table", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth ref": "r39" }, { "us-gaap-ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "lang": { "en-us": { "role": { "label": "Error Correction Table", "documentation": "Disclosure of information about prior period adjustment to correct error in previously issued financial statement. Includes, but is not limited to, effect of correction on financial statement line item, affected per share amount, cumulative effect of change on retained earnings and other appropriate component of equity or net assets in statement of financial position, and effect of prior period adjustment on net income of each prior period presented." } } }, "auth ref": "r147", "r148", "r149", "r154", "r155", "r156", "r157", "r181" }, { "us-gaap-ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsTables", "lang": { "en-us": { "role": { "label": "Schedule of Error Corrections and Prior Period Adjustments Table Text Block", "terseLabel": "Summary of Impact of Correction of Misstatements", "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made." } } }, "auth ref": "r23", "r24", "r25" }, { "us-gaap-ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackScholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet", "lang": { "en-us": { "role": { "label": "Schedule of Share Based Compensation Arrangements by Share Based Payment Award Table", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth ref": "r307", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336" }, { "us-gaap-ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "label": "Schedule of Share Based Payment Award, Stock Options, Valuation Assumptions Table Text Block", "terseLabel": "Schedule of Assumptions Used in Black Scholes Option Pricing Model to Determine Fair Value of Stock Options Granted", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth ref": "r80" }, { "us-gaap-ScheduleOfStockByClassTable", { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "label": "Stock, Class of Stock Table", "terseLabel": "Schedule Of Stock By Class Table", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth ref": "r32", "r33", "r34", "r35", "r36", "r37", "r74", "r76", "r78", "r79", "r110", "r111", "r112", "r184", "r279", "r280", "r281", "r283", "r286", "r292", "r294", "r571", "r572", "r573", "r574", "r695", "r822", "r852" }, { "eldn-ScheduleOfWarrantActivityTableTextBlock", { "xbrltype": "textBlockItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "ScheduleOfWarrantActivityTableTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityTables", "lang": { "en-us": { "role": { "documentation": "Schedule of warrant activity." "label": "Schedule Of Warrant Activity Table Text Block", "terseLabel": "Schedule of Warrant Activity" } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreement2024Member", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreement2024Member", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "documentation": "Securities purchase agreement two thousand twenty four." "label": "Securities Purchase Agreement 2024 Member", "terseLabel": "2024 Securities Purchase Agreement" } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreementInitialClosingMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreementInitialClosingMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement Initial Closing Member", "label": "Securities Purchase Agreement Initial Closing Member", "documentation": "Securities purchase agreement initial closing." } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreementMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreementMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement Member", "label": "Securities Purchase Agreement Member", "documentation": "Securities purchase agreement." } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreementSecondAndThirdClosingMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreementSecondAndThirdClosingMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Securities Purchase Agreement Second and Third Closing Member", "label": "Securities Purchase Agreement Second and Third Closing Member", "documentation": "Securities purchase agreement second and third closing." } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreementSecondClosingMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreementSecondClosingMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "documentation": "Securities purchase agreement second closing." "label": "Securities Purchase Agreement Second Closing Member", "terseLabel": "Securities Purchase Agreement Second Closing Member" } } }, "auth ref": { "eldn-SecuritiesPurchaseAgreementThirdClosingMember", { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "SecuritiesPurchaseAgreementThirdClosingMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Securities Purchase Agreement Third Closing Member", "documentation": "Securities purchase agreement third closing." } } }, "auth ref": { "http://xbrl.sec.gov/doi/2024", "localname": "Security12bTitle", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth ref": { "dei-SecurityExchangeName", { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/doi/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureDocumentAndEntityInformation", "lang": { "en-us": { "role": { "label": "Security Exchange Name", "verboseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth ref": { "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role-DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Geographical Domain", "terseLabel": "Geographical", "auth ref": { "r189", "r190", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r589", "r590", "r648", "r650", "r653", "r655", "r662", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r676", "r677", "r696", "r718", "r719", "r720", "r721", "

reason and justification for its use, and the periods for which the method was used if it was not used in all periods presented." } } }, "auth ref": ["r341"] }, "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" ("xbrltype": "percentItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" ("xbrltype": "percentItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, Minimum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" ("xbrltype": "percentItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "documentation": "The risk free interest rate assumption that is used in valuing an option on its own shares."]] }, "auth ref": ["r335"]], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" ("xbrltype": "percentItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk free interest rate, Maximum", "documentation": "The maximum risk free interest rate assumption that is used in valuing an option on its own shares."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" ("xbrltype": "percentItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk free interest rate, Minimum", "documentation": "The minimum risk free interest rate assumption that is used in valuing an option on its own shares."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share based Compensation Arrangement by Share based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."]] }, "auth ref": ["r307", "r309", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336"]], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" ("xbrltype": "sharesItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": ["en-us", "role": ["terseLabel": "Increased number of shares", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" ("xbrltype": "sharesItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": ["en-us", "role": ["terseLabel": "Stock options issued", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "documentation": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "documentation": "Net number of share options (or share units) granted during the period."]] }, "auth ref": ["r908"]], "us gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" ("xbrltype": "sharesItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": ["en-us", "role": ["terseLabel": "Stock options granted", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period."]] }, "auth ref": ["r318"]], "eldn ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized" ("xbrltype": "sharesItem"Type", "nsuri": "http://www.eledon.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTotalNumberOfSharesAuthorized", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": ["en-us", "role": ["terseLabel": "New aggregate share limit", "label": "Share Based Compensation Arrangement by Share Based Payment Award Total Number Of Shares Authorized", "documentation": "Share based compensation arrangement by share based payment award total number of shares authorized."]] }, "auth ref": []], "us gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" ("xbrltype": "domainItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": ["en-us", "role": ["label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement."]] }, "auth ref": ["r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336"]], "us gaap SharePrice" ("xbrltype": "perShareItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "SharePrice", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company."]] }, "auth ref": []], "us gaap SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" ("xbrltype": "durationItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedInBlackscholesOptionPricingModelToDetermineFairValueOfStockOptionsGrantedDet l", "lang": ["en-us", "role": ["label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."]] }, "auth ref": ["r332"]], "us gaap SharesIssuedPricePerShare" ("xbrltype": "perShareItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "lang": ["en-us", "role": ["label": "Shares Issued, Price Per Share", "terseLabel": "Shares price per share", "documentation": "Per share or per unit amount of equity securities issued."]] }, "auth ref": []], "us gaap SharesOutstanding" ("xbrltype": "sharesItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": ["en-us", "role": ["label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."]] }, "auth ref": []], "us gaap ShortTermInvestments" ("xbrltype": "monetaryItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "ShortTermInvestments", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": ["en-us", "role": ["label": "Short term investments", "label": "Short Term Investments", "totalLabel": "Short Term Investments, Total", "documentation": "Amount of investments including trading securities, available for sale securities, held to maturity securities, and short term investments classified as other and current."]] }, "auth ref": ["r84", "r85", "r946"]], "us gaap SignificantAccountingPoliciesTextBlock" ("xbrltype": "textBlockItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "lang": ["en-us", "role": ["label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."]] }, "auth ref": ["r70", "r134"]], "us gaap StatementOfClassOfStockAxis" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "StatementOfClassOfStockAxis", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityTables", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": ["en-us", "role": ["label": "Class of Stock [Axis]", "terseLabel": "Class of Stock", "documentation": "Information by the different classes of stock of the entity."]] }, "auth ref": ["r96", "r140", "r141", "r142", "r136", "r163", "r164", "r172", "r176", "r184", "r185", "r226", "r266", "r268", "r269", "r270", "r273", "r274", "r279", "r280", "r283", "r286", "r294", "r426", "r571", "r572", "r573", "r574", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r601", "r622", "r640", "r656", "r657", "r658", "r659", "r660", "r827", "r852", "r859"]], "us gaap StatementOfEquityComponentsAxis" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "StatementOfEquityComponentsAxis", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrentActivityDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": ["en-us", "role": ["label": "Equity Components [Axis]", "terseLabel": "Additional Paid-In Capital [Member]", "documentation": "Information by component of equity."]] }, "auth ref": ["r9", "r57", "r60", "r61", "r99", "r123", "r124", "r125", "r139", "r140", "r141", "r144", "r152", "r155", "r157", "r183", "r231", "r237", "r254", "r296", "r349", "r350", "r357", "r358", "r359", "r362", "r370", "r371", "r380", "r382", "r383", "r384", "r385", "r387", "r398", "r427", "r429", "r430", "r431", "r432", "r433", "r436", "r438", "r453", "r547", "r558", "r559", "r560", "r576", "r640"]], "srt StatementGeographicalAxis" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "lang": ["en-us", "role": ["label": "Geographical [Axis]", "terseLabel": "Geographical", "documentation": "Information by the different geographical areas of the entity."]] }, "auth ref": ["r189", "r190", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641"]], "us gaap StatementOfCashFlowsAbstract" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "StatementOfCashFlowsAbstract", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": ["en-us", "role": ["label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."]] }, "auth ref": ["r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641"]], "us gaap StatementOfFinancialPositionAbstract" ("xbrltype": "stringItem"Type", "nsuri": "http://fasb.org/us gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "presentation": ["http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": ["en-us", "role": ["label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."]] }, "auth ref": ["r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557

"StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": { } }, "us_gaap_StatementOfStockholdersEquityAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { } }, "us_gaap_StatementTable", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParentetical", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r139": "r140", "r141": "r183", "r193": "r438", "r493": "r570", "r587", "r593", "r594", "r595", "r596", "r597", "r598", "r601", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r620", "r623", "r624", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r640", "r731" } }, "eeld_StkPrOrTsrEstimationMethodTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/eeld/2024", "localname": "StkPrOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/eeld/role/ErrCompDisclosure", "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r748": "r758", "r769", "r801" } }, "us_gaap_StockAppreciationRightsSARSMember", { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/eeld/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { } }, "us_gaap_StockCompensationPlanMember", { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockCompensationPlanMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareSummaryOfCommonShareEquivalentsWereExcludedBecauseTheInclusionIsAntidilutiveDetail", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Member]", "terseLabel": "Stock Options Outstanding and Other Equity Awards [Member]", "documentation": "Share based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares." } } }, "auth_ref": { "r861" } }, "us_gaap_StockIssued", { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssued", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Stock Issued", "terseLabel": "Common stock issued in lieu of making a cash payment", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": { "r720", "r721", "r722" } }, "us_gaap_StockIssuedDuringPeriodSharesNewIssues", { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common stock number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r9", "r56", "r57", "r70", "r571", "r640", "r657" } }, "us_gaap_StockOptionMember", { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail", "lang": { "en-us": { "role": { "terseLabel": "Common stock options [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": { "r730" } }, "us_gaap_StockholdersEquity", { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/DisclosureRestatementOfPreviouslyIssuedConsolidatedFinancialStatementsSummaryOfImpactOfCorrectionOfMisstatementsCorrectedCondense", "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.eledon.com/20240930/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders' equity", "terseLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": { "r57", "r60", "r61", "r72", "r603", "r619", "r641", "r642", "r716", "r737", "r853", "r887", "r937", "r986" } }, "us_gaap_StockholdersEquityAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Stockholders' equity", "label": "Equity, Attributable to Parent [Abstract]", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": { "r7", "r644" } }, "us_gaap_StockholdersEquityNoteDisclosureTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquity", "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": { "r75", "r135", "r278", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r290", "r291", "r293", "r296", "r389", "r643", "r645", "r661" } }, "us_gaap_StockholdersEquityPolicyTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityPolicyTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Policy [Policy Text Block]", "terseLabel": "Warrant Liabilities", "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income." } } }, "auth_ref": { "r7", "r644" } }, "us_gaap_SubsequentEventLineItems", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": { "r434", "r458" } }, "us_gaap_SubsequentEventMember", { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r434", "r458" } }, "us_gaap_SubsequentEventTable", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": { "r434", "r458" } }, "us_gaap_SubsequentEventTypeAxis", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r434", "r458" } }, "us_gaap_SubsequentEventDomain", { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventDomain", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": { "r434", "r458" } }, "us_gaap_SubsequentEventsAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "auth_ref": { } }, "us_gaap_SubsequentEventsTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSubsequentEvents", "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": { "r457", "r459" } }, "us_gaap_SubSidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions", { "xbrltype": "percentItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubSidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "label": "Subsidiary or Equity Method Investee, Cumulative Percentage Ownership after All Transactions", "terseLabel": "Ownership interest percentage", "documentation": "Percentage of subsidiary's or equity method investee's stock owned by parent immediately after all stock transactions." } } }, "auth_ref": { } }, "us_gaap_SubSidiarySaleOfStockAxis", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfSeriesX1ConvertiblePreferredStockWarrantActivityDetail", "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityScheduleOfWarrantActivityDetail", "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": { } }, "us_gaap_SubstantialDoubtAboutGoingConcernTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlans", "lang": { "en-us": { "role": { "terseLabel": "Going Concern and Management's Plans", "label": "Substantial Doubt about Going Concern [Text Block]", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } }, "auth_ref": { "r47" } }, "eeldn_SummaryOfSignificantAccountingPoliciesLineItems", { "xbrltype": "stringItem", "nsuri": "http://www.eledon.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies." } } }, "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "auth_ref": { } }, "eeldn_SummaryOfSignificantAccountingPoliciesTable", { "xbrltype": "stringItem", "nsuri": "http://www.eledon.com/20240930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies." } } }, "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": { } }, "us_gaap_SupplementalCashFlowInformationAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOtherInformationRelatedToLeasesDetail", "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flows Information", "documentation": "Supplemental cash flows information." } } }, "auth_ref": { } }, "us_gaap_TableTextBlockSupplementAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TableTextBlockSupplementAbstract", "lang": { "en-us": { "role": { "label": "Table Text Block Supplement [Abstract]", "auth_ref": { } }, "eeld_TabularListTableTextBlock", { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/eeld/2024", "localname": "TabularListTableTextBlock", "presentation": { "http://xbrl.sec.gov/eeld/role/PvpDisclosure", "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List Table", "auth_ref": { "r795" } }, "us_gaap_TableTextBlockAbstract", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TextBlockAbstract", "lang": { "en-us": { "role": { "label": "Text Block [Abstract]", "auth_ref": { } }, "eeldn_TimeBasedAndPerformanceBasedVestingRequirementsMember", { "xbrltype": "domainItem", "nsuri": "http://www.eledon.com/20240930", "localname": "TimeBasedAndPerformanceBasedVestingRequirementsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Time-based and Performance-based Vesting Requirements [Member]", "label": "Time-based and Performance-based Vesting Requirements [Member]", "documentation": "Time-based and performance-based vesting requirements." } } }, "auth_ref": { } }, "eeldn_TimeBasedVestingRequirementsMember", { "xbrltype": "domainItem", "nsuri": "http://www.eledon.com/20240930", "localname": "TimeBasedVestingRequirementsMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail", "lang": { "en-us": { "role": { "terseLabel": "Time-based Vesting Requirements [Member]", "label": "Time-based Vesting Requirements [Member]", "documentation": "Time-based vesting requirements." } } }, "auth_ref": { } }, "srt_TypeOfIndividualAxis", { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": {

"http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail";
"Title of Individual" } } }, "auth_ref": { "r868" "r944" } } }, "srt TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024";
"localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail";
"terseLabel": "Title of Individual" } } }, "auth_ref": { } }, "ecod_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure"; "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total
Shareholder Return Amount" } } }, "auth_ref": { "r797" } }, "ecod_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PrpDisclosure"; "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs
Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": { "r794" } }, "ecod_TradingArrAxis": { "xbrltype": "stringItemtype", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading
Arrangement [Axis]", "terseLabel": "Trading Arrangement." } } }, "auth_ref": { "r814" } }, "ecod_TradingArrByIndTable": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual
[Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": { "r816" } }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "TradingSymbol", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"; "lang": { "en-us": { "role": { "label":
"Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": { } }, "us-
gaap_TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAggregateFairValueOfWarrantLiabilityDetails";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfWarrantLiabilitiesMeasuredAtFairValueOnARecurringBasisDetails";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"; "lang": { "en-us": { "role": {
"label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other
financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially
favorable terms." } } }, "auth_ref": { "r195" "r196" "r197" "r198" "r199" "r200" "r201" "r202" "r203" "r204" "r205" "r206" "r207" "r208" "r209" "r210" "r211" "r212" "r213" "r214"
"r215" "r216" "r217" "r218" "r219" "r220" "r221" "r222" "r223" "r224" "r227" "r229" "r388" "r423" "r460" "r461" "r462" "r463" "r464" "r465" "r466" "r467" "r468" "r469" "r470"
"r471" "r472" "r473" "r474" "r477" "r478" "r479" "r480" "r481" "r482" "r483" "r484" "r485" "r486" "r487" "r488" "r489" "r490" "r491" "r548" "r704" "r706" "r708" "r709" "r710"
"r711" "r712" "r713" "r714" "r717" "r738" "r830" "r840" "r841" "r842" "r843" "r844" "r883" "r884" "r885" "r886" "r899" "r932" "r933" "r934" "r935" "r936" } } },
"ecod_TrdArrAdoptionDate": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": { "r817"
"r818" } }, "ecod_TrdArrDuration": { "xbrltype": "durationItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": {
"r818" } }, "ecod_TrdArrExpirationDate": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": {
"r818" } }, "ecod_TrdArrIndName": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": { "r816" } },
"ecod_TrdArrIndTitle": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": { "r816" } },
"ecod_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate
Available" } } }, "auth_ref": { "r819" } }, "ecod_TrdArrTerminationDate": { "xbrltype": "stringItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"; "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } },
"auth_ref": { "r817" } }, "eldn_TwoThousandFourteenEmployeeStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname":
"TwoThousandFourteenEmployeeStockPurchasePlanMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"; "lang": { "en-us": { "role": { "terseLabel": "2014 Employee Stock Purchase
Plan [Member]", "documentation": "Two thousand fourteen employee stock purchase plan." "label": "Two Thousand Fourteen Employee Stock Purchase Plan [Member]" } } }, "auth_ref": { } },
"eldn_TwoThousandFourteenStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname":
"TwoThousandFourteenStockIncentivePlanMember", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail";
"lang": { "en-us": { "role": { "terseLabel": "2014 Stock Incentive Plan [Member]", "documentation": "Two thousand fourteen stock incentive plan." "label": "Two Thousand Fourteen Stock
Incentive Plan [Member]" } } }, "auth_ref": { } }, "eldn_TwoThousandTwentyLongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930",
"localname": "TwoThousandTwentyLongTermIncentivePlanMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureStockbasedCompensationAdditionalInformationDetail"; "lang": { "en-us": { "role": { "terseLabel": "2020 Long Term Incentive Plan
[Member]", "documentation": "Two thousand twenty long term incentive plan." "label": "Two Thousand Twenty Long Term Incentive Plan [Member]" } } }, "auth_ref": { } }, "us-
gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfAdoptionMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"; "lang": { "en-us": { "role": { "label": "Accounting
Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": { "r97" "r98" "r99" "r100" "r101" "r102" "r143" "r144" "r145" "r146" "r158"
"r191" "r192" "r228" "r229" "r230" "r231" "r232" "r233" "r234" "r235" "r236" "r237" "r253" "r254" "r257" "r349" "r350" "r351" "r352" "r353" "r354" "r355" "r356" "r357" "r358"
"r359" "r360" "r361" "r362" "r364" "r365" "r366" "r367" "r368" "r369" "r370" "r371" "r372" "r373" "r377" "r378" "r380" "r381" "r382" "r383" "r384" "r385" "r386" "r387" "r390" "r391"
"r392" "r393" "r394" "r395" "r396" "r397" "r398" "r399" "r400" "r424" "r425" "r435" "r436" "r437" "r448" "r449" "r450" "r451" "r452" "r453" "r494" "r495" "r496" "r556" "r557"
"r558" "r559" "r560" "r561" "r562" "r563" "r564" "r565" "r566" "r567" } }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemtype", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TypeOfArrangementAxis", "presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureGoingConcernAndManagementsPlansAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureStockholdersEquityAdditionalInformationDetail";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"; "lang": { "en-us": { "role": { "label": "Collaborative
Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by
collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } }, "auth_ref": { "r372" } }, "us-
gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember",
"presentation": { "http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail";
"http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"; "lang": { "en-us": { "role": {
"terseLabel": "U.S. Government Securities [Member]", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by
US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA) or Ginnie Mae). Excludes US treasury securities and debt issued by government-
sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie
Mae), and the Federal Home Loan Bank (FHLB)."} } }, "auth_ref": { "r683" "r697" "r955" } }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"; "lang": { "en-us": { "role": {
"terseLabel": "U.S. Government Agency Securities [Member]", "label": "US Government Agencies Short-Term Debt Securities [Member]", "documentation": "Debt securities issued by US
government agencies, for example, but not limited to, Government National Mortgage Association (GNMA) or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury
securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National
Mortgage Association (FNMA or Fannie Mae)."} } }, "auth_ref": { "r732" "r733" "r734" "r735" "r955" } }, "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFinancialInstrumentsMeasuredAtFairValueOnARecurringBasisDetail"; "lang": { "en-us": { "role": {
"role": { "terseLabel": "U.S. Government Agency Securities [Member]", "label": "US Government Corporations and Agencies Securities [Member]", "documentation": "This category includes
information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National
Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac)."} } }, "auth_ref": {
"r955" } }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USTreasurySecuritiesMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureShorttermInvestmentsSummaryOfShorttermInvestmentsClassifiedAsAvailableforsaleSecuritiesDetail"; "lang": { "en-us": { "role": {
"terseLabel": "U.S. Treasuries [Member]", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States
Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short term maturities - one year or less), treasury notes
(intermediate-term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."} } }, "auth_ref": { "r683" "r697" "r699" "r704" "r955" } },
"eldn_UnderwritingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.eledon.com/20240930", "localname": "UnderwritingAgreementMember", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails";
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"; "lang": { "en-us": { "role": { "terseLabel":
"Underwriting agreement [Member]", "label": "Underwriting Agreement [Member]", "documentation": "Underwriting agreement." } } }, "auth_ref": { } }, "us-
gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail"; "lang": { "en-
us": { "role": { "negatedLabel": "Undistributed earnings allocated to participating securities", "terseLabel": "Undistributed earnings allocated to participating securities", "label": "Undistributed
Earnings (Loss) Allocated to Participating Securities, Basic", "totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic, Total", "documentation": "Amount of
undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two class method." } } }, "auth_ref": { "r170" "r173"
"r174" } }, "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted", "crdr": "debit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfCommonShareEquivalentsIncludedFromComputationOfNetLossPerShareDetail"; "lang": { "en-
us": { "role": { "terseLabel": "Allocated undistributed earnings allocated to participating securities", "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
"totalLabel": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted, Total", "documentation": "Amount of undistributed earnings (loss) allocated to participating securities
for the diluted earnings (loss) per share or per unit calculation under the two class method." } } }, "auth_ref": { "r170" "r173" "r174" "r826" } }, "ecod_UndrlygSecurityMktPriceChngPet": {
"xbrltype": "pureItemtype", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPet", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure";
"lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": { "r813" } }, "us-
gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit",
"presentation": { "http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"; "lang": { "en-us": { "role": { "negatedLabel": "Unrealized
gain on available-for-sale short-term investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": { "r6"
"r6" } }, "eldn_UnrealizedGainOnAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.eledon.com/20240930", "localname":
"UnrealizedGainOnAvailableForSaleSecurities", "crdr": "credit", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"; "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain on available-for-
sale securities", "label": "Unrealized Gain on Available for Sale Securities", "documentation": "Unrealized gain on available-for-sale securities." } } }, "auth_ref": { } }, "us-gaap_UseOfEstimates": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": {
"http://www.eledon.com/20240930/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"; "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text

[{"block": "terseLabel", "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."}, {"block": "auth ref", "r20", "r30", "r40", "r50", "r60", "r70", "r80", "r90", "r100", "r110", "r120", "r130", "r140", "r150", "r160", "r170", "r180", "r190", "r200", "r210", "r220", "r230", "r240", "r250", "r260", "r270", "r280", "r290", "r300", "r310", "r320", "r330", "r340", "r350", "r360", "r370", "r380", "r390", "r400", "r410", "r420", "r430", "r440", "r450", "r460", "r470", "r480", "r490", "r500", "r510", "r520", "r530", "r540", "r550", "r560", "r570", "r580", "r590", "r600", "r610", "r620", "r630", "r640", "r650", "r660", "r670", "r680", "r690", "r700", "r710", "r720", "r730", "r740", "r750", "r760", "r770", "r780", "r790", "r800", "r810", "r820", "r830", "r840", "r850", "r860", "r870", "r880", "r890", "r900", "r910", "r920", "r930", "r940", "r950", "r960", "r970", "r980", "r990", "r1000", "r1010", "r1020", "r1030", "r1040", "r1050", "r1060", "r1070", "r1080", "r1090", "r1100", "r1110", "r1120", "r1130", "r1140", "r1150", "r1160", "r1170", "r1180", "r1190", "r1200", "r1210", "r1220", "r1230", "r1240", "r1250", "r1260", "r1270", "r1280", "r1290", "r1300", "r1310", "r1320", "r1330", "r1340", "r1350", "r1360", "r1370", "r1380", "r1390", "r1400", "r1410", "r1420", "r1430", "r1440", "r1450", "r1460", "r1470", "r1480", "r1490", "r1500", "r1510", "r1520", "r1530", "r1540", "r1550", "r1560", "r1570", "r1580", "r1590", "r1600", "r1610", "r1620", "r1630", "r1640", "r1650", "r1660", "r1670", "r1680", "r1690", "r1700", "r1710", "r1720", "r1730", "r1740", "r1750", "r1760", "r1770", "r1780", "r1790", "r1800", "r1810", "r1820", "r1830", "r1840", "r1850", "r1860", "r1870", "r1880", "r1890", "r1900", "r1910", "r1920", "r1930", "r1940", "r1950", "r1960", "r1970", "r1980", "r1990", "r2000", "r2010", "r2020", "r2030", "r2040", "r2050", "r2060", "r2070", "r2080", "r2090", "r2100", "r2110", "r2120", "r2130", "r2140", "r2150", "r2160", "r2170", "r2180", "r2190", "r2200", "r2210", "r2220", "r2230", "r2240", "r2250", "r2260", "r2270", "r2280", "r2290", "r2300", "r2310", "r2320", "r2330", "r2340", "r2350", "r2360", "r2370", "r2380", "r2390", "r2400", "r2410", "r2420", "r2430", "r2440", "r2450", "r2460", "r2470", "r2480", "r2490", "r2500", "r2510", "r2520", "r2530", "r2540", "r2550", "r2560", "r2570", "r2580", "r2590", "r2600", "r2610", "r2620", "r2630", "r2640", "r2650", "r2660", "r2670", "r2680", "r2690", "r2700", "r2710", "r2720", "r2730", "r2740", "r2750", "r2760", "r2770", "r2780", "r2790", "r2800", "r2810", "r2820", "r2830", "r2840", "r2850", "r2860", "r2870", "r2880", "r2890", "r2900", "r2910", "r2920", "r2930", "r2940", "r2950", "r2960", "r2970", "r2980", "r2990", "r3000", "r3010", "r3020", "r3030", "r3040", "r3050", "r3060", "r3070", "r3080", "r3090", "r3100", "r3110", "r3120", "r3130", "r3140", "r3150", "r3160", "r3170", "r3180", "r3190", "r3200", "r3210", "r3220", "r3230", "r3240", "r3250", "r3260", "r3270", "r3280", "r3290", "r3300", "r3310", "r3320", "r3330", "r3340", "r3350", "r3360", "r3370", "r3380", "r3390", "r3400", "r3410", "r3420", "r3430", "r3440", "r3450", "r3460", "r3470", "r3480", "r3490", "r3500", "r3510", "r3520", "r3530", "r3540", "r3550", "r3560", "r3570", "r3580", "r3590", "r3600", "r3610", "r3620", "r3630", "r3640", "r3650", "r3660", "r3670", "r3680", "r3690", "r3700", "r3710", "r3720", "r3730", "r3740", "r3750", "r3760", "r3770", "r3780", "r3790", "r3800", "r3810", "r3820", "r3830", "r3840", "r3850", "r3860", "r3870", "r3880", "r3890", "r3900", "r3910", "r3920", "r3930", "r3940", "r3950", "r3960", "r3970", "r3980", "r3990", "r4000", "r4010", "r4020", "r4030", "r4040", "r4050", "r4060", "r4070", "r4080", "r4090", "r4100", "r4110", "r4120", "r4130", "r4140", "r4150", "r4160", "r4170", "r4180", "r4190", "r4200", "r4210", "r4220", "r4230", "r4240", "r4250", "r4260", "r4270", "r4280", "r4290", "r4300", "r4310", "r4320", "r4330", "r4340", "r4350", "r4360", "r4370", "r4380", "r4390", "r4400", "r4410", "r4420", "r4430", "r4440", "r4450", "r4460", "r4470", "r4480", "r4490", "r4500", "r4510", "r4520", "r4530", "r4540", "r4550", "r4560", "r4570", "r4580", "r4590", "r4600", "r4610", "r4620", "r4630", "r4640", "r4650", "r4660", "r4670", "r4680", "r4690", "r4700", "r4710", "r4720", "r4730", "r4740", "r4750", "r4760", "r4770", "r4780", "r4790", "r4800", "r4810", "r4820", "r4830", "r4840", "r4850", "r4860", "r4870", "r4880", "r4890", "r4900", "r4910", "r4920", "r4930", "r4940", "r4950", "r4960", "r4970", "r4980", "r4990", "r5000", "r5010", "r5020", "r5030", "r5040", "r5050", "r5060", "r5070", "r5080", "r5090", "r5100", "r5110", "r5120", "r5130", "r5140", "r5150", "r5160", "r5170", "r5180", "r5190", "r5200", "r5210", "r5220", "r5230", "r5240", "r5250", "r5260", "r5270", "r5280", "r5290", "r5300", "r5310", "r5320", "r5330", "r5340", "r5350", "r5360", "r5370", "r5380", "r5390", "r5400", "r5410", "r5420", "r5430", "r5440", "r5450", "r5460", "r5470", "r5480", "r5490", "r5500", "r5510", "r5520", "r5530", "r5540", "r5550", "r5560", "r5570", "r5580", "r5590", "r5600", "r5610", "r5620", "r5630", "r5640", "r5650", "r5660", "r5670", "r5680", "r5690", "r5700", "r5710", "r5720", "r5730", "r5740", "r5750", "r5760", "r5770", "r5780", "r5790", "r5800", "r5810", "r5820", "r5830", "r5840", "r5850", "r5860", "r5870", "r5880", "r5890", "r5900", "r59

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

~~3YIOX#VB4Q2\$% M7CQ^OE9\$3~.9.T.HI3QL8! ~*K<0R<0VI4G7GWIO#WK^S[7W20 MB6WEW<0W3S!>|L>+91+CJOIH #6S.3P\$&<~&YL.U#Z6ZT YIU<-V^0 NOF\$F
MHU#~WM@7IAU.ZS <43KYMTB1= A DQ25=-8%Q.L9!>COZF.G.SJZ3?>|Y# M#= U353NRSK52?>VA6!E.#X.YM."94VQR2K%#OUOQF3 FU2RHQ=>~7M.B.MQ |IXT.A)O.H5!>P09T?~
N2UM4N.T.L\$~L\$!>67S.WT1=1157f6\$!ZO.A.BX12!>CTW5.\$KZ?6YP24W<F#2H.V.1\$4!>.SY<~S.O ZWCE.MWC.G4#>KSN.RT&#~VTW\$~fEKTM<2V9K.O!>~!BGSR.I<||MR">+O.D~"
MWGC<SO T^3.D3>#T %L\$#V^0TS2\$~#RO=TOGHSH18+18F1ETM/<~.5VA#RL MID=XVF<-W@X.M>~?OD5~,1%Q.FNI UTRI |J5X2?%#B2AI.6SZXS<UWP.M?>%SU.BCF07WX#CP
MP^C1>9XU.CEL.<T^TO>IOGKCZC<G|HXYG#UIQ92Y9.P!>.40JKNM. M#=50RT0KS05OW.WL|O4!<-D!"H^KYK>ZDUP.NBM743R20S.2>~+=D0X.MC.|W.@A.F<~<
-R.BPOY.82R20>R.BIC8DI4HYA4C.KAS+~M1B.RDS.MICS#+s4/YH5~01HW.8WC.KQ<C~W.BB.IJ|M<~#U.W.MCBYBVR9.O>BP4REDON2AW
M#.FOI>X1.04CGMSV.M.SIJ4241A1.4.74KN2?<F2Y>|.SJEC3.LD.CA.MIBZT.CK<S?>F.2\$J8I.<"FN9#A1+=~|sY4G7NZ\$5BWDA.9\$~|U.H1+FY.MOY5CL.
ZP#I24M.1.C4.AGVSYOB.D<+~!1R.1.M4.73C.CB2.42+NisY8XOMT?<(F.J23UE.I.B>B9R.6HAU9YF3>3>XIO7.M.M=82?<OO.QHXK=S2X.6"H.U!>
(~W\$.#1#3~8BR0SHIDC&V!)\$NOE^0.Y=OH#7 MSOKAL.2#" G20JEIR4.>#%3TAP1|JM+IT>4~I|H7NVCD?>~KH.SR.2WI<Q.WL<~82D7+4H^6IN?|@82CCG|IGG<D~<CDV57E^8>
L1N&N#M.#\$FLIO.L=RCZ71+IM26|MP4I54.D.6R<MK2PE8V5Y.A2N\$>~VU.EF#<~.19.WYD9R#R>#E1.8P.L.#M.#FM.F.9D.M<Z.JUBK.#S?O72?<~&XG4W4<QY7
PYAUHH.HY<~# WCDPIPDFE8.W.M|UCVDV.FE5\$>|Z\$H~IX3OMVEY\$H<~|A1! OTJ |.2\$3QIAHF.VAI.MP=5&ZMN9B2P5F.CD190X2P~+=D9V#1|TL?>~>2>@<\$Q~M1BUFTG|B#BOXN%(G
MO.9A!<S~<P<K.IXTLS41+~.~3YOJ~XN.CJ222.G@9!>B~5CLSK3.M.S\$>O6W+~|(289Y<@BQOI.G2<RGVF>Q.O"N.SNLY5BN9D5F2.IBZL=~!MBTEFP7SK|L>2F6.
5Q=MQ\$KKI+W.L.FLT|L.S.O.RIV78<9@I.P+ MP6\$>~|LYNN.S8.F.MV+=UU.LHT.XD.WX3+=#0 .UX^8ID/UW<FLFIEFI5Y#9|JURRN#RW6.M1P?
0?7X!.7#%CIFAP#Y.^D0@IWZNPC+ULI/2012CJ9Z+=!7|@80^O\$@6\$IS.MT?O!M.fE7.%EW\$>~.077H!<@F8X3FV#77I.W.#1.TQSCKI8.#W7L2B7.M|6.+|F+!
=3#U8|@N118MGXK48UEC+SV\$>..CS72P.UHLT+!IQUNH.M<~8Y#<O4LOI.7Z>+K)>K4DZPSI?>~6~<A+PIW|IK77U6.LD^8.FE?T\$M2Q|>WW@<3~3RMUIUW/F?>
<@B=77RU>VINDHDK4BC+I3+&4\$~MMJ4<~|FL9&N.T~|T+~<54\$5ARIHS4)=31MH4KZAQOS>~OL9\$4AD4PUW.M7<S"C+9+UY876~LLPZ0~|W#<K2GI.U8T+3>~~

1-9-2024-12-26(2U)>=&U+M?T^2<=,20PP2ZTEKQV7<=,6X5 0KHMG6:KPS9Y@KPXW(IE?<Z<1.S.MBC.N.U)<1>C|C@=&9W'M-F|QJ?1.U.WXN(KZ2=55ER.8.MOWHUB.O)=180?<RXX+L+QZ4L+UXXP+X3YS=E.6VMS&SGD>=ZCGX5ZK0G2.C.M.L1155GS.LT(4624)H06(C4R,(45V141)KK<1312W@PWS2M.HJGS&O/H.M@<ITNOJQZ2881)=&M=WS0372?&S&L+5BE|<+&L2L@A|2616#B2>YHJ2.MU23)NBI/EY<=&47&G(V>YQVYXO3M#<0-B19.M.%1|CHLX1@)STRTK.OL98P>X6>7C>+|D+1W#|H|S|214NKAK.LZ2.MH6<6&K2-QV1P0C9#(16|NWL<=>=>X5#7&5DNGX.M37.O=XGXU#&G&B.MLBS.MV14H4M5V3/BH.FGQFOBPBK<XBO>B.<MT40M2D2R1F8P.M.O266B/C@&H1P2W&E&4.AZ24|@H5VW+1|OW@&=O6M2TL.T6-=>=>R08B8.MD2.FM5Z|SV.4.N3?>74G<6C3|J|U?>PG0S172>2&A2KEHBW.6K2.MU?>NV&#>IMOP3?Y.Y.SFK8<8&+VW@&4|DVL3?<=>Z.PYT/PT0U82<1WL.U.5XY@9L.CF&K61XIVAP@&@>=>Z.(THQO11|F&KZ1.M..BTV176=>.MVU|V&L+1UF4H2WG.G.G116.B+PR.B1+PT5?4Y0PHNN5.DV1.MH.B2U<+AY+K|N1|O5>V?<=>WAVE+JO5RF.9UB2&8B1XU4&X.NPUP.WK131.MH149HCHT749>52FY?<4HU1=>HJ27N5N2>2AH1P4&8F1H.S85>U5G.MZ<=>2H.4YU+?>2F&DP.SIE.5MHUM>Y?2.FPZ7.6WK7<1YR.7@<M.C9L7J.CCUGUW.PX80X.VW71>C.TIFFEY.9W@<G8.8C9QY.4U06K@<VLNX.M.X&N.C6134195.731H.OLX.XX.FR0ZL2<+E5S@<KJUS>U6=>8E25>?>K<=>M&G<Z1Z126.U5KXQO2I41>D1F%Y.5=S|V1.5V3.306&PR.H4=>E0X6&MOS12UE4KP8K7K1541V20H9Y14R0O9R@<=>62.H2HKD.JSSYBR&U191U.M8=&#.XV19U1Y5AYC2P?IU@<7=5-<ZQX<K.#|4LN|QY<=&=>PBE842?>3L@<=>M<=>H1<+P#&H1>+V?>M18C.7D9MC.M?ZVU08CU<178F1>=>Z>O.2W.6W4Y=>MGJ5O.9.Y?>1RZIO@W5NY2<=>OH+M141.8I02<4AVP2<=>O555<=>FYS91<=>J.M.ABBIFFU2>7PFQIU<4D.S|LO&W&E&IT>U1NA1J@<17>=>LHSZ.M?>SOCN1X<G50<5Y8OS2>1JZX<=>O<K.N8&+U|U.C.GOVG&O.SHO.TJKO.6<M>1K7=F2?<=>71H|EOVD1|.OB1<=>4J3YPUK12U?>#AM51.70CKW1U?V5.M11JG5>2JH143OMIC?ZKC..|X.C.F+13V.1K6S@U.WFR&EKM5DF6N2.M.WB<S5M.NK=>~Y7V102>D.84<=>M.L.F21RXY>A?>7.E@<=>G|N1.M?>S91.L1.(F3H2Q0P80>+|O2AG&EU@B0K1.6Q00L62V>820141JYGR&E7M.K1M1-YA+U?RO>HJMZU0?>|14Q02BZYV?F43G|UITC7@14FQTN>5?>=>NU<=>M6B32U@<=>SVH27.7E@<=>O.BI2M?>U>Y>6FCR?=>HO.T11.WAN6Q.U1.B051.79QNB16B2?=>1<=>C185H.M?>6B5515U1YXN&L7.H1U80M5?>7G0?>2U1.NF1G1U<=>MGTEIRL&D18@91H4P1INFX3XO4H9Q3&E6C0&C24?>14H1.3H1>..80V<=>Y.MA@<512#SKEZ1V2>P4X?C2B.ATW1U4?>4..|V8Q0BXN?Y.#@<=>MMBD.T4D.CAI>+1TO.4*=>45W?7EW1>=>=>5H1H&&MW1Z<=>+@<=>OY2CL.OAD.OVW1&192L(X?>31%?>..51Z.6V2<=>Z>Y.MA@<EGM0K1V1L+166H1L2.70YB2?>P1YJ&S&K377?>Q1?71JKAHUFKJ61.GV.N1+20GO>R51&K2>O>IG6I2<=>=>H1X1KKTQUR.U?>R&HOF=>S?<Q>9<=>19T2Q.X9.ME?XZ7.3W?NVZ1L1?7M1.OF1L.NGH<=>X&WL=>SJM.M8.M8.O?>H2D1250XSOM955U0?>K&K&JHPW8&=<IG6&W4ZNT4Y.J|WEINX2.ON>=>=>M4W?>2WC.E&M&6&4GKU1O3.Z1QOR1>W?PY.GU4X1.7CY.NA1@<Q>LGMWDD5>6VF=>Z<=>M85?NP?>KYM.K2X&=>SXR174W1>+2AV.O1L1.GST>=>O.VIL.S5L.IX<=>X1.#?>OSUV<=>1+H1?<=>M&M&+TL3U1YAK<=>17&A?>7C1W5&S5R51H12V>+U05M.T.6U71Y?|?7N9>=>1-B1D3+1H1MGDTK<=>400.K0JKM1@>BSRVLS&50M.M=5BE78P&=>3391Z?>.%@N61.1.2.9>|MFHDK74QH1ALW?<=>=>G@<=>54<=>O1NY1&M1BYE?>X?>X+1.L.Y?>2AT1BM7?8Y1?U2W..&T1+M+1S1L6561U5>1U.MU5796B&E|H0KRD1F4.QOCF&X&YK|W|C.X05<+G<H9G&YWM5MMH1JHJ?>MNI&Z1<=>R1X&6&.OY&S1Y1RR141UFTQOZ142Q.Y>U0<+13141UW18GLY&L.M.<+ZMRWC?>74VZN>1U.MU5MBX?>CRP<=>=>Z4U1?FT15+7Y?>K&N1U?>76FL412K2XSDMOCQ2IQMPOE.M.O1<=>U.LU.H<=>PNU>=>NFU.O1U.M.N&S.GW?>31.3T95OQUW<=>31U1?Z2YEMO17L1FW1P.H4K571H.OCDGQV.O1XG.L1X&RE.OHKH<=>FFCZ.MZ0?>7ZDN3.25.P1XOR1N1&AN11NNGM<=>O2&R1O<=>E5NL.B55.T&S&S419.M1?>W?M1H1U1>#<K6=>8&K=>S0<=>3CH8.T7Z6?<=>+7TMM1R1D1W1?>H1Q2U1M1&F&N1H2KH2N>5>5ZC5(5<=>EBX3?>1?|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

CGLYUD+>3FL-QG6SLELLCG?G.WJBWUCL?IKM M6F=>I&163.*^ HKSI.C^MYITWMTWB>SUCN0+U>JL>49/I#HPVQ=>F88VK M,\$! "9@=>C^DILSTQJ&IV.*8&S/>S-D-TI
AYVLUL3L2PDI2Q?O?H&M?>>2-M2R2?Z10?E2R2?2NAQV&IVANN?I=>I1YXVYPRR?8J&=>I8U1U M1LQ?SG&G.FO=>SNTQ2S2C?PD9&G9IRLL?>2ONI&E. Q83W2UL.XWJ&A0+I^HJ
XW&A&C484P?>V1P.O?>3 V8I84D1?X8I1R2I&W&F&NV.&I&E4LO8HS4/ MGRB5?N1?>I?FTG2.KI?>81>I14DBI&U42426R0Q&5=>HNAUCQ=>QLOI^Z^Y I^M^Y.XFLR?7/7/EU?SN?V+
O?>1BE9E181^OMX&CSGHU?1.AB+1^?>S1&L3?>K1.BH?1=H-DH3INPPZ?>L.VY?H8C2QI&PHTH2N1M?P4 M?E?G&C^C1&I2^L.K.QI.BZ0&I#?>I^TVJ2Q?FPHV?>F89VK.\$! "9@=>
MCD?DILSTQV?>Y.ZUTU?>S6GZN(\$%I#L?>T3.AZX&83010U?>EJ?8&I?>U.HV&I?>U4P?>LQ1?>8D?>L&1.#9CMB2I?7324?>=>C^P^M.BRWB?>UQ?>U4U?>DP8FXH5P?>Y4U?>SL<ID>L>GF^I&3?>
QCGNAE?#6IV?>I4VP.M#B?>UHR.L0.M%=>(XR+I54\$S@R+I6^BGIC?I^V#>T0^W.#>I1^LQY.9Y656G?S6?>S63S?>F#I^MCLV?>B3E.\$6 N^UR^>I2>7-WJCCB.^J5T7?>BTD\$>.>53?>WCP8.^I7>YR.7&>^>8 M^ZN
P#H@>I>X^I^L>P^I^L>P#I=>=>#W?>9 IP^I^L>=>=>#V?>I1 M?>6V?>R?>I NNNN?I#?>L^>X^I^N^F?>I8P#H?>I^EGF&E?>3EYU?>Z^Y@I^I^M^>I^CDD6D4HR.
#3I^I^PUHC.8QV1^H/EIO<8&8YI98CP&S.GY&S^8 ML&R&W&R0.X.O@X?>G1^VITJZ>556C=>O^?M0CGA.5NO+>I^P&B&I2P&G^P&G H^M?>=>92?>EKZ3D8.S+32I2ED?6/H4.IO1I^PHEBA
3EENAYE?>QUH.ZNTJZ.^I.BN MDI?>=>F85SYM^>I&R&FXI?>Q05/ISSNN?I^U?MBJFF?C^SB>Q&B&A4&PVD?>I^22 MOVNDA?>FY&I2AK7AW#H?>IL.526&1^>+I^2I7H XEP?>9(IUR5)?IGI?I^I^=
557+8AJCEI&Q01026@?>I^ZKUY?>E177+H^Y>34&X^>G?>M02%XA+7&?>8>A<85DPM15PVBTO?>S^T>I^D?IUF?I^Z3K&ABW5&D21UBFZ?>I^34&E#P?>I^PLZ?>M&=>VZ?>M0&=>4C2I4Q15I
C?>9.5F4NP12P&HAI&A&K&MUGDS?>=>K 7^?>M.O.554?>I^?>O#?>H&=>ST@>N^H?>I96G&O Y&AIV?>7IO&B9&S&Q2IYQ<MN.#8H.A+I+5>2CC6C?>I^?>UO?>XK6D<=>
=>R&XOXL?>BP^>I&K&H.A.13H1.M.N02VT7H4I?>K^O&CE?>E&S I^L^I.OWS.X&S&F+I^N&O1^C&D1V5I&L^>#&@=>6.MLDR.22^>149.N&K&H&L.WZ.D>UAB.^I9C?>M^I^I^UMVYVW?#6WK6I8Y
M.MQ3232MANZ.84>=>8^H1DHACV?>I^HUE?>S6FES.O&S^I^NHD?>I^>SWSI4DI+I^WWD.M&T?>Z&M?>M^I^POX?>WVG?>=>CQ.^I=U5Y1YU&FV&K?>I^Z3&NN+I904Y.O&S^U2ONLAI^
M.Q3?>ISP^>X&CCZU4DY+I^OCN?>2^I^LQ6+I^WTRS&NHE+I^G1^I^?>I8?>8?>M&T?>KEM28M/5L3?>7&?>I^?>B&N&S&HIOB?>SDB5U?>Z35Y?>OJH^I^MUT2JFI^#MP630^DSUCW?>I^FY6?>
K&S>=>#YI?>A0HFI^>N2+I^H.FZOU4BUL^MCG?>C^O3H6=700N?I^AP3HB#>YXEH/NV.\$?>P#3DIX&I.XZFI^HBBI2B^MF<2H1A.#A2.D^D24DF74?>2FWJ2UWA?>O=>#
=>KB2&P?>I2=>2AIB0?>I^M.M3&E14?>O&E&=>=>4T+AT?>I^F02R^CFB9I?>I^R^H14?>2.2MEEY^I^I^ND5K^MP?>P>P&KR?>I^A^>48&P^F.VI&O&S^>S&S&U&I^8AG&AS&#H^X^8.UR\$5\$=>BKI+
M&N&1+I+TA>59H0E8AL13?>8HJD?>I^H2XR.L3V?>I^?>YI0PD6.W.PPVH&V&N&B01^MOT&P&S^X?>OFEI&KD?>92?>=>C^S^D^MLSTQJ&IV^>8&S&S^D^I9P9@>I^L30PXB&I^N&L^KIAI3F^2&8&S^U^I5=>6M
I^O?>9&W&R^Y^Y&N.DHOQ0?>7Y8T&S^NODUM?>YRL+K^K89&S^I^7&D?>S&I^I^MPS&O?>I^F&9&I^I^J2I^>I^I^L^FSVQ?>I^>2&8&C&S^>I^>E&7&L^>M&O?>I^I20?>H?>#L?>90.GUFIHP?>U^F8&8V&K.\$! "9@=>
M^?>9@=>C^DILSTQI&V^>8&S&S^D^I9P9@>I^L30PXB15YH1H.F3&S&G^>S^>I^H^T.A30K1Q&4&F&I^I^ETI^>L^>S0?>=>H^I^T^T0R&H^I^B=>I^E&7^I^C^I^M^FV1<Z>R.L^S^O&S&S&X&C&I^Z&K^I^X^I^L^?>7@>2
I^3I+I^F&F&Z&S^R&S&C^I^9V+I^66PD0I&S6V>I^I^O&E&I84P^I^M3?>C<DO.MD^P^H@>B.^>V^2UO?>7&S^Z9?>Y^X.QI&C^9^8D>W&K^Y.L&E&I^PDK48VRI?>@I3.MV8^94C^I&L^#9CMB2&I^LX.Q^6^I^Y&X8S
I^O&I^>9&A?>2.D.L84P^I^>V^I^P.O?>I^M3^2V8I8DA?>=>35&@>B?>=>536&?>7I2?>I^HQQ?>M^>K&R^I^N4R^R&K14UL^MFJ16^D=>I^>A1F0I^L&K0&O&WR1&L^V^>=>I9I2Z.93UH&I^>G59STU+Q@>W2
M&S&N8.LI^>K^>P&B&K&O&A6P.O&M2^V&9&X&8&W&L.W1^G1Z^>CLM07I&D&I^V^MHUE^I^C0G.N^O&G^I^L4^>V^<=>=>#W?>78 IPV?>I@>#V?>I8C^>Z?>I^M.PH@>I>X^I^L>P^I^L>P>I^>I^>#W?>8
I^P&V?>I^>L^>I^>L^>Y&A&I&K&M&I0B^I2&R&K&I&D=>I^S1^I2VH42A@>I^2?>G0&S^>1&U&B&G&I&O.F&E^#I2^>C^>YUJOI2P^I^ZIM.M^>2^>F&W&I&W&V16T^I^S^>@0^>=>H5^9.^?>I&S^>I^>C^>
=>6LUTCH&F&SPRU?>I^2%>B2HDI^HMH12?>219.LI&B&D&K&I^>K^>Y&8R.N1^>K&U&F&Y&4&A&K&B^>H^L^BSZ?>P^I^ON&M4I5H^R&I466&R&W&I&S^>5I8&4QOLR&I&I^>4@>2V9N&BEG^>N10IPX7U/G.
M&O<8&8&=>R^P^>H^>I^>3WIB2?>56V^X^Y0>4HPV.SHJS

```

@:JT/+WOR_X3?YZ#D0*$RX0020>:-,ZFROUJFVFW7WZV*#@V#A6X#M#JG44$JBEA#)*5STAR-VWAB#58,0!5W*V1Ts[*?S.SE3MIVZ#AIUK#M#9"Y>Y?<>5%[*7GE0T@I8R=?>U6E#K6$2-XA.XXD!>F!0 IR2#PA?2? M/H#K#JHX$2?P0& 6KC<?>#H$H#OT#K?KB36P#P8$U0DN$5-1R00?H8R=-f5U/M#EJ8R$K1?>D4I80?<8.N#X?<RPU- W*7?>1?010?<S1510FTG@E.$*2+ EIB#M.#.1L11?L1"YU>?>O#YV=-A0$3#RH'P#J0#IAXR13.Y238<2.Y2G?K#M6P<#MK<#&160 3WZYKRRG<G0546?GSRK<Q$0SRJ"1 7P1PFS0S#WJH 6!MI@.VIV$S#> B2K<PIZ#M=J12ZAMU.W=F8%K62.$Y0L#FA488$8F#M2+M#*0A1+OQ8?7LUI?>|X.T71+H1.H%Q"W1"ARLPJ<3P.GH<?<C#58)M<Z.YA9$US9.9V6D.F>E.S4.M>|V1.VIRWN4M.7U.BZWWW?>7>+JU#MZR5Y0Y>2-<#%IZ2HN.&T?#JMEH1X2+FE.INO76-WO#@#@SG?YJYZJW.MER6K<I#0#@#7U1#4Y+PSC<CG.V167?VY#>POL?>IHS.B+OXP#SOWK#@L.MV11<G4H<=-2I.TT#K#E+I43A1N.NL0C2Y0I2IGUC.FUY,11C"K.ML#M.#=71C4.Z33."HM#@M?71H=WD3F.NAY2?5*KGK8+>1$P<6X1.MI2>|>|<0WKK7WPM.J#MWHC17BXIK0AA#@#@#@145842<C14<+<I#H.MS0L?>A2I<+H#B6Y+J#Y.K#489?7Y1>?>T.O2&N13F81Y4=08<0!>O@A3EFN0?Y44M&21ME<#<C1AP"42HX%2S0C.I0N.*ZZ+Y1>3Z?>163V19R&R3#6GLN0P!%M1.MI.O&SRL2UJIVOU#H#<C.Y%1|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

```

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

[[J0B6C2YF"V1:;:SPWH=B\$"<7=4,,MDM#AOHJ5D#X-7G0-27PRE]M\$<3\$@(#-07WSYHJ#81,"3LT-D'SI@V:T)6Y:,&HGMM~SC(0-EX>A9.YA-MOKOHI.XW.I6I<C0RF\$C"V\$C\$B1#
KVZA09\$X1X5\$5>1%76=<4>+TP2I-L,M,HJ@:#0@="E,T?2@F=LNXTU(ZLVJ;V?WQ2BL58#OE:PYX4UQ;#HEZM#
MOK#-1567F)GDFDIF-5KEAKU01K;#SHM@-OGBD89.2A05BFFG@J#R5F>N8(MDPH0V)TL;MO1S-8#<X9>1-L\$TLWV,CQ^W^+IGGQY4LJ2N\$HEDT(E-MOJ#2618MIQ
H1H@E"J"UR/G=6+Z^+5W^+>BKJ0013-SB2\$S#KYNOUV-MESXITL2I#POJ3G=BH+J#KJX\$2^=>V(PLKSQ&6\$<6-&Y#>S2IPD;#X1KMO^H>I>T^X67%#(H4I
A+<LE44KR-RV-7BF&BM&~35QJO1YH;G<@>I7D>2-M019RU#EP5W*7-0GR&A+>N1A,X\$2^=>I9.S3N17~Y1T~SOB1#B.N.ME\$0&X*381Y%V#VW+<E+NF\$>#
<8.X#0I9KA,"Q@!SW-84EU#EVIJKNV/MY/85#W4FJ#RY5#>:8JIB56MSY282I90IGC"W/EH&Z1\$=>B*8033#>0Q58H-MEHA#U-E\$5%7/M<3JN&#Y/D?2\$
J-H#019N.N0+5H~>L<=(C0C7I-6X)>+41A0HQY0R1\$1.M4/TU?+<+IG02I258-L0E37G<+<+&89J#5E>=>2\$TPD1L,DJAX<("M,C,M1#E):H+A6#FJ#16IU)
JLY+TR1+ME#M(19)52P+P>T1>28YHX&A+6H+J#M"NJ1#PCSP7J+>5HJ=>DKH(6H;5%B)JSM2L1#F=750~<9FD6J#K1+2)
M463J1JH+<H+R#R.6K4SE@H@YVPU&ZJ.NZMW99KG<6"HP-165201W"26LMPA2">T@2%G0+H1&D67V<0)3H\$-B*F">I49Q0V/MZJ4I@+<+OG&+<+U#M#
MWOW9&9\$5>5M\$2AEQ\$BIS5HHH/4L;+<H&42P-6H9E)PTB)3F&K\$5VDI"PV-MYVM-ON@6G12+YJ/G327&R">UATHASRCXK;QIE6G\$SCZB,CZO.B+<+M#P62)B50UD-U\$*#D08;
Q'AN"JH#0JX-F059Y@<@>W#EIK<+X-MEXID\$3;4H;8V!<+A3CF/HN1.12A#4GNIN/7<@>S#A9NVOIBKO"/PYG<=>P-M7IZUL;#*H>@>IWI,K+4.NUJ-BC\$1_XK7ZP-7H0-K\$%\$<ED^(<#K?
VH+WOO>Mik>=>G(WGMH&A-ZFGYRI)-MIX<TQ\$W#M#B97D+G7BHFBU8H(OQK7#%#E&AN#NP\$ZM2+6;5BBN6H6CQ4\$1-M&K&9K-8JAC&5DF3HC-R1GME.8K1M-<2Q
LYA-X53INT#IRX\$S-IWM>@>3XG6I2-U,M,<#M#<+<R#H+<X-B-BK\$<+<+5&5\$51"(A@E#F0M<+<B&B-EX1\$Y9"SRF"(U+>P+J)/DCM<+Y&5-H#M,N#E&:TMZK&4/7TSR?
5*N\$152BZE0+5%32,928/PYAOI?C#H0L,R\$+<#M-C3GR0?MJV<+<@>?<EWHQ)3\$-6;"WB>BCBJFEW44GH-1DU-UI+4(FL419\$P-MGJPR;Y7BGN2-U)I6">?
I(9X(RCX4)0Q3I7\$-UO+<8GKJCH180\$DKRT.MR#3.T3B-<R#U3-Y>S=C9.51JWEGM1(27EX-V6H+<A">J)M4<4EXVZZ?7I?9(I@EAL"V+<+<1R+V&6@GUBJ-WWITP.%H
(9AS.RTKT6V_M_@6L_<=QV>G<K4)0?~CCLJL02+6ZZ8MM+\$Q>IG^%#<+W<I@I=IQU4\$W-MJ&S7KA\$5*FOOJ,B15E;Z#N6-M7WRFNIHW7)GNTORJ5L9C+<2W?
0.DYM7I7FVVC;Y,EJ#N-<G\$>IG>Z>M45F(9I+2E>FOM41X#OJH=#B\$<+<JY-VU>ZG.SW97&3-WC+F1C1VJ-MBYN
M2@72E1UW0055\$2D,IHQI#NP7J-13EZELQ@ZE%<+L-P6T3K10WAYHQO2I?P.WJLZ-YW#<+A@P\$W-ME1#>+0.S\$#N7AW/P/V23DQXCWST"N5C.V15\$D#1BDB#B3;"/T?
7>EO>#6I-MOX-B2#Hes2?GVH@>QJA12<#(K9FE">=>NDI,T@A008"GM7(6JHWHW2S-MCNZ-HW-Y>2<M.WSRD-<A3MV;H<+5G7W1&YFE-Z-FS>7T<+H@9;DKR:0L#
M1C6L3#1652Y1#>H\$<I+2.UHHF-L#>I@<A(RG@H&A)2>8AJ9R.UJ-7.96N\$K.MK#H\$<+D48-XQJ\$<@>2G&X-H<@>0-663I7<+<1OC.B+<+<7H(VUS(C33G1-M4H)3YM/G-HZ?
97N8H6\$E<2Y2I+<H;T&4+XQ<@>8-(N"J#C0@8S#C)M\$*1C1\$-H+<+<ZKCFH12B#B8V-D.<+<+<JMJL\$C&X09G\$GHSY"-#D0WL-7L-1-MK\$K1U0AEW6<V-Y-06Y\$G08F5\$?
@<2%UC0>2&195#&J8=OPT-N\$8.04-PI+7YB<+LJLML1\$2B\$B<@<1N66E1.4DL50W\$99U>9.64YI-BD)M<+<+AG,B#D)0-ME#N-36PHI?@S615123&EE6\$-59PY
6BBEL-99TI1PKFYKRU@<#>VIZRO@34HG+HBDI-TB1\$<+K&F-MT4>+<CV>@<@AE\$<+<VKSQ0)Q2MWIWTYF#<4>B.\$5YLPJ)MY-P&E99Q?29PTAQI3\$<ON\$
<+TJTW9G\$;5E;I@OJZP">@#PDTJ#Q?F-MR#M#QI52"~D47)8UIDH?9-W-9<C8CQ5409.A\$W1"CT6I<+<+S&CWU4+5">79\$M-MHMGAJ8-FI?0-SR?BL<1EDK?
7G.N00@>6FI<+L&S883XBKU0_M<G>2HW-MHHY?JEOG&A<+<C&7HRS6-M71A1CIVUQ-F5C<4+<+<M\$<+<3&E
M.X#<X7096WZOPWO-WR11@=<+P1\$#R3L1VX<76/L@EP-L#6L+<+W#<70#1-MXO1H)R.OD\$<+<+H+HZM0AVC+>+<+<2HQ-EMP\$<V6(4PI%1%J3V6V-B=<+I/MNTMC<6TOW4
779F.76E<+<3.M.FO&DD-<H@<+W+KLXD>+<+M#0?>S\$D-MRCS.P&8;J2L#L;DQ/0617+<3%<+<J37J37M(KQAWX4NCJZV3<+9HY?<+M#H6R)/R2KA1/NW617?
K1+<+1WK3#<07)1#UZI#<+<PHB08D>-D_H\$H(6I2)MB-M@<+<D4;67&43I3I3I.0+<+<1\$1FW3-7PRG>7206_ZV+PIOBHFMCTP-QL5I7I3_ML#<+<C#<+<WAR2_#9&9Y8ICD<31XJ#<+<DP8SC-W
(TIV#<+<I2Z5L\$M0<+<5W-Z-MPS;ND>L>2<@<+<NOY#<+<81QOSI#K.UJ3AV1YUR-U#JCT3420>+<EJC">6FT-MW3<+<8-O&+<W3-L8V\$<+<Q9&N9EWRUIU4@<+<MT+Y%#<+<N#E@<+<1
T3Y4I8I+<+<F9-M78I1"9HFM.5.9#<+<1#87\$K.6PHZHW&EUDXPH.G<+<URBUD>XN\$<+<SWRS-M&+<2C\$SL<+<SL4X1\$<+<C\$HOM<+<OSR<+<C7J3K-UWP>+<KHNOC<+<1PWHJL,RX#<+<8
M.C(5YJ\$<+<+4FB0T?P#NL@<+<55CWSE%<+<4&S5-<+<BZ=Y.B0.G9U)A.WW.G4L=<+<B53=<+<F6Z-<+<SWL#<+<+<2.C?PQI6#H8-MBW1.06H&VEKORGMX<+<5L.EZOZ-<+<1"~
L+<+<8VXZIM@8G2FRB<+<WHNY+7<+<M&#<+<+<@<+<M=2-0DIWOST-V7Q4V-<+<+<3&9D3/GI64I<+<GC-5C1<+<N703.Q+<+<+
MQ00F#X1<4RD)OY<+<PBZ.G-6%<+<4-V7X.9B.HZQAS">I-LTEDY\$5&127WZ>M&Y9)<+<+<VU13

[illegible]

[illegible]

4V:# Y,4G,,5S)-+LQ&M5#:-]NE0F ?!%W|X(L@\$"+H&2\$NH6SC^=P)3Q_7 M!FVV,+N4)
<<9H&=Z>P%/D-6F#\$A,%,?"DDM=AFXEAD1(4JD=|Y>K|I/W1 Y M|V4H?

S6RK3X.!9V7_-;V22C^'NW2)Q%Q6+0VI8_H8WQ(_G& 'G0)2H.::?%0(3\$?X/L#D
M61')::8"3/3\$G1.'TRXGN1/4/2DQ5KBHY*[RK_9I5RU"8L1V0POLV)+!C0?
U)+17/)*))W5N-ZG:ZO,;1, TO\$B"(\$9B0\$ M!N?-Q7SG&Q>%1; 9U!CA-
B;9=)DNUI5XE)0.P5;@Q.JBZZD",U0LA*UZL,^9 M3/*^Z@B5J/!=T4H!>?QLD%?T==?
CK3LL<_X=QL:H GK)V4+/NMQI&00%,J!,D M+T4* *N2JA,WUNS7-4W==^&1/TOPS5:8-
;ZU*N:9.<^V%/RU3RE/"_)=[L6 M?
(AU\$RN).::K@NT8.D!0V!DV^!Z!"6J<@I=3>)V(W\$#.2#*! 4CJG9%?
UW&U\$9F.AODVU<:.\$!^9Z! M?+!QY6 ONBIT5_E\XM9LB=>J#W;TJU M^6GB6K!#N0%?
WK;.:9/1%||S2@S_&)25\$G;.:H2TT-H?LZJK%I\$8DZ/58&6 MCL>4Y)2"H?YURS.-M=
MLEM@3Z2:PWU.K7UW(OG/SO8;PM?52+-S!7B M/^I_+O&^?H&!6_@5^2PG)+G34,!0-
\$^0LL\$H!C4!6D4"L+?Z-@1!UN09=9YV;.!&|2O%M2D4S=!(EOE;Y3*+&V!;4
MWKP&.)O6G*T1?G MS!H:!'2BK'L9B2!CI.0**UILG&+/%:N1H#WV^7%-
&U!SCE!GM4;>+.N!=Q
M60Z#FJ!+F(35+E3!D6VO'26;9!DD^!H/W!33GL!*SDEKJSS35YBWL.P.:UOQ M!^B?
DJ!9.1&A@)Q::X=
<4FV#%=&B<,\$>U\$X!MZPQ;A&S<8\$Q!3.H310Z*H=W1VY^62C^V4JJV)H2!2M)OI#8D
MW(MD0X4-3%)+HM\CH8-04MDFZ!=MDY_R0!M2O%O&TG_3J)^ W0(%7ML\$K: M?
6!RXV19(',&>U:39\$V2=?U&L>#==P@_UB#3G',7Z@XI+CB.;&H?CPFD,(G?
MS<00<+6K2!+!A#D_/>)^3U"\$W_WIG:'D4',!I_&7!W6F*(! KDW&SD:KQHAM
M0!VDT'Z!R !O%1%I@!1GP)NPX+32K<\$I28S9B#%:' M'\$J8C41,HOL
B!4@6M)*2W34\$3E.QN85'_%COE@4+GF1-:U!3/>3Y'I0^>
M9T6!KKH5!X@O7+G"D),P.7&4'E_'6Y/<>D!Y>C)Z+44+F""LCY9PR-CFM!B!
MJ0G2A5E3Q/L0M;K+Y6JY0!/%&B6"!JPS!19&ZV7YY?7>2I(>T1OE3=UM/5=F M#
(!%4IAF/(%LFR0@"\$79*BY-DD_0E,LXJ!HGD7@%;)TK;4Z\$:/IU54G!#L7
MP&\$B4RC0KLP,Y:5#"=T!>TMML\$>!6Y'//WK+F^!=;J9*[S*7S*M1!B^4\$+#+>
MT+W%S4AQFWFUGV;G@-AM0A
M'K#O&6T;W!B_R/X&@4"6)!W+0.=#P.FOOL82>T9C7X!(>|CMB8^@L^9C^#A
M08F/X,OE(_C\$@OG;G1;&FJ T4M8#EH/Y(56;8 2C9S!GJ*34%>O!4\$3=JOIV M"YTT!SK)
!/?&7IHICMG%>;6Q% VKB!EAW^@K".#07'<;M/O1HV!V3%R M/R?
MR4)Y_+SN!I8!L^\$DF-IE9@'"VRC3L;8WQ!98>#\$.R%35X70%<().=9'K
M3>\$XSC>3OW,Y%%!67BB0P=C#&BSR9'L5#[4C;)'!X.8=:B4.-+QW()RP3M7.
M:>@!')B6NLRG^AN*,E3P(ZSH"HA/5'%56;I'8P(EKM-C6O"\$+P69(N7\$4^;
MLZ8;45Z@&9"_%MW)T!J:@LT!+O>B8;J>'%)!422DO!5&MJ3.V+QQ<|L?H'14_2
;Z8YJ3J!>X M7I+JAO(FU
!@24X#&BR9NP)5*NAV#.RT"83!AJ;.@5>KLY^B#T*R\$V!M5ME M-
259<61#!S3SV0I#/'47*!O>NR-=5M9! G=^C(%5T7LF6XY(U-D-NL1BU""%+(5^8.^
UZHD|=H'P&B!AH@_>3=5M*:B M?H^3!|F<@XR\$38;HJ1E!_CF,R1!9!V^CRS8,
M;@'GO0X+U5BF^B^!_,B*O-9HD?(NSGFZV3N"2,+@<=94-CES>'K<@Z!|A
MP;K"V+%CK/XYVA+!,O6S_S=J!UQ!K*K<=@86,!S"S;JG+O<|HWA_@R*C>4A
MOKX!0)N!=V06?I"N7=PF@:83*YAG3OK +D?6LQ?UKXAB>@'^?KUCW8<_0R=T
MT=)B-^_S@NTV&VNV?5"C69\$93Y-5QC56?3Y!N&>ZMQ;^(-)Y?2!UGC?,&53%Q@,??
IZ@!H);#Q3N\$>.!3="@QG\$!4=-@ M!TOA8=\$D*UBQ4H+^88#9!FS>4\$-
U*;9T3OLM%QX=34WX)!-!0_TPS%S;YVE) M ;R5M),=.U3#V!#D=66.;AQ!^*6C!"6)B;0!;
!NA_LH7N-#8F+PDW"+(858*
M+A;!PKRIZI@G;60HX5JTY!K\$/^OF!K;"C&)YAS%8,T"EH.&R?1IT;0=-/V
MD!L%O^C;I("'=A!W:V9!>Y\$X/(MDN8!%8>(35+!@!N MY8O&K)HO; B4+;^_
YYGC4"G;)Q\$S\$S82@*V\$!H'7GO!9AZLWT++ 5A^*&6V. M(K(;?
=MY+S1I7_5MN!KIN'G)J!XN8-PZG;XUC&S-T=/^:XLH_180=QU'CVX)
M)F7%;6.^(^\$D4,%MV#=-4-?I&?'80E#=#A)YX%E4!;|F=Q-H'76!>TP9 M0_. M-
BJ!T%,01"_9?*M/!3AMQ0W(7E*LV/6%7W-,!E8Y;H5"KG,X?I:9Y/?=>J!RO@11N;UF
M8S82"P8=K0*M!HBN)HOOS!C59YQZ@T6\$AY!1R!<6LA;JBL7UXV3-1-H<(98 M?
Y4G6_!3*W! A\$!#2P2)144V &!'_ &%\$A"F_Y ZSF0(EB;!?C8#!6J-!# M"1!OA"8V9(=!/VU
TNI(=2&MV+A%SP8;.%\$G<_ \$W@ !.\$?82-/L+BC94F= M\$;!(MT63T58W21.0?
L52N!NZ5.OVE)ZQA(4L^&>#%/NXO!^KXAP#NB_!7L @ M7. 5V9!PV*.Z/(#12 MU%&2-
V3&2BUT++Q^CI1"FTR!JY\$YQKT;9#/8U-\$ O\$<1(' AC.)525OQ!(!#OLPWE;/&UTED IV.V
M2VTA86^VV)!828?);Q8 !3HV82;(/Z5;3LBZ@.(OKU36P!=-,RQ*# M!
!(VI@F.!|&|_O'Z/KHYJK=DGB5*O":>?;@TKF"@.F"^HIK@/4L,Q#:CA
M"R=JY!6L#"VN#,+."GC:_J!Q!OWG&34!KRS8(:WZ%4)!(_5-W%'Q6DV"XA

M9Y3(%MELJ>*UPOP/KTU37)Y.N)H)5W,E7,W)A*OYTJ(@'X6K^2)=K*JV*C J>CC/MX=?
>6"(H6VYS)9TL3FJ4NE\$@;V.*4)O?/*@W*/3D)#H|AYW.9&&@*6!0^P" M3*.BS3=L1'E?
QTM:/;UA%(PMH"0:3"09[GJLUEQ.JAORB@\$"),%\$AU!\$;'18B M78'CDQNS4T;
>:;!LY@INK(HHE@#N#=#X/E0RHB>D|G/C1 BNW|XA?CJ)\$-R:4Z(
%7)ZJDX)MXJ+\$G6L#*8^"7,AL8 M%)(MTF#.'IW|(6?7DP9)2M#GM_+M7?'JK\H9A-!J
L,15#4HY&,F2F2|;.^ MU6WQM0Y46-F+UM 8R64?70Y^S:'|MI@|7C8;".+)) 4R*^N
L(OQCl;2C8@_8'UPSC_IDZ)7|COS7%D%0?J J2|+5Z|0%_>Z+NIREF-B6;067Q.D;GQ#|
M9)'ZKQ8^B4;.?CP65T?(IMV|<*Y.NS%?0JR0#)?PHQ'E;=I OS?;^WEL%J&6
M6M39158H5\$,/ECXPP|/3@5;ED&XDT;/D&1NGWP5FVW2E90.!20%#9K,/6"?F M;L?
1P7RI@6B"!E)1E:BJ*:>T5W(F&#%3*MH_J/9KO@915|UT1X|M&9J6DI(A
M!DN@J3G84EAH3|^I\$90"=(!-LT+4CS_GJ\$RAS1OZ'CY\$@|^B4X;,'4B1YF=M=?
QQ5D>RB#)7N|5L%D,8YPUEU)0\$;2\$L744.W))B>J,|+=3\$"T?O!65D|0&)
M(^5.#S/1U)7OED\$4@OH+FKTL\XYVBS216 MB(FS4_321.|Y^3TE\$
7B*9J*28:&G)*;='0L@1
M3TIU:%Z@L9G3,!5C34QZKZ,@6PJM&OGCZ<7L'F6(>A3%D=C?9Z),+8CEU3)0*\$*;
(CZW,&I2@)\$A:K4949Z?|+N MP-B/I+5ZB5GV\$%!LYD5%S0-
D|)+5BD,)YCSGRBC67WA/3|J\$%GNY&_42?PC
M#%I@,DE|=F|LVR@'9|LPC0*B1>_CP9X\$)O.|/KJ#:MSP+CR_!'%.S|D*Q|H" MI=7@=2-
I0#H"NM*)NR, @%7->|E5/M|Y)ESL.L_%7\$FYZ5;\$!K@9859D>|A%=BX>5XU&X<)TK-Y
M&ZDPF=RPDK WFGF=\$T>#+"A_5PFU=3G>RN=,F*PA')^7DTE*4,@P24&I^S
M.RSTD5G'5GHVPZEE|M0,3AZ,/V#=%?V",M0;5UL^0+ST+BN;*Z V|3FV@LP
M*W:R>.>"#9T?80+OO|#+5C-8RP#BN8!6S&MSEKEAX_F?I M&#>U8YB8H&ZR.?
I*!LLWQX0Z/2#5\$OO>)(2W)H118H-D3FTH"XB81&X2N5L3 M.5|O&SES-9JQDYQ-
>58AXE9LI<*)\6Z3@3!)W;6EKNF:K9.> M A&.CNI1|Z#9DZQ-LG8;?M(6"1
9VRU=@1'(|H'_%0&()Y&;1.|Z(J?YDL;E M_ ^YJIPS\$;!*G29RNWTSRGUT98.>JOD+?
I'E^GG.7BQ|GA(/GJ#,H94O_03 M3U5Y-|J\$6P0F>O'+&&I5((Z">I0\$@5<5N?
Y*B=@I"#\&9?4!_-RX=5 XYH0 M")9UW+I%GF&N-
0E|/U*J'Q)"\$.7HMMST@;@V+/'REED5BUTZAI_BNCM/47(
MM!OWRV5Z/&3_=-!G/T2%|=D!AAH'@NMI"Z^I#.9@&

5' MW.&ZDM'R!FHJH5U4HS++5\$CLB\$2&NA=DALNV4#D1UBZ#B|2*?
4%3(VAY8YRL\$%5<,I4^9-COTXN#9-K^<;Y M0GZ4)C-A*XL:2?
HA'C%+H+XJGAE+YA!GZP43E/R2C 4B ET TDN\$)Z#3E76Z M,*>LZ9=)XQ-%L60Y"-
:0GF=H|""MV\$H5KZT#)|IHHO|;HT3?4XE?;Q.G1BV_6SDL&*F_
VYOP;:'QBJE""23\$,'^>Q(V60@_55)2/MN:>;6ES_B(4CYTG0-<8U3@+=RB@:5JF(49
M"S'A,&C2N*&+I|@-"I14V|7M#+_)%_ ^YM"NE=|+=J.MFB O%.'XSXH-HZ/W^?
S|+)N_3_>J M9L,!1AWJBYW|;>^L4M>'Q013:' #/B-\#-K'_5()4/NP8.H|=+D/X+|U'/2L
MN\$%(1U3.FVS%-M&V:_7XH^9\$3&H!3Z_FCAZ9D(7FBXYQW7?:0/GK)<(DM"9|
M>1*3%;,RJ&#S#5+D80NKP%9/AWRY"#07T<%2+:.42%%':2"2PFUJN#.G7=6L
MKC&*Q)8U49!;H1N0V"Q|MM=GAD:CR3JF43O&O:N|147C6-_*VM34/^JXB8+
M+9"\$F@P02T2,|A'3|(|;VG00%HX)END|QJ=(P=#+>@P,F|<6H_!|L.|#VF?@U7Y;-
/63C(EXHN%:9*6;3K-Q|E;+*^E7TE8AT,'VNY# MCSKXG3YW">_GA-
TOE;|H'(;7B53|BI=B|(<4A.LQN(!'I?_M%+O_-\$XCQA M9: ^\$E3V=L+)?
+E;VJ^V_IR9;S\$D^HTT;WWY_\$RZMGZ;1EKO#.W#OXE|2*&! M#L.W|A*V*|_75/JIGZM:
(YBD;L_FY%KI1Q**/7GZ|)%_EI?_7QF1J!|K:EE M-
@7.KCR/>>FL&_>_'K|SQYUI,^0@ZQ'W=9X@^6JJA9X MZ3K;V|:
(2VWU#;Z0FBO|&MYO|J\$DA%67QS^BY(PQ*8@H\$Q4!;@YL0;8I-Z M)FQB1
|OU'D|JIEK6AY(OS-/E#|ZPTFGG|57)*Y?RL^%|O2X;+U|\$QB2+Y9+MY.0S|&&^1XHWZB,
|7O_Q8.!R<\$WI7"U|9MP9'DX|2%NJJ D,Y=B/DU?.\$@"@1 M%1G<;,!;|B)LA?
LOLD6GF=94*=#MJ-63JD*>FE7DD9#QC1AQEM!1FX*"8?< M*>|77#(9=UE-O>+PG8W|
(%L9')#DQYCH3\$+|HW
M87'%=MP8=80.S@*UR,|)0|B&6|)2<(68++FF5(V/BICRT/21\$|A|@WLZ*:2 MS+@/I'#-
LTG|+SLZE>-P%RD;KTQ#;AH'I/L|M:FNBOKZ@CUK2#@ITCTKE\$KN MJB&E|(|KQI-
1SP<*F.K.'T"@SY8\$Z97VJ^HM.<=VPL#8*_|2)?+R&P.G:
()TEH/D(4|K+6N)WDXN%@;WH@/'9Q:4AM*7<+>4B3AJ3@GF)8/VE_?W/
M1Y2_UH3'KPBZ0M040JM0!UKCKMDU6&X@.E3@0@<|=Z1JSH0MBYJQ?K1-)WD-MR/'
(Z6|H|R=X)%-/|H,|L2Q04XWY#BUT|5U!|^8+|JFT&9_ |A4YI!Z|H1/P*2QI5SFS2
MR,N,Y7BDQ.T,&C1|;#R7"|74^=%[6E"!F| (A/V6^I^G)IR.>=9 M/AR?=QXZ7*%.1&|09*

<.4ARF\$Z%I(.8.XP=(\$B_=?#<@;"E@A%K ES">A&S M_G:J|;&-D.W|_@=A/5-
<) H8=,SJF*0Y13?:AB8'1|ROD!!Y1:42|=UQ+| M?LSU-S%C54*W6CSYSKNB5"Q")<>%M
>V|JAKG#|=8A=.,_KCEALX1*8VZ-J
M>:1CR=H6#F+X:@W_8;K^=8YQGY5M6501I@#'&B;6D3GI?|>5XA7^&_WZ^5PR
M4QWQ?ON0 HXX@S%BFL7 @!OT"W: ^I> \$|RK6>T0=|1-05?7|(0&3D6X Z@W
ML.VH)S1J4 R64;B%+HHF0.[85,L6GYQT6],P14N(L+FKK@H6C7=3LI5&FIJ M|"G-
38N+D15(4'PV_JU9Z% 8N6\$4VN#U*M,> \$WRC;%)P22N=LZI0E?1^-:0 MKNO|V&B>2P?
=00D>>>1Q5P5'S45"@|K9U1@OS!@XE|1)E:OD|S7UXA&P06%S%SZ"-AXW<_*9
K5AM^+'MNG0 M5@SQ.8?>&Z(K^+#37|-YF=MH>+N&>6X=J_%P&/?.7WLZDX7.)|*
<=11)YWAM56*?&,(Y)SD#J=D+Q!6*0UR;|J,\$(#|751C-RB7=& M_25-
9\$)^<.6QI_)E@0=M,Y#;AH)SPNWP "JZ? >5-." IO NWO<55N*3Z. M9H2 MAD+|R?
(6S5|J@WU3.Y:BPR8895TS8R*B#ESA?X+GFT;8#/^2XM'Q'N%R)@J\$ M41.+G%H,X|S|?
@.*XJ?.*=SOR;>A'#CO>;\$D_A7\$|LW3M156_#S|1'GP<)4:- MO%\$ EVW(9!|2%2&T2;
<@>6E2%64L525L\$&JHY8?&E8'|8T8|PD<,8\$CK@2.>#"(IY|<,07Z5YSEL6W
M+=|TV_2M6S#J6#>Y?AX5':6: Q4|I.-G;A,06"+:..P0'55*:=#D958'JKO@76@
MW*J_+9G:1>WZ=* " STS>|9.8>HW>8W%6D&_|3GW|@9|B\$8@7@VU^WU7224E
MSH78^26"31@> I80(487>R8F.RK-:%CVFT|5(V676B-|S077%6-OCPLM/"Z
MLL@NT%DC2N|I|<\$=;I>+QH#58.PMK<_.5>TY\$7"4#C9Y)@LN?=XSSF18(JL
M/PV|I|CET^0&#W|KN5S1U 594#1>QHW=2DHQL:VPD23V7"LYX|)%TIOH4/ND6> M,
7^Q"CTJ3^R 3FK' #A^|,VI"%M#|2&=XZ/%@L#RW!|I|/^U#_C4OR-9UD6L#
M+|:SV#1UO|74Q/,G<,#N3&@D|14>S+@R6PHGPC5O)&^"X4S|L,_"@U\$3+X
MO4TN>:>%,TIQOS|:'AWOSA_|Y*|6)_>H70YJC)FT+9VEX1RSG1?VB;@M"P2
P)D4;WK/(VR!O#8A0B,-NN;CKR=RO?"4LB.+ "XU0:789Y|LP?;_G88 M=B<
Z:41(1OS&P3;:3Q. .B, E,L2Q<%D@'HA/8@W/!2."JLIOX12,#C|.>F*L<|FL,2.Q MU*
@-|&6G92KJ2D=>NI6 A+H9QC1P|JPI:Y-_|AZ\$=*|96/C/0HQ,L<,R@X| M-
KWD)W8D3"@XN5H68SLP_,#9VV1IX2--|9%7&+;3K;S;|?_/ "X9H?N0%=:
M0+;>1)|A|S@BUL1-P\$0V3/X/Y:|9F=!"O+F4 HG#|JN6%8R;B|8I!%M+R2
M.=3R').M|4>S/Y>_%?@NG4&W#5ZQ:N0V)W2KMU|VL #TO=XT8Z3'^^|1,GM
M+U/8Z"9|M|?3L=AY9DBX*+K6A> WCLA0<*IY-G;23'2IMCR/|@ (WBQK!ZS5:
M'Q=^3T=0=.;P_@3'|H@#9-I,X@ (N+O #DET>|'"&3*..7&N?
>BHPWY(!^V@0KAT+MJ"LA+.PJGY\$K|E,H!
M11OCDF+|IP^_"N)*&F|JEH|0E^.;MEHY&K7MV^P/CE4' MFAL#^KI.'KJB8>R!
|KJ|@E>,1(D>KLT0;+C M_9>F0|&E.EFZ=EXQKVIWH,YE7>G%_.=)9E2G,PQ<4^@\$4Y' I?
N 6Y4!B# #P M&L^UALFLFJW0J@V^4|#N|IM/H1(E?F.9=8Z,H|7@HS|I,2RII-D9*BP7 5?(
MM*ER#E'T?UZAX>;4GZRWW'XZBLR"Y)\$L-YZ5D(A.;>SI6X)/Z,H83Q(.D-. IX
MKVV!F&TS *\$#;.,=HGHJQ;S9L@)ZP%PDLY2H&'&D-DOJ=7
/6|.=+S|I!,2.KZWI\$M|4:'U&BF<,%8'ZE03+
MFA%;1!MYKA_OXAUVZP3D,.37Q=;AP+8)G,(P !#Z-EX=ORJT"NCF.\$1I%CLIMF-
RI@H^D.2RWOBQ|W=A-7;@/N2_"";T.?FKOJ\$B&|_X=WS0'2=_@;.&9)1W M(CM)
(5!MA#B4T644A\$?4%L,8 P?&14YG%1S|;M&W7B< PF<-0'@X 1"^ @#" MY--
+62D55N5%_SAUY7E>5Q)E3=7#H>P(=S48LN.CL-PCC+);
MAY"T9D(|JWJ37I_@|3@3EPD<=X_XEFY/GD>UYJ8D4B*+;;I;TE/F_ |M0+=Q0@I_SB_
M9/!RO'^SH6IZHK; DARXM'2\$3JN932,\$W30^?X>5^*Q;6-|2R5S6KL (BZXU MNGL68?
#)5|F'?QBZ|1@G)+|EN@ \$1>F6U3GSO' DEI|3',P,DV+BE 5*N'8 M.V@!;B#&4JC
B:@O_+N;F6N3%8556QB- M)-2T5ZJ("R\$B+T?5211D0J#N,>W\$2#8)WR1|Q(^ ^N,
:X8IW)CQL5%(?FJ MG-3@)(F?6A+1' 1#3SM!X\$4>K,=X)@@WYIF<(L_Z-\$ M40SED|!
GLC@07EZ,H58DW8"3+.K*6J)SQ@M5T_21RD|C=S%3L<5S\$2'IA
MK64Z2@D41|2T\$7!=E"KUX6G66N X|D-9B)!QEL&OZP754?!8@K)Q:"ZTO.1Z1
MPPD',D0OKCG^D4+S3#/_^|T(#V2O)*,2:NNQ_Y1B%2J3J6O!|PPS:L0)D|)
M+M|+,:%FU*B\$|L!:Y0+QI@0F@!|=/(RL2%7(U.3,06GUD.A1@1L?<1'=1.<0 M-
W67M(X=E*|W"QRI>|B|.Y31|U.I':#.V4H-R#6?< G7)&U<(B|H%+QC%V MU*
<*\$37.V%3,J"VXTT++&|5OT#D.'D.FYHH#5NJ"AEH?T""W|L;XV<6W < MG9G0T(-.T;JS>
(AD^:HW.|+9/055(3&_JV9|Q+ #FMO|H,U MN)U"S+ (N7NMW1L59|R.I|D2S+_J(MIGPR-
/^WOOL|HUALP^O!&5|IRGA ?'5 M39G.R8SX: 5E271Z('0T%A9U=B%U)'8+V0U!!
(M<,>8_G#RI221OZ\$FQ< U4 MS="?"<&P5HF'72|I;#%U)R8%LUU??
FJ\$ "K;N8!'42U.N|8%'-6/#\$1!2U.X@X M9L'H5|H0^K#L\$+/4:105\$8!
<=9E."G62TTH|QBL7%AGI2A\$.!SSUEJ,B44_W M\$MI%95I\$/2NP<^6L^B"5U,AB7RJMN/
#B4)+AFT%.T*T4 H=JZX,KE7LBRV9VCPD7Q\$\$(!|X)+N3|/Z|I(1(M!*7C2,_E.I|SV!8;Y*|

(^L"Q6V/P;*KK<(P7*KW22ZD^A>6W1C!C%I6+)-V M!1,B8) 22NB4*==*UF'3F)'B?*A
)284>C5HYBNF42>*,^/(N#11!PY5(\$ M3#ITN&7RD)A|I<<|2TY8!!U|L|_O/1XE|_9(B
B6.41\$9#N=(S>[TD (M'9\OFX2#E\$C!#C9;\$&|C\$3EM3!=G^WUIJ\"#I4+,F?-
#+936X+9R_E\MEN17 MSQ4!1\BWFV#=1E MW!
<@0.'J>H"P(!;+ #68R6|42UPXD>HXRV5|Z3*?ZE(+D7NGX-|AT&E43"
M(|7>7FGLB5#KL@WM^R@)DQ4'U64U^,R_78=EKF9\$33W0CH6JX"WOBN\$7
MQ8>,B1(2A<^ZO)#R;F0FSO'&1|/=D?|#^2GS9N^-TNAUD\$*|!)/0*U(MJ8?E
MIPU6^SMDD|W'S49=-0_M#M"^R!(K.ER8E&/&O|T&1|3&AEKB--6A\$G|!B@W-
M*LT1|TO>B#SG>, +L|H!)\$@2^%5"KH^,DUS_!DX1Y)X^M-#E3W1E%
|0P2^'O)RB|U;Y^?8)9/9W MJ(<2Z7;T< VOQH^37YD?E@E"__?P/T+9B("T#VH?H?
^G0>|+ #X|%-).6EEU5S>UCE2XK3_B. M.U./|HYTDHV(GJRGLV(7)2?
5B>+3B&'NNTJ#3B#U7M6|'A4,,:WA=L704.Y|
MJ#LBU2Y48U95A3@_ =MRZ+1OE:S:"ETA|&|.U26R/^E?0 1(3E0GQC@(TZ?_0
M32QF3U|^Y);KV!=.7/8|,D+0|19",X):|RH|K")^:YWO@E|Z_Y)01S\$=6?F M%FRR-
0@.JOV-TU*S>5ILL\#*5^|/H|/P>MY|N!LOO=&P<>F/2,MZ;K(8C4I MISQKA92L;S?
9/|<#'UD&\$+7*ND3UI*A&B%N^*Q_J>1:|A1SR03M"Y|=U'5
MQ0(|N|,7|."I"HBXORMP<#IW??0W9@ITCL*?9/' +OCJ<|1|V,Y,L^<|VR8B
M%:\$">Z5OT-0D|\$=B@_AP#|Y8;\$!^%;M/1PRNMQCE|W&1F+= \$QB"=X;1V'SO0-M9)
(;8C>B|CYZ;PR#; R0;DT&3P@:VSC'Y\$|_45J";ZBV^.|:
|3///6R>FN86;K>@6K_6^9<2\$'+>4 XVM2EO5MULJ^L@T'@_=@3LSSGONSY%9%
M(\$W0< >M_<;JU'W^M21JR4|@_M^Z&?
F"9OLF):YFGRR_ _HG9!L0U^6:+M>#9'+RWQD/(_HIMU."?|PPOTV3
M/|= @ (5=%|B.1W;V%G|QFO./^!L_ WV3@= !5%K_) \$&&RQ+|8M;5=NZF|'ZCQR_
M=#:"0+L:)>GE|V='GL_O\$E(|:3YE_A*D%8K'|JOZ-./#SF|= >7/V4E?G M(R?
G',,;L"MDBIL.7!;S8P^/'SU|>|WV., 'SZXYKEM8--A^;|^X=PD_ /# M-#W|T_/BH^?
O7G|R|OD?|Y,TL_ /3_ |L/K_WKU/H/4|\$ _|O<_ /#|O<_ O MIKG9GYL?_?EZS?O7CV?
YF9_ JA+BOZ\$;+W/X'A;2\$:5LEE_H_ ;95F&TO<9N M*U38Z|@!)O;-WA9|NP<|P_?D-
F\$GP0+3(B_|M|(>WQBAZ<_ ;|J^=G?S|CD4^3-R|^ ^-^_OWGU&OY^>
(|_O_KAE_|^H<7MRF2_M5X|6/-MUK44Y*7X+R-\$_YR#T("'
|ZH|AR;Y.;HM_/8,^Q'!+.U);H.'^~? M,*!_|S8.?O%_WVE (\$W^7NTPXQ"#5_PLS=
<|Q%|77X5L|W M;07;SX+/'\$|#2GLJ+,&4R|U7\00@934Z,O";'X>\$ (L?KF(
MQ;MT'KWN(M;|BI+ZW"W"H_EK9.7C\$F|74)M08B01CAL3O|2823^VYWJ|9XI5
M9Y0EHZ2*3|>G')Y9N@N,=|6,X::H=DR&P9J6?NO)A5N-3C/GAH<04_#(1/GC
MV+X,N=>\$H0=GDVZ6BGLS02HQJ_DS1>U/9YCHPR;:M6F#,|U 4.LTKG3E3#)
M1*AH^)^CTF-7QWF5SZ2^|N6!6')^H\$*Y*|O30KFU:M3^+8G8L0"5"/B?)T+@
M0J87KLW.9KTUY3\$(3A.9'PX)C?"-IY!FEF8)QALJC?P5W N>|^7X#D61_M0Z//\$\$^FI
(F'3W'K74|*,.OI6)8DZE|K>W|U+5C,O?ZVO:|^!^*O>_&H G-%' M?'GWPJ|)S6XG/SH,IO-
O3/#>=|6YU-X'B>L0|N*+R35)C^%=UN1ANK@#*|P: M9QYPTV8;,+L-
FV&#=!ZUR8GT#J'CY*U<\$K)B,-7%#NVKE14(' <9Z_3BPA=B M-
YNY:KXCSG,8DV)_SWH2#|11OJ(\$|%|S)\$?@O:"BP%,*G%TATYZ",_K|O|O M|N:W\$;N-
=_OKT#TC".Z)TB*9+\$VR;X1LA9?S72W%%W=M^ ^;B1_%2P2H&P M%O_Z.6LN
%A|2<5B^L&6BR202)P\ZW>^DQET6)GJB_W7&@X;|R<|H4QZL0AR
MHX"0H/F*:@OSR'C7\$LTIP8*|T58|59|)\$#!R@,%="81!O07X?R&)D|(F;B8UA7@KP
M^6^?+|SIQ@2YYPV"%F @_5RSG\$&"R09|Q1WGI&+|J6;H8S.T88\$B^XW<@(@+
M|&KW28I6MTJOZR_865DO"// MGJK:T@NREE3H8(S#)1/7V3:S.D
/\$|YQ,WS0GD#5Z>%M;#EIOM?E5?>W-TM.(LP6V1X9TD|FG.LY8AR9\$O-A3
M\$WXH+4GGD=B?|NS|!0?R2*P|^2,R|^*OFK.H0DZ MK,%K1QWDI/K"
&^:1K|9'QISNI7K%><+.FZ:CZ.)KLM*54;IL6ZWf">B,^8IB<3TNMR)3IF"38.
MC^6;7T|(M8'_I2LF*:&LZ63%W\$EQCA&;Z)W8NZC1+/28DCEWCCW-D15&&HP=
M/_GJ5ULUF+V3EH#2|_%?>5@B|_B=8028H6-:RR0:N'#-Z,?BY+%AVA!'|N|_M,X?
5Q6P;L;C3Y-43B<<*4G|4ZL(Y& 4BH1B+M?/7940QV0:_ZP0*9X8D!@7
MB'#G|'O^S3_C" F^#P_IN718KDX#1Q_VT<266!6>%|<JLYRDBGA/?
&2*TWYZ'HM)1RN(5>|_XLEUG MF=UTRK,A*1?V@906?
Q/#@H|Y|%,*ZV|U81J3KMDIGZ|)Q,*G;0M/0A=N.U4QS,W 8 M\$TDSVTC!;/E%>FTO<"|*V
X)6(&|G/_X3\$R49:6BUS2263Z'9Y-9T.U(K2\$P
M3O)@^ZLPB|553=6<,G,:E#;MP#6++=G,'(CY0!EZ-^*-@/QP97TQ<*)%S,(
MBHTVS@G,3'S<(U,MA0B0BTONTZW KWOM"JC=|FS_QR!G&I?PBK3A@%*E:6E*
M&Q00YSBX4%IN'%&0C|U@E=H|_|A@F|_%1P%<\$,%V^!H>#7U);N|7K3+O+|8

MKV:UVR\$,"C%/\$%& TTRH!:TJY04Y-V;%M;:/7Y#-=4&.-@,+;O#V5I7U&=9U
MYK0@IDQ#&#=#UMMR&GNEC-UHS0=H3)BN4FVHV3/. 9#:SBJLS=@8)9D#;W@SW
M\$J:ME?-R&JF0LK%^S[2',LF599)/XH(@^20GQA?Q>;7.:EL)7FM5@GU/3A9*
MKI:3;M\$K:*>=\$:Z-? M7(DUVMU2A?;T4TJ-A?I1*) M=5H)-?ZFW#X/#"EIKE_UQSUN5<?
NY1&H8#+5BCI,JG@C>O U/%14>6V)SX(B4<@ZO3(+ #HAO,*&=3
M)Z+T7%FMN5"BW&Q1I;3,:K9@^WQ46C=)TB/JG>WT0WP*.3 YT?I>#0?#:(GC
MX(L\LO;>.0P=!0O)><1?0&5\X5E@A#I#B 4>1Z*+UQKWW+^)^2U&AA3/-+IC< M
) +IN.;&?8/TW"E9G=1I ML.L;4YZ MM'>IH-
64QVVB_<+AZ8DU[7^FF)AD\O#8RS\.@CKY,2FNY\$5++F;7I)YL" 3 MM+?
\$H.4WPP6>MIH\$EP1U+%0U+RG/39R=#W!&?J,A"+I96XO(X+=4G>?,"I9G
M(TSI\$1.4MMF-^2:8OVNJ+QP.M/!_E\$9H<.SL5D\M^Z3P)\$H M&+W58EO-XK|
<7!.Y!7IZU3E4IDQ&48CD0=BV 2=A#PT+)U5 /*)T*X^+I..)*36,+1S::O J1 M+B_W|"
ISD"IZ87\$J|_R/BH' MF:I)JX*TB)U|*|KS_&ZPIPW-JUQE|I.
I#8H.S4R')!05N7W5:0^W&C9)V % MI>4-M(C:&@E?%)N\$BL7TBJN,_|HU*4%ZO
JZ!\$YN64H>KZP()?Z(HIT4N6D3\$6XF6/=9DDNRFQ
MBP*SJ&FY=.EUT1E=8'S*1'0.SY5Y1I<4SYUBR.4-ITB6%JW59MJ+JZH Y5AK MU76.
I:ITN\$P>R|I8I%-I45I3+()8_#\$GR*B^USSD'J2S.UZ/J<9,!TQ0*@:P M+@_(FZ-
>;*5D.;*Y2+YI^0,-)\$;0(Q8(SYYC V//6DL^MJR,':!X=I7IVC5.
MM4R<'4|VCL=>UC'Q5*^<7\$|:F9?1?F@!ID6GEDJ%4GSQO:44S5R@I)RZ,:X
M>|I"7YDJ%';?3L#<(JK58;EV+9A,(20Z"K9+-'"F.SHX6U1);OQ_*R"@'\$
M.#_L=KS@BX_H=T7O,05U\$6-'0\$|TL;|55DVI2E<;33*/R9X+TO| ^@*!L4 MA|
IF6:W0V*XN(:/6HD'^IC69&%LQ%W1%GEA;1U;"VD63F:03LJZL?7\$UK#\$7
MC0&Y9HRZ4^%H&1KNFV*@?OHG7D8I3A*"^50&VD_-&J-^N;3Z=6Q3YA*>6R9
MTG/N.NCVO?C=|N< DD2@,TD13=H<9TEQL25L8HWUXPW!H8-
(VS0Y>#";IXXMY797GJN;
MEM3OSP,&8ILP\$,RM4NZ'7E!.ILPG_1)9N\Z&*H\$#>"GW,_HVG+;S*P M|I)O!*>QVIH&_Z
GU3G#9V,4IJGCCID"MG&K@29WIG?3>_7:85'GDA"-G*\$= M=R;D8LG"I9I|=;,+ #Y+D-
,K3SD^=|Z7.CT4N)JHP|2XWLF0GV)4S&-!I7+<,4
MVR"'IYMB"R8O0U6*3XW)J7E'4MYH5HV^^(D-\$A@D|&\$D<)E5Y-Z!X|5TVDR)
M*L0)P6R2<%-HL223X70,Y6^LRP|HGPBLI-KA=H('CS2Q-7=|\$H813KLW.9W+_4%/RX
MN3-,=6OWOV^,2SKP;+382^EI^,8S*8BY|;&6L802##?BZ0:9H+I
M>:LJWHBT&FN+,8TPDQ99NT+30"R)U2KF^HKR:I42()7PR M9Z1"9BHTR%
<&6PIA>PKQ&|:PC&=ET4_AK!4X|L>FQ!FXV+QLA^3W""PN@YF6S,F" M^I8-1"O!
(.5PBF@|?/18;):41Q|17IP1WX8H")=BEBLJ8J%*?) +\$-NB,## M-
9I3IS&U)H)^YMJ9J3+!K?I)W)U<3;E06)#.>L)^!P)4JL.+9W02K, M-,3;84^+!F-
#)|K)3L/\$=CC>+PO5N47'@LX2I4HQY^*JB99UN4H%FQHA|L. MD2Q4:
I'3;W|I|Z#:E*U0Y3=K5"!UHY5EZO.|JE
MM"55QH\$W7I:UF+ISU>S|%^JE'E,FZ6J8IJD"UP6V@11\$*?*#L. T8^'N,F<
M_IH@EQESK#HM4#3CVX;_IC?)&|*MUD?C@ WR5?#|;?8-#)E,Q5N6|;,+/0;
M26F:PXM<| ^((/17#H9C+FWC)<-#|;JDIH1:Z"+DR+I"V?A#SDSCZ/O9#.
M" T^MYB2R?LF@39NX>I5E|=4R.BV@I2&J-0;6Q;Y: ?#8*@2!D:#U7I'6+>2K6
M.>'V.Z#+F3I":?41#A=2.<<(X<\$9,00*(I9+HC.LG4I3-C
M_4VJG\$5)#OHFMF1+CAT33*XVB(+ -I"%R7"YYY M!DX,E" I_KR.JZ^5(0EW-
U|07O|7G2W5+B=M;S(:1Y%=C@P^7,YE9I2NBFVO MB_MYQBF&Y-OYP!T1-3:/R#N
U'+;JHIEB:A-:K&I9>?8I/29'A,?M\$>.OZ
MI7,LE<|+QR0:5G\$2:|U4D,1&9L&:VQ:H^:8<*V\$KR0[6BAY8]LW MOX:|==-|E).-
L,|7-.JMD-#[AV1JHDO(/TMLI@)<9,W-IU+/-O#EXD-?I&>
M<1N|A%V341WJS,;WAA!BW6BN=RD]5N%JZ&C/8?5(@T8+TMRAF2>OM_TO"B M-;
<(K'DP#&#-9P#6?&Z^J8\$EI\$96>40T:#"9ID;I1%=X.;I%FK8H>(>EXL
MLD(I)Q@/5M4Z3>0+_ \$ZU"Z3(I'"_M05I|L*O! M#N1+?Z3>|7732H'.4WP,)|L!MGL|BJ-
>_Q.N@*|82KEHD-)TLH?'@%[7 M2*4I90:YC.Y?
%U@!JIV(HI6/@BEW8TJI/V<9>5LO>36,7^L K5Z,>D"%D.D M+US*7 RP*&4ZJ?
X9ZX(2C#?(6PI@?8;:|V|X.&28EB<7Q'W4TMO%+CMI?. MDE+00"A-
2Y^KR3Q9=PZ0.2I,D9_F4DTDL6=Y)X|WK**G,,UITI2J64>GSH@/
M34P&)2=&1AQXV|Y_\$(?)2=MN,*>Y)<\$J4:R6>P4U)D.*+=G6/_5D4X7R*TK MV:2Y)
3_M<90+I4DZ0,L'R'O;X61:NQC1&5|LH-IJ- M@U2DW%A&M(CD>*MX:8;\$|-@"
<|D.B(77H?HA)_8Q>)0WIUD>.:N>!5RIGQ MW9C:6@<%\$MT=%X4A*F!,*9HH7;-?
62SE##S>"-7^! MS8-E)%H8P0UW+M(3N\$W;Q&ST=5@5>ZJZ,12#MG:M(QU@TT&?

CHZ0&JT^A> . M>>3=@JPD&RU6;40;0WM%V^4I"9LH1E2@ &7,X!
=M8\$J/"U9#RM82*1L0(E MV*ZIH!"%3A[/%2+;U4/";L)D1%3WN1.
<7"Y4C|B;;RX"CJ^J>4P9)*3/26=3 MZK,=@J&'QZ)}=*\$Z|. >*6?!W1/F:;!0/5
-7.#\MV%S3U?K.FE^24 _+N MC|Z5A57/4E&\$YO8-
G6)*KIW"HN,E|+CYHI8>|)=G93;%D\LR M+>-RW5VU|(^-*1Y)
<0|=P= /77&|Z.Q2+.FV/Q>@{|C'5?Q/^1JW'REMOV#>&
M%D7D,&A6T#@P:/NL"FU|A>H(FI&UCM?7:| #BZ|)TN)+C|74 _*JZ\$ _U (ME\$= MZ%H5+
|AC*_MK+2Y2JWEWS...(+AN|UHZFWL9+>^E|!;E4YT\$H;(%I="A-CU MCO%Q;OZ5I<
G|)9&|@M+N7 %Y^'(NE'8\A>I@&UT-#71> M|
R^_OF\$O.OX=1F|=5(6'W((R>IU+3J>R639N67/D*6 YH/P"EHWJ3;16-| M|!">M*K2VE!
|= %R=UD2X|;2YP M@K#I2I.F)LS%OE.@X/S Y+&|= ?6\$#:HOR2R.X.!_Q3:"V>4FPAP*5,PT
5ZV MB4C5Q)H?+XJ*|5|Z,5O 3HC6S=W|+%'^ ^N/K3WS\$D7:\$N/94W',R0Q-
Z1+S/MRA%JWH,DZ5|LR(:@JVKP,W"), MSC*NE%D#"?
CKK,;#L,)#W>9||\$SQ/\$U|!;3DX9?UC CBLMU^_L2)?| NEM MH9P<4X7.)
EO<7Z"0L6Y->\$13 _;&FLFFG\$<:0>;4S125|G32(7N7-I ^VZ/.ZU#EX, MUQ98#%)C%L1&)
_F|0EUU5\$#)"';8(A C+DX1E 'D+OB,HQ8O56>K5'?99?NX=AN76 _!#{ONR)L|
M/S,VKU!0NL. VW\ZP;_NY,DH*E(&|K&Z!6)4|4)253|(LYHS_(Y)FA,CL;Y MO@:0||Z",_?
KY|@JK8G&+M _EA4UZKVV(I"LZXHQ6\0%R+|W|9;%Q*,T>2H
M7"*9GH;3G!>)RTSS5RFJXHI+4F8Q)<-|9T/3V42P72X;Q;@WSK
^C2<|;B1)*|1F3/&C.R'(48B.^&1(36MF5|E MU *&F7^G4P5"0U7SJ00)(;*73N*3GV&9X
MEA4\$X:/+>'ATYBYL&/_R5G:5,>F6 G';;7 M#"#"B|
(KX:M<0Q63C4>7#;H;;U@KM=TCYC8F185EM.*K5K6=MG"YA#QV3KLO2PL9MT)U-
=S)@HAS"TFBRDMU2Q M#!#(AO?;H&P6Z0:<"NY87;Y3IX!G;*T|(R,Y,-%-9#-
S%\$3,|928\7XK4Z%...ZH^+ M\$*C2NK9 Z2ZGDQ&LV"X,8:A-#X(VYD_L\$UOX1L4
P|ZZDY:@V8*L|_|47%*< M\$;|2,GWT?KKZ80?1>Y!)^_Z2
&Y345%2"W8;ZF5DH0/_<|P?'FB1AX|B^N" M&G%=";M#
|Q3>|&VV2>|!%4D"&M6<7D'5|;@X;N!5>,FF1\$=QJD"9E'W7>^N
MC:"6F5R.C|A8BX&0000U|C+;JR6^=H+;JADB@-@-V2AK#OL 2|ZM@D(J|0E
M'E;"|1G\$DT0&7J= D^|K@XE|>|L17=-N7:'->R&?LZ6"|GBUO'YU4WM%XM%
MMO1|H|BPB|_B.G'K:9G,.-|&TZ"+C<&0=&M<.NZWENLIB"/D\ (9 CH*_|HS
M_1|00<"@#&_?;Z|)X6:(Y.0>O>BH|5::3\$^FK>'0Z-
H*V7UIS1N8LGTW.W"KYMKQLCE| ^?7M M:X|TW"BR+DD(PDN)WB#-
|33XM#)|;NS=H"6S MMH1A^%L02)"#;\$8E^49LR=
6C!R)QS*3B:0;N59)D2V4Z4FFP*US_3^N;O-E MX|4!7YEKQ,HQLS"(I.D\$JN;_|(5A)0
MUF|QM)LTPW5F(& DGC1&8APP\$@\$C|4R<7SM|JR<\$):|JWCE.P=>3I(&)WK*,
MTN5J45S*A%'U9"! "K3
WM!GP|,P|VU|P2Y8,KXG^NUTZO+WZV/38W#1IAN(B|I;D\$MQ"0EL6-1|)?*-C=KJMP=Y+|
MBK5X;=9P7YLV;=2ZRNL")G43,ZE+L7DW)T5F;UCL@ @^MDFN%O9%0*RS)\$Y
M4VL3 _-"&5Y _&PE?|6;ZNUELR/LE8QC:=MEU=-.#|V@UZ!2|'=\$?9D-^>J
M69138WWR-X:G4Q_B|+?24#;\$;SH^?AOWBF3V:'5@>FQALR-8*!"D& L*&8 M?
=WF/,2WL)\$R!9. (= '&_L&HST_C@#"NPV2*UL9UI0FVTF,^?I-
LP4L:QY<9/Y|L9YI!^0@^L6YG&0"TME:ISK/>>0T M^N5(<^A9R!Z:T:.;?)HD;@=.|T-
Q|O4PRRSK&G<\$|VF%&C:WZJ@SP^E#S"OYB|01KKW*F^|QZ-
MI71Q\$S;=_#5UAU4H<8#SY2":033O)9J@ NO,BJ(AOW*0GFC5>|S>E5-#&=?W
MG'P|U8.D)(HT)0GKEUY7(6@7;|YB5:(@O@'| ^S^"-%+V:S6;G79JV4M(Z M;; "RBA"#
(:9/1>JH|H>@(&RA'D*H@57>6JIE#I@|/L|2|?IF2 38X*?' MG\$)PG,>+R|K-7)V?
%M*WVJRUIO\$,XGEG|901)3*IB|O|^B.0T,SNE;^&C2 M,_AWXVQRZCF
7V)E*LAI D-'4*/FE^N9SIN_32-%_7I+"XMA7D%RA->[*LH MR%R0N;O*',A
5B3P70O|+P_)H1PI%HB58!7J 2#V 6QNW.MGL|9 P@DJN2F7HDS103^
>A|W.&02(EUUF6K/UV|J;HXGD"IST-(GA
M=Q'*F87QK8BBIHR906\$3UG*7R:L^Z,C%JNY%|P+GR,EKR61|G/-NQ7=H8E=C
M>5>6"- &8CW>8N2X2+6-@R4CTR D0"6OT2\$#_3A#G5"QLJ:\$0JBV1C1-_5!_%
M>_201NV'H#4P?(DKV9|H!Q+LT+!(Y?M8ES|9T&-N<_+!+VJ9S NP0M3)=
MK7G<5^@,W:K.T+W0&1HZ0Y)UXL_@R:MD)P YP7Z&IT.&TS1 RQ2QS>,B|J-|8,I: _^K
MSO9D-(#E*T=(O>/UZ|_|POW8G:<+V?,(Q8Z->|&V+)H(BU@EVVWGE,FH M|
(SH60S>Y1S,)BD+0|5Z0UG1+EN?&(J|971*5>LN3BO!..??"#-4C-9LKJ&Z
M0D,2EPZ=KYDY+,)&W,R*F-^H_G1:%7O:9-P,?62,>=<&+/>YI!#6A./!<2O
M|FW2"TX=1@OA41>.-I+RYK2MN.(AG,2 \$T<+\$.TU/"@9Q28?,'HSL1CLG) M+%

(+Z/7LUH];UE\$132[2MP2Q>N\$D1_8:RT#&H4) MO*H)
<4\$F+%Y%.\925)8JIE78&Y##+XLH7;<49)RIQ2.E-SA_!|AT?B'FH/ MNR:A96Y^|SP!&N
=,?:<8>1(KHCE!IB|K%HXL;I&AZ8=W*&X%PF^&QP+ M8FNB?-
!PF0E!;9VJA.CZA:NJ%YTJI?PT|1PE<|;4N+"UGBF_ M5I>J:.#Q2QZ1?X_>|DM?
#80GD4MPO< M7T=@6|PRK/AD)IP:
|KQR5="+@&-3(NN#K8"8MFF;D|+ECE1C(27IU&,R:4/D9H:.*C49)GF6*X84-G_ MO@%
|R00Z6!9GJ=>D<.&BN>OZ6_R|HGBXY(FVXN:1_H|V+L>=V%R;Y&|DFB9 MHNO0|X5
NSG%(V%Z:O;V?)W|G-/N>Y1IA#2=!W3J65\$J;I#%9-7G(2L+\$5M M2R;X9K%U!"VXT3
3T* @JUJEZU@(&@K=T(C#U_Y>0.@4D;M> MK7!?:=8')!%QB:?.I\$NI((HQ!M;V0";8%S
M5*|_ID28V3JF^%M0,10VUDW=0!NYX<*1Z\$= <8=NN+R"7\$+_F7JOU0@;@A
ME#%OK5.=U!P+"|? ?/D/!)F4@J:.^1*)|H|?PT.*PT|\$;ZO/"7?)R")@ES>
MOOT#BX08WQ;WP\$HID5T&,0QB^*!6.SFCU"H8Z&R6^BG%AIM)|;:BPJ9V
M|M3A(5HQV6W,6'C!#)AZFG;(833BBW;!PDCT&Z0X2/"H%AG4#7CZ\$CCXR4|
MIDUZLG<91|EZ@21WBP7BPIH"J_7"VTP*JEHOU95U@;^=EQF";SBS"8L*XAS\$ M^7Z^
78,0OC8M&I3X,;!1F|>UBDP9"3'L.1R317\$6XT3|M2U:(9-NZI5B&: M:|V>7|N(" @-
K!\$U+VS)|M2JR"B%3_+8_#C&Y! M
:|7?)F>!'DX, ^4TXLKU(L50KAOY.V|@L0=DRK%#_@MUS|N+;E8 =KAW^F M.G9
^+BEQD&0@1A"*6H*2'\$BK98|"NR83'F0.)5 =KCX9GG,J5AAAI=);2B-
MRYRB167K;0Z&1*_|2UF<(RN\$/Z1|\$+VF;:Z\$W^P94A,|>NDLLX!H@;L8+\$6 MM
^;'AQOS !Z_ "X" ^NV/J7*4-XHZ4DB|P=L.^/DGC9^?|/S|_|#//Z9EBK*\$
M';/X|_8+08%W#|!#|H;OV!-;D M|%QT@CN'F08=;1Y"+"T|1A+|P?/ /_ \$0|NH)/<0.F_)?
L9AK\$+C?9>2-/8E| MGY-T'F/GQN?UJLCA|.5947ZV#7I/Z!SN#:*WLMCH#UCL\$Q)G.'BX;
|YVVD! MS| ^W6\$| ^P^)^2,"SS%\$R*\$S!+?#?I@G);Z30?0++!)T^/P)23+L5_36|M=.B_\$3
MTM|GT\$K.U/LGI<|P^BCXB,>T)""VP.[7#\$0Q!H+" "SO"Z)|\$C Z5IW>8
M#^&MMENF48X*> F?G.)(|P0|ZG15\$|HNVAOVHO%P/+F/7-|OH;TH1S2?)%U, MFXPW-
+K=;>X;-R |.(EW:;7|3(MLOEIG/>?|P_W|XX.H/^9#Z;|2<' ^V/^ M?
\$L|<_&P|EL.IZGH|V|PB8#2 TMW3^MQ_>?X;IL?3|<%Q?SP|2/N3Z734
MGPX/YOUADD|VI@?SZ7QT|\$.4QTM883I+7OZV7J2CX71_!&+Y.BE@VY/WB_C+ M#Q\$?
75!|%S5LR\$6:P.(75;IAJ<-).CDZF!ST|P|B<7^R-T_Z1Y/98?_P^.@@ M28X.AO'>-GV7"A|
'5;|>I30#!SMKW|ZOC_WTNP480?1W"GQZ-Q>AC#2QB/ MCT:|H+^|/XUC|+2(YG|
%T>G3|D(+|>|G,ZSO);3P;|LW"|WE_ W"8J"=' MLU' Z"">|R?CX7Q_?#B.AZ-|'|&W-
YLL=|>"3VPC9(+M4K"B8(|U&YME2V MYM+@658+6)=FME?
K<."0|7<^.*&N7(#.%X3'!JODE%) M|Y, @Y!&).8G@AQ#-
PE7Q/<SZBC20//J<7!;Y|2KF0@T'T3E9UAT!|U_|/EPM M) PMQ N=/CD'N!8|%K!T_'H?
5&>0%JO|RJ W|L_Z_@32|B596^K)C"Q*!=
M:%0+7_L'O#|LP* @&!#EP3_E+_;U";Z5^&"1H%D|A?WQ,IC|I%|L>%7H|O_
MY!A4R<%U/_ OKB|IL/HUH&|S =+Y0!U/#Z@W_T"\$:S66=I24-E990L5"|.@I+
M3=BJOE)XEF507T\$Z^2ZMPS/M/D5 M1_JK30|9|GV7EIVY';SKYUJ;P?K+5<;*>XW-
M^RN|0L#) 7I(489Z'BJO_3| M|JO -NWD>#"Z3D+"+H|,2
M4VFG=;VJ7KYX<7Y^/JC2V>|+I\$F7^+R11+7|8019#@9'XU> M@\$",1L=
|H_\$^5@0.|D:3%|D8T=D0X(Y'@|_ZN5F6YO-N6;+E)>FL8)+|E|25
MP|CT#;O|6D>,\$KCG\$R:9BGGTB|'H),2M:..L7HPG5+X8|Q.<3TQ2Q6/Q:G*TK M9"N|
:1K> |5+ _J0SP:|Z%<(#+(%?,A7C\$|64Z+NV_CAN!?)|_/;NO;K/%UD M%UG7A:;?
YQEBK0W|W,F|T@B)ZYE!&='<.;R.HW0NSO&-'C89?D^Z)<1D?| M_Q?Q-
>\$OS@/O|P/_9.00_@8097!3_?E|=9#&9MOYGT^HI|<L|/7'VEX%#<
MSJ'8"P|CC@4H|G>_N1H_!%"|HZ/-W4'&E|:VR)9A|/XLX> M002CT L0NWV+2)-
:3XG6GOM"X2\$66?U3+VIZ">D,VUY+PZY|4LM*C/L|Z_@E MOHR.R>P?/K*?@7?
BA,/H|*>|ZV(\$PQ|,?S#|P?_D.'?"X9_9PW_ ^'D;?DOQ M3BS>|K+&\$B.4&=<@Z-5-
MQ+\$ZC?Q&L;:PA>PW/2A5OP7,%KN*W7, E>PTYX M#>/A^&!R-#QXD8R.CH|.GTRV
WD Q07|H0|<*9TT8SRZ..L+K B(B 1X, MZ-T:!(T0S'PP|T|>6W! 3_AO|^42_'H|!
M>)B,/H.H^ ^4K;JUNN =6&2XZR><_ C/OZ;7WT@9M)R%_QOG:TP8L+,P>F1G
MH7&W@%4(7DGP2H|6R4'P2IZ|5R+)A^%D=#S<>Y\$<'1T=3KXK5N%M
MBL.|8|. '<9*6R*\$Q/V"5<|HC;+3^9\$8TG!!U|0UL^STZ\$|ZGTY*, ^ ^@XI_*"
MT7TZJF0+GBL8W=L:W<-@='?\$Z#8;\$)^*,X16|_H"|EGEB2P|_I^%K- WEBL3_31!^|
|'XS83^8YG;6U.5 M;XJ#N;V.^S%|WK+P>3>SN1.'H@FX*H"?)
G:=G@X?'^<'0X'\$ ^&^W0'>Y,7 MZ2+)^ ^G%Y#.G 73Q?;@<_)F(JE|*Y>NW,,UD\$FGH6-
I_OR8K_2>Q2Q-6X).2 M8;_A\$9(W"H(G|PN"\$71_R+,0|'%Q4R7OS%'Y_ M9:R.7_S'^LN7-
=ML'3&*S+SX(^9@1?"S>#"E%QAQFA-5|&&V.Z'F4JJ 3 M*8U H\$9U(T|Z>

!U.:B%YF!#=#!RO_-!375CQ9L/*WMO)CV,VJR?<|,|'6?|.8_M_FA\N#?4F'XT?")!_95&FGKJ?D;
_N\I&\$WX&_P(?7(4-S#0#Z6=/TU<3YZ_MM??*O:|7EW"1CE_F.9@FH-
I#J:YX6K=H\H_P2KO\$5664SJWNCS=X#+2?/;
MIQ("UFP5+|_#D02A+1O(CC_7%S'BUEBPY3FBLHM%>W!|-?HQ_HC!XM)_(_Z,; M*|V-
CI!|=R'M<:|G=-YJ=+PW(=LKPVIJZY_P/,9H;S@VQ#AQ.8WSM.I_O%BD_MEWJ5|7
XOE6,^WA3<)|;/?@8V&,SLY9U7&PJMMI5;|_#5UW+JK|/AAC^"?|*M5C58U6!5@U4-
5E5WDOH;PQQ:S"QVVABQUL0N(Z.HC|&)X.W.V.,1WO|PVLMMYO'P(%C,8#&?
|*D/%G.G+>8X6,PMM9A//R@-%C-8S&QG|RC!8MY6ZC2:/#A_MUY-@)K?_3#|0*_PZ|!??
GT7<_??_LY^H!7=8RPV|?%;(T06L+MC%Z1@I*[Y9'2,=M;)E&";9-
\$@\$4F6N@G>8OZOUN><"#"0PF,)C_8_+O8_)/WOQ7,(&|:0)_CR^*MO%A>1N\NX-
,*@|23V6FZC*,\$>|Z3FW5SUG^=8H=L&HJJV">@GD*YBF8A!W#K*^|V4ZG
9Z.G|)+U>%T7KZ;:@.M*2EI+E7W#E
M^/7^(KXLUC5<_B)-7O&M1L/A8/@7_0&|U\$6|JM*75;J*L7-5MZ_DY477_J&I_MV\$#;YXI
<_.+3|9W_XGQ_07_>91_M-?
0J3A*X+PO88#C*|BYEI=_BK97O;==!OK;TM%T|0BZ>KLVX|ZB\|)X:W4|3
M.L6\$UY7L,JZ*3K*S+:|(JPJWZDO: SXLDU:O"XO!C6=N_R71?O.SO09HOTHM^
MDI5<;T*ELU|FKY*L6H&">XF?FAW5)Q_L9ZQ@Y9/(5"!O_QS7=79_%+O2+_M
MIWG2P=7KZ!-1EJ1;_O221N/K5AC.%N-Y=S%|ASXTS+@;5Z&;WI?O"!|8(P;MU_FP;^U;
M^@9W?D4=:DA?4'_1@HOPW>W"!?"4|=J*;?01|F%|MI+6)=Y5IW>U%-X:D=O_MV_,L-
R/L"=RJS;@'O+P2YR#*T9E;_PCUK>CHH1_+U=I7L5U45Y&X%/G^\$?B
MR>00!^_>7CWA|&|WU|O_EL8GBA+_O8#S|9EVEU1RD|Y|#,9R1G)*HGN,T40FOX
M:&9Y0AS8-#V-%W-D?,0+\$3Q;OH_CH|_U#C^BZX&V/"U*>-YD21I>3K>
MRR,|Y9:F1O:;|Y_H&-W^)|Y-O|YN!>1H5U&=;'G|(!X-S@9_|8>|ZYX
MR&T/SJ_B,7P\$LOYP(L*#A0?|S@_*|GB9|L!\$WT/E?X6?,"7T:_%F1U!CX5"\$!|O9
M!WL>:NS-:9;VYQN|EYL|^/QF|4VE|>\$=2C*Z\$=#S/-<'K+U|GZZROY|S|Z=
M4(<*=:@=KD.%)-=UYL.#A0=|GK%@_M4%KA"(0'VYD'>QY*BQ-8+8KEAX**WR3'L-
7|H,73S4FS%|/9L4ZKR%:#VFE_MSK12Z+MZTGU71|^|^|JO+Z9%W/C.)|O^O_YM%+A|
(NYTQY6|RE73;|MS=-:\$_*K66=ORVJZ:WM-Q8X(F(8G3%*DA*;|LTG_XB_M|2+XID0
I%S>C>F2)3_3"8!|(A^_/?_|74=H&<(<)>WX4_O6|TQ_??X=PZ\$:>
M'R|_ ^MWGAY|P_EL|MW_ ^H_|>_U|D)NKB:W:);_(*F;NH_XPL_<8,HV<88
M??|P|P/Z|>S^&CVX*|QVT\$7D;M'\$SV/LP/?HPDDQ^LN'Q_>^>)Z>G+ZX?'TXU_ ^ ^--?
WI_>^/KS_M'|_/_?_ ^7|>^6Q:+.+_>4J1=^|/R|XBO_.00P\$>(>N_-)7=)|T|(@.D&S
MT/T138,W<-C";K'"8Z?L?OB,_OX.?@?.'D_BB>QZYTDMVR?Y"TFP>Z/R^CY'?
^1=EAYH+9QKB\$9EUQO7C|2OGQX_|TW:|WUVS>1>/
M#W^O|CMI_\$=-/SD)%C*B_WJ3I?|T@|WHOBVG^M;|H|:U&_H_UF)*5D<
ML@|XW*X_5%'^|X=_IKB;/&?_GP"S7!,5VIR|@%>&/9X\$F?=6CC)\$WV8?)GK_M?
D)NXFI;X9=\$S>?KSSS^_H|_|^|Q_ _M
R'Z(OCK312GB+T/UY%+Y6X85/CK1(SL"7Q%7F"R"/\DQ+Y#8>6;5#;M|_IU
M0BRQ@SHAU^>AG1"+\$;C_5,>WV(RCT/?P?T4L5%55^=\$(/,6I((??
O|XI\$"N2W"?;FX7_0SYN8Z),A_M&|YK\|@5_F#=I>% "9C|V>R|I5^QC_4LR6_CE\()2O?
8!"CVRG6*/?"";ON^1_M|ITS)X_C_6&%
<9HH4|G/4RTS>@HS*NDAN!=PDDBEB3A1Q*B^3:S&B;US8M)N
MA5.?"S8+.)=M\$SYAX.F"V78_+ #VQ)H6_+-4R=_3>:|^48H3FSF#WJR9<(_
M=ISPC#J*%BBC_S;56|;Z/%J3P5F|TOR,9R&AB: ^C9.JYKR/3L@C^>-BR#%#
MC!OZ/B#|WC8_/OB(8W"D+NA7>2U5400737_*N?;ED&?SIL@R#D\$:7_-N6M%S9I_MH_
B1O|&^C.?&V3?P0)^KTMK5LF,J??_HCS_|!>SS,M_LC(P*P)0F|S
MUC!GV0!^BOQP25X"%|W|JS1XEB#A%>M?.M:/XA093JYU1V?
T>MNNUS^(F>DO0Y^<6\$Z83ETWVH8I&>@|LM6Y/JY^'SL^MVC+?%RY-
:=+3|..LI(T'L:;(O:;|JRA.4QRO9^\$S3E+Z^A5?U,HV+5/W_M;^6I
RHGCX0,4NB|35.G;|R_|B+\$VSQ#7;@|HYJF|4,E\$ _ER8*R"!*!ZF\$MWF:J^|YY%^-
XWN77S>@&2;D=)NG*QR?;V.P#4V3)&^HW//YAG|Z7UI1CE5_M),C2LY\$21IPR8J3?
YKC|')S)|BTE1=^|Z3'Y!>UIR,'1YKF=_3TOQRFE7S_MJ|!|F|SNDWL>K=
<^_Z'(#!&5\$G0+^_';J.TWM6Z;S0VDZ%6)T)G/DWF9Q#P6V_M9.NI5E;+S5KF|&-9NZFP|Q-
53<5%(8.PF\$|_*2#4QQR;V:IFH/U9/U_DE_MA%1*;Y/5;N<-L8HW, @D_%#C&'>
(*X\$2TN>;TM\$MMS5.@U6NHW7NIPH33V?K'/I>?'KS@6E?X_.4|!K|7_">+?>?
MASM,_^,Q|OL_M'VZF5:>Y4|OF^?Q3V6Y4;)|FSL-MMOJR6MJVC)|9:M0C1WW;?
H,&70;MMT|_M'F^9YK*UJ+-Q|VWBC5AY&Z:|H|MDUXV-W6S^+|N%
|3;|-4MS_5,L=E2U6C_M&?AM:K78@YM4Y;K&+1-

9MF)5QP" ^S=|^2E3#^P6IP=XVP//%U3:%P|;9T7:~ M0S+@MU'H0GA^
*/-8|7#Y371AW!R@5/'#SX4E3"3K%K63MFJUKP)G"#1(AS
ML3XAT2E\$>X5RW4*R7XAU#&.)1H6L_H |O*|&'NZ+F,M;4MF4M5_0_4=?%6RM:R_ ^?
QMW>@**IJZ M'NV@\$RAYN>QD|!YOWD2D>77\N6Q|JPE%A|N?9*,F\$SAGWA:0.:|~
O,5/YX'3D0J*YI M, GTF(PW'.OG^Q GP W:W,37K56| #9IFU++>*@+AJWU%^'=(V:;%-
UC'D)\$AV M|83T|00ZA|++>O:U(#;XHQ:HAE,Q9F*00Q2Q)>\$MOFLJ'Y^'T'J8@)KL&N8|Z
M-202+++.6%5FVH;YPP|&%*EG*|T2#WAHFJITYB&:
(MD|1+OWMB1U+\$FOY+DM|51.KEN58M@HW+,=LA^1|RC EUY%IT^%|ID3(|>S4K<6V
M&Z*>_7&Z7,9X2:|?V7HH+IO=7FOO(,HM2ZUL1.ZV\|DNJ.TKUN#N;57I6%4-
MRGVWQ=- (H&6-E(W+|6ND^2|PM@ATQY%T:=-PM=3,HF4AE:W-1|HI=>5,J
M#,2N*.,=|:|N&.)6>\$4A=,*C8F:3N.KP3*(V*L300-MRVO@F#)| (65MBZYLF+
<64?:V"OM\$IN|M4=R+0LNJJ4F;+|:POBE\$&D,*29+NF82#)9|*U67@6..|OB4N:XV1.?
|B+?9>|?S>1AX/'B P|CM=^J%H2 M*0/6./D\$QCSLU5B:ANQ*RZ)L#JS.UF3N>I=U&4&?
D1|BVNN3|!9MQ+J">,<1 M|3D<9Q"@5U|F*|P'\$,0+|D.3TKYD V+4NJ M|L:|>4FQKJ!?
3Y'2&21|PW>BMX5G(IQ_C_"_0FT+)|8*7(6ZPAW!1VF|IFPG:5|>1M=6G(-|EC
MA|G|^>8U|G/9|EV?F?*VPQA< |D> \$89LB? EZ +/ #L|V%O(\$|'6P|Y5*WA
MG=RRD9LO"+5KART8SRY:55K;>-ZTT=3MBO>,*?U#HH-H07J|(E'|'4T"|
MF%KUMD|HKU,1(E>|9OZ&R9|?V;2<8=M2R0,MF?0TYJ+E|D'6'?|8A"
/@K)P)U0G\$INE95?'L|CNSM M*&\$"CZ%++>|'V<,PVO>CK@@E=^FJY0BIWO+V
AW;"U3"11E#EUI>H++KY\$A>MH.8RC6|OS|&|/1_'|_9\;'M|3"!L6WE|LNJ6W|J;
O|!DSU=9\$'X>VEJG=B% M)^_Q O&/ZOOT|2D.?HSBY3L_3-
IY_OH=;./."8+OT%=*817C1>X%E |H>/_ ^M)TK"2T_@|X|?|\$^|_*D^FI+M_2|QUYL ?
=4| (9| GH0"\$C)VS#=(#^UE+MOW2OH|7CA_T|G2-CIL^4QV*\$ (W=|1,^D8-T8)|;*/7I
M.3V|DK7S(|&T0;^H9S?D1UG(:5X|.&)|(\$F|OCO:|J;D,49ZEK ?
|IVX^HG3FLKN+=>:GK;3_YKRUET%:'S< MXGKK509YK|6V#TF+DG8I?KR7G-
T)6I2RL0KP7N)UH&1S7ZRHB|O?'EA+P-)^ M5U,RMO..U_B|'1GJ*JEVE:'Y>:NG;+&^Z)
|G:??C=F:A7_7-KG.E@|OH|":C M^I-->J@#@H<>0.RYTD|IT%V\$W\$?&@-
JD_L*TX'(R#3+@U;D_H1'I64>)|/._ ^M9,>A<1XD:F=Z@VJ?
A^VE+62&U\$3WWCD|4|E0*|U7G_Y\$Q|_=[2NT/EY#VS;_M4|/ZFS<|D!^%Y;/,_.CD.3K-
5|_RT,90.!U98SF'/FJV|FX,J*GK*T?02|?7 MW8TA1U03FGZ_|=3:B5&LS|W@X#4MQ@-
X#CA6S:EXO8:D"^F1W=#W0?;6?HO? MG_FH;OJ'0%5KM@H&|
%H,1|>3'I(R0_&S>LW*CW9#NA?T;.)4#J4|H-RZ|<|Z#969-MS@PYN@90N_J-
L+\$.6=KM|L*9ZKR9'4|U_-Y371!+-KRO>OOZK^MWEU|3R#(F4WD9;M<|W?
K:3XJA_SEHAA(|6&+O<.)F| T03^BJHR(FV|= M#T#2:_)MP9"MD8|UDE4T/+33Y?
T|OOD|O9:=E4Q.8&5CD6MGNZP)W_RF M+T|L/4:|S|QN_7\$&X|!
(DV2Z35=1#+:6@C@F.6F9Q_2|/RZCYW<>|MG|D0_9 MM)\$ _LY 1.+'+11|8W*_|*|
MYHA><|6%_8=;SN%<%D|U &D)\$&9 |B7#P9#;FN6>SZ MZ%N=4;"XQ9N(J2GTH#B'4-
IXUSBUS4|J?JVF(0Y|LML|KH@VM<';U'>3Z|"E M 32^>T>V|K5SG7KU|H1^!|(8|S^FA-
^FY'T)/;(FZH|S4KOA7ZJSG?SXB|T|& M.797NVO|C(. *S96:-L!ILX"
|X98CYC!^=KXI4MSBM&8.VIP831SDW\$W8W<+)O M'LFQG&\$;*>K7M3&IHUAT/Y7#(&
|C5+<M?;/O_KR-H: _32|H|H7<*DCA5A|_|E0T|^>|OCV 4GR|FY.KU|'M;I^J*4|JN M.-T
SCH90#J|I_ WE*FVXG=6W'V|!_.+L|K/B?*%L:(V&R X/#B84J-&Q3|VH
M3K("C8O\HT0X57_-> CT(JGY77|B1Y7T39Q0N|JVL8IQN'E>A-\$.|PB,N^V
MY+9/5&NP%==;<Z@,MB\$|@RY3(ENNW#5MO|>)^UARYP^D45(7C&#YE+)PJK%
M|)Q,4@R!=A|^ ^HX5Z'"5+<;P46IWH09:NO9B|9@HO+3JG%WS+<9K*OD A*#
M3>\$"LW|GH;0UG#L;/R7Z0O;M>|X3<2#3?+KX776RT.P;%:R(JNDRQO1.
MUN0);'MH4#L3^'W(R3W*|*D9V&*R;)(|YT4W_BAO|ZNZT,3
M%OL1'0L<@T\$8KK@C0O@A|FC>K4=\$)V*#"2|N|LIUGW2-;MLTCE76>VLS;1Q
M: +A0FO;(D;:FFL|JV)PA&E5FW "K67@>A2'S"/W-3U|4Y:0G5-MF?A>51/?5=72JEE0<8?
6&_2++<9E"FOQ28AH>T#SG9WZ48G<51D&TW-\$#&P+W
M+K|2_3=M5G7J|X'4#D^C4K\$LF:Y?RWQLS8X:EX.E0M/=,\$,\$<_*ODW.: M1!&0*U|,=@
_K@X@|DO2TKY|'T#K>;H*^ ^W.K-)Z*VFIJF@|70N/\$(=D1 M9+XQZ(AN76A,95O-
2YZF!+W Q3|<=K 2-#4?4*6M"!AJT8:GQG.+5|P=U|@ MIS2SS\$Q==
|O>4K"I3W&4))|#"^WA!'W"W"AC MXYIGN+|H@*JZ!+R%P8>RKPO+)|IN%-
NV|X'AEC"S*9;4>7|7ZU7|_FP|G-? MWO@Z;('UC0=TZJ;D'<6>.#&4=|E0;
|/DNFU|4/-0"Y7G#(>4@1/,7T(RG"M_M<^VO?68F(?
NR"R:39>7U:U2@VO4J<.'VKJZF&FK+Q%OGM,7V^R@PW(+4YA+Z#&1!S
MVC&T2*DT'59A

M*FQ7MVJ?*,XTJD;8,O#EQK54WWX(%_7E5{=(^OFF_OX|^@,=WX./T:V\$S:!*M:
"5L(LIT002ALP V7VO@NBE::N?,2J!YA"(./XX\3IKL,*4-M,JYJH PRG
M3MO&^U/71W6G;J!J MLMS\A+>);&# Q^BQLB*V\T7ER[%IR/WK%GH;>&
I>@GZ\$QWN>J"@ZF:FIE9 MH-;QA42(=&B9%?/'7 &G^V*?
N)IXB;VH&HU!JARYDH_ZW\IM8^S,%^Q->.@X M);M432/-O9#(TW
;Q0D#E"9["CC:X/V\$P(A96"Z>5M79@VD-?^@RUU56>ZA! M\|VY^QDI0T/5=I?
>S6=40C[\$#LP-Y@_7=S7?#<5L\ (AFZI85P*%>=;4)ITQA12E0-*E=IAD7'YX+.1\HF(+KK-
KM#\X!M 4 MJ+/8YI&H;3ZD2R^I4-=IZY0V0V*Y8\$ O!74?L#^C#;TBLQC)-LB6UB>'
XJQSMXJ^#C>@G')*.R"S/?76S,[K@)+>'(O;H1F+>,*MXXLMQ*;*+H,-
DZJY\LCPK(-V:FMM3(6@W*DH M5B1?
C<8CZO!*NB^I04!7>GL%B)J60Z8K5JH@|D,IHSHF&PZ\0"5\01M'ONF M)
I27#@(@)^6NBQX(:1321%\$-\$,"9G5>4J:6BN;/D\JS94&79"<;<+I25E6-M^MM
8TZT5Q"G&22OY4K26NHNGQV2/5X07)+*Q,F###9"0'98O&4MEV2\$4%XN4K
M\7'&TTR79X\ON7;&3)^3HH?!\G/Y55B\I">+Q2)&IOJU6V'#H&A!T;C%;^B
MX>!@JPQ%922VD#T3!SH^K/W2 MXC\3)G>!XW;PUS:T'EG@:N>(B+-
=-8&&4\XD1\|VW97(:QYZ?0J(3W+6BN,&@ M4M?6:009U?T Q_\97SBI4ZV9MS8?
T@I\$3TGLT9SX#;PI_2U"%20'3*QDMSF? M&0?)J)?B QN;#JW(>U%/C%EE4\N%=?
YKZ\1D;0<I,N517/4&U+4<3F\I(T.4 M"E?
DOU!:UBDVO6C;JU+6(47*WT9BNP\$X@4Z&&IPI1!61F@\$CNC\W,";)O%1E MD
UUZD9M^P&C(B@@"P!TDO#4:%BH:C@H10,97"<".3J'AAU:!)2Y4HH:O*U
MEY).#X\S/(>I\8>\$Y_G\<4X/*I\V.L3X5!!8"QHV=>I_#\$C:KIB4&UF7)- MK;:Z:O4/'#S8-
XL UM\$G\HMDD_I6B1KD7C,,=2I5SSZ:V:(I4/T4M\;G.YY6"5 M R3R<7W\;D/K,<.%-93
BB>I0_.=L\\$(8)M\&589HPDB M3VCD+R7N)\$UJX MBMVOR88(SJ/D'@/NM1-
4OM:6NS!DK8&<:>.&E@%9EX^%08*5Y+KJO<\$L8??%+ MFT?2"@+;D^J8H^Y.JTATIS
2V_K?,'CMR)6+O\$G.DEIL0:6&<#;J-G)\MZ! MC#&0,1K&+:L))F+8E9UF'IRQO:D-#
IR9O7&=ZUY7/.*I(E(Q;:60>UD?"5\$W(
M'D^;B\$.@"E&8!7V+!5W9UY8G=!LHMD_D7GL51\$[*ZX6>.0'821ZC,Y8V0&LX M5-
HJ.CZJ&U6JP@=OCT'U(7\U AWO_?B0=U!NBGB 4#8GHI+/&X\I?Z3EQ<=
MMIT_.SP\G#;JV_JZ'8,-#I\AS4SQ_8>U>?HHJ'I8*#R"XHR&:@OZL_64%0\$L(
MZDL!9/LZ<.L'K\;M@"*PBB5D(.BP438%#.W%XU1Y%**E,=I#;_."92-CP\F MX-
^B^>RJM0\A/1<-V?!= 'G2TIO,AW-W^N\IT4\]+4XKFYB!<)Z'^R(VUSTQ M-
C=G>N\I\$8Z\GE70VOL\VRH(MR-.T9U5+<>'L639^;DPIFZ8V@W/#O\4LI M4@!(I)_#Z
G*\$L\$,S,+EE8NB,@^&O@L%5T6,J"5W^4&U+1(S?"RK+1:CA+V3
M%X#\XC\MTVX5\$ML?.KX\MI<9UHHMHIO*E^GF)=I7W!'%A E\|M:5/1RFP\$S,,D"GS/
M:2^1U^F1,8\$2-P8,U\|C-1(EIN1BV"65Q8GLZF\4P&<%(7<9Q%)I' MY)
I\C"A"ARH+@BNN6"M\$Z0 <3UFTS\A.69SX4STP!#5\$JB<8!E!/5ZLZEPV@-
MERI&.I*0.SJL+7)O?_9=,C?5\G38H9+JGQHW.JTL+!VB5V3%XI@?DY5KNZ\5 MN!;Q-
=&19F1GV*O(2_0H(>H_E.O%,P75LP_JO;#PG\6E6\$D;GX-%1S;"(T MG\TJ8CXUX0V!
#T_91>4P=;'AJ# M48Y%L=)2+J78UN\FN4Y4QJ#/%2:\$5S\YV\%P4\IG=E3@.E;:'(2(OUB-
@E6W MU0Y\B_?O,6/A)>SP=O4=R%B+P/I;.!UZ/BHYAYWJKS)H_>R"(I9R.(IF^V+
M*DD;4U1>03-+-ZM;G;\$%NN1!D;\N4=@Q)^5MCR\|M)BA%+3>ICER6\$W%!X&
M5P\|E:-I9ZA\;(O=&J?3UH2W\|M=V#)\$V<-7:UY'6^7'+#B%F\;@,O8MRR:/Z
M=F/3^_F=5E77H\WJPC\H#OT'MHX/*333-8T^Y*RA+WB4IPOHH1,=0XR-?PE?
HJ9+0BSUQ8HF)A3_GU\$2#FU=I2P^&JIFP=,+%A/'>: M\Y*%77#UIDO\4>'1V\|X'==)?
521*HQ\I-3+KRD8,CWER\$YO\|D%K;.)Y##: M@J^QBT:/+\$OA%I)
(>9UE@/'=AXIZ'_L007RQI87BZ:YUAA=1C/'=!'^I/;US6 M\|OY@L6V/#>GWANQ#ECE;K
I3ZUQJ?FA '!R:6YDDU1%-C?!\\$W9X=;M^.(N_%M#XK'8>EGS8H#;,3#->QSZ)
(=#G)K(>@,3RB^W/#+7J>V*N&O/OD4K,)<*VQ MAF)3UM98ZD/1:FZWM(-
_PM\$R=C8KWW6"&@C%^K;#Z?L%(U/!!)5!8-#8LNR@
M@=.E\;C20UOS"_AINUSB<(7I==:5QFR6Y@>&R_-(P^1H/Z:C&="R:'0Z-CL MXU6*LTW.
A\|MHZ\A%U^G9H14^_F/7W:(8"FY/+RRX"7OM2T2V0\J53VO%L/Q; MW="^W?
"\$H0*_G%,H=DK%2FM-?OP?L\KKGG\0@#F6%,K9H0Q-!D^>G^L.6\ M,X&J=.NLFW+/
1@9%19\0HM3. U\$ "NS0^_D0\I\$H/96/3X6-SU*.O*3ZNMKVE#>4:+YV
M^TS+W:QJH1MFI"5Z7\$7;A)P!CR\|D('8BN&P6 KZ,_PS 2@VQ)7L\|WRVH8+0 MTJ8(-
C\|S3A\|S@?MTL<7_C9WXD?"LLYSO3V=L-D%NYM\;+*@\YQ7()_"T+86
M:YN);VG,>"HNJU5?8@7D:Q%8,W_/MI0E0-#5+2\;WF5HE(!8I'0 5\$-BFFA MTJN\+XWA-
3.&D41=)8O/'8(=&U:6N4S \ZUFTU %1XG O'51"IS\$*:AT1U
MX9:8Y8Y/C\W7NI_W5#M0R':I=B @_I%?AO\I="DB5\SR8%@"DVB-+><@F/8

MOHJWA&H@TJ@559?YQ>?O+OD MQON"3V\X(&#M)A MCFDUE(!HK?XA?Y4?
UWMJ+!N/T7HOG"*76#V\RS,GVYT^1"J0\X>R*WA,2+=
MH;J6^A_Z43P^"S;J#_P97/66*!\$%PNK\>%7?H!CD7Y6&QF>;Z6J\RDD78E74 M735?+
!E;TG=555KJ&!:N@WH4?P\T&9!G)56\GR+(??OK-JZ=%X_1HH2SV\E
MS7K9_G2&5R38\$:IL613ICRH&WCS,XTB58*?RJ%-P89-L#17W**\Y\$|H8TO;M&%>
&'@6F+WJ&RRJ!*, \$ERME-:7#>|\$'BH11Z_0J\$<+,8!UYM;@=AZH+K/.JAXCF'W?|3?
TQZMMYN<;Q\$O(2XN@E7<&8.V\I M%:NZ|6!C?A.%>'?CQ+_C% S|S?C9-8V'0\O.1R
)HP6SN"C\4O2H%AO*:,CL11P272R8AM|46_LA7UG/F,?4-KY W9X=#CZL:Z%(M<1|
M&|9B3Z(C4\3/HX#(%+&IRI7JH49*M^9GU:|439/4QDAWH*^_/@"EN,-3 Z|F
M(DQ,ZRJN?6!DNHP@.REJ.F'1L-JQC'R>"+IJ67(-#QRC M\3)S-&|f(B
@,: "2H9HL.IJV6AZR'EO& M3 *-@66|R:|!<\$X&J0Q#|8.CFP0/X+%6*!NV50R,!^9"F>|f)
<8C"4LHI. M#3NVQ4Z,QI?7\JK6-M<=|Y2#UB);WC_(*#U&#QOLDBT<>V40EG:1>561E-
43:KV=|K".-0X51^L0B0VBR0J6V=|JB?BPPD'0
M%@F0:S2THG471PN<):28|@JW(9^W/&1UK!^=KS,/DME!|: > 1VJ2%W|@9. MVG39?
*,1V&R|UGEK3>7O15+WG5_ZK^3Y+0-&*R^!3>V'AJ* X@V^HB:GK#Z M-
O,MY!YOHIBC(*:5U90;FQ|!ED63L6Y?*L,|N#MD.71&|B+UE@L*VW|=VUS
MNWB>Y\$+AD+V4Z'G/?K1-@AU|<|!7B|W0^HA=?"R"#%:BY15W|9R+9 L\$:5; M:?
BLY9AL)8!=L2(3S^"#!.QD+;IA=P+:\$V(;H9DK;TDMCXS\$--@ \$M:|S|JEF
M8*GE5\$&4X.\$%CQ'-JVFNHWP @5'!U|4'#|6UMI46!^ZM&#OGD5>9"J?^; "7/
MAB7)=,^MX>V'BU/_3RE\$2*4 6.EW*/A,=*TG,K%>8X)9QX?'@/C1?'*76+ZL
M9K7|TRG&H!0UGZ:>65VW)2'^72\4G=EF*.T2|5TM(%C_F3E-^K*D S4|0L
M9!F&8&%C+T&EW=@PRZ%M3,V.N#Y.O&-0E+I 6^|+2?L)
|HMW*X<Z<";G5N5V^#^5\$;BH)>2QO9PWH^BOD_/M^G|7+1
%VLCKKELCH,MO_(!LLN3|\$\$'25U%|Y< <).8!="|CX>WK<|?WY_ (MH)E40!HV+6Q.
(Y9PZ.X5>K87C8'1:2M2@QJS"-J>&DT;:Z'JS|JLX|B(?_4 M4-HQEK>5C#E0"ZP'(9XR4Y
M|6|Q"F/9\$*_?>'AXR+R8"DMA;";|D)L,E4L3'4'4FOS|>U7.F3#YPW51|DN
MM.|>UD!|0+@9*/N61:8W|LXUC:TZ(LXB);FBPL??-51G)"|NT|64?6FU>\$!
MHW%NW)|KTC9E>1GV=8;IW|L,UIF2Y7>>)FCYS*@.WJF&|
|W45+M9%&|DMY3NZ6B:F%R%)\$?+?B6;58#(ZR&5/#@DL*P\$J#P|3D1PT_A
M4|TB5_N\$YNWES(|2|!'*(B6.SKF\$ Y|?5?|_6Q6|0LY7|&(!0WF#|=W-P^S MLR|7#W=?
KJ_/ZPV.XSM% C5AQ0;KBYKD?A|PWU14ILWJJK>'=[0]-0:0H:8+ M3|'=<*DRZTT0|3
Y|.)GW|4U4\$XL39<>|;"G+4,8?|882P\$>VG91W5R&X%Y M'M7>G>"..FSD"-K-
|YV|S,68XAG8:I&<5+D?'%IVC>^N)'6@-.316E'XO3% MN8C6QZBJ\$(34J;.\$Y;:8>!.L-
"|&EH!^(7+OJD,%P<+%^KYHH!IL6/_;8MFZOBU109HY^" MX65&EA)1!|9..FO-
@9DLU6_H;H3W0)UJ84|\$MAL+G+QU)GI0%;-*K6QX:#
M>N:>|H!'H*Z&|BB;QD>&|W1%.R=(Y^V#G0.DF:50(JF6,..#X|AUMV4I%|J
M=@R(M3V3ZP|D-^!4|D9(;#-%:&4Q9.C?AAH3DFT,JZ ^UB_?;\$2(C PD9A|2 M+-
*B@X\$JCW5Y#X>0&C1&&V+4|L'5%17D&R*SNST_ M|5=6<|HJ,V/#N|IXE= M9JG%W-
<6#+=?%)S^ M(/N8K HR,) ^"Z,D)?L%\$*URY9>|<1)RB:1^LTU3(;_NCP^;E*?
\$HQ:B51LS M30|B,2B* +F2I#|DIF^?R\$4KVJ:?(J8@NC@.6|)%3NA,8?@<_VRGEN*|BBH?
@_M-A61Z_+D&*/H|X^9'UT1)5XPK6M*R|Y4AGOC&M%:V|ZV;@^/WC71TQ4Q|H
M>S|@|L;.\$W:#TQ5@8D+L <;GV_4VH!?'##U1@BS24B73(% OD@W;JEX^=O'G
MUDX0"&2"6DM|OI7N7-(0G^V=(-'^T&@ 3?G.UF;K:'UL0(&8TS/U%UGUT7M M
P.ZE67,4??|?M#NB|^UP^/*|*C;G8*L P5.3M8*O\$L='E>8;.'KWT_#J:F
M6R:6E'|.6@*L4K47LJFEH;L2!%\$2,Y|0%^ (1=>MOY<>D'U\$ "9H-4>P'
M41H2<*XJPJ4"_:_%|7, H:\$+?21\$)8%|7">(B.P%YVNP3=?3S\$1_JCV|/#3C
M4U8U&_X>6'67:XP\$ZO*DY@\$6-QB9S9U,W95/=MW*+*F&UL/(MU)+|./>U0<_
M#KW#Y:|CA7NF3+JG/P).RFDGZUP',J-!ENQB JIN/VS-'C6PN#?:N|L3@XF1 MQ;:#DB
G(/#TT52(T?C(V,Y,%O!O:L:CP'\$K+N.W_)0E3! 'U=!'^13N"3| M>GCR^>&|G'PQ3B*B%=:
|>C-'|Q9B8)PXZ2@3N|FB_KR:7|V(G@)!;8X"S(;, MC-C+R|N/=-1@P#Z|?_Q'?S|+HU2)
|@&UM_ |AV")%H0G_KK("3TDV*)H@< 0
MCC)N\$R1|@>:_O\ND.N+Q"70.S2L9DQ3":Y<,VO&C="\$\$7%R M Y#
H"40G7@"X8G(SR|.IL+=:GZ#,(M?D&.L J254DHHP 0(;^!<1!KF0I-62&U.TCI#SK; M(;4=
|Q.BG6+|/ &+=00,%:YF@K&??P&|Z' B",A>#2DLC(U<=5\$<9U* <=7W&L
MW88/JD,'E1|(*&2#2C;1A VJ(WOXHZE1S6SY4|^+P7N3|^/Y#%PCQZXTA1
M)*E.Q\$<\$A-%00-KX)@I7@%MGC=D%_U U@!!|0 7|QNB,O-NYDUKTW>A;60JX
M8=>N?BH&42
H322(HM|86;/'EB99@M(L+MY)FR0PH_)!DBRM'.1)H>@>)9)@TJ!|3Q&@B0A0!U>.01=V=

M)OAY&GK-6#HL\$2/.1T:#6># ^03^B'9@@B03:HY1V:#?*|+2Q4RR^--Q"!U
MZ.WZ'\$R>|:| FLV1GB!.*\$4QX@PLK5^ME8LY"&E9'\$%(0Y|<@EAX1!XF IN
M!+^ML37%WJ M>TIO3)>2-L5B\$&T?*Q(11*\$T^JYO*31)3FWQ#8\$5-"9\$T
VR83;L8Y\$#+) ; MQBD7Y PO_3 <0!8EM%Y^_4G"SUV5SOJ^>|A/LK.>R1HLN-
^L62|:@JEN%# M_TU!U6089?+R VWTP?CV9T"T"OUL**D.-@Y?|_40 =63IV:K^A.WJO-
V>:NZ M-:|=4Q:\$2E8T>U|G7^<&5B|@=L\$.8P?PIPA?:4C8(F"C.=QCT#P+0M?5'P/M'
3CJE#G0N'W.-'E2*8|D<*4RD|9(L87*8R1PMFJY|E3#@^+=_/FY:5G.VS
M5T#0#OH^%F11M/CA|0C*%P!C2/1FP1)1GN2D%%PG*(W0\$T8_,@F&CFPT\$...
M@+WI@>E4F4<&"1XX& H3^A|DV*",#_H-.""*ROC:-RNYNMX;Q3>N*4G !FKB
M/=01&@U|'.4S@11.K!;N>G8K#G.@#@YAO G2\,I8#@,O:74PWWU16_Z;7)Y2NG!#E
M'|(5.F1X0/(.3-|1,>G%JBC.UD>_\$_>200L^T%D!O!&K':BH:|?-
H\$4&>\$24%>F(RD<8M5577-'A,A+3CB,AK%B-*T MY'6%+#5NOX&X|?
E"45HA?'3_+W,,F5)'IAQ:RC\&A:GS^ZJJ\$RR)8..("X"7+-_G 3G|Q+T^3(5'!-Y+2
M'65>Z(*N01B2NR'CB!:<)<)B(&B8.=J(@=@0ME:5\$/.#(X|KC@A 2K85>
MQ+J@|8(S%T5?+8Q9 %2?ATV|C9IU-=U6)%TQ&,+&"8-'@'6"|H5MSL'2E';
MM#=\$O^#|L1"^?8ZA'I U#3|I3_QKE_-B>&*#5\$R(V^_Q7QV-:\$*#OMZD\$*
M^E_<6N\$9K+ZU7?*NKR82R;4TO-|H&X6"ANGN,0|CWWU:~9Z\$+J)GX K_-ME>J3O
HSXU<,\$#?"Q8_(#|4HE0X&PL|M'F959:7?SF|Z7K 7>U)\$<+(AG&KDD;RL?5+-
|P>L5K935+\$64%TE'BF@| MV+14D!.*F'R,X<*H(1YQ)7)Q&,DCD:08"\$?\$29@X'/G\$/RHE-
B(ILFQ%!.1 M*=9Z*K;W"@ND&0!%'\$L,F"">.BYOZU|I&@'_D15IO4)|8<0#CAH=<&'F4F(
M|0G5PSC)?L%\$6<|S?#GMF|4Q/30?1S5N;-?4P97<^|GO5V3'GH5DE'"2WCL|
MOO%#*%>N86VV9^U48&%-U(|L3!)U%T%LDNHN@OO/\$>_RMCKRZP('LR0+&
MR!=C%-L0U"5R@%|Z^)7U!Q THX01\$=%Y^F_0Q\$7ITW|?&:"@|BZ
MT,S^&RV0RLUJB)#Y:;@+W(BRP WS2+%Z;;*0\$'T/V@LN=V+KG|WON6NNY
MSR2*7L%=")6K&&Q0KNP:>B%|XSA@"5^VOW:\$"#.-1S"RP0T*XTKT4# 7O
MV:)7E8.34>;SF'8"(E.D"<%-(D0)NL@2;WN-G7^S+.1P\$ M.|&FE;&S?BI6/-
,K+DEL>B+57%|RWY!!7,R^T>(MR#-\$S->|!ZC'9V01|B)PIF9W.O/BB^MY3FOFU016
M*..%5&9V;DWFQ5=7^MF7J|'\$|6V|%>4-B'9!;RB<0&?U#&'\$|DIU"KZA ='G
M.KB5@YCUSG(QCV=85+@3GD?/..YY/:"* 0 M|AG5|O@RA)?D+;D7"i@2,CD*P?
(SM+1\$A*&R4"\$F4'C(=X|"%F\$!XK3@ M4LB.Q@EU%1V'\$H#L%82PRX^ND-
!@2Y%PA"Y<:(R)5LDHPG95+@4:1@|H
M).EC\$Z:@8E5/D7&+=B609L^#LP8ET^)|16LQ2@=R2+*YTZI*1WP:@FWR*R<;|
M.227)1K)!O5|S_BB@&\$J=|+)T@BH&G|VC6(P'RZ.Y6<5;J:|!088C(F4?|M
0A5QG,,10*!|/MM^"S| M|T.):UR9,+F%22B1"?|R|UF2U65A0T|!CN"S* M*N|K;9,,)JP6,
(2S<(@:)>CE&M>'J=|M%6:=IFCEXQ2RA%9D=|<-4O! MJ?IE+5?0Z2QQJ=3.L4J?
E4'J+'N^7I+1W558C<|P2-D|P?
PE)*_RUSDH+>A/DA>*|#-6')XY=C:2W3&+'A2DSM@@R0=EC-#=JY"Z M<,@>..?
F328|J_C=(Y9&*5-NM;9Z7|P|.R7*|_ \$2MK0HWMWX;FS12\$6%3|F
M3X&_I#/>'K3T,L#|=TX*9@9=LPVVO<" CA|+OP'*V|!;\$ M4_|FK-
%3*,P|((W/@|B2@FBE< &"2^4.6._"W;<)GWDXN>B_0BU2:=%,"FN M N.&\$9H7=[Z-
X_X>!9%COZG9M-'ID"(W8UP\$ECH*I&207A&?LL;HDL2!P_
M8^|BJ^V9%U@D:2A#QZB&'H&*Y+R1(LHIJ@1-JYEQ@<@R,DN:BMQ%"8>):O
M2L|8H9GA: "[T;5/= @4/TB-"|H/"3^B09|'(8MBNXL"W|T=G"99.(D+|K| M+ 0WR-
MA|R>.T9%Y9.W0G1;17(H+(: " M/L(S*?(9X/H(.@".I3O)(|
|PGE/2NG@^9IXMLMFV1ZJJL262Q4R@..O|// M#E|"+4Y!.Z+)|6A|VSG:?\$ZBP)#V;4S?
UG_L4C86X+:I>"A801?P|<\$%^^(, "
MR9=Q.EZ95;LS"\$Y5SBV3507D.V91*|-62|*^LGE57MU1B,JREBD&UVF?^I:6 M0-
;Z=+=.=>:(C #@8^WH\$&OG=_IZ|7FA|LSC-H,N>"0.7>Q'A%MG7_&;/D
MY>LH@0IU|T7/>"G5C|P95R5&8V//7)Q@|*D\$|9;>4.7@,+ #DRJX|/^)X#<@*81|1FU1:;
.,@KZQR=A=?18P,1+N7BN M8?\$JLEP>MD_P&|Z&#ULL.LO?)Z-GFN\$CV^RE)R,>|&E
R7'6ESZ26V?'I# MC5CP-EB'6_ ^+*7E)-(FB)'+06MVEBTV_:78G58F<%16D11")XS7%N
'6O-2' M7T5D&EP M1RADO7/*VM3ERI'-*8ZDCL(LS,:Z"5HODV3U&%1?
^/!|S|2IO+A\$4E1.0 M0+ GXKGHK%I ZQ-
=@+:D\$R<+V@N9C#|A:_SU#=#6AJ)%8C!=IN\G&Z^6UCUJHK0*L..|EEW;
<2TLE28S*7RI0PH>@&S:E6: ^W M8=&#|JRC\$=01P/' M1#M)=SUCC%52-F*-
=74_K|_59##|+LFZ(OPLX3?E'77@ZPJ3D<5"%-L-MT?L
M#.|59N03+XY2!\$48|@0#Q\$(@K\$7%&)*TLN9+5!;7J&S3|:.)?P|VC->P'?
8=8/&G|D|YZ87<#6AX@OO-)5E/-*RB54'*>H8IRB;)PN|S@+_6|5|57!A&'MPJLFD

M5/&\$L=61E3?H]=+S2@:FW^Z^O2T77S"KG,78F2_8J?"PK)F(
MG3.)D#2L,O>50:P*T'.B&/3DI(=|=SNG#%N!OM_2U.LW@XG%Q^=8,MN%X
MQ@QT&+@FH72,2QWMKZQN2KR*4Y^(A|QA@M'3|DNC'P!BOU MS&# X_LS.
MBE\$)L@%1XP1A0"1/BBC'-&(Z(+0+?^9&2A>Q8 4MB\$M*|5X,) TLS(-HC_
MC\$*:+|NXQ9-CN66T+ 4=:)4EM|-E:/-WCN^=@(.3)Q8.6,_A^JZ^|FLZI?'
MV(&%!PWF#|=W-P^SLR|7#W=?KJ_/R>WN/(K7\$2RX3T'TY_2_8"=(5RY1N&^<
MA(P\$8V>@4(A2,>/Z;H)J?YS:-G_G@K%V|P?:CDB'H"P%D0|1 5FA;"\$B8C*B M3\$C\$I|3|&*<
(VR9%,)G_#ZR<1W35,(OG_N@:Y640/M,-^9=,)J"R%22O|ED_MDO|_IP:3SM-
)GGM|2375(&ML_XUGIX!G.L J<"61J3.
M,R;BLX!A#J:%,9\$(P5\$A#A:4Y5MRY&|R%.@PH+2;"_VL%|[XY\$|TT,1+97> M 'K6E-&>
<8:U|L&(!QO:"^|H*4G^6L HV>N|?&J+?GL.HB|*|+^E>5??D_U
MO)/;|=IA7HW:5_(%DR|P|Q9ZPJZS33#U!|.7E2+=^@"PE/HG0H7/XH5>WV-
M#P6)SE3N:>4#8HC3X_#J;-)*,4V2|9IM!/=^|OM5C/\$,0G1PDMZ36_!P=H4
M^X|2QPF"7B+H)A+|1-#1;VZDU=T Z)TL8\$Q|,2:QP3'A)M^UGZ2^B|D%0|D|_MI)Z&@
A!7EH(QU+,4*%?RN"U"UARH|0(:CJ@5NSG=|P=+&'C|/S_!\$=- M\$<3RS)
^YZPJ4_H2D5,WVB9PR2N(*U4_@+RM.'\$# M,J|!\$!6E45J35_HI8>!DZO_61ZZS0@:"
(B,MK?YB_X|G<|!7W,S%,4/Y# 'X MIP9R#62H@>1'(02%->RT&'EO=H|P+3Q?
@Q5"7S4);6?S,"U)=1|QVFW=JL5 MA:4O,/M7262G&" +700/D!^2ZK1\$^!
6G*!T_+^,1W&R7%|5"%+1|C
+L)ISW)94;B,P?)52YJU'4.!ZAJ9\$K|K*I1=^ME#62%CP'S,X,CB+V74WX
M(?;LIPL,'&JD^;\$(5*I-R&61Y+6^7GTO(@H?0<|E0""J|OZ2YW|JA%+H:R_\$|LK|.)G=7
X|G;_6Z@@ST(8 ME\$(|MFZ;|N0+6D3CQ*V)6_@9|9?F48A_M9;_I46(!Q101*3F
7W8%_I9|X&_M:QVX+,!7D:'&1_^GKW/G^,5(IA>.)|P2"Z8_7F_IQY/WG7_J|ZO-#2G2M_M
M/%U;1:\$URZ7.E"J4R*N2\$.|=1#PTDTR5NF()E>@Q#%N&DB#"N=M)C"<#-
=Y;T)M*F(T'7;(M96|(?7U&,@KI:9?%&PF^ILXVH|^,/B:98.@8*S. M.0B50*W*?DKD;Z9U-
EMC4(2UMZ"Q.3M(TJ)GA>O&6R?H"S M*+(3@=.T\$(G\$ M=IXP).RN?
9=ZT!Q(X%"SO@*|T:_HI11P\$BC=48;+;|I"Q|4HF3@4G#22*%
M)B)\$CT68W(\$|G\$1W<>1B|"60I%E9W8&|7*4R#K=X|Q>L' VQX9R1LX,(D)^
MZU+56T(;NU_B^U5(G|_E|6C4=BRJU=)W2)!A44":|0|3-@JBE,H3#H+GW&2|K8I
M4'HGM|RIGU\$|BD"50!:+G9V7 *H%JM|J*2Q9J@Y.S>;5MC|1Y3|+|V@@:_H
M28&K8<<\$.:ST?BP1_UB\$(&V9=DO6BKZ)X@?UT:P&|>> EE7NS|(|L M(-
;EGNZHH@'64E"0%AGR|9DA|=C.|TG"@BD70!^\$XV\$FK"F28+3Y+Q7(A6G
M+&,00>%@9CE&?8+.|>12&1"QX'NBKL^&NR;">(|_E9'O@,6CK4Q
FBX^4(9DUXEWP+R*>*1D^KZ MH;9&Y6^VO:8K!TJFJ@_9
;G3(G0>J*ZOY):*7%"5OU>4O_2"|,O_NR5;>00_M-U|Y(:Q\$ _YRKZ3E9|L|M5.=Z=+
|V#|/Y_ ^PH*UCE"Q0AB| O.)X_>"O_X&_+|+%W@|_5/O.&H(L(00P*'6>(-MMC20-I<)KRFB
/V|LTT;?|B:5_WDO\$|W)RCK,&(|_GY_I><4> M:REE5*-\$094P#=-O--\$UC_VF;4KC0-
")KP,9M6/\$_L(#"^39-4H;J1\$HQ>90+K#)?B1QW@>|J!9/EA-%&4|X(0%:?@')A
M,L\$D18M(L?J\$*<'#EL0R#N'4#SG_:%=-H(>=L@Y WZSQD477N2YY|7VRH;# M@RC6\$
LO:2)!U%(KP-E,#BL'|27\$?>C"B?H?|P MY5P;>^CS|J2P4B7^@F^+
M_|5U8C*NP8Z|&E%|Z"\$H"%)#C%Z1R""NJ|LRR%M:4ZR@O|HU<#NB;H4^!^!
M@!_HYJ5^H;0|=*G5"8(|L6(9N@C |B31RZJ^>^5)|X56-3,D2"L1;\$CY@
MI5B;DR(|50+Q)YYA<.0LT W#<23M#V _SN'(1KJ|N)U2:RZ_+IM%&W|A&&G
MO<1B|%,VM_Y'TJA9I%?/1X AF0^K/H|2;?4<@-;X>|H4.<6U((%:A9OAMMY% M@>_N>E?
<5.C^3*\$|1HH|_XOS9K9^J6LZ+@CZRO8:\$L"@OWEI\$N%WX"X&_M
YPKI=#0A0^)^Q8_G9R?"6YLHXGK\$TPZ4X)J,IGG0ZP#|77=\$^=GU"A3EA.C! M>!N%,?
|3""-CNZ7_T6M,1A/7E*FY<5(P_N_,5|^_VD*.D@180H#CV&UN>"T M#V@X36'7-
|Y6+0R'M+0 ITE1PEP1GS0BVC.MNP\$|XSY '6)JO.@BTZX7K#) M,<#T"SR
XY2'SVM|,KMUU^)|\$T_..QX- ?0/J0D8D+I3V07.P2Q<10,J|>/*
MCSWS8+R4S6B@>|L+O5_Q7RJ|+1A>%G-* VR ^W7DL@CI?G=8)@G9CWA(JR-|
M\$>%REK*,-\$J7_YYB4F62"L(V3#!DSRG85OKDBPF|2=%88FF"F)|=2TD?9Q?+
M5R*+J:Y|/0D/3_LF/|SJ|,5X?#M#&QE|@V-QOW>#|&.: |F4B'H6?GHKUG" M#(
2X7@1Q608T^E77W "%XU|3\$-GZ:6K?W@5,#RA TOW*H4G_Y9S12L.WJ#
ME;\$ (WH:A0HTJ#,>F-!S/?#ABA;|I"%@U=EDKN&LA;-D2Q*M.@>3E-5^XW"IP
MKDZ!JF/*AY!JNB37|C@N,4H".(@CB'V|B*(92"-*|)(7L|S CS?COE^3)?2O,E"R>ZBZ.0?
&36IX390C2Z M2>ZQ2^@&.T2CH#%SQ6!3'G6QRXU7Z^\$3;V,0|C_LLC@J>>1-
LDY^3B/'Z.7 M@ZM6LFA@3FZ"@ "#\$O@+)(Y BIX|(IUWQ-5AQLCIMX_MBPEKV=|U&
<_@7L: MLRH3&00\$7,: ^.&F6;2"C56,:V;KC>/.*VI+7N?M>DM|<76H%EI24@03U(|M

MR:&^_JNP);A747QK^0:|~L|Q+=1 M^"6"<^<|"IJQG/ID8/;:M*Z4>80%>UJ\5=ZI?OU%
(51>/ (MG\$#!O:49\$:*^((N|!\$63F1>3:1P+|-|40UK U22L|T=Z9N6|(%*DVS6(Q8> M!
/9;X#A S,|1C&5=9 I=|U5V<8&|2FXZT3+T_V4)\$)KH> .ZAT5*4 *(4+&F"
M/< .BJE5;XP%1;+.DN|,LE'X|F3"FA/Z1G5/Y_4I\$T|U"HA30G8^7SYF%9,/% MD(HF8D*
(+@59W0D1DJP|)^AU0-.N OSS EPP%")!S5T,L@|3;3;?*HL|!+-N M2'49*CWDM
M**#).@TM95"1Z#>Z?YN\$DJ8Q^!MA7\$,IOJAI10"P=1G3(T8^;8LC34SOQ K
MBT+..:ST|U)>J+275)|&CO=1H+*,Y&[*+U%W;0;'MJ*U|RU)UQ6 WX)AHCHQ
MYF|89RE#BJGNR%YY5;-DEWH;FYWE(:F|EY?&Q:D:%|/|0T4F4|~JHY6I M3-
;*CGX.8^P\$8,WX1&|8|>O+/'1&92.7X5?*7D=J'@&R6-TQFHCD_ U M1F5C7- "V*
UXX.>>*H*RY!<2U|'***^XYC\$Y*7G\$ZX^!?.?D+<@# L!\$>I-P5%C+CA*("D0LF+\$|5K?
E_\$S>SH:%)RO M:"YPX;*+)|..:&P+W'<'G6.7-ORX5IS-:+|RRJNEL6PCEX=&(\$CF. <=|>/_A
MX_N?C<'2 ?F3|S_:#%G2+V=|PON-L,K=5H|%42\$XA/%0GSPYARB70S\$1_66H
MM&3R4Q1:S\$M.*#_CBC%Y72\$Z/A|)KTF1!^(A/Z"0"&!:<=N&%YH :K?@P+S21RGG:("Y
M|4M6_.#N.HV62F.;D;D!=;Z3Y/9+H)H;A8H2!)W&P&Y95(F9K0D05:.)^#Y#.
M|F60H;E)@HE#E1;V3A'= KS8-E|U2=^:*,F|W3MIR#&*Q"";=H:);16@K@
M_ =|=/4YC)X2'#_#7,|S1:*)|;@1N;0%/M72X\$|RBR#ORIF3^(F|6FAY985+ MUZ'S_H
W*=4ET.?W\$U|"Y|L8%+Y8LKBW2:ZFP@OI#U(|A%B/4+Y+4&:"|PG1
M3BGHR784EU\$,9OEHS*^Q"^SR)79*E|A'&P;8*S|QG8 E|UV1|PZUD4DS+,"H
MT@\$IR:.0H|/*&E\$5A.N\$B&|*|/BJ9:E&>O8ST<0FD7|/;\$;O-%N|)-_?SZ>| M@'WC9S|\$#=
)_\$44A|YC'N+FL%Z+"_ ;T>G8UO|/^=38W:/YA6=>\$G#%|%@\$^% MLU"+P8IK;9|"
(/|F|58:1>-SPP7226L>%BM6*VTBY9#NAI4OAQT00F\H8S* MFP." %3>.0/B_42S-V*9*
(E>=,T!*(6X)O&'8,Q+VL|/;S7(| MLUY!5K3 ':.J.SV89|N\$G
|),G7)^DY|Z,SE8H%%^6N:F"1_1036S!|"JT)
MDGQH05R6BR1_/FZY< HI%|XQ+QPI6V|./5MOI@|/T_-?/C| M;6/RW#*%-73C)
(GCKK8)3BTDI<.=AD.=0@|!++U 63H=&PEBK3'5.MIHH|#VZ M2^G|Z|R1'+)&C4|9|DC'?
NCZ&|/-C6A8=<:%^\$FW?4KP|/P=6WGF|5>|UEQ& M#U&"=A=?ENM:~3Q398*?
AV"S8<=Z5D1 ;THPV GKCV6FV,C#679'+<@P* +8 M\$\$-8FT*LC,GGA\$&|G
6.^_L):17!B|.Z1!&SP*YX\$WED(-*(7)HAH)|@#Y> ,@_X&8QS2R+8E, NNC('GIU G8H MX|
<7EF%@>|N%+,94LL%TM8IO0M9B'N&P-2CDT1|X@('P8GF|3V?EQ^Q;'K
M)PSH3_Z8|%^37CJ|P"+#G ?;F,0"M"IF/F"16E"H/8(2.(%>A:?
T1;EU79)?!;|S|=JF&26!6&|OZ|QJ(5|3S6=&|(>#J|G5K5CT&Y!&
ME/;1B98+YZ#R*=BAR'D@UN3|_E.O-<#Q|>T;=@I*,@XEK*2=F0^X.H IB
MOOQ("O%8=W'T|'O8.|O!36/&+1_(3C@%TQT#S|21^ BA7XL@>N\$UAWW!|CF2
MC|%,2'LB|Q4)E8&HQ((5&*V_YU>Y'Y!DB#*.E;.(Y9++A+W /W<3YFA_YQ<
MOY91O)LO8"0+;Q>%4(915K-E="4^8*>I5?5DKCYU5XGL_\$2\$DX,|;)N4@(
MBX;O|CT6!5'PI# CSX2&,KD36-<+1, _DN!\$UXB|B6ZP>D*T+%MGC%9 M|"
K#@)1KN62(3KC"*O+HUA|JQ5K2V\$-7/C|-H7MCLT4G9->YI6*YJ| M
+\$=Q9LHIC80+684P06I;.A2S!;@9AG4S(Z?P=57)EQ?/4MU(.V+F|AR%K%8\$ M
AAXL+Y1I&A1DV86GD=AR&S)\$#C+8;PS++-9R+"B6\$P+-2PXM#51!;D|Q&EF
M0-."L2"\$C|NLNH^?HBR+K+(9(\$UKB"N02P\$P|3BP3=*3R>TG"7H*X(|>Z\$
M;?|F;=I&.NB%344=?%+AM| M:A,TC\$ YTM'/A576#3VMVQSCD|4VA%N6J&E<-26-
B"6U\$V|V|7=#BOJS842L M/X|\$>M_?=#Q+(G;|Z|H0AGVT<)+6 V3*I0>VVJH1R*H
R9U4O)%@ '54!@ MQR56%6P#A8JW5IR6_P,7| ^:BNP*@S^|U).KW5'(TE1JUY9
%0ASX('2G>-X M7:@D9#VQT91|ZAO>SZ9GL^O9X^SR 4UO+|##X_S|W^97U|7D
I#R(V^_S7_9);\$:#'QK M:N+ODZ@\$5R4*TK!1|/L+P4-Q:1RON-T|&9*1XLDP6^T-F'5|J
X|75/T<%Z@ MC4BMI+?.%S177=V"=#FQ;)DCJ SK_/ZBPAJ-TB.'.EHK.<+D1L\$ E*T!|?EH?
MH&*|N|8Q:AL?L|=Z^,3*&L'&-/ZRYRU*)5(*RFJN>5S;.:@GN+VCNXI48T|
ML.C|STK=CS3L ;XS%?"|+"#V,M>FR0|0HJADHQYESFANH/U15K BK6"XO0G(A1
MN5K0/"4G@!U@%IX|&Y|L;|JAIV+B'0TJ3?P4LZ
TS#0H7LT9&O0!LYC>S/P7^DN&/<7>+ #B!93IYH'@K|K*Z,72194|+F7:AA|>AO_!=?
AG*6'&K MC.U05!XB>|Z%Y*:.?^D^RI.>A0->?DTA=D|?QF2|YS%#YD(451Z(+&Z)S(F
M,>L&4OIA+;ZO&*&:52O|A;R01":HCGH=)&V;=8*@VD^&;&JJETV/>OG#!#W1GJ#L>DQ|
F\$GD)MZTD2)9BHK:;F|3|\$*L2/3;AA=7(ST@R|JH>L6J2+3/EV96J/\$OG8%D|UR)N>4/X5=U
M.&+OX\$1K251F#XK(1<0H'Y=8^;TP+UW"i&.!L31|0*OB9,(AJCHM9*H/>(|2
MIQM/CL/1R10TBF-S|S4F8L&EDXFZ59F8QT%:@?MR%JIE-3EX86TJP|2+-BGV
M>L694;80*^5D^0P;P7FB?IO(+ (2W(?/>25AT
M3O)=8/#CJ#!&TH)IT&1)3^E/V^42AROLK|,^|RWBG=%4_*L5?+6*E)!XZ@5
MS;C.|3D!|"(|D|=DU1QZ7! B-/Q1D!GR>MU/H-R>6I#JN-.B^|BSAP ".H: M'_&0CP

&X!GZ?>0H/TC&@8# 1BPO+ "FF@+U%5@'K"]@0N#*>LI%J2WYK^@K
M=*T+DI2C6UY;QR'M)T8E_*A|60ZN<22+9RJ@_%".SB4J_9>(:/T).8|V15O M_-!?:!?
#E3Y2(/^5SDZ0Z"[*^HONJ56\$=_G;?'P<'H 8IN=LF(P/\$P-
WW&L;/\$|QA@S0E7FMH*D*R;CX\$GQ.;4*QX,2S MBZ\$HRI&*RI>R%)\$S0)
(#3Q0&'K8R=XP)FPO4Z3*D)E-E1&CPY5>7>AYNG?6A MUW5!"@E:"(B-O?/Y;|R|,H
3XAZ+V\$=Y13L'#P^-.TZ<[H;|K^H+*C\$JC/* M" T:ERA_U!= \$&* /
(/QO)>|U1=:5+0=I;J37MXN7K+S;):#PV?-\$-3', (E+|)I MZ\$55TA'5NHU?
LWOWO)S"%4DAL&\$A&'PN X-|P'#\$@:'L,'RY(OHQAYA+!%GD M,KJ&(8_U",.7DQ!"DC,-
_=3ABK /SD;UJ#O5?M-GP(!0N4G?HJNH0HVY], M%U@!|>L;+YV
HQ8>/O*4"N(XA6;'74.G<[A|2L^-OK"/+|'C*MHFY#K|^\$*6 MRTY4^YB1-
RT\$K)@|0K>_|>3#^P_O\$=!F%RU)'0%Y.^8#DZ(63A HW9%R7BBE MS% PL.= "!"N/
;PM#LH6)2;/Z6@;""|V),AIMIL?|)R^>%G[A!;.!@B1:G MB&(D5@# 'C.MJ6N4)2J(H5-
%O%GU8UT1MOU@JHCG,N|VW9"<76_S?V(D?5T2; M/_@D #X3E"G9E-5\$XL/M)I
K^(0IQ-P\$ 3|&\$1|!"1VX3|E,K\$D|;-)&E) MXD4U%*VM|NHDN67!)\$5F(9NDNQL|^.?
N""<|4 MA+681('OT9C%K\$ "I5,B-'Q506A' T*D=[?H!444."@;/1+:70B2H!
M|LU"UFUA6|HL%FPH\$KZED#K+ 2/|<+6)#R@CVZ*K9-Y*LSF&4;T!!6 M!B
HRGZ7R2X=|Y.#|&P|0S^OZ#)MA|3F!&!U|<,67XKV&
MDCV)%B<0|TTI'Y58>==|AWS7#M T@|PCTZA9B%Y%|8LMJQG75>% HL>!?
I(86"SL*L94?/*996|B2KP0&AQ MO?RJ4**8QG3|K!@OA^0"N'2Q8H| 3=- |Q_!|=KYUX-
U| |^\$L&_ABF2H8V0-9#DMRAP=P%%85SH|> MC%|N:9US-.LD,"RU/!28M!"_KDBK)J-
S3E8BVVU(GC|C1B5^Q>6R_SURQ)UM MO-J/N=|E=&&+_99>)|75);_|Q2?*<
<>RN=KTBU!00E"1(=>+;Z1=K|6E4G^|J9
M=9/1L%9BLU>7RV|##W'BEY*!ZJZQQ\$@+==17Z@|186^9L^P6O|"?#M8C;!@5|
|8P|KQ*HO '0@KV"VMQI*)6I|VQ7-U0
M6K6L(#BRU&9>>.8"LW|G8=XL0G>B:2@+_>XNMO@Q(K+37_NFBXNJ-Q|G#FLZ
MJC(,4_*Z/RMK0P14A6_FUD./W;ZACQ-T&.S84R-@53(#/^T; &1O,E;@|EE MBKXEM-
\$K&IH+&B_)3/:O\$|ZGR|L6V?|3:_TX),11#&7Q QHS5.UC2:@O& MS0E##H21/B<C^#
(\$GE94 M1MSA7.9P?IPMW(M9-17 |Y,@@(^1\$@K PUTT^!=N2|XLIU#)3O5L)>@\$/8\$7
M|C'H""|/#<&EAQCQD=!,0|^ #0.C@9|B1(KT;\$<'|67&HJ8@M.\$^5:Y..\$
M6V&|>7@/R>2PB8./-OD<1D)CII!@%FXV:90 TR5,ZG/F9@7;"^+I)|C8)
M#@O1;:C6)+N&:-^@!%'6.T2|A_+|LP6|H"PC\$7JD\$RV\$W9E\$A)'9TTF;*\$!;
MQL1;.S)0S"*JBP91*FQFEN6!.PTWR%_YB>L\$D+1Q&7H71!\$|=&*X69|18WDI
MEU#Z@Y |!C%RDS* +(?NJZ3!;13&N6WVNJ<#_-"E'K#E-ZPG=6NF|@I3>ES MZ)\$H9
9WN57J%,SI14R#29KJ2P1XXFF5LIRFAV)2EQP8(G|)084\$**YD7<* M)V;S^" ^X%-
IPED2I!\$9-P,&^ -U)ZO1=EKH&5+4='1?W7CS0V|Z??C'E.X M|CN SE\$;9.SG?
I+CZQ^3B;,%=F?0)8&SQC+VPIGQ+9C|H9KVKG%EOOJ V MO/D(' @6;79V#729!?
X>+WW89<*T!T8;M|YGM(QCM.GH?(7_P)(\$\$MX?5_9F M?B\$Z P|_10:0((A(|JWN?
Z&:AP9!K<&6Y|D@K9J|Q_6<;B;-"U=-5^ M*\$687|8|46=8XQD<+*P&JECD^.?<
*VOBR70TP\$)2#*LZ1|I2Q<('=T5.U(#L M|:V>YZ3.|?P(5JU#G88+!Y2A@,8LD91;_J>""*
MTV0XK7C,I5!;!5=|0DU|QMV.1H7/Y|NQ9,*7XB#D/8W*"!RUZ\$%^RI\$ '<|R MTCEPT?
QU3;FJ\$|XBO"7%CP?G|4L;\$0%^MC)4,F6UJ++0D3O;_9<7A>CLHY16
M)6#RN2':)_>K42X3T-B"+:W_|/@2G3!TT!N M^J|5&Z@|QJ139^Z5BIA77NM-
|M:0HSK5EU3A*7|J08W"+U%*O184/-(G)|L MG42?-U=3LJ)V|N#M_SU%
(51>/),.RC@+:&'2L4EOAV,I""JE<\$-"N,Z+|2G MG>7JTT*WD (-J?C>IN-J|
(YI807(4M#6N/&K0'+EO#-6=+<4TTL#*YQL|X
M..UO6%)#E1CE":*TT:E|". ^H@7#2Y6#P+MP=LD4?/K"UPC+|0&G*0.1T@-|
MZ!\$F/'(@5MB@1/(Y1EF#HIA 'U\$&2.6 'HY:S% HPP_99-;_G"%#C64C8TV|V M".?)()<
(S|TL1L#MA-9\$D*6S,X83 MF;!(2|<3IK*59|W&9&D|E-O|8?|17O&O%96
M_R.6;Z|A;'D6UDY8(S(&K>)Q|M;\$S(I;4\$546JIX("&-Z;+&C"?%4)7TA<"L M,N@I-C^+^)?<
2!>2WB\$V#&EC HMW=FI_5*,X^IN4<^|Q@T\$6B_#U/5^1| M2U<.W';4APR;E5G)"_-3);?<
MUIQ'.RA!O!^7F*T.@|H9\$DMF0E|%\8,3**_B!7Y*L|_T6)>.51JQO1 BN:U% M|CM91(\$)<
<#Q6"=50C@YB6HK<*&/S|CP@*N%WK6W^/4*V|XO/J4PK_/PZ(Y| M1^JIC8N9/
@K|6W6%X|N' B;@7#E6E):JF%4U,@R?G70)PI?|HP(>L*V#AD MYNS;T3-
\$K#0D(|97G#H<=NYBAV<&;MZR B_+F\$P0YZR@)H/!1C)7,)250K*O M>(1J2|HXF?
20SAF%)W3<-RX+>2XV01DYM4G>^4KR<*7MJ(|>_4ZOR59ZOH>
M524.\$NJH*XCT6GQ|E,|X|BD^M&B(I7L7*VOL+D8C6 I/SZ,@L
M^N/OMTS>+4!/H^C(!5GS)VOP74VW'-5H83_P1W@V0G J7./X68'B03P |DP
M|E|H+1GD=QGUGN?*7'YU5^#HA/0&YHGHH:!/6)\$3A?L\$91U#K GL.X4O|T^P

M'B,)E ^|Z/0/:HZ/Z#B#0F)=_J8GHE1WA8T/!)'"&..XTP\XZY/M?/:^E^A
M7&.,%A*RR:0_A:@*_R 3!|@|;+!+M"#LG>\$0\$VW(=X+Y2T@VBY6_N?:7/E., M07SR&
<"F,*%/U.5E/^1"FMJ6>6\$0[P_8 V2/4-8E)/N\$E\$XAV2N4=>MU#V+P M-GZ|OJ^(-
"O&D3LY49*-8R+|2D;QTB.8Z",XT:XT;VS'C0@KR"SQ MR4NM@|9NM.8W?
|J&E(5YP4K0"R:(NSA:X 1R"YW@"N.^!6BYS5&E
MBH"LO9Jf6L7*x51RV3;J;:%!5@KPMQO;|,*Tl.E|G'D3'@@\$>MM=>)CF^X@A1
ME*=JS3"G29Z*UBZ4/EZR'W-|@R6W|Z%H5^O 1-%WO.-.C+V+8.T2| M<@3|^)6/0)
)OV_Y0BNOUQ*OI4/-PKY:H8KETK\$4X0#JH)41R>F!BK(172YC MJCTI\$*)546C)FBL=VY|
(7#,QH4MB5.BW./0(=K|78R?_6B;|!#MVR&"O5|)T M1@X)>L83I4V(D|N-)F@PL?
25,|/.%K&SF;ENT|02_=3"1E7|H0*D(<;R:B9 MU.XN^%4@JQQY1;XY.,&24|O5C*0\$CT"&7
DVZX(TA%!-0^|A15Y(P|AR1+4 M)M K0J8NX(E^F0 W|O/C9_R.5_(@\$|HJ @|SIFP8W-/L-
8BLWC_VE|MP/AMS
MSH8T>SZ!"\$'R=KD0&W@!Z'|11@,"VRP|V3#R*.;TJ:Q>QL%LBH5F|?@2GH6(
MDT6"+H"3=Z,|C%)E0LN:)|QNZ'I?0!A2V'V L;2\$J2'5M3@4ES|LPTL"!U"
M*)M@|XQ82N#5(-.&^B,>4B=..TIVAI=^&+)K=0"1*\$XQH:6F60W:P;.:!PBK'T(S|CAD3YW
>5G|A0S*BS? M*YF0"A,D2@8_1JR4>
(*8)=>EILX|CQ9"_QH1)"*:TV!;T;U;3I6L3;K%@2*!\$_I0"=#"85 M<<&'S^?1^HEL*MYT#?
GA00Q6@/EEL1Z?&8F"3)@)R@"X|X:.*"1),\$. -RG+(6 M\$=OV\$-
C2;45Q@O6+=%4(68MM|=|Y=8+H>".7QRH\$&6VC&^+_QG1_P@G-4LL@ M\$'8|
|!%D+,JYD@CB7S,|HPJO-WC',2,F77@?H*F=R_ GTZ-5E4!;,@+K M(HH(2,2-.RC')
(7:&+:5Y:H8T'5&|E(%Q-=+0^UV0UI9&,=%)>S4F&T(CI\$ MC'&^5579%i&0!30OY1C??
8/+7.<%?=LV|(IS973X:QGI08"J3 -4':605:EC
MF)6=86)&5\$P+>K=9,4LW"F<4PG8/0!C|!YYK\$5?A|;^|18V/1N^>|=RXK4S
M"UTM|T>@B!A)"C|EVB'5N_2|23|#=VV@3\$O:E;SRQRAML8PIWGE^8|<_KOED7+
(0@@@U_D M.G*=X&X5A?U 2D91.E8R#GNV^E|P4!;/6?ZKE*=.!^&D/U"=UD<%
M7*WA4B%LI13Q\$^,Y\$0A.15X(097|I1@-Y>!T8SZVL0EN=
M9VXBS2BRA>TRQ=AZ"Q|@P.'CFF2>R&*+(JH>V\$DLE|9ICZ M7JF,WN57
#W%'GC"P3^P%805|I 41TJ M4\$:A(|3DK|G8'KJWWV/(K'"<;_R
W)Z(6B\$*P%Y%|94?)^FU|)5&E!MO.W^ M.F9A:Y?|T%HP1!O.\$2VB&"V-)
|FL,Z9@:P*N9B|!Q@>!KXY,>,E(%,-=\$&&% M*"DF""|;AE5T^" V??
N"E#EMP&\$P;1/B!O'H>NUGHR&0|ZJD?)4(KIXR M*4ZU>:D+!:L?
HE0REF18X;QD|BA00(-86=6 MSS H.5_)(*E@@@02/>?XBK#[91MZ9%,D^D4
|DR!RG"+4WBQ|)0D!SYHQ1B! M;A%0VZ4\$@
AQBA)@9G9^C4G+9Y=*R1D@SD&!N0!@%,KDR.!VA"YAA-,)6 MAY1Q25^->*JJE\$'84|
(93L|.!NU:"CS6*V/063P;(!5?*E=?XXT\$J5!SQFQ8 M8EJO*"KB|N<-
|1#RZY3^:XNTXO%@MBWAH|@>7L\$85,"E|#D%=G=G#<".^Z* M&;
K?!.F|^<>IP|D+0B+82|M0A#+|(^V3E |8A2"G+;K+4,BPQ2?L(!0H91%T+
<755R&B,O>Y_#;A M7R>B@,7>M1;/JA5%,8HI:&I(.2L_);)2A6AS/|AB\$J,0@LR8)
MS|+;%&|?W+GE\$J@A|Y2HR |#7A6_!>56%OXI+I4,9FMUEC(H<2 |#%54PH;|!
M+|;W"l%-0;L:|!&Q2YX5_*R.S6R&T90A^2X7S7|54I8ZC0#|U>NA;.;2T'K M-
ES;W8B8?|5+|8;T(QD4,W?5\$K+>1N').:&XEPAE|L,6!6 M/KY\$AX:
<4BX3U&0V22/T!!\$!OC=A")F\$W9%+G_)TOGATOAY3 M-
MR\$^C|(%ZGS|9L: ^U%DR'VSHU^9:CO+I=K,JU-MI_E4VWE+JNU,IMK.LU3;
M"76%D2|>O|UA'SB;7%WUYDMKRHI3/4,_*0B=QK!/H<)+E.'(-9BAZ|L)JOUQ-JOI
MG7>8M9L_T':DUPAF@_0;D'_6A=&.>K_/WMOVB0WCB0*_I6TWC7;|SJDM17 MO7W|
(?)2YTQ*D9,9JNIY^Z&,22(BV,4@HTE&2M&_?G'P \$E<)\$ \$"0=+&IDM2 M "\$81&<
=1W&1K!/?GZ*>\$<+BF^_M*L;QEDC|NC|5XPX^NLT|JY>SU?TN
+!4'7WOJM.0SL;%9;M./Q0YC273IOH5_9Y=\$* M_7P^PE;(|"&NIX-
Y)|S%,X^F01&@&@8R&.;AQ7Z9*5JZ=4MDIFC(B)F\$LAH
MURQ;3BQCI7051;G|"E5ZWFEPA5IWJ*HS?? |HU^4N"S+F%4VWEIOX;L05W
M3"*M|I%B/P@/;<;XC;'6M=@6&/Z-_Q\$WI3@FQUY:Q|DZQK?|U!QP&3/05F|E|
MJA5&UQ&A+M|4>H|_QQ>"Q_|)>7++08V008LO*ZJ#EIYO_83TO<;Y-S' U^B3
MAPUI=IF|C;NU1>QT%R-W|<;2;UIYU,>OG/SK5P?R^=)_ 4.U\$|6=|&-;J.BIZ
M,KK*T\$)_|*KXZE7VV=*KE?Y,M8>?7LZ6*FTIM=!,4.S*'+UBXIFCYD*T*MW M;K\$:
BOC+?G"W^4E409OJCL(A-56@QBR\$M|;5N"5SZ#;^GF*PC>P*

/PV>MX9"&DDDXV?X2/=+5|AD62Q|Z|*Y2X"AFJ- M2@2C,VA|IH-
TSF1G%,8*Q\$2?;X:IMLS"1+#4X0":TGBSYP6-'%&Y|1 K3 M<1(Y98UY

+UVW[S9U4#1(9,L[L*41\$O)17I=Y0S)PA53QI@E#8>!K2+0F@6P M1"V1?
(S>0!RB|WV5E9(JNFE5:^7T-U|^>'EAZOR>U?X@V>ZR-
UHOL2AP!&85,GQ6N&@T3"
XZ/6VY7K(@|*I#0234/^MV|F#5X<*2SE|B;"=H:% MM1)ZDP-,%
[H>TH&_15,4L/@ F<2;|YV/FM/##R=X_ ;B+"87HIG_@K MI(!WE#>+'5C3'
\$X^N (A%BUSC|V-#566Q6_G(Y'8KSN:90D_9C+6W55KCQB M0<|
[745>B3OM;|H4.3W(CK,\$GQ?'?"%U0D13WJ_-T.E+ J59OSBW13F8\$=X"
M%S|D5Q_>?7<%-?T/EP=<6:6X"MI_G\$)P|>\$G#-8?+PFL:N4D P3X')V=(#U_
M/#GHRP D=-G4/NU|LX6ORI5Q:\$.^|G"75 MKQ!|G_H'T*R!
M.V+,\$|:T:PAYRBJZ_|_?#33^|@'%GB"+I>/WWW\$ _G_W)+OG%(H.N.@-0>)
MS<:YG,J MA>-@!ZX"M?5"%TX|;|PM:K1XAQ=0&=
<5BKRI\$3^%K)65@;Z(P1\$PH"1'2 M1/==^<>
[SU'X"TZ:EU1(Z^7(R|;5K(>&RZ!E>|OZ"C=7*XOVCW=789G6+RC6 MD-
O)YH+>H(99R06?5>6]*K=UA?
9%|_E98|PJ%DR8%V)K42D|2%>1Z+|3GT6Z=Q_9
MTY/&C\$3./%8/87**\$0WT+"E4K&/|OEE>.W^LS=|V4ZVW6WC+UB&RI|KU|&
M*+T C%)4OMP) A1)E.5:5T%OKNBW^^BMMX4\$)%1Z&VSM1
4N/#74.X/ AZC MG=!W5|5\$^OTH%QFC5RSJK%)M%UNDIY?
=3WI9@W\$'8!SK"LJ/7"QH.2M&|)#4 MF7K_6ZI,1OF9|>HML""O4T:!!^OH|1*
(2Y|7*D&+TXE=U:0HA|!**|U50PJM5 M03S"12,C.W.Z,\$16L\$|0\$R*CA-!*F1-
7|)DL&J\$'=YM3ZF57I|5YQ|'@0P; M*ZT=Q*
P>):@03VF%C1)#ONR(*O9<^4G-W"Y25)N!U6V8>IE2!?!+LW1PYU:4
M=@^|W"G1N|8H^3QI:>CSU""L<.6Y.EG)|.^W>".%A#9T-
=)Q|51H\$QE^T'>O MN/H_ UOCSKY,B5@5^?AU8@C6"GJK2HHV&#/70T-
X|XT+@H WX6=A,F< Q6A.7 MK#UU#'DQI(&/0?
3J!'|3I#N7:CV?'(22&RXGLI11XY_JIDK|IVK|D-7Y\$MY
M*9J1:MH!/W8P.X@;#1F:PV^CTFJY>HU/Z,2+6=1?\$H19:P M>92MBA?
R3\$SK\$XOO_) +A| MX.!|/!RD04|PQ0>N|!>N'/2)JRK P8Q2/;VC
MKP90E!KP5F|02-R!O!T*MAX#KW<*12V\$+?O8|P|Y&M46IYH!3,7T?\$=,|'
MN R,B4"* A;LMY. 01)'6T> X.0G CVE..6?NLJ^E?=%PC)8/9FH0,!(05\$O
M_BZ\$TIX+G|A:|@5D1+T?
WW)Q*LWD*E|^U&=W&\$!YLK48<%LRQ4=)D+|48.DK M3)R.AZR:;)C%|9-
&|HXC(ON=#REK'I,3&)Y#N(X|H;0#DN3QV\$E ;A AA_"?X<;N#H67QT^6_;EX
3!|2GQ0WAQ^J7^XJ6N M|K4LWSHCLW>
<_6.KUCH\$UUK;|I=L67#|J|>L9;I3M\$Q'9<&0T69@WXMVX'+|
M.03JNM\$"E7P&J<7_## "1K?OV. .V|;^WH<4R:-/O8,->1&*R%!|H7(L?
O4K)=Z^|L-7V^++F_ ^KR#_R1!|??"J_";"PU7V5:I(XRA2PUCHJ_@3CS*,9*1A
M"B>N&Y^ =P-|_%TGZ%A+J7X?R*)7;K9J7EEI8&K7 DI.RQD(^6I#U|72"\$%5
MEJV>Q,!UK'.!XPD.V30417I!M7Z|5>AM|GX, 8R@>K?3T=BV\$"R3U(7B'P4
M^W+P9Z^R|XY5|'T,; 0M\$+&;B(:QO"8\$JBE
MLFIM9R'INN5XV#^;1!|S<+|MOEGQBQ /CS(V1U-@A!T?#B@^,6#2_JL!.7
M0_+DG%'H2L:8J|U*<8(2|4^EU)P|!7V=/_DFKK)=?'>5/Q#45|^CFMK3#2/+
MW115'D?U%IG%(M5S2I_)FR\$#1R1EP4GI-T#2:NM,+/E1@P>|0U!(W:P
<1Y M6)%3 PQ!XP!&"T@NU'Y6S%.O GB!;^#A(|FC!C|E)7Z2S)|K|:2N,D*@
MJ!X\$+WZV|K!DI@^F_*DDL*RW5^625_F:%P(*S;
[*LQD1GL8UPGV2DT>DY7_H M)^N|+)7'T8SY6J\$J|)\6=H\$34%6#4NH!1T|
|2B|A|1J=FWO?S* MU=RTD7-E|,6U,'*HDP:|53%M|^*
<0_2U,2(*|_%N3WKWAA&@-<*VEZ.Q\$8V054X(Y|VMCSBDA8Y"1)2, M+-
^|Z(J"HJ>T\$E"-9|D(@H/S%W,,8*3*9LFYH|H17|\$|, MQ_%%@ABH0G=98-
&WBC81'O+Z(4YZM45@XL1D!=A6L5N!QHG=?#_PCY(M92-^ M1.TDP3'|GB
|FXX,WW3=KS+E'@5QK4+ODY,B3|_%YO:UG,Y8^A +54>^E,*I_ M-(R&LA-

= 'D/ & @ K YRNCFB3.) W3> | E/ ^ NS ^ 603# S\$ 1XK(JJR#3T M W| & * / K* D-
V5Y|4H0# _) K"! WT,) B306Y*. M(& 0DRM@08=6N>(JB0! ? _ '/Y\$'A#>F, I(*VY+
MK; 8? + & HQYM19HR4/8VK5+1P" GUW>0Q<+ ;'U'>?X&-U95FIZZU1!@N*/?
_I3&&X%.) UE1K\$0
MWGM5"Q@/, W(CCY@A&TTF4_ ;%:R@B+LXCN* ;", HS)\$, 1H0, IJ/X"7=U6'G_
M/ & 6Q|L| @4=+(>BUH!4J4, H.) |A#*M2|G|A. @-IYL_ #1?34KD"&H85+:9@J_
M#PL!|5:P NBRC#&6|: _./.)>, *U8*AEL!30\$JB:5=+-Y^":/7!, 1O://X\$7M&
M<: @NG(69NO"DA _B.%0B|S30^)#P?P, ;Y1@'X&:0L7\$BF6
%6LWV\$P^X8P1=X
M6BYA7&^ZS0*F'L)M!)4!3&KU:RT:9UY0N06)& _M'X@+, <|
; , \$B&6D%^F%GN MHP ^>PEQ%Z.Z7(JOBO)D2T^, *4, I##
<*#K.#; UW+XPZR@NCPT|S>9A; +=8P|
M; (45>Y@*T!!3IM, Y\$#6X_66XK=|8| -EA7 (>T@|MT4>.Q.\$NQ_Y3|4?=8S
MST(V7Z/-/CHE3NC=1Z2|04_-;M2GZ3>0/W#3S%V
G@.P*^ _2R7Y++@RP(HM0^4,52(!MX#|JR\$|L|#0WSM%/H=PBN&_JLZT
M5J=V+G6P: ?J&^9=7D!G, |1U+9EA!#50+#^)>(AUZ>08|QE KP"C99", 0)+R
M7<#Q2010)T/+&Z4"BP9_ |Y|=| M2.T/68G"9R<%GTC|2ZV>HY;?M@+1S?Q
GA9|)%HG/FGL'U|9|7NSHTW=+A/64\$'
MQ"E0Q*Y*A\$S64\$OTLRR, #&|O'>.B%J\$K#CFKC35/UAGKS"L:9:RS09+L8<;
ML907G66(K?UL! ?4SK:| _<-2OWA#O(B MVDG!T|;:+V'%&786W/*X<|@-?
#3%"42!|B-|SCP5,2D|WW@>6IW|9ZP5@-1K...&|=Y:ZMHRSLH=:
<5)/8,4WGK@_MY4|8Q1UNP=9W?
28YRF>9/Z%O@;C1=SJYZ(TRSQP*""F%CP#N78U MZB://2=B2I-SM%
|""B(DQO6LR(7H46, .M (\$RLB:>:Z)E@QQ#^(WX\$'!ZOX\$
M\$0|RNZS\$3:BVB'FB??0AJ7G(-AEZ6>U=)X /&+\$5X+9|9Z8?HOUL*|XY=P|A
M#V1V2-@O26R;57>18B!NWS6M0 RG '0A8I?
EF%DH4)|M!;#\$F8)| ^.^81@KJ M=RLV3(E;>83?,09[*!G|;X
X2%!Y+'@,ZRU/1VRWA!5@LS+'4 \$PY!0+N: ^,
M?)9YOENU4+Z<70|)W'03O1R!ZV|H>(-
\$,F@B\$&)U+6S%^:NS%9'4T7X5*X!G M%7Y.B@_RA0QLP3PK
/P%RK4(_1S5A?K9BNU2TMV3\$Z|CL;U,*9S,|!\$*.1- MLP*|2B@|J6S)IS'N8/
<52EPXNX;9'1^ G"H3+6"#SZ9;N\$8LE7-(R>KZM.W M*M!%% 5J%\$B#9P>?
@704:47T7(C&&P|VP*5J0'QTXO3, LOOPQEA>D7X:'8G MLF?
WC",9^#JFXCSS *[23T|L.Q?*X3V=P/*&|O8.? *|8A&FP<&;LO'W&|O
M@^V+Z|KX"=PLP|)|(# 1T&E|\$;|USK MOYF_K:L8..LMN6\$O1|=MRB^_
\$>8W#=#6RTNP DKMO6>MJY)1&; (-CV\$A393 M\$%
(#MJX+67'O"FF#N'>1528*L>&?HQ8))Y@_578TW^,3^|H?'EB_;&('G1|:
ML'YY?/KT|G#|R_W+TR^/CS>X?DY|B-#Y?0RB5R?X.W""=,|"-
>J3DT"QAWRN M5:RAH=U9PN"Rj.3L/X|^"
ZQN1UCH!U7J\$Q,8H5EP4.Y1:|O|B29L^E|\$!# M-
;*.52|8,M0.,%3L#W;9'1@9RTR1C|Q,P\$/%R!'?/J59?ER=V!1I5-=7|[\$#>
MT(EP3%P._5'S#_(J/D#%"HI|F6>2>H?X563E<|P#)L@R?
O_3^S^VSTTN9QE_
MF5=P/Q|N|!@XN_ IK7/G1_#GD>EN6L8'#'/+JX4I&Q;8+6,&N!*4/J@4N66Q'
M>;(5H'+V|AG.)\$|+!"EDZP K7@"10;AOB
KME|F|SPYOO<09JR:HKA.R1RL/'&6@%(Q3;|!<4Z7
ZS8,HI6@|-1+;|;5+T|.F)K XG# M%i87DTVSKR:V81OMF4.-.X
>D8O9/,4:C|9@>F/((100)8N4=B'G?0:J* M(!E ,L6|L',/P.T)I=DT6R,WY!K!6/
".3@AQ#^.WP3@BAA!HTF6|%0>*X M-RB!1+EL0CBO@!|%,ZP
BE7B@5_)B#_:"F"J4F,>Y2^7+_.15@#QY>4C2M\$-
MT8YNRE8S*)1_E95|+V|/_T'ML(QYMK(*GQG)'VSV,/,;|H5XGCSEG5=PPJR

MS;IV8/I"G3N<0!@F(QAN_AQ780@W|BU_21\0KDM!2@|<GN4F+_+'F:|
M5S)CT"!SD5JP6:T@?Z^%K"#-EWT4IRB\$F|J*99MSF^,L:"CG3EK,?X1\=#
MV,P;&^8+5B"M^L2+I#360"M R%*F,7H;OC&,X5I5H
W?/%"YYNYPHGDVU8@ M&GEHUUL*)YGESG0"A
RL0B_-7RC2W.4%90OFG1U,9E66F\3XELH71F|Q" ^MX1C@S*-/(-UK?KO:?
MP*5#/(041"@N&V@%.MC2QIY2D:;P5_N2UA\$ZW>*I#Q_GA^BE)"D=
(8Q3R;%6>@|6"1NZRM-11=41.C-W#KI Y# MNY"-
-7\6K4QG^,T"BZ0%7<|UVE|8OZ%YP68-0M8XZP (-%)-
MO\$@2T\D:9_ONY5T0_ ^ODO/#.!\&=(&U'#>4)YPCR+3'.4%9L7-
A7/:Z3)\$SXZ+&,%^&QW3EUM86MK*C.M M %(84D:8 YMBI=/,B|J"^)G-
WH^|SM\$WS=E6G&6MB|=CUAN*IW(*AEL!#KM9 M*K>+G>T%
<#PVRQ9U#8)FQ)>Y4;BU|9&8G8%N,&^9|U:/P#,:4CES^(<7MW M.
/_4U9TZ1E@LR4V8O*ZZ799Q3SP56.E)\$Q)--@|**L=Y/D|R"\$ _@Q09E?/H
MTOK++QULQ?W^#+ZN7!>5KB'54\$+X1R*+).3-5E
AVJYAW+Q02:R^@7|5V:ZJU4M%S@!*?SAUI!?!@KE,?
FF*^7)5H!*E&M1;%|UA'E.1_D, MZ23!?"GYQ_K\$,C+D34MPWU7M.
(DRU1P6DI!9B#D9VRXS\$OI):&|L|+=|B: M\?
49%9!O4S=AQ(W8<01HSSCOC"M&XE|MXM5-8P|S@
7WGEN|A^JNC6J/E|7 M9<@?0LB|L%\$^"|)^".%-.!PENCTL,()
S(P|F|@Q0OPXG:*)<;|O!4'7+4&B M'JVLD58
45I:JQPI,V9BEM)@2XFXRGN_):U BT)-F<'3;&
(TT!A7IF9:_E'A;Y&N:9)E4?!N5E%*VPD_S *-ZE7'NS|5)6 MG#_#|2):,1&--
W^NU;9MZY ?4|8X1_6IYL'\$8398'@S++(|HC5!\$P|W#|3 MZ37PW?L@\$1,B
MR-I3F&:<363X/KH_[KQTZ#!*NJ_FV<7626X==BJ0P5GN!7DQ8D&2&^<.#
|/M Z|_H0-)JHA4@%N&(*A%8S%*6@&\$U FE&)RKV\$.%/M
)\$5KPN,)MY""RT%N1LJ0%!VE4&7DI&|T7.(=Y\$/&^6DN6MU#C=,)2/+|/?RW
ML,Y8N0.MH)AR!SK-(43S/HZTF|V|VJXMT@_V3^+2/W_Q:5-?-?3ZE"+W'I
M#"O(1V_QB8|QIU:B)^Q_GW7)ZA(HLKZ%*DTP?4Y|H9;D.=G8?-K|0LS7*W=
M"N;OYZ?F_?QD|G|BPLHDP :IR>RN+XT!5I#/#23M*/|1|*R666|0%QVA/P
M|Q.X@^T I?"@L#D3U<@_JP@D'*T,'6T3>J'C"Y8A|2Z.H_@F@EJ^>X*|
M.R8QDANK4R,-7\$W;R|)HZG:>;O,A_&3@M9 M@8(-
W%.RA4HCL,X7J!_Y+CPN=GP)XGD)^R<^W|2Y0O&7^QZ2-HBSY|EY SA#
MK#AG)H4^0FGN 7(>|;YZQ0PK@\$%/LN_Y3GRFJK.+NA\$Q!UL!"J=[.'\$V|^U!
M+EC%"N?(^*'S5U@*&S63XFJ=0.?QET4G|=;1'?Y"(JWRAV7L@(-S&9@PCLJ
MGF\$%4)2-DH2HX^YUC'T#F0/,2|"H\$@0_YP@;NSCF"4^J|*(ZVK(-J|ZC-
L||@J=YK/0VS+B MZ2\$D 4/\$7HAE.P>/QK7B|C7+
(-5F(-5(W|7B\$HC#89H5X)'(8Q*4V@Q"XO(S|@SC&LP=|7J^|H>PQUHQ;E4|
MYQH_J|R71^Q%=Z%W6VLOR1UDQ1EQ=)% ,O:=UD1::#&.V^;<4;|3Q46;?
ZH # M@K.4&|AAR@V|WE;JOG!4.3TK6D\$!/0LZ\$LB9|Z..A>U
41F>MXDX7?/812*P M237Q4T"L:H P !34L OQ*MP0B:&_:?Y"HO:/*
(A):#,1CS3._:/^|R_GPVL4 MU+E^Y40@&R<:ZAD|\$@|4":Q2:/E5.=: 2C'B\$ "E
MG^>1F:22^=VW%%E8X+_?A5#,("JLBB&JT\|6H(A76:%;OH|I%|(*|IQ0@7V
MUR&ER<0^"M:./:%
_L(=K|\$VBD'+POV|V8%*ID>!%G==LD<.P##9)V0: @+U M#G=L!Z%PAA5
/80X83Q)V\$%W_ \$)X2A.M /%C%'E?_2!@|O'L_-/2"^H2@U33
M+W!8C/+O<'80/^!\&>9(59Y 7.Z#S4'RHTAT#P#5|X6K-|S\$Z3/98S7BNC|&M|
M!-\$N=HY|WW4"5LU@|D_K3K1NOJL9|JB13@4LGS:T'LF?!VU+&S^/G|
|78@ MW/_4&Z>GXXF'&W%>7|)D#LJ2?T#Q#W3>%, =8?
X\$!G3#.E<'M|\$@5_::R/|K7S7,<@<,V_F!FEG&RXG60%: M+9M)2*._L58
4LODXT?A,0<:E^FR?N'L|N>5'ZW MBS:JDN\$EODW*F_N"#6T
M^U/HE1I:GO.%(G|Y%IY|W?NY70X."AYY|7?A?|6 M=^%UH;P^R&*

(3.4LRUR7^5:<&|4))8S2BNVRBN^4?0G_[D-N\$+M|01?5@M8-M
7*E+#+73B44/L&++ZDF"+'C49UL!+/&YX#+.E"&B-B?P5?|&T>C5YEIGB|"
MS39&S^LM(/|)"*O/+B9*\$<5VA/4FC81!#_VG1:|5K.CC/OZFC_Y.5+""G
MS>.:IFE|X^8A8OJY|P,0Y_FQ=1,18XAYLE=K,(|HINOM%I5XW6&?:8/@NRYD
M'@6H\$BC:#0G9;C|8*C|;<3,A%DF(PK1*,(|-A&EZ62:GD!";;V(%:#33DPH
M\$%<%%>EQ>*.MPZK90@;50NK10N5N@P,|#WSI\$^=M:2Y(G>D<5"!<|5_5M"N2PRA5RE+6\$IZTI%&7IN;@5J*H;?,6>/=Y@2^|RW0'\$.Y00%4=?
TSTZ%"?D MZ+/,H5:G
M=!_%*%N"1+#+6X%.&P)E^/P5YYD7N17REBAXY7^|4|>P|Q'K9
3^|#+^9FVR2G(N|J^8H|'
M;_Q#VUK_|BE6T,1MHU"8^!+P1EL!#%N&S!U;ZE)G/L,*H/A|PJL9_|SP*L6Y
M=@#:"#<4D2)_M!7|+4T C%M>SA:68"4SL|'DQ V@:N?R<0HCB#|3@?
\$K@LDM4K(ZS8 M=/LVMN*R)7W6,_(E,|*00@H
JV;NK)@L!5GRZRQS7<\$"H9;PBHRQO4,CE&<MU?M-
3XU*1Z*Q5IR+>F(3UX#:<@DKP"YB'Q02E-1*(|59R H4U,Q0PL>"-J9X
M99H7J%,YD(=#6?7-CTY)<":7#-'CL8C6R|>8! KMZT6UVN43N0.A,6V|5B:/
MW<-_:!&SC K|@;#'(2J NTAI9#"GGA9'8Q7N79YJ4,22.%I@XI'F_%Z4E" M
07#S)|'MI93)7VR0)A-A#/MB+>#WY&AU6PKSNJ:41*5\$P/'&6JO+P)3*\$-!10
MXOZD?F<\$|696R8>0I\$LCHRYN=4TWQ+#+?LX+8E?
S'G1W/5H"H+AM*6UBT7,;|
ME5FGOONT=Z!L|A#R6M\$PQEAQ;NMXYX3^O|/%4=1.%213X'DF?PCT3\$N3:
(YU? MBUM7N,J\$JK66A8W+0(|1U.&>|E'("3NH_VZ>&.DTGZHF4/Z"
|PV(|=MDR6W M7L(*4F9%L\$@Z)\$JF6 %6SP;-CZ*",+K6-
D_V1PU9UYGUNN8?|>4DTF|J-3G *0AV^T:E AFVL>T'NX MG|^?0@|2'F0P
1*\$=KL8|*#(|QFDZ+!XN4'*,ZT@8TX)+8&2+YYA7 3,|?F4
M^9'YILK&6G\$Z7\$9(QQ)|.6*1/9/T6O%3_C)6@A,4#O?,AV&_V*P1QIWHUU'
M3NRMM|<^BOB(XN1F|_B0T!@<4C|:/\$|D1D/DF>Y%HS|RSV4WAZ: ^TFD9:
MSF#UB5L#^6QY3*4^SOSYP;M_='PO;Y66VZ8RSDTBL?
A.G5:SS0/|@Jvw_V@A M?;:89@5W;-4GZFO\$--BW6|+|J0YL?L:%&FLMN_WT"
(_|3|B2/2|H;:YU+7?I0" M=Q|&0;0|X|-"&0R/3^Q_?WA@_0+%;!V331
/6+X|/GUX>KG^Y?WGZY?'QAO-T MC?)5XR)UUN>:TP2._M\$*LOX2Q|
)D!7G(U104&CJ.I3\$;4FF6 \$6%50K,N/5 M!EFQ|;O#,8C. #XW|9OO DXU0E)T
3|ZB&ON0G0>)\$X?5P,2,FG-G|_|";2O/ MP|J,\$SQ!+>
AS'IK|\$|?.,\$|CO:E*CR\$*1TVCMO|Y(HH0V/HMI EIUKFG\$2Y M> JH?2;B-
7TJM 9RFH5PC2?;YCGH9(T9+;O&X+-O5F/>."J29+I#10&%M
M8Q::Z+6:%=1\$#K.("WC,^!L_OT8XP0J05#7DS^!;NOD*@C?
P*0K3/;MG8<>U MK\$ \$-O80*P|J7B/P#| &V@-"U8PE|G-
P1|L#C+0%8W.4<3MJEHM6+W/, "?U0
MFV'%B7QY^1B|@3C\$55\$SGWP1TUMU|?*EIM:+6 \$Z-C>LM|6R2&?RO|
((0K69 MQK7.C9|B<|4#I#8HGIR<-4HP&D-*
(|W|Q^A7(>IE)TEU7*Z%6=:S=(H6SZ+ MQ#S9""L RUU,J)8.|C%)HLY\$XZT
Z#DZ.T%Z_GART#Y1-0,J2(B;?2"?905P M%-OGIE#5QYC7#
8I=ZGGDJW;UE" ;TK#0NM-3K7MP)AF=#Z\$":G&!\$&"^CZ M&"LVWJQ 3
J5K4.8LIB&"/90|R=[|\$|60_"/!*/P;1JQA'4"A>._"5^&3DT"=&|M0
MC|P&R|ISK3BO6GQY+?J3T"O70Z)1^C(C@ZX(X M%!?
N4IYM!;#%4W%|SIX)7-:Q8:T?L<0%|G)P@B"O)L/V>52&F)>5
MUB&X;I<,)9UA!1G7#0(9!Q5:C61SK #LR|LFQF_Z6_BTD=
(+ #Z&;Y3"7@2#L:|9U(0M00\$JFW,|_|1|4#
M&;YLP3#SVR|O2MX+LL#P"XIR|J#LN=G|,=QYE*!D=5|629=EK+B5D)VSXK
MW8Q\$CL/VJU@!?"(:E N0|J04OV?D@%E5"R4>O5^P?
R%*10Q015IQA@K3KMX M0UAZ,C_(36&:^7/)E<>BFD:R|#\$4Z_?

HS_||"WQ_B|.;9&*2QOCD5N&A QED=0
M6R5X77E>C&R/2?:'#5R?|AE0&Y9,&&G;U&>KPA>UT^:8D39W#T|2Q-
GGJZR>MVAYKU\$@;5*F3(Z;1H)CP|3_!F;O'^KAQ-RGL^-3<*WOX2%O.
MOEY>73XWX@X=%;NH)7%|S^|BV(^
51'C;I|IM>PL<'JJ'\$WR&@CV=P?/6C4
MI=U!@6L'|"/.J*PN+%^V2/'O>^*V3*-6^|:-+H%Z|:C)MYF|(AHVY-TF:S
ML4_>>!.J6O8?)(.XVZ8-=;P9M^WV.Q|(YM%O7+6|2;ZRM(G>2--;|2GS:|C
M|#.CLCQXNZT/-|EIP@RH>#_ ^\$>Z21%OP|7!8PDL C"Y*M)!_"SS2EGA-
#:AM M-8;K!O|U|F)4Q#G;0P%FE%|Y-BF T|Q3I89H3YTU N#*F/\$QXC4-
|7|P89 MGN.S|.: (9XT\$0!;,<'|W_A7G/3-VVQ@R|M;NOKFXH"-
'\$V4.&_GXX25!X8IO M .I
3LTC P3AWYO"Q>":J6%"/|J"99N5WQJ9HP|T6=|G10?!_|^|H/!?"TN\$ M-|+-
&J|1PRX>Q1Z(_:'G_YP=41=O.'8O_T!RC>G!&XQ.I+;5^BW+* _VD6"\$ MNWF|
<^+@,8|CKG\$|1P|3P#UEC'0I+|\$|LU4-@!=ZHUR@!C_8BAWFEQ\$C,\$/5N
M|N13|RH, @1;|Z4=ZN6KNC0Q+|R>,)35';4%%31:>X>C##PN'YKF?
9/"VZXWK|,17|>4,3W/F8X^LN"(ZGS,T/5 M7Q=4"9VN&9I^7M#\$<_CFLK96
>G"451S.>3.6)|?- (I2S@XIR_ "R2N#"R*4?3(GZ+
MXZIR/"UBN')05XZR11AGAY'E^%ED<'XL6XXCK>*W96|P+A>/'4Z78TNK%&
MMIC1>8)XG"QN)_?O_CQPK\$!65J">NS|P=8&BY=Q-%'JH,|JJ\$)M\$@>_!/?>N
MG0#5XW|9 T"5|AZ|R,#625XQ^K*"#23|\$@1IDO|+&8=9U@|>^EQDKD%
|6\$ MBW;9-*EMSXD@Y0PRO-F,A2CMN3|6V;9#1-6Z8T3QV<_W%4:|1-
49MK#K3 M29+UEK19956#\$ SLNFE4#>O|G,O@W63%_&(?)"I-
=IAU(JM80SQ5!\$9M3LA MF&#N3@L+-4O-7NP#2<+R@FBGT4P-
<|(-62U<|#/T8@*U!LA&(ZJT5<5K6
M2(.XS|0\$50\$BSB#SFZ69/*.&D7R|>1#6VZSXJ1,|1<2T(J5ZA:GF \$--3%|M-
ZHH,P|0UM!A'NGN3|.U#S*G=8#X39-,,@,;899TBA|XWRC7JO|@>-;)8Y
M*973S+(NH|:'64),N/WI>ONEULA+2\$OU.28?
8*J5=UXVF=E!N_D@2V>:%%WE M%:'YDJS"7\$N(KV!*S?;S:LR,FF?
NM#S/)X:S)|Q|H8Y^JD34!>>=U3RB<: M^AA%WE<_J-
<;,QLA|E&Q51CA3(GWB|CH+%_JW34KFU?,4D,R7-A !A@RA, M-09|R/;|T-
T"D"53(&H0ZRT4*_ALM=4JFD7;AQ WETR29Y)W:1V8YJ"|*2
M:653;+@.|GM@;IO/('7|\$'AY4R"* J LZKL^|Q8K3#3W_)92COS)98XU*F=+
M>@4R1&|>#(L,7H&+|/K?"5M8*?,(V='6VDAMV|#000HZAS6=W;-
D1Y"FNB M*I2|=O(NZ@T?V2R0QG>J49VKVCJ|9H\$YN5=,WE5B?
JA253JKIX%V;7#6=,G/A,D M*4NDU#,Z"|3(I2M)6,,.)6RR*
4^C!\$_4SK2*NU748EMF)NF&O|+"H\$AE-J2F; >-
P)IT06XY9U>+^)H%DC0Y\$@LZS6)4FF4&3BSI(TY#ZKE,D"BTE=0;;=-7K
M#;&_CO'V/.QC>P(QKBS. 41Q|E+L96|0%7I9J\$\$LUB '8\$^ERL#JE>_A(AMX
M2FRI,6FI\$-\$#^0|), (37 MA3?:GNW++XIPBAVZFUJ8L:H@/(O(I"6A:TD@61)
(;\$)6"H5?;\$!G\$0VZ!/TO M@<7&;UTN|TB;&H)4QR:G :/ |H07"EIP;/PI+?
&%U:OQ|VD|. MCCAB,:D16N^,|LH4>S&+7^\$CE^4QP%|ORX-)XB8+2"2>
JYH|W5 LP0F6:<0
M_GB#!>)8@9G9_CA@B.>8/XTR&E=V#M1(I_*,J7FS=/K|;W\$GM(;QW_!A+G>
?#?:A M?B|L70|A) |<3"N3+A|"NV|H*'N|Q='9P*N#-R_3K6\$*88,-
YHVX@SVY>JY|7M*G;HF!(5 M@YD-WA3G9^'|D:HSU<0;H>
(P"X1UH2U:|!C\$MV%;&D KJI(J0|-P!|6A*XFZ M-81?R,)1Z-L5
M/2IZ|"Q<3"T0R-&L9^%E:H&FEEK|>+ZGRT!?!|M AL*_+BB46!HR1/V(*JC
M32/7'+2JL,\$%.8DY%6LNRV-,!?,2\$'!)A@9@ZCEH2JO886NUVU?!JXKT)8R!
M\$Z#(G|I#W@^OXD?'#|0%6U^\$+<\$|QT29B/X\$ _W<* _ACO(^ _S(NP;;* ;|9G;#
M?<|D.DP=&DE'/|\$,UAZQPLK5XZT|G\$+31H:\$#?@E9Q))6,-AR"|U./9G2P6
M3)H52FJJ*2|,-F|H'(<%|G)L4 @V0BZ85&(:\$FEB)SCCG/,PPS

MTL"+!F=%O-[R27)"1=VPF2M_-;B#6HC \$+L+CKWZZ?XK]-
TC/97^RA_#I!KX M+N\$EF[@)\$P>/QA)ZON9-E*0)(2<6Y&-IVASYRDM?
BTE9>?ZE\$476%|H 39 O
M&TP;J99=%IX_9I")PR9<*8%_6V|5>%7/2|_M:|;QHB!/:ZD2,^N11
M?"*O#K;N'5 T';:/0/X@B5^"J!4^.:|@)B/GX\$;|4*|"@MEHWW6.A=9M7%(
M*V|79>KBIAS4X/G;N_<7J|;^|NZ#;|W|/F5V
M+C&HSR))3)VUM^;LTT9<"U|/%EL'FA24FOOK7YS*+XI;JS\$ _='3,+Q"U504>I
MOSL3\$C+({#*3Z"R*KBKS.IZ?<198TD65'9V>2SG;X3V:|TA4-H7D*DN==I:S
M+APK^'5GD?8| CZKY#GM%&@U|?P'N=9I%&K(5O-
&SU(VO2%8HR=B/A.CR&H MJ&-
CE4FVJ|6^J|91U"+ZMC25^-6S|Q@R@YQ;*B0KV7M2/0&^G,<*!|
MJ+#U3:3G|1OD4^9ZMQ1U4S8@/L!#3K%M|A&).QP\$"*?8|N0PZ+;;DR-
:2#.W MR|O,WD,%C6FA@ _>Q88J#VV8QN|B-!%.!G)P5WVRT0JH@C;D)
|E9@T#3)S6:TAQ/DA M3.DRWYB|Y"|CZ|)W7LL8
54%,*+"E;R*=S5DLR|S/@Q!W@;- 'P%>-ZL:?ET/ M+1"W+E6@2=(5"G2S
M0*0F2;>K8WK2.&X|/[9QA\$|;V|)8:IN_%D@>PPY3!IK, M,ZS8?39@;;?
8;*|5Z#%J%JR#:UM98"Q8|DF?0@M'|KN06BSJ!DVEDM'&@VG
M%=OV>G5&91W#U&2SM!CT6)2L&OTWKW)X8Y#S;W:IOZ=E15B1M\$|!H'
MPA:7H%|\$\$WH|_J M|D)_C\$ADH@OB\$'O#0V='2GD|!4YX85=
|'>^<./1EO7)R%G3ATP|FV7L,@D7 MT+.VN>I*IU=4M2Z%V|J-3J_IZC4ZI?
3ARQA%BP7L8!|:B:%2!K %*B?,0VJ2 MP^G4B@BI<)7V'J M|NZC.
(6|.C!28B_cke(1TDJD,F32K9E-)JT@*?R C9E@|)JXL/;5 |/=K&|
MK&3'+6|_T!'+EQR#LV !A5'I\$W#0WR^0!Q1')KGJS7'&;G2!|?(@I'=7/,>.
M6|H|"OHR2H"?|+6K"<|99G4|8>7F%",|5|LP7|95K\$)4S1'/P1)?TC8K:"|&
M)C|.WB7ML(=-|;#B5\$1U:T0-I^+K5|J4*N-4FP0X!@T)Q
)E:+9I@K&H'51YJ1M:R9UKS1RSA\$G("J#4|U8KH^7.%
CE\$TT\$XN@FPN8)\$%Z> M\$4T B'IM|E9KF%//5;8IU?;<6_9AR/N#
<;%R(3O9.TZ-OH77M:5+*!|;:|4%T; <
MEA|WLR|/-;EH217N.>BQJZ|KZOZ7W+&\$'?
5>U@#WH(A68GO;\$|"R93Q)7" MOZ*,\$XR1=Y?%9/*>|_GV91(;|@QQE#?
D>S*|?;<9EE!T)?4P'L\$|Z C9"6 MUP3|ZP37OGN|/&=8??
>R7GJ|X49#UN@=J42HL/_N'|5UX| ME'121/\$_Q>#-CTY)
<":9#73K64;LWF5=TR=TB"2IM,PQD;K&1'/,9AQ',4W
M\$:0Z5R7TG#OUM8OENHH;HOWV^'|_WT_|?H3WR2XU8A5J=T!IKN;+@-
"% M7#U?4,I\$ZOA AFC|_XCN@-,|@XSZ<;)N@-&H 90V\$UUOP!H+HB,0'LD|N
++* M7&.@L7>51;8(5.9:;|VE?J/8NA:' "E'4H;X#:'6J|C\$4N+C4(Y?/LD-M;
M)H8JRD.SJ,#>#G5B:6L6)5+5\$-9%^)M%F;EV|%87*^=1\$*KME>0+L|.H@-
,2 M7VI2|RS*IK3@96JR^WA54:S'6DOU(,/<7Q;M=
(AIPFT,W" ^,8+D96RCN?32^)|T,&Z<&-4?NI=9S!QR:-R&NS
MA!USN<3=A'* _="I=;|.PNK^=#H-F)&-ZV5*95@N\$!)YS(*B6A0 M<
@%X@28K)4;;L^0;;ZZ: 5|Q-|+VL\$Q.M8FT8?<"6M'K2N67"07L;)N"2<4
MZL7= ^|4 !R&H()|88!4C|4LN>QJ)49ZHVX^=UI07.\$2+_,*HK@|H|HV5(R
M!DY +PPMO M%LPP&*N=);7BS61;6WWS>4DU_/'F\$E.HG=Q&!|1)9"L):?
BH'@> M^JN<2XG?
_=EAB7D)AY(N9H%=J5K)NZPYP>;FD!^FZ#R1U7J|1'O(4O&5J9'0
MNT;;1;'1#3:"V&_6\$W<5X!WYJ&MH;:"^2G)|1LUS6RHN8^|/%#C:DO|JLH9.=
ML"=94I/V\$GGAQ1>F+:F|OC<4_NBB%\$D_."%'43L.U&XU"|!A:GOH@|P(?
L8+QM*(@%W)K99*+|=,*F;/L=35RZT M&.PE/E 3*@E+<8J|=53DO&?
N65|FN<^2=G"-UJ5E^Z%QPN)I+7CA%B1N|!|)
MV|P^)^7X(DF3ED1I+3D"%TMR"U/?D"Q|O'W#,K4D\$VVEQ-V1S1|K|. ?H)Q
M+8A1X(W6|/#QE(JIA2I2B|K&W.WH(|-YMM^C^OX%;^,ZAV.?BEW?

J6!M6IQ@YA'>^<MT/HW9O:@JOSAUZ;DD>LM0^*2""IZUC;
ICBOR[4J=21Z/G+2:U((32Y EY'B3
MOF%KSECX\$959U&SQOW%Y*;!Z%BC3^@X49"EBG)-
&:XMG0XEQSL+X\ S'RPQVN
M:QHCLOODA\$/FLD&>&&N4N=[=16AG5.A\AB"5=[*!?
TH0D3JG#@G\K#PK^Y;<-M(J7U\B'T_#??SD!0\ ECS.[U5_] =
(\J^CX\ YQ\$IV%|\&J8ZPM#10W\%,B_-'&V\1\6WFCM>?
EW%_0L*"4DH&:PLJ"!DB>ZS1K?N>|\1GZLF1W\$7V>L|>3=1 +>+30AO
MH"EPNIR?>E3+1%3VX<60VH;0VHOJ\CKXHX3P".U:Z-88
;GC378"ZXWP37L MFHVZ(QH_8;!I5A8+^!@E/\$BK8\93-
%|0;46OCY\6L\$DJE%|DJD<|MM-
AB@;\$/="=+|9N_'&@Z+O9+!7GFH*PKP\L@MR.I.AQ..
M:KX%6|_U>4Q=8>)XA|3|;&PZ\$MOX!7@)BJY#D6/P12R3\WAW1S)IO*/HA'I:
M*\$=LI\9:"=Y3W'=A4^V\|P'LLU1;AIG)0N#,MN^W4EEM=>'J>Z8(:&?
-9Q|_^;H^/J\$K#A7\$@@O<,\$&M7OF<264#):4W.JJJ@|'W*?
9=&;5RA\MUGG??0.SZ"D7I0B9L1\FD.;J2JXVFH\8/ZM2I2^KY%=S".>%
(Z%*LX\$CAJ9P\|P@9S M8-*8YESZJ2-7>Z3PD*FCG(0IJ&
MP.^|5(P:._CCI%GL>,("T\|R!(\GQ W:1-LM|*R-GO4>:W8P?UHN0<=+P(O&
M' *QUE\B-CE!XMFF\|S@FGMHETE?C7#\U6//>AZ+Y!M=DI_'7B,O;0Y\"/
MYLT0 /-"YKK)7!YKG)N@IQVG8X:7-Z.=^B\|O7N=\$)M\|^B@(?=-
>"FO95%CK"T1A_!4)(^%.(2E0 M-%Q+UD<"W!\VT=N/'O#)&<_E*B'?_F-
%662;:'QLV9DK5/??8+2P\%Y"%T^ MDEC#EHI)2\6DI6*2P1/(I%
A+ZZ.64HI==ZZ1P0;(*90XUMO)13(/,+/2?V
MDB\|U/L%COSPT\B)UQIKCG0RMX=|U\&7RE9+
(82G.GT,W\$#SZ9M5O#%CYU M296\+KH_P6.^G65'6,9&'/H%T M'V4!V
#@4)=M%1=+\$TPP0KG<_CYMIH^DR3V"G1,0?
8WQ\+!&6,6=Q^M\$I+,8B_!-;(ZSX":R MA*J_!|#!(-C+,R_((D-D/\^2\3Q-K@B\9_
KEC->^);J!VA\&OHLZ(*\ZVC6%D\;T\$*M\$?
412J3K;8\3>|>/L9>_|!*QZ*_S6DN!L@XL@XO.1\|Y\0\LMH9\H7XO,B\?
M0L@23GA;.)#SF(82'!9"', '>@,/G+P)_4C*%?H_AWY-JQCG\J!"R :B.6:I\$#
MR3)+73QKZN(M5=,NMVK:M H
MJJS1ESU+!XN'#_*WOK4?)MLC3>AOWK2U7\X
MON\|-4SO*11TLK'O90@6TJ0Z2E!QG\$IS^*J+;7>F*.Z1JO(\$|- \$ST+:NOD
MNF94S:HA?>JD9FN9.^OH2\GI+FQ\+?!^3QJ+?1SJJ#(?VOS4D\;|NK.Z3\$5O
MXSR>-/*Z^M(1*IE.ZTEC2|'_O?2X\Z%&,)SSLR@VIT<@_LNL<-9>8.&')4RU
MYEY?L:1SY,2D*;/NZEHIYLJ00IBW7*IHFK8S0NO_3#-%U*7WM KUF?
2Q>UT M7%:NR+=@3H\$VV469IUHQ3
M=.TV72\1B\KG6LNO30Z1LJ*8TZRM-
@#VI\$4O)UHI39L'65;E3V_ML\O4O,7\$ MV*^0WV(&J,8Z#NM-
I#)H%DAOC\|X**=J^-5,UP!,U\|&J&5"%#9)1(JT:)
M\$L>,'_\$%AX@'WBI9O3E^@/2?;10G\%TJ\ _L002^U6
M7/RDQ0+&@*RAOW8XK'(L;6::*\2&PATA\4V5!"_00X?|M@&*V0K3-
@_"2M+ M:~V\$,41|>=G\$P(%47C;OG5CMXIK&R3/CQ%4)T-
|2#L0NEA.H\$&0\$*OB\|L|>^3/' KL MJVM;=?:%=-F3",3K6\$,-M'!,
|U/QP+G3\8C6\|0\5US0K47204*KH\0);# 4 M=!=
<::0J28133Q\$;0GZDD2P2NV81_M\|Z#QQI7TIDZ0\$A&W\$OR@E7:GCMB A
M'R%5Z7W2T?'CL555=6\$6Z.
I(9%M>B:GF)1CG\$#4=3VM@N7WQ4R9YA\$2MG'1(
M_V!DSE=>APA9M\Y+5L1)?L*"/HF%+I',(MILI+=*RR#+&P8*I='XGY,^U
M@'7VOPJ-<|V6-(;
(3U\$(SI^<^>0WI\|3PPB9\|Y@ETE"3ZV?,%>TM6QDSZ1"D7=4;:|1"MS-

30FXL&"">4)^" (^G-,%O MP3OA513-,J&C\O2\$,P&N)"/YF-0V%18 %
<*7ZVHF#7?/#5)%HJE7.UTDYWEE/P?O6C|= [TV!0OCYU M-BB99
71W43Q\$;N3;D(Q4V;XW MB^"K07CJAWFB<"B>*K!O#H)@V]**.K-
3D2UE",S9Q\$+|OT%ZR'F4*L'615OF
M14F:A2S50RU+7K#\$6BZQEN.#*K|VF%"_A-%K N(WQ\$OP^P|_CJ X%?
B82D5Q M:MH_8QYATPJ<62J9***JUFZ6"6EUC'E2G5?
@H@H3T1Q8W.J32_T:XT|50P\$; M|KEZ-!_.2@&A'C8CF62>"I8(SXN(!)Q(
.3@P7-+Y-GE6E^&4J(6A (2=LU MX7X(=%I4M7P)G#+F%>BBHS
QKHWC3)UU+)6-|_ \A'XQF18S+SZS1+PM\$6^7 M?-4|E|Z;,:!3,\$N|V&?
39+FAKLA\$'2RC199&K5NELGF\$>9>6RW2|&%>WX34S/
MEQW5T2,:2"D,H/?ZY@W!T_+_+|6:ED"))5!B*8W4Q4_YJY_N&|)#4A4>DN<:
M)-DSB==JX=CL_ZTE_&)QO%
XQVUA/P^%U3QCG&3R)N|\$^X@U?,E3U3K.?2H MWUF/ VD1_1#>?
7,:!HJ:|YZL03K*)S5CZ_6D4-1&GVP*Y2SPA..M(LN+XK._M?;:-
R|:ETRQ>^9%KQ6@|P:D?Q00")&Q"Y^#)?@.Q^2'.Y0C@4MY+ZL2I54;4
MQ:_^_N)JMQ=WB:K92:IN|CUGW>S,:;CHO):@^HK6=._I.|D'N2|B2\5,^G!=
MIHC|VX=AG.:!\$R+X+FT=DFS=|Y7D^@?.\$AW\$;Q
7_Q(IW>I5_)8W)YU+HLH)YVW3)(I1|_ZPIYOJ|H&N;
M76*9_Y8|JK*|.P^A&YP|_%^V-RCU.@&+","?>PGBW<+/WXUZ7D+&
'3*4P@M6_ML8.Q7XJ|&V4ZOC*4N-Z.P<_"3B.4.BIE|=IB?^KDJ|/*LCLF,"
|YU)\$E?*G' M,D_UG|/97/&6KPOGJ*9N6AWP=6\$)+J.@W??CB!;
M|_U=IWL0WYQB=!K\$8*0RYA*;65?ARL\$B|.3_B76N-BMHEL*S3|_D;|K!-D6
M6.(V9Z0QE3#;#WP-
3O#.NCP+4&.8L0WC0ZT>=7:XG*T+)I@%HD*9HLU7!YHF
M%='|ZGXS+7G5.G"AXD7C,8%9"\$T=\$<=G0|/P?;,\$FH@7SB*C5?^:@QL""_7
MU/"F|!)DB/SC\,7|38OM*|>-H0)=%|DI'9Q*I96.O43A/8.J:G6H_R81W|NM
M82|_-+XI_A|?Y)CJ@\$|P.)'.5BZ4@E9F:|9(IR_(@(.>5?8&A4.'V5\$N),DW
M5!|HSFE+|O,41UN0))A|W0,@D7PEDPPK(T;IZ*,
<">9/ADQY^C#=#2QYM3MQ_MV4HV@PKOFH6ZTAF58K8Z"Z5%"^X:#|
L|)7>-UCV",U">^F-1=GK-XCJ,CDL M*CZ|&3+_-'T|\$+ZK!S_-
/6(W49CZ8=9_41_|>F&:WA1"%U>/+QM(IL|Q?(NJ
ML\$5'G*|4G4(/H_TA=!!|)%YLV9_.+4XS3< M/0(G
6QWFWBLWJTG<4IM&_ZMW#+|RV|WD!P@_X<|.3U_=@Z \$:G,'3;J1I_!
ML>Z,KV^*6?FDW=QQ04)LA7E|Z|^.NJU/SC?_<#IP-U;|?0FR;W'8G-M5_F:N
M,5\$4|C8@/N01+R53O3|?. "G81:BK)N*M^0A/@._^NJUD(/F>
|PBI+75>SYMT5_M9=RPQXYZEUZ@#(JO|4<0|:;!|LT?J.N=N|
<>.NV6PJV^""^USQQVH6-M?;+10_MUJN;O0^V+U_9@&I|DD+:3&
(!|XG/X1_1<1ZYV+5_LK##Z%W00_&ESK|+ZH9_MRG0_#?
P="KU0@_OD!P%28_.BL9|!^N(\$@*T1M)RLA9P2X/ZPB|Y^3-)C3,@)
M_8DB)?BWWVY6=:+) _M5<|@Y?
O:1\D6(G6|LU=*M=,7#66T*Z+T>G\$6S&&:3|_M/H;@NC6%RB>-1YF?
F)3YR2!E/H(D_: "J:.*&G&?(G2&\$" WEZ?B'1C_M^-23NZ6O"B^
QOGZBRK?)TW7G|N2(A+CW, M&F:),|1G-EMWC|
(LPFVD+J>*=Y|MW)DTHF1>(H2?E@Z:R>.+X=G)T53SKDP;
M%4JN&NLJ\$UB#|J;J+AN-(E-&@V:7%25!K9=W3VS0+30&Y33G|'_VDD?*F?
M"B3QO3Z31U+K@(U"8M7@EIHT=C4YK0M|MW"031JO2GY:?
+5S+|RDT='+N=>(-M:6Z^)|-GI)ZR7-
!SB)G0TG:H,3@62!%%VM7|'A/&I_M6/JGU<31T)"
MGT6*E)132>P=LT22A+18@0RSR!13)J;.9H|9HK&%^;X1?
C*+W#HE<8MM|Y|E_M?O@">ZM8H4%2#6W''9>G"9
|2T0)N99JO%:&N3|OF)'/C&6X^LN"*W9X6H:?

MOR[XD0;/9:CZ>4%5UWB^7.5>+(%M8@(+M"VF"GF88H&L1?
E6")PLL+7HCFU" M,PNT+1I2^I#/ GF+Y,^/2"V0-
(*0;W')&E0E#CZ*Z#WY*ZVSAPQ0=A?ID2U NW3
OI/#U,IJ/"7\$(1.OA**+3H0YSD[DTUM] M K\$+^*6+VRZS5'D8'M27T_%(^L\$I
6+)|T'TE7J3)\$"JSC8KU.A|Q/A23OD2 M3#KBK|N#PT>;"C>?/D)%3X,R|IC,>-
XTZ:P#/"!9TB=.KBM;.(3NR'Y18L M>!8!>?
VPR>: XX66C6ZR:&FMN#^EJ#MJN)|"2%>/D>AB_Q. 8I^J;Y+%IE!
M:49B/RNDJ|^YX=,(J'X@'NX=Z=X+^!PZLFWF-!NY%P>P*?
(65NOH+@#7R" MY|GGUH+MNISU"\$#M/D:J80|7^4RP(7?
Y%5X;.^J2#WA-12.\$KE;WJJ-N?
M"X<*BQ)U6\L2LQROZ(JLM&W;E|0_\$T^R#1@D(76!AYIWX;*U#H%CT;BU8!
MS2RZMD|I%L+2HG1K1RL1RF:1|S4:8L?L\$CU9?/(E3:U|C|3Y(8XH-6;%JY
MTNP@V3Z3HTZ9* TU#VA^9\$@+|N.E#)D.8|.I4OLH@/ F=|Z04@GTT.Q-
&QC M(*-/X&3"-L!B6;M)-
="WQ/HF|JXR:Z@PP|/7;2K5=P5S8E5,P\$G0WUUN* M>(4=UQ0F&@/J*?;?
4.!)X+C|NR\$90+3:U\$AD>?5.|G:7R22"AH;B.<9 J>U&
M>\$788PU&6+XFX%|GA-(W|K!3XGPSQEMT;_%#(H|WF@X;Q1BGBED2+
<9 S1+N"XBAJOR/=0B>I|X(Y^BG30#)2:#DK>GV |W3Y!1|+
MWHE!|AE|Q3_QI7NER9J9S7^ [1: \$H_ ^P4<&X|(Z#65T)Q2T6%:<:05'TU/
MUV?Z%|'=:+&|A? =>%3C9#Z\$+ZAVCNQ@.WSQFJ7/EQ(E2@1X*FN6XL\$-\$
DD MW9A+/SGQ|R!=8|J\$=RA&|9;9
K+"!,V|@U(8>H^!|RLVC:."ALJ|H>.J%WXH M5B|JOP|C|K|I'(6_1,CK0XRVJ?
|:M!6 U=?0# .1:&Y1IQ# |916|L U\$-<U M9U"-3JS>8EZ/&#W#UZ%A0
SK(83_|@0W M092@&G%=V!=S">WLHFJ&12-\$'C|6KNKI;#%R!D9?_
P_\$(#NS#%+9Y.KX'O MW@>1DV:<|=H)4!+|)KHFM>0<5&J5>?B*4S70^
J/4N#NPRB(=F?,>="C=?<- MWI5P!Q%(ZGY:.^PBGFI/:UZJ-CL&^/'8W?
PIRCT^G |U@JF%<2,FZQC4D+| ME":I\$WIP?
V)=D3|ME+OQ^,3^|X<'UB|0|4!;0P/6+X|/GUX>KG^Y?WGZY?'Q
MINUUTOWA|T*TDFT7I"@*WN9VY).T
MR|JRNCB*)&+UZ>.1E5BY4)NH>;=YP?.&+>3N&XA=/P&HB 6E7| VWGJ-
\$2T M7&S+)QF^G@R5B+YQ7XY16%Y)X9UMM|)!;KG)/5%MZ|9|!#2,Y2#
MPIUI3C>FD/L4^ZX,&YX&V(E2#@#3<8YQFY 'C)?1P=L-
TW1\$VLZ|9!;MRG MTF3+@.-+.KSM%MN51#Y&;F=%XJ7:#H&_P+42;-
U<|JG2<| M58PQ3"22;%JZU_O774(;%\$%:?
HWLN*&R\$@(YE;5(CIT%1U/*IJ7IBY.S.@|D MB9-
>JX7WN0FF4^=;PJQF&D>,-#-9)DQ\$G'39G3;64U\$FC0BF_E::5UI+7U&|9
M|/VVD#9E::^3IC!FYFPA!="W<-)HD&?
IECVE5;)G9X\$L=LYMY7D7J31J=R<9Q*W
3CHN=8^F%R!L>NTILXL&F(;GLV86M
MX8U9%&D>W0M5W5/R0DN3QM<0CX3V\D^3/H&^3+/Y#
W13G,F#)-5;FCJZ%1G ME?*R7H-TF7; MO0C2TJ5#H.O2:8N#X@Q5/T|:5:&.I
MX.^F:H%L&7C6N21RCL=IVS+Z166TJ;ZSM;ET2 M.D??S-
4&S=6H|_C)F2L90|6|SM\$(S:PL33)062\$|1Y=6E>1B663W8MTY'K5J M+)>
(1|7*WSG"%EVE56WQ'&W3=O3WHC)6|/|13&1ED7/435SG:-SC?
8;GZ'U/G6Q1&AS/9QJV'N\$&4 MG&)TX1SW/IV%E!2CI@0).O"2JY+//!!LHEN
MO!7P%.X=AYR|?\$'R.#D(WI@@@0>'7Y0GA**\$ _C;'^K0_:%"/N!;"M K_0>C
MG=:N'8@'E!\$\$\$PB2C|L*U?WTNASPY9QR@|6)O095!H10-
"YLMOU E29Q2Z(1_*U')J9.2 5S_==1MU>H* M-S96_7U|C-
%ICG5|X=^,W0MV'= :\$=<&F;O\$I2=?=JT2WKVJ^/WKEU7;^M/E
M#:M;3;IHKOFF*3;\$.)OM9F\$#!L0Z&:'E_EI
M%++T|.NE&BU?;!6I#G'===Z#R1_A?

**7"6<1RT^^P|)8AZ91VFKBSVFFV: M=JS-@,LC%, R?W|3B+K)
{Q)6;^F^H% . ME[BP: GE8N5UXYY\HC'+)*]#.A,0SF!CFV?
F7(C'GF:.S|YCO:2%;@WU#>4'-44K(X;T8FR.>MIAWDT M-
8,%=EA&,R2K(%BG>Q#+J8\$STB1FL1X%4.'-9W!\$4E)_+#.6U QA600.=YI
M1>#RGFW5P'+^6;1>P^OI%=7N>A|.N9))>&Y0#AA*TU|'4'OW8PV
,9:F06"U)E^=^/-+!#9@'9'Q|/\$>SB-9IQ|=D9#I?E&FZ MJRQ\$X!!(M5
_|W!SV|LA9Q':-22!4I90K;C|F> R!#M4'V@NV&398;6&M4T!
MK2W,LX,\$GQ%%|RYLHL_F|*F<#W+
I@BSQ58/\$5_%|UDW%S#\$N6S1/EHBO*9?'3'Q?
KI;26UWSY8(@%VLSD+7M%96.IU&YZGC:W%W|CX M&Q=_XX4075^S|
|0|&XN+Z (0V32/ZC';S|J.|V\$8.|U%=KR:":^9B>MY/@'R
M(=Q&|0' XR5:Z)X")T0OG=
:5QND68'FTM/>/F^@.WN'TS&1/758PEY6=|5"!';LRQ-A&?P%)
M"A|YP3|I\$::W*7RWJF., ^C.8#>NYW@S6:)NV+_=;<<RQRZ|'"^SM74#V(&:-
U3&ZU1#_0)""NNV!&&MU4(7_Y0|), ^OI/R8H%&@ MD'1:R!CB2U47|QPL:
8+48B,DC1IU)I*)*[MGHN.RO:N(TA5Z^TM/! 7KIC< M|*%X?^"HG H3AE./-
U|AELZ/4;A#6D9|_5@^_)T0?P_V;5ZP@8D815Z79^8
M8(0\$)K=>QETUPQ9M2=H"OLHK1, UVQO8F@EPJ1|GD:(?| MTN7=#+K':?
{0\$GGF8QPEVCT,@B|!&VC8,P2-S+|S2R<|*V<>+. (H+F@^MUL
MG|FD3TGJ*,M;::+1V44V|'PS+D56I8E5C%/'!|-?1J.CYJ>.:C8DOJYZZ#/'
MKS15+'5JUS-=!MQP.,VRXYO4ORJX-+,@E<&|:#1B: ZGJ1,=,WRBE.:| ^<)&F
M085Z_&5+0|?^XKI:L%C^ILC*:|<|('T:E|C11 M,8H@Q-
7@IMZ|4E\$DDLL_D|50>QNPV, BX)TP|PA'=S_L|V,Y*PU>/:*8@@
MQ^T/DQ.^!WUV! (;X(:C5)GR*'YSV>O=D\$669#*X27#*+.I9#1F-5VE;PXU=R
M/"|!OP3^MM"3BYK=@WJY9'J_-;QJ*='T)(7*#H\$OB8
M;5:082N:81L8PNP=|9PEV7:P9-LN:2F|ECCM>:)'X+%!R)|@|
M!PN*DXT!AYP64!|9KT+X2+V! (#KBOJ9D6|)D)969QL#Z"\$ (0.P',|5<#7U(.LQ
O6T4OG4#V*@=|X2-MO:OX-
LXBR\$|)7J:QI_3XS@)UH|UCVN_\$U&./6A.UHN@U7L"@0?/19Y 2_,&
M)I!^,+E-IH8QLUZUP,C!'V|7*QFA@4,TPYQ&|2A'^X*\$H,E"KIXDC% @M?
@4(IP05:3OD;39PEQ4 M=+7W@D972Z8|-Z6E'?>6TN\$|S&JRIX!C
E+%|=31IR"|TOT!V<_,U)'4GM-U M?\$UGE@#7@^/CF04BXIM1H\$2LUEZ\$?
I'U*3QS0D #GQR@Q.|O_?P/)"IZI1F MJBFXVB.US@7;\$7 LC8KN30|T6
26TSY>Z%N4S;)0\$|WU@Q,4_#3HHOR5S(&= MVS5ITA(U">&.GZU"K1V
C\$S:FJ:TXP!5##X1WYUS^H8@_2O5IE67T7:WEO^ M O5,2++^*SKMG
@0% @M?Y"9Z"IM5|E\$JLP8EWZZS! ?639E|%"#^ M\$!:530M|Z-%W7OT?
WL5>M3O|W|HA*Z//%X0EA,., ^""M=1_ "NV|N0\$_I4QRY M '@)///+U=N-
|8|+Y2)^ ^@%LCHKVZRSNGN%!Q;CVWT|Y1:41QMP)%@%QM|T" M-
UV'&+MUL6R=|KE21:>E;)-3*94N@^-,*CG?:(TZ0?|^%T*^\$V/UNYTPVW)M
MV^YP!D7C&K:|Q=Q5K*\$\$\$6MBC|5FZ^GA#?:#FLDWVY4+=|4
MW#;!>|GK/!*LAV% /VT2EXCLL, '-HF"@U/G"<,M7|#G|TG^|
MWTP5R^L@Q(:J+=E\$; ",SNT*OFD5!NC;('=>&/(NR7L-RB3HIZZTC-
04^T2TX M5FO1' NUF"Z8%%G(,
|3|9;G*4J2I6.0S=/YU0:>:8MC6SI_A|^=%-.UNX2^4
MQ:E;?'30:4V_UFJVF"C*ZJ+-,ZTZ\$ |HUL4>GPX')S|S0H|!?"OWTCX|35P
M'8B3S1|@@.0\$;NT!RNFI|V5OT"7&'|/|+|_09FGL>FDGV32S47UT00.Z|P<=
MOH|SPWQP+B+&%!EUCU&
(:|4H!:@RYYASNU9W(Z0K|EAC6V|1W6Y72#O|?N:<MK)%
{T7A.S^P%!,0WY!>MB1BXN/CRTE_4|WS4LAZT?.12+TU#^M)|0Q|!-?W
MA&!UB\$XA|^|H67N00'34+R3G|D7V8ZFIR4+3U::;H5BHBH,-7SQ/XH'@)&*
ML%;1Q=@BT>2C8\$228*6=QFC!:C:A9P2AK5*_4'K7IX|P;F%M>B2IJ>-6MS

E MI\$68<[NXLO03':INT+L<|?;|,UEE26JH\SMF6\$-B@EE2^.@&388VTA
M&+'/G#G6V:O3PE|=))DY4(6DF!Q"/^1OJ="FI?/TRP=/(OPT\$H<#Z\$6M1C
MX/)% ^Y86RA\$Z!-D#;5EX|+2\$|SA5A\$XG|'P1MO-R"\$YKV,LK'@XN2'7X.2L
MG3O37.D'8G<1,T4^?I2|X42K).X-9+Z/AES|;#T M=;3!%,9IH?
ECZJ9|F=VD6IJ%8Z)8(B:6B FI58'EHN#K^U/'DG)<"<.,(OK M)K1*5-
PP;=G_U\$E+:D437,%9D9BR":80%?BVD+D1%=?KS./^,T.0N\$R\$YE3
MQY#\$((\$0C2.%F3AU;'05SOJUJ%F\$URF)5S0XV"^2H|G#N19U|S%"+".>W3@X
MS6-CC*8B-7\$\$^5%BGNQ!CYA_I^IA-
NU:5\A1:0WCC'/W4":@-4VQ661;E7KGLZG (DO-V"K>_Z/\$ZL,-%LV;:LZ#
(Q.O#8:W.@'9J)%HF1 M857GR%V3=BH+)#>\$(8|D-
'4OEI+TQ6G%U%G&F2I2A=)W3F1RV6C2UU"_K,RX MO?:(-
#^.E0DW4E[7)5NJE"ZGC1ZAKFDFNAVZDYN[=>ZJ6+-Q .N'9,JNM\L MG+
|.;:NB@,|"JZD=LRPM>+S.0|-V3Q6Y@HM :ES_%* T|K!=TFHH&.63B^-K
M<7PMCJ_ %|37\$J=::A3,/J#IF<7ZU?"9+:?8+RESK#5;+UH_*6T^'STQF7L<
M*4.K7=.^CM^+HV9QU-
A@_ET<-8NCQK+WA2.9::6(%P|":@,5+HZ:Q5\$SFVLM M|D"
|>&MZHk/>G5:KB|;"YK3F#>#O%P/XA29H:(Z=7&S2BTUZ;J>C4VZU;5>
MN@"8OV7U8 =AL5_X-FZ-3B^W3(?
EXK&>0BA+!*2V_FKG^[A|7R#Q/P00@%R M,Q_"I|-KX+N\$0*AB=#BI-
U|3)_6RLE/&_/+,"M|CCFOS(&EWOL3DBGSO(=^ MIRA=V
2T|&|0^4BP9/Z/=Y^C|)JE%\$\$ ZHU?Y^Q!N\$LF-
LHQUY<2HN3L6E#KEAUJ9:"I*G+DW:;JXJ!<7
M|27*&;JXY/V|2ZN;X.N|YDWYS; #N1&FR'|X#A9SV1').M!6R W#M:|9;L
MTFYNT-; 9?<5'UQC'K24NV*8QS1GO?;GX>I/TLL>G=A,TE@UC%.'Y88IPN-
M<3+MRE@BFT8|/"6RZ0(CFRX_+&4I:."/5YHDB|)0FZ<9_Q|^9|J%_'EP3A
M=0WE*0>W-(97|/\$U47KC% A,50%5V^!;6+R+BW?1L@=A MU
(+T_2;+6|B_?#+&|'%H*CLNP|B'NQ3U%\$#VQ|XF2@K*4U,V)W&^HS_)=?
M;B/W1+@ ^2|\$^%V80M ?PFT4'_#6M)@J\$^#^L(O>?O2
3W0F^(=258)_*;9" M?9EG=Y0.UZ+K==HRR|PB'#K25LFIKCP/TEP"7T?
RA|+|>V/#D@DC;9OZ+-/(MR!YC|^9^@|?;.06:S(?R3=Y#<@-
QM@VFX80W:N1+A% DN#CXY|\$.%G|00Q^| M#YQZ.|KF|R/CZ2EWP|W"!U"
L.JXD3=Y|R>N\$ _PW<.)|/"|B_ET?:62C!%=J M6Z7'CK393>R@!CTOY|-K%#
V6/U|U!;?E&>Q|9(OT|_.@46.S&&C;O\$&'EV, M-
#V/?/M/4,|!XH|;=Y.G.,8Z!#*PH+.\$8B&3&(7#1|HR|O7RZO*Y\$7?HJ-B|
M|P,0W|#/|J*83P#54:-N|.7@!,'U*8\$2;,,5S1LU|@;W(\$!|#HY.R\$=@9="H
MV|N#TLL.WH://>Y|+R,#<>"9H &NXJ31+Q1I2"^|3=F04;>V
M<;X|>)#E^%O?Q7J69)^|284L^P_2)%|Q|TP:ZSAS;YOL=GW1C9|_^XCC?1
M5Y:2QAMI8J,X/&T=8XM5Z/(E*LYP\$UM^BB 3"OZ/?|R)/.F&JX/'\$EC0|V/@
M<#98^7FD+3U&2)?81R&?
CS:&C*P; =?)B5,0YVX @694'SFVZ0"EBODD7%NR MT|;042|,"F*(X6?
Q.X.O|DUT@EK'67ASQ+-& N %N"=D\$W_W_G6# ET9NVT, M&7EK=|H
<|!GD:*+,82,?/|PD**7Q#4 =R,ET(|&Y,XW<|3>#O|/W1|P^% MFP?
J*%7O#GW_1-9|Y+CAC,W,Z@+'3&>L_-3 RM8)\$M :;/AG\$*)|GN^|BC&X
MQ(&:#3|'L.Z?""@9P9NW? 7EG.K|;"*|?NZ15|7V!.\$Z38T7,8J&+,9\$>06
M?'^HN!Q*%'"=)SGL3,?%!0/HZ;P@D_&P?
\$O@>Q\$&\$'0M%/*9C4_HK1T\$"18*?
2H>X\$%P8:'XUW0G#P*YM2(@UUL|!"|JL%0:9_N|!4&"M1,CT MJ@^"
@OE0:ZO?A KD+7B("|&8! L6"L7LL,*!L&!A>)A-59A\$*@M% R;X1"# M0&ZA-
_B-MA@\$ 1:*@/PHCD\$P8*TH* D.&009%@J\$S4"302"W4 YDQ|\$, KVVU M(B
O1\$8-"UEB;35QUd!;5%CD%\$O\$'C73H#*P|H 4@38X4 7|@)U+S^?^5
M|_T+A67,+&FVN\$H2>,"2&G.U088WF|TWI3W7QQK;.LKP7X4>^@^J@/KF!

5-M:D\OG#@^ ^ ^%.U*A+;;XYT('E2;!5D)AATO&0,V5[%Y|(-\$I50U,|NXVQK&
M\$\$|5DE&|\$X()YNZTZR(),GERSH@3LN--)8-M.
%X09MECM7/0SS=_%M&WUV5 M/KR-|9?
(GO360=#3'E!"4C82D;RUIVBD.=SOH8*_?&A|/I#)7O6T&'>MNXO
MFK7O6%TZ!.\$X"Y8>8*& (M6A|F"3\$|^|M|NMY^20#6!Y1HJ3|')-
H.KYW|PUU^@!00EBG>Q!7%!L^'Y7. M-"GOQ2?@584?Q\$JG_@ "H.)
<2XB08\$I0E7"L.#-JGKG38G>BH2X\|ZCD\$XT!
M|3&*O*|^4*|3T_C9#DN'BH7#"AU(O%_&0&.;SKNV0>Z!V;V@M(72%)/,|'0X
M!E*39K|BB@*+.,J|N\6*TPT|_R64H|_R66.-2IG M^T1Q1*;>*\$32
A=/AF)9EADKU"V4YA^;(6OK!7|A&DC|&A:O+P,8:)|5'< M=>1<.M-
#=1|.MZ%R|<'3P#=#E%UX'V_J|+QXGX%TV=E M,P:D-5UXDI%
=FI2C,T84)8HA\$|6^:XT/(F|<1'|7?DPM&A+%BR7<7#KVZ
M'&E\$>AP1\$^VD1YF;>CK(: "U%2IW>%XZ;=MAH^LPO"SYLRGQNE|HG:S6|_
MQ_|"D=%:Y59Q|D|')ZUYIT+,P(5CIQT^5
(.+APA.F);,L&UXQX5CA||9U0)%+K0DIV9+_L7CH1WD M*K\$L%XX0!0V,?'
MRH15:=5P(84C-A>.E'29842,7C@!52_ [%5NO5<0/&-N&/
M4*E#|TO)":F;,"6')|S>?@|2WX6P&,|J?5S*.HR1<@E/?1WCK7G8(/T\$8ES.
MDP.\$XN1+S.A="@|,|N|BE!2U'9U2O>0W?^|Y,3""|&8M"3Z|D#^0Y*<6B\$^
MFV 5\$/+L(=DL&Q)|6SX3*C-M \$OQDHMFV.&|+KP1MNS??
E%:=L_>DE:L#;,: M3@UH55'UPI\$QO^C|)4+|SI:8V(^%/?9R
MMVZ^%BS%XIDN
/ZXQ5.W>.HNSE.G:C"VR)? "25T0WE;QG&\$N@88|,/@5X)6*
M@T(|"F=9;RDV!|\$6A2%P\$1Y_|=|/4^R_07HNDW8?PJ?3: ^"|A+/(C)DX.'HT#
MI_,U;Z(D30@YL2 ?Z|,VUQ(4D|+R_\$LC"E;IXS&_;\$V90.'Y11?"*O#C;
('5|V.VZ4|PS@"Y;X M*8!2X90OQ(|'WG/P(UVQ\$8HZADP^&?-
UJ'M5HEYT/++O0&#.RBWPX&@.F:) MV+\$F&D&;KV&L=")#D2@B.RV-
!HY)|4(PH50RL!)R1H1;F1=*,;\$7C@9UOFB6+>I"R1 |@2U<3#|<5P7QH6C
M4IW5J/LM)AT;JHOY,(QJ4QT3#HF=WAWS*0#>@?WV4PZ(%BK
M9V<(3/UU4I@:D*1^M@51X_F)!E&!K+.?FZOD^,XZ"TG-HW0QB0JX|-*MGR
T MGF+0=(E@_3IUSH>?HPJ?|N>-J"|++OK*#,|);?
_@WD,|=!U.B0WFJJYAU7!6(Y*H7C M;6_12-ZX1O+&DW-&MV?UU8G)9M?
XY<2&A9"5E#4.Y!_\$Q|/0!^YV\$@(X5-2 ML>R*&/C=04_!|"CCTAX/F:I?
+;8#4V+M<=;I/FS|RX!5EV*&C'-"EC.5&ICF MNU 7-H0|&#(B)-
*6(3UTY>6.8L>8D91W1INM@L;EJ*F\$M4MZ>%1T?
P(!\$S|"T2+:/N1M|M*;:U"+QI#-QF@'DY(A %V1|_1 M@BK4^8|)_FD++,'/M>
VHN|^"?,&AVM3MC?>PE:|_B_RB(^R=^|)9S)88|L_2G-8.B_RK
M.BCRC|_704JH|3':!_!YN2%"5;/,|N5FE@T0L*&2=-|L%Q'=|'*2UCR%-W
MNJQPW>#9K|?VZI6.H,_>@?QG|3Y+=5:-B1:|F|#(_TE2.?
DN%?,!K2|N6W63C>?1!Z,UEQ%\$HSC%8:@,(= M:@VY%#O+;4VPDQ-W?
^SW)=,">*B;Y"T%CC_6ZM:#3>#A"C91?
>LE^Q6.B'*B.KD/B\$VJ=TTG1'T0G|ME%.V0|/ZH\MOI.7-A/F7O4V|6?
D7M|9EHPM?GV<|4R9G M/DO|\$NSVZ><3O>) \$A"VYP*T7AO25+YA4/E"1F-
5Y50@R_PIG^9XR:A4.AW6> M11HPVV/UTA3H%L7!=5L+V.ULFWJ-
KNC%Y,'-23I?9:FUR^T68>;J3BZN7;^U MG(LO&|./S@_Z'L|I##KT1|VDU-
\$05ZLM9NC7!8TO:>B2TLU+D=+) ^D(3GCA M2V,AY6I*MNH;'9M-5?G.3|/ #
(F(L;FV%"|IUL/%QB-YHC>) 6>1X \$5?#+Y3E
MX.1N2|/0:UT+J5>S403(5'1Q!#>RJS(6Q-"1V76T"M@79-Q*>\$Z/-,JY4?
HX'<4*5/9?'_\$^SO5M1T*6| "N|?3-62:DN|&OKBJ,S?&>\$2->6Q>Z:D" |MJB+
/|60<KBD)H&/CKLL3-5P=J| M;4Z'@X?/A)4%NRC8!CZK9>
|'IXB:E5=Q&/CDF9BN>K'>?BY.L)&79;C\$T+ED M6|7%CPVF?
Y|U1H8^J"^D)N\$/Z@<%TTTOUDPP *Y-"WE

MO\U*Z(POVGAXDWPY;@@;)"-__LO?Y\$^XUEQ\ MH%5-
31\B_!E\U"0I3(3B4^3GXH>8S,S6<)7\YD).\$/L;3-%DXBGTB?!="6Y/
MZ<:LU81X@8G\$XB>T\|),^7<8\X(>/(ZC/N7!?!4L<29"/J-T'^=!M C=9H\$J
MP3NU=?KDUGD\ M/R(\$*8AN8MMBO B#.M:F^3N#OL=4/?>H49-7^*E-
M>C@,J MJ_S20U;Y91PCPQ.B5D+J"4PI"1->*6:NPK%#M\OE.LE?
R.W#@9^B#?WMV4NI MB^B<-7/G\;;#*O8H?4\UA,>H+KH%D1\|
<0R2D"B8?BV%(@<))?? M_/"T(8CZ1%I Y;; Z8,78.80+QU!//KKO-
9:ZNT\$#.U>*FBM%#5X82>!!!@WV M7!&I#TG(W(@-
O.@YC4%COXM2.KF0.05:6AAU!#&RZC^C8,-&D!SU:SING5+
M_-.@|2/E+A*W-47&I7SJ"*@|?F\$(J_,W;)^)=#ZIU>4M:C++1+|_+6QQ8L#;^=
<&*UA+1OA M#KVEU8;;6^554S.9:2^?N;6=UF8/A#"#?Z,-
O7@W7B*N46*ZC+TR)30>@7_3
M9A)!^)TPI6C'5V"1:2#A_R2MJC'H)ZPAZLOK&B.A*YS=9#2\';)!&M
27\^%LW'J>YML7\ M_"E^1SAB5+U#D<_\$ASH(BMNM.=VYLZ?
NF+!.OKDVJ+,OA1"!?!PPUU&7F M^CXU#UPXW;G\Q5ZR>|T0H"41@PYQU
BB\XLD<_G:<8R-(;+4\$2H32R&C3KN_MDX&B6<=>+4-*%C!2\(&.%\$-
_PY@Y*?8Z@3I8C90EWX^903!C*_8#H*N1.(I& M\5\|%7>4&
<@PG9'IL:4F.H\|&\$/2H4+LA!HS8(4ZRP.>C^*4.EGIGLF@4K5BCC
M\$5<^V2!+\$@@@QK 6+%=I=1N>>L?@%N@*!R
M#PW\|#7N%R*JNK5ZR)YML!6C*'\$AZ<^W9V(L3NCF7_F/&'"/;G)_2.0IG)
M76^R?>#J%_ =RIU(3N\|D:WP^H\MT%S52RRYO%_ZO41-IK26N(>
(XC='|V\|%>4 M\IRBC1Q\$P6"K96TO42IA.I(),RE":<=1FK7,Z4\W
M)5"D^+,Q*?
YL&XS,9*)/A>+QSD8YC&*B:N37Z!EV"\$ERKRP1F:>AFO:S+#@
M"*JD7M=I<.5\|;HAE=|Z%D7F#-!HTKJ%:EM',|NV#UX=P9;L(DZ'KJNYBYW,
MP%P6QC/<7 MRQA(G#,Q%D%&I'>UFY!?'C4IG,Z_091<92E\JVIA(C+HP\CF!'
M4\|:&#U7S<|%|CZE('IA1W,|+&UHN=-N&-J\$B!M%2/CIVI SEI"@,C%"QM^D
MDH%4^78\A'%_WJ5MZG41HRZL;G8#*KQ=4\$OQ;%3RY+
M"^I'OB;V0U_E=X+M\4L4OR4(O\|C9GR"_!P3AAH&7HY\O0C8(3\EW\76'QI9
MS.S@G\&L#F\UB!L W\X\75%23E6HL0>HEHM++F0-L?8)U6W0R|=+_Y3>
|GT M0S@4D^R3U/4'4UY%M.&5!..-'LCE6!34"-H*UQPRF' \VODROTT-
,C,92SV\ M+M>Q_01WEQJRSS\$ORW0U\KNK4A5 HW&.@YD#/*Y J)BR_MHQ
MS'K-00T0'/(.^\$ZK6DN\|48\|+ZW&73A4SV!45\|;V^?13-;K39 MC>:
(&ZU&;K\|%Z?Y"!DB:0D#RTN)+.2-G:QEX\$ _I:W;=S=XN!\|Q=M'W8GPI1
MBNUXFCZV#4@G^>3 &'I%:9HYG2\|%1AYXTO'N>|?
&"G0=4*R#;*LR5YB'\$G-G M\|LW;\$8R#Z2H <:|/?:'9XV+|/L\#R@-
|H9Z.H9^):921:|'\CX)\N:)S M+7Z!Q6839/M^C+8Q/C
AP\;Y/^|7_YK&_E>5&9_%D#1?K:CFS;GUZI_LL9 M\FS+9.WE=D&I?
H<4IC3^6'L5#*N-)-F-|ZJ_)')1\YDD+34^F:XRN)6E2)M>
MG;"_|Q*TV&\$\OY*|8'-+;G3(@-:EQ7@EWM8@O3 M4!,!9P%E+G/2MX%?
=Y'\FR.I-A^1QX=O34)_Y!\XR*C2\$PH\LOR;V
MF7%>T.C2,AM(W_I&|053U(+&C9J4E*S%SE/GN,X\X@7E/8S.*&HOY'\^K\2U
MV_AP"-("2\?D&25_935U)#J;-95MF>X1KNU9I;,)QUM3'-I;DBEM_+&SSM-'
MXET\O:X)5KWC^8Z&8,9'9J2-3\|&&\$3AAA\$^!3\ZSZKZ+A=_.:|FC/B+D>?2.
M/R'"TNZ_'>GN1-3"3OLUA.&P M23?Z@H\|M9Z*|*6YTC=GZ_:ODV\KV?
L6'\$X'X<::O\|6
M.X/#%C".ZC>8\|&>_:|53'.W6"!|**;B21HCB\Z5H%|-2:52F*D9L).30=36-MX
NV*XVA\|+K:|PV^G3?B-25\HGO\A.(=\$?'V@>_Q"IK)QTZ\Y)1@T M-
)%&Z;;XV-23ICNN9^YQ/7<_KOZO'DH2A)KJ+WVWR*6-HQ1\?BIZX-03+0*5
M*?%!5CW\|CASICT(P.\$.!F"Q>@MV><,LO21:HV6Z;|9^
;R3OT%T8\|L\W7C+)<'MQ/M0IE/EL1)>U,61@%'X^T;=@N=7#

MH&3TP/LJKT?YJ95WSC+R8_P0X"3-[Z;%8XW)_ZL,U|D<"AVIY"/E_L8/D6
M!CO&?/D|UYDXM+03121.3><.4>R?"A=|8687*RJT>--+8F
M&V_MJK_\$9R|SY|. 'G7J(I3477,R|JHQT110Y:8JNDQN3Q@SE1_C,[E|LMQA
M|>E#QY45?E!YTB%OF+,13DK7:CU&0^#\$\$=#P2HV_,0'?7HN.(,Z,=O@L2-
JD M\$4XJ1R4%WM"AY@@R> T0!|>&|_T.:1Z? A\$MKQ|H(.=
(OQX|XL(165Z%.G\$X M J/HZNL Z!E&L56:G,#>'|=Q=M T1|E)@T|S(YB
M3"N4@5VXPD'M>'J%EL8O|D)#AGW8!|8F#4,&>D)>H!&NX"BFS'C |T@|8,+"
M&\$96/YV8"LCX&(XO6\$B,_1DL4?!B4B!C8'@RZ*SYCH&F_P!***
(H8(BH&%:@_MX%O6QX#/_X&1@GFHU1A8^2|@6#&-SOH#)|
PXDZ^FL,+/P5&!:X(61C0/XW M8) K0|= &43"@N=N|!LJ-@AR0E@G-^+M1\$
)-35.'^(V"!FB*B48|X2AX@"IW MZP0ECH(0:-
G>4#C&B!)GZ*HR5=+8C#Q*5|'!)|)_?_>R(00*R#,YKM\$?\$ M"PJS|VT?'-?
Q/>'Q*|;#5)<5|+?\$KV0D|&XNMS7BE18OT)AH#:@5#MZ)O+H* M/5|_-
Q2#KZ^VD,VTO3SV)I,@B!1U),HE99WBTBCR.=9:;>U&>D7X8^V=PNDM
M8;TWTOMW^DJ13|GP+Q@-: ?MR!B4<;PT\$JC|\$\$>.94I9T.0YF.:Y')@#Y<Z
MJE'2N|49.'@A=AR@Y)_+""*W(,
(00VHCOC-.01)&OCHUCL&J1<^>PF17!Y.T>8IW4@JC6L,@_)225D|?
ZS5K0>;P,/G MFGROD!+XXR'4B+@|T8Y#*(8XLWKWL,H^8P^V\$|BJ5-
K|L"7X'_0=LN XU-U P M",A|*^V&5';T(DGU+,V9|B7_ ^HNA(5?C
?!+.N6G9MS_1<)>3 8+@ #2|\$48 MJ|K'9'.Z#N--GF_!DE9-M'0:=6.() *K'8W?
QQ&#?_P<1|_&U*N4&7/3 MX"TT%8SUUQ@8ALP,S@X*W4|JP0V&|M-I
MMT/1'@6'ZIX_A;|X..03IF-8C|2'Z(5|.EIQEQB<733-LW2\$C&,(1P_N@BEM M-
&I&)AX|#K|8@%W8XA:KTUL8^ |A|*4Y9|WQ0AIULXYOLB R<^57<8FS M
/I3FJ1>M""|DUN|Q-,F(:RG%?_OCX^|7XC"0;=&!RQ?GU;/KX|WOSZ|KGY|
M>KHUI<6A/SP=^4|4NG\$J)T+ASL_5XTR^R=FTN#"F>IY;Y,OZ<^%#3._BIS!
M|)_('|,JSZ!JF8.7%DC<|,-3LW-R?9ZWPO92M NB+QLK&+2X,*CFBZ.,G%2
M?_IT9"67S/4FCE2P|)*01SN*|7E&:AL*RN|I3YQKG(X=B MU*E%'9#1&
UA^RL/+S'SFVR81+)"F.U1#8IPICUW40VY*Q\$X*F#\$XR\$5&I!
M(!IN,7@R:X'|@.,#,YI&M.I3V| F#*;4F@P.,+\$\$H#|O<+.G#B(4Y|X;6Y
MC9.T|8/LMQ8L TWQ8%:2Y*T7AFASCNN\$|ATB:\$UN 8: M7T|O_T)^NHY?
C|@/M@\$A'FV\$CEH@ZT-#6;RWS1V8%S@+SX"|+\$I"-?HI2DG M3?+,U-
XU(KM?*+Z?+_I,|5O+X@%=:HV+4TITE>#?0EU,0D(,(9:@>9D(,!E M2%
<|;:%2S0(\$C54 E\$T9++60FK|H7JU|NR)?
\$M6MV:20S3U^YRZ&..9*|7M"8418@ER;_%B1AG'8+&B=J:M'/O:US
M\$5%R*VADS
V#3!MI:.7,UNE"D)EZ!9B0YZTV7EAQCBAH/*AYA33ON(X"3HZI
MHZ#/?:*^BSY1:MH7IZ66@LJ710T!KZ'3EGJ4Q:G(-5Z)V@DBSJ.!F69 |E|
MYP0*M-|:1YJ PL:M|NH|EYC1S!B:ROX-!
(N8J>:!W+O55BB3!3&7+KGC&NM?3WZFO M)5SA-X4+#+@ 9'78%#GZE!|?
QU4'D)62K*I&:% MX_#KAQVWV5+*!&_R|KE-
AS%1K|7N\$MICZMHUVGZ+,N#%2"CQ.[3S"VLXCBZ
MM'T5ZC(LCF)B#*8S>-F7JV@2VY5/7;I%(*/#+H_B50EQ'%OZ+\$I=;,=15(#F
M4::U?2 W?!Z+EYFX|B#C!X()JB%Y#C: ^G*Y4;LD3X""?BS.J\$83Y-|J8S\$@
M0;PJ9%38Y35CVQLGQ)*><-?4L1Y=|%EAN(^?CX
M^#_BJDH<_ =F/#S|4Q4%_2+UO<10?SC|P+-T%"47S":-Z^'/FLZF,|@MRX <&
M0/(EH9G1-T1E_)KX9#BY%^P'*O?3:(MX@|)U?(>H?9:@|,\$+<)>X,QCZ0#4X^
MT=<&;<@P+PB3/UIM47'C\$9!HE#.*\$B|CS|*_ =7.NAJR|,W.,?WAXA|J-
>@F2KP|8H4<:R(*2|)(4| MO\$.3E?9W)^W&S4DUKO7BKO|Z;9/P9C&ZBXTU?
Y|>8_6*'FU|L=^N|U|D:4VV MKD?Q^2OL6>_ V6?7SMK9YY^_#@3??
SLBGRIX,:V,0|MF37R|Y!NX:B1/1|?R M# =A%|IL:QC<3&-
=\$X1#U21KQ@W:1R+PM,J"S NC@BPG/5VAE/|@OYG|_UW+EY MM,_"3X-

WFIO'O+ #6G+ #< < %*5@U4Q"59W;YDW5#+!GFE)NQOCV^2DGFBO32N-
MU1X7\$, %@>R>BTT"N?1C2.=9 D5:W;(' 'SMXDUQA(I\ S(# M0\((PV6Z1UA-
#8*1-C'+5)\$BR6\H"-IYOICF;/DP!!6)4=8T596>*J3,Q;L2
MW^1WTU%;V\^DUBXM%W*>VVI#;="MHU_ \!FH?;GFZ/D\
<|=5QUJ<.=G>;ZS' M9-
IF/9!;O4E4;.=!U^>^0@^E9FSP,PZ\|E8IB()SX6,C^NP%\WFYMG0!@K\$X^QN\
<@W;:FHA2E^ ^"XCN\N:9G\DWLLH)UGB(Q M\$C6&6-^H ?/\G8@>WBE,
/6WZ5Y2D1%>1(+<^PO8VI:AMCG%GJ_:)0-B836B2 MY8V&M'VY\5XX?
JZ3>3V%"84RY1/V", \$%.-NX1/OMM-"D?. F)MA=;N_ ('GRR8G*
/SKE0:#2:TP8S_RP_B X M.M.,IU2U-;< J.?#08?2NY%3\$B&P(-
Y(BWL./8DK+#2N8@7=|OWPEUS?3-<0 M-
%8G_.)CHRM=:I5(*1JWWK'(/7"K.W*"TH0?F=1H0^G\ (11T=9)%\$=BO, /0
M@4A\7AA;K\H4S*WP6E4>GZC@FEEHTWY7@9\TOND56\
MN4\|R&&5OVB<(<)X, /V21?NA*T38(Q=^/%YL+(AB14\ /2-FC-B+QIH#'X'
M_3UTJ\$05,2#A"\$Z@0(LKQXCI*^D4G#0^TX+H!9F;CN;T=1;+_IW>2U
MU49\|LH0Z*F34#?=X3?Q239@0:6\T5T9".(Z1<;ARAP +R'BTWZ92X". C+3>
M_,BR /W\|O73"9Z\C" /U\5FN7.-ZPI#EJW!)D3,.0:YONQ;D5Y)! ,4Q8:
M\AG3,"BSX0V=6V:.3IA75+2E1I?4.P7+,@O =KP\TC.?06P:4ZV!ARU5Y&7?
/^(
MR*OOCL+XR)HA9=N2)A;KS+0&UB<4(>R%9&^+S8\$|W4F*/>IMT@%,;ZZS;
=6!UQ)!H_.+QL\$"0JLBR M&=HZ8:KE=IG-T(H-D:PS?MX?<;:6Q5.A06+145
MV%>8R&Z7!=I%U7RZK>6N0J_UH GT<|U7 \3TJJ4P*M\9;N-
U(6AT+&|2B MQI?(|+F C)\NQBL5<5-
)3@Z8I3IV(|FFQN"C7*2.3_ ^UZ,C5G_1
M=R\|\$+*#!#T\|D:P\|S=2P=\$IS4Q59\;FV#C"U^BX(3X0\FBK6%\, JM;Y'@=0
MKL4KV1;\$6:2)CBY7'VBQW*&@):_4T:>:98_T"H-B'<>R(OG"|=9 *%G=D\AT
M7',16SKU28?
NR:YP9:_\$,DR27'P1KE'P50H%DMGQ#I>>82T_>#HT;##5^2?
MR&,9H\$1FO>B\|-"|6*LD&\5)0SP8QB58O)/GF?+V=5S;:MYK7'8J\JNX2)7Y
M0S@|718+#TV9>QJ4^AB5E=Q*\$?4I\Z"D'U\|S6UJOS\|D1?Y 76%\$%A.+(HX
MZ\+X&-U_ |Q%EW"L<^PAM\$G+DR^W: ^|:E\XD^|<"MD5.-
^3JSZ7E\4!FN@W=4 M7='%&_6"^JD +LD\$0\$#<;|?
(3Y<1PVY;S%^F>Z%4T6DI>_U<^ I,39+.X3AG ME200J?
JQTAB#+D.:R\|\$M(L!* P/4#&P@"&?Z4QK\$%&8L,&9#1HUOU4 M66TX1N\&
<8%&@;GE7X>OM,Q\$COL^|/#C&1%4|+?I=\$Z^OPG+|= (@|1B\ZCIH-
'(D*FP29GW):# M\>I;J;TAWP21ANVCO:"# =M&+H98'\$/S7\$Q;|N,!!/F*O0
IW\|JF\|H=B/" MZDGW-%^OFS/TUH MI I0U9ON; '#!T)(E/PAA&*',
<7^K+F.Y\#V*)!O0^#!SP3>3\FBSF0B 89PQU" MV(8TZ0R(;?D-
<3Q\$R\$18,1>V(2,'\$(\$JQ", '#?6M/G;)\!<8LW:WMJDRGHN M'&|/D-
CJ%BBS:?.&VC-1U#IV\$%;RF1!&|9HM\$0V E!
MZA*S)W/#8JP+74;-8(0S[64"9XJJ]+XVQ\AC,5[95HQ56E.@73C<=KDJ6'5C
M+8)>QHZ79H-;+PQI?
F9\YR9(,%AU\K&618%-7H4K;27VRUEQ.T4>O7X2?;& M\CV*3|+V\$?
K\Y,QUUA.LLGHT#%-<P-DL_.R;.:|:&T@\$KU?L=Q8T(<0ML!
M:|S_ FHS3,AU>QFSJ.G1H/\$PH-^>HX>#!EV+!*2:>L//9LI80>/&F%E>&HxD
MM^-*4*!M3RA?3|B#QD5^LY"B4M&P2ROI=Z*POA1QX(&^4!V(8\G4(G-
+H\|C M0_LL;1EK(,|. ',0WB#JXL8J9Y""QAD) Q."@+AR_\$2*D9<<X3>@_B4
MA.?,3' =+|/ X###94Q"S+)I5\)"F3ZA\1Z*UT^1ZC)&?!38^!TFYO=C\ZY2D;/:
%+F=0&H M\5^S?4\7A6V\|@NE, |:O40%:-F580!*Q59??11YY!I5_/L%'6-
_,^"TWCD%KBK5K5RO<)\AE\1'6+E7) ML(0HEHV&\$+;#C\$;J&)ULF+TP\#
(K8.4%F\?HUCL&J1?6-B@ 06.B-!:>:%9# M5%7Y7/C^Z7

*J9QU1P0_/O#EUFM,M%MY):!(F>F8(J'@ G4\VE@JC!=AJ\$1 R M\%UZ6?
145#GT@1D9XH-#.DH+HX\ M70;'F8Y>Y+CS97B%@:-
VS8Z(#HZ('V=/Q.R)&,,38:*X M*K\!JQT=EPDTQ\ R ^@|EMK-
;FW6\;.UNIX0KRTP@#H+'|O5FY9V/O;.P%Q8,\$ M0I2CZ)G-
O4/3Q82|LERV^5Y3'RW\!KF?9H/<;) #&1H\<*C3;".S:".S.O:Y
ME*C\4V@|":6UV@2#OULSJ\ 74>4UU?S3CQ%YBZ.,*?|6I'O"E-),3|&|RAC
MR(1ZO06!GY&(+7J'2PYJEB3)4?Q@HVG_/)W9NOM<|Q%WBR3^AY.5*L
BC|
MG:;)R81O09NVD\$R:9_O/'SW'T:YRRC+ZRRW2ST4X_%'3|FL7@^U(J7<>"@!:f
MZ+QY3'*O>E.JH*PL 7I% ^#U+S2>RW ORXUVFO,BR#T;_K-
M.JMGG,/L[X<' ^>?9@SQYLD!YL
MAZ+E9|_UE3H=YP0HU|V,0|"A6R_9\$ _R\!QM:./5+0O&Z)'JEQWKG\$|Z+JL%
M9K# |\$F9/2G Q&6(3H4K=*+,IO/9= Z*.;B;\O7=VLQ=M/QVD;('V'DN!\$F&
M.\$+3AQ_NZ;R\$6DWO(T+^V,M6H77@:46/Z-T'V_D<;4;.X=6N2I#=#6'9%_?,
M% @^V_JCIW"+| (M>W-J.^2>)N>TDOIQD9W|7)Y50DVI=*D_!61+_,-:)
E*^89_JLOMB7!#JE-5
M=/2!:"E\B+|^2|_T>#RDX,DSA&I@|=U_K@#9%-2T0.Y45#025_54#E(K*U;
M=@D>E1 ("=/ 1T_VW0N9HYW(%1B?"9MUF7(E8"|V/SX10%?>F2HXSIXL#
|92 M_'M"7H)88>3EEDB&;\$9=X(<.HA|;N:Q8Z0Z\$7=@LA3?(| 1Z<>.
('C4BVF.- M|;H%.@_*N_SYS&QO: ^|;,:?QGM\A8R8-?|S%.UP@?JD
Z_E%"A\$Z/WS9Y4C'G MW.:
|SIPF#|9/<;SY"*BQOS(M0(=&C^7HE+QU!^8N3)
|E4+MIXBL1Q6;._2.POAXJ!_LS_AU.3+51EM=IPT/!*C/:6DOJ/* M:|F"|XD(Q44
1.@5_\$K>|L41&"7Z6\62."SX/ZZ%>'5JPG>&>:(TZL89MI.=
MLQ\M;Z|U+'#W6(R9R^Z8;%I=/D_V\$D(:1JGT*^|_R)|&
2#UWD%L4WXC.0/M M=974LPYSX=";:X| "BS_?#
|)'VQM\PH3+Q<&^9RY<;G)AH7V5^'|>13.L@:\$T
ML')!4/")IUBC|WQ|6%\EL8="Z:DZ4C|X//HQ%;|X<3AB?+(Q"H#>|G-WQWR
M*X0016|&+-<|5A_&"12":(HM|YZ_AX+NG#Q&G<|P#U3-
TZPP<@G@GT!"J*94 MROT(WXN;J&B?)/20\$BVB_80B,BHD-+O8'((H2%
(ZY|TY8(6'.DTNT:735XOV MOX|B!EUT,.6&>2/M;|M|U42;+L=9E*FDKY5
G)+-L2O92OBU6,053|)G^U\$Q M9+Y)2#%K+DUA4)K",3U_H#I#4
HX6VO;:21% AR1F V!%)D|OD08>6'P;|3Y M1QQ24|\$GHKI21"RC5T14|(S
<9"0G^|(/Z-=EO!Z@|8Q1O6X)\$-9;3)_CPI+
ME_X>X8Q9EM)\%LR_T_ ^'9XV3.'Q MF0#W0J|_%_7:++?
&Z(M0EQ.B(=" \$*#95,1K3&1MY!-'|B"W&*ZBJ+\$+AEO^MS' M&IKH|2-
4^NRE| :>EUOQW70&.V"O)9>&'4%JMV?0EC'1)10.PME839\6.ZOG
MJT+'#=@|R^6ICB"UG^A;J2&5\$,O+%X9NIC6@W6U
G#S6)C"&"U+9_O/JZ:- M1_O8"|4VM2IR(35=Q6I*W/0* M\$B>W;L)-0+M
\$DU=|P+Q%A@XTJ" _#?0RE*#WFA;S.3J;.OG,HN-JX5;,&/J(.EI7+LS%?
Q%X6D*;%A'LVFI.'/R*I M:8-
|'K(90^|/;7C@;:%\$YR1J)=#4@<\$FFXV)SG%"7HG"\$\$_B@/M4&(4>MC%
M\$Q'(\$!(4QSAW0GQ4""=2XX]?P_HSZ%R'V'!)|>*7OB6SSX4H;1R_M_JVL9L;(-
=@VB.V|6=3#E/|.;QTH,\$4,PVS:\$5K@6-4(RL0.ZT&438|3*(TV% @>F\$'@-
E31\|)^ (5 MI\$ ^V*R;:MB739: "K,L;NF!!*'0TGPSQ@@ "1L_=EGNM(*
<'Y)3"EC< M&:Z(#B8P\VOBRL 'F1*KAE;9IPWWJ+M6\$Y|
H.Q=!*P,LWZ<.G/A|9<64)K MM;|F|0Y#SX_VYY;|-2;
MEA6!N@ZH2T,.'=6KQF|D,%3#!H|WXK.!R_#
MP4B|-2|\$|YAO@15/@%"I56/S0M*%*%FH0YHJ14X|)%HY\8521NM&\$*|9?
\$4|J_MX4|;/G>@+Y_Q'LHX*S+K%;TCQL|<|&?:!_"??
3HH@2:#G5&0L>^+V6T4@&W;!K8*?_ ^B|SI1*,F(63;

(L1XKYBT2F%\$Z")E].\$<()0<<+9ZQF/N"#FY M\4\$]*F!/_\A#|LD>HZ.
(3+W,Z'8|0<*W|\$SH: ^|. ^6.ID .)9CU1^Q,.9G) M<\$+8.>(*M&!\$N>|I-E!
KN#S%|0-A*X7*|7J5|L!QX!)2?K!7>QBAO@9DRJ MA!L';A28IES1?
Y)4_A9!F(E'^9YL/2/-1=NEM2/-C1GEFIVIS3/MR.K/=76 M@2,N-E++RIB?
=5S+||W|3M|X2FMD"LL<2-=A ;0^,[\$FAC#I4#-|P0XB|U/
M0*|4!7N6K'WD)N(6R* ML@Q5OX&.I1XMI Z;X%&67JRUC@, @-QA39X"S56"
JP.,S>(:??D|)%|K>R|J(M\$/EU'6!AMPKS"-J_3/IN(H*K3N6MQ!A):C>@_B4A.
<,HGJGD1+NJN5(F8;W M>#AZ?DK5&HR1G^DLST%2KISD|/ 5VTU,
(.@Q=:9-%3)^DKJ|1L.CPKD>J+S: MS-"SWJ0U5YI=J.=L2/K@;?8;
()LTRL6NG?K'8/4"VM0=S41 P58IVDW)|(!
MC!@NAK+U<',&SMWJ>|LNE2\$D(
)%+ID6=Z|7P^P%.&BP(7Z0@WJBQ5ZV:E;# M!4CHK:\$F/I*_ ^?
-2U#VY_ ^@>SS|H|Q&\$3;F/XI_T,4Q9D-F?V_-HG(AE0B M^T.PR45@?
FV|!;VL.S;TYEP-R:WPBP|\$S6!G,OGT^&-^IW8D&1Q2OG;,|"2#OR?LUT?
RCJS)7_XA^3TEJ1!>J)?^H3CT|8F#|U
M|+^/K*SNFBVS.6&V+;+I(&3*_/_Y(Q'MR5+>&^UPZY,'8^N%1< Y'X\LOB/9
M5R5J%_G< A62 0UH4IHJ.C(T|-|28(@BD)6|R^K4YJS|&='C*."1C|E VJ3X
M3_2_DK|O8NJCM
S62Y!|I0_0E|A'F%Y)>@PKHH;XYS71JFY"QI_4&;6/C_Q)"GMXA0&'P+D04>8>
MX*|(%SAX3^FF":7A))" OY+U4+/+'PD'^36F)AFB/+|3H@S(:LU;V(3=?|Y(
M|"_*!%_P(?|/((')S|3L!-T|MW5PR-|U7|/V!R^(M0K(*R74P=09"1+\$>C%W
M+G%*!H \$J*JL%>RB@(BF9,=YN6C;,)D^?X0@B3R*Z\$:3DDY-
IX&3>!9AR\$*2 M^<1?M,L1 M!3QJ*(1&4^J8*,"PK6-PS_0Q(IN.,B\0/=|1
R&^::G'3B ML=',6U:L20NG);FM*T/75%|#0W,^D?+D1%>Y9E:|@R.>WD|#7?
QSKZI-A-PAX,D_DP_I'F!Y0UNJR"" 2 !ND.) MCX-C%DEPAG*+*Z^D6Z">(4^?
LH#N/=F3VH M5*1|6O'_OC(^X4TM0I2 BI6B?
W):*>&@R<+?!X3/EHY*Z1!W^*^HI%9I*N?
^"@4^#FB#*@@@Q*L'6'0SE|-74OHNCD MA4^!3P^2@8"H!0X|(%0)|I(A8-07-
:AE88E+-9;|DSN'R/ISE KX\$K-HL"+2 MHS#|Y7|;EG)C!!MEICHZ@G2,0P3.%
|HS=M8T M|: 6|J@CSLMG@A1+%D^OF;WA?\$.=(R/|&>#1,<*<
MX2W1HR@!Z;F-#2: !/C3:4>X^!X%ATJ1>@K|)I"*02 !TS+52QP_YG9_16(
ML4:E8;Z;.=|%;;S9!V49R9K-9V";S+@.&K@,Y=,<#/+ \$JS ||EZU+"Z|GT "
M822,\$HWS=\$#4N_:"CM3;TDVfy2T#3Z:E72IH)#^YC5GWQ++*R6-
4:ZRSW#;* MO7#"IP=8")X _!|"E4?Y5\$Y-6OQ11RKSE"0=X-
C113,LMSK9#>;J M9,6?7^ZZH MX=({Z?
&^43=/'IUR|B#AGD"30=,Z<<3YR2F 4>(_)W/6W1?^#A(H>S_/T;-
Q"H6YK6(REXSYSO"RN+ /MZ(/|6AYWSU4<4@ S\$R2AZWV MJ^\$D1&FEC!#
?90&-"0,?(POSN?58XD\$#|
M&&U.|&|M+TW_A4!2%'4XM'IL,U|+Y7*LE""Y|=E+J:A|7K%OUUT5IC,GYZ|J
M:"0J(+ /PE:LDOS9TRN%U4*'DV\$Y6">2+/CJ
M<^|PA9HS/GR1JFE3J=A)I(<5+'5B7_C#C:4#=
M7C65)X^N133|XI_D_E,KB|HZ6D6L|UX(#-'HA.Y3:
EL)0RER|LJ>M8T9,TC6;N.!DD-? ?@^P5D#|8
MQ1@P|UWY2)36L5)Z+GJ5\$1;W\$. DS:/P:>?>S:FRLG68Z(|C|3%BYYLD1.U%
M'O;WA*IK60J5P44Q# K\$2C)X(\$+=/T|1AF#F62N?V& "R#MN'DBA?N<|&%|
| M?@&>0599+2L3#YKV94(IYD5 MB6->+BUKZH'N'-
PH45=|N87!) ^"Q"UDQJ||WR7^(@Z5TXZI WV1G@+" 0@2J->V M-
/33)FZL28N@=8+A)+!LTBB-)7-Y=,J *:8"%#*+*UR_?<|Z|Y*QZ+!7#X1ZY
M1B&W8|MV:S %Y"4OZ/)."RQ3LQYBW&C=U'2LZL|;E,*U;3E2X|V.|EB*|?G"
M"+="X-=@=O<8*5\$K_\$EW-,B;7UW8RBM7=(V1A5J;SP,)_LC1#GF">O)""
|HF M52N&R3|+|^YE _>D2(B|^OP&TF'7M&E"4|3E-*S-N MXG;|T+1-

1J!7B%B*N 8!%#@#UT5_?78"T:%F.:%>)&ME)I9(I)WLO>+P@<M%
/Y4K//AXP*XP\$|V|M(K>'W^9W(R|_ '1_ \$2!8X:B?'\$B"5S?JG@O|^6W\$ZE
M3AFOO?F/+ "MC/= =^5'\$AI)ZF[%6U&"FI(2E 3@N?LN'HVV!%R%G;1B.
<>%E M@_ZIU*._\$ZD%+-+D9%1*W>H.^M_3P\HXZ:71J07%O9S!:&(6B9-
D\&)L0)L M@G?0SKAJ3>1&>Q*!=#BH"AZ'0P.C_\$Z/,YY*=4R_2!+<.P=S-
E[4W+=RDZ,MIZ9,!R,/ "Y|P):J8O|,38P2HS7?|M,%YXM"3J1G\$9>Q(QZ
6ZR3E"W3|3F@R|JV>2DC?G M|S|<_ '3QYNS#Q:_ O_GBZ2=E4";:-
_/, "O>BQMWPFF17*F8,&UL,#>|-G/UK@> M^Z7_MM|C&5@O\R7S!??
IYZ3H"V4D=-"/5>^W3%_W3DY/GZ^8Z27KY&'T|+,+M5O_9,_LS"7,0F
SIV.\UMSB6U9*|YHYF='L)V-+APDOS.3LW,%N_15G!; MHE.UEQE7F-@+G?
5'^U3N(/3C/ON1.TP@IJ5
MD2*7FG&J9+7VM@9TEWLHL35*,&IW0I=,P+#G*&:8)-EMQOV"-
U%Z"PA/%|;'M/)8OK"|;I M900;O>QUL.A:9VYXNX?C+D)_T6+X|PAY%K\$-?
0\$ZHP)L|E7H:T M7C!N(0 (2\$G"BC1#!"U\$R5=0>
(D5F)UI0I+UT*Z3!E7HQ[9MT9%)%769"#P MMF, "'!P!B,2(CO-%5G
!/:7:&)>U|K5!B>,*3X>D!' ;5X:F(5_%2\$O76\$<'4 M/J.ZUP%V!!KYLK6A_)JA'
U1G.MP1PGB#WOZMHO0^2%|"PY|P%R&Z?)NH/5H M)L|X|;97H2EU
@B:QE*RSDI54AH958K3K,"AA6<6/\$\$U(BLHTN6|
L\$2!!SAOH@|H5Z%Z%/UE&^ M=;&| ?;MR^36F,=Q@HM<@C)W1G.:#
|C#84"\$EO#-K6BQANB7?"*5| \$MB#IO, MTL@+L R(BX/FFFB'\$(-I9|\$\$5-
6V0L2|P'2RS%@1' C4> H:"8Q"X.,3J&A\$
MD0C2_@AN"FRPLJ_A_>Y\$8=E5%.XQZJS)'5;<+Y%7%(R1^ M
K>YP:%7OG\$DTMY8=|4GP@ULLRRE|P?
FU4F!BD+"0B)'H96#A#O6,0=31+X M27R^';;P5RTQ@#
B:YV%79+#_6IP1ZO!,X4,\$;V0B\$1:GM-"Y. T&FXP-6J M;
|ADB;WR!C#|!ZX;MCH;?>|/@F0S0(J;HYL*(Q7V/?832&:9D|:N#6XKYD|7*^=
(40(+1:='J("0J%\$7(5M^P:
MO3C#2CTS:@8TS6H^;7Y|L\$UMA;)29@GX=%Z86%#Y-
7@C'A=&M)_@\$"Y'17W
M/C.Q.TRL1^G#00G:49V\$O\$OIN,ZH.2M#;M#1&8R!Q!/%E|A P987(\$;1RG P
MZ ^>MPH8B^*5@|3%U3.TG1\$.B|2VPR\$?
=,"VUFDM'RM.VNHW0B@EKD|/!'.G
MK_HO7SWO'NMI0FS/|1QY<8OJ|YJ)_V7QU_7X&G_ ^VT|8M=|Kf.%1
R48D MS3%/R02GA|LT_ \$WHQH;>GA&K0K|>X!9!O^6AJ:|!-&
|/#^UL\$7|K>8;T|)UAR MAL<|=CPX?G'ME-2&%+0'SL)0&/2'4H|>?
5>PNX) ^|!' ^N\$P?1XR?%-6&|)!OTP(OPZA?!Q MI>YAE;HG.3CN#CIZ^?
3B_C|JL.(L M7PD<)V3>%A)R=+R"KZ6=0|FODK4|PY*D932+01T.J@
M7YUWPCIO@.4X5R;Q5Q)ZZPL35)=Z)*2K%%^F|+1|W:RS&))ZPYMC_ZL=_8
M6@RZ"6BQ?Z6L^TK9ZL6RXHIP-!Y+|=|EU;;7/-
A+^WE^!:R8=>T:4)3MN>Z0N,V|J MS'CF)DW3?.A7D%R*.(
"X!ZZ: ^_78"4:%F.%><2V6=E)I9(++ "IV>+!Q P M*5TE7W_)B7P'#_9Q DGX?
7EG|'9>'@Z.0F/*'#22DQ2G2^9=4L)_J^XF8J
M5,QXX_0_1%5KX|AR2"Y7|'0F5PR*.SI)*J*
|N:/@3%=;:"B>TB@U(|L0,DE0O(BO^)H6I-CF8 M"-^@GDG=J2BT|\$G(9?
Q056/8.YNR#KKCJ9%/M MG*|B4>)@X2(NQ53%\$@I':JAZIVE>"@>1K7D&
<6T@FAM>)SWU|ZI#77.1NS(N MA(LRE 1%2GYX.?YQE\$Q.J.|KR4F_ |\$+?5?
NX.7HH2X:ZOE-'S,MM8E?C/R_ MY&Z/YR%NJ99YLF';0|K@20A>7/Y
MX>/5VZLW%Q^O?GOWQ_,RK9,L*OG7^;HU8"|YXUD_Q8.|_2_96"<*);;E=S%
M7Q*0K|3_OM,HNRL7OQJ>GYV|W%37"|F/3S\$BXR&|8B6?_3,P\$S""(A+/N|
MX09'KERR#T#S)-.*O=6F8N-1| #O3!;N4D_.|JR4W%1K5.)%Q:0?L2F7#Y!#*
M/A^F2_<(L!Q+!42W:M|!QC-,5AYB-J0AQSC8TH|1A5Y\$(QKI:L4|(^

M((E&H@#B5".8O#KKI0@(D4J@0#-MU*92V)+\$2:S"
!\$H9EIYS83.I;8/U2+_1,B"I-CJ#'%];=H3 R0&1&-
!QN#0^/X)C7W5\GH>G\B(:*N 8&J?4=IK 3L C6S965%Q
M0U&!BLC/3;BC!/&' WW;A^O\F/T*%FW 6/KIGZ@#6@FSWAC=Z|"4VH*")I6
M4YBD=6.P 4QM,V%JPD0I4+X=XO/K5-M/UV\$;:!'8SM)K) W:5\$Z%
M,NVF*U M%#EWWM#4BEQP(!@!\$;B\$GT
4M=18FM _JH+6>#/CTJBV@00I3.56JD="*K)&<
M9@5TRQNQY@E8(I"/.EG";RF0(,8,ZT-^2-3I<#W=1/G.R>X6V="/DSMC'L?)
M3.0\$96ZUXC0?<(O#@ @MX9N;O,,;HE_P5\$CAEL0-AZ1\$7!LT-T1XA
M|M/.HG6H;DR-B+>>Z629-KDWP%/C*2@D,!*!CR50TX@B\$:3I=PX|D2-F?|
M[WVXGAVSRQF7C<|T%'LH"J2F8H91LULHYIJF)"ZP^-VVNGAC!4QI=I
;E/= MN+M-V&5RX2MI(.9>W+|68VFW)O C%\$)7H#T)-7Y Y!Y.@R%?
0V%|PYI-7@AD2&B%0*12,MS6NAG A Z+1=8K J "?*!%7?MN^!> @S+!"S;2<
4VSB_D; M7QI,FUNAJJ5> I;.2QT2*KI!;X3C_X:&#!A4.Y&Q8-
/2.P/\$YM>.KJ0OG\$P M)R+K8CJ6TAMF'U M#%UG^*,AH6U_I<-,)UV6LN'C!-
W|5LAE,I79V6\NO.??_9A+3^=4=X3EQ^ M1|WQPZJ|&IY|4WUGY.?
=JF)7|QF-|8'GSQ"MJ)HCC&*4IP:KF/_-Z(76WIZ
M1HP*N7J+603|CL>COO6PN OKOR+P8O8.CTU8WS4%M"T!TM M|+@-
!P+E3SYKF#W.?WD/?QE&3|-'S_+JRTG^'9S;'6F,1@U/*_1-K'?V)A M/;\$G_-
*VWKB&23!KX"99YGEJ73C\#;Y/VGE;H|IG8GN50N_-I8.7S|_O_M_-
B/P|.OG _>>)&3?E (*|G:U _1;V+-_X/;/3AAY0KUS|#Z MK(+M#UV_*F9
S|HPV8O^UG?|%/+38W3NH=MS6YVC:V^9Y-92(I)"T'0.71VT MJW|=O4(
NU:HC>59(FT67+ZZ_,2&5P<+!\$2:\$B5F\$#HLRYDQ0+Z-LEID(A?
%SAT+89=/'X)0LO(Z|8Y\$XUD
MX+_>9R(NI&:&21\$IRK%AEQ3T>VW0=KT431^I%,,;3I!.-PJ
P<6669V01!;.%K M2W'.^#*:L)QJ=\$87Z\$+F6#2"4VF,S\$'6T-)XF+,9
%HS+)K5;W 2R:6*7@3N M)UYDS%!/;%SBA4:&HMU"XJ.
6%8FIY"2^9=L7S0%;%HR8+\$J9|1*0I,+:,"PS M-
F4&52ZQ/6R\$6:BQI5U\JSO"SM>P|O9(JA4;8A+!L.+R>G)Z:_.1V=H?/W
M%^/W_,,)FHQ0>(C>^V-_X*/Q<.:P^Y^T-INO|T|C3;*.?TQZA^/SB?#XU6/
M_?3,XQ-O4N5-<(!&)VCR^Q"-^Q=O^V?#L3?Z|,?P+|0?3&Q+)P@ZV^ P-|!V
M8A,FVO/WN|V7M^%^4%7D-+WW-
/5|W\$|%@@=!\$SM!HP4S&3(91>_F6\$%@|26Z MH'9!@*#Q1*HO7I2=(\$SB
M@LJ>A<&=-RTG,P06EP M!"4M=(PO&'ZG): H:!'S'_VF)%#
|TS_V6VB0,0KT2S#%+F70*\$U9 F8#D.VJ M9MMRX_,E@B;#4K"XA8JYTG-
862\$C5^>7>NC=_&(Y8R)A*,@-|4;(9E8--,9J MB@75WJCD=(GZB;\$M-
K,L)^S4K-R4:M>2,8T^"KF 9W1Z'NR;Q.2|6;5!V%;
|HL4V61W3X4_9XI_(X\$U#T@OP MVGJ^99LQYPC4H%|B#G&A"P@%7=6LE
DL\$OL>.B1N?^6*(DC->14X\$BJLP|2W MJL._@>G_
(NCQ_/L;98&3SF|N= VK'61W7/'4ZE@_G%FV TW<+ #B'L=+.3?0 M
'+QL%X,)QH6FD:8"!T|09#+?MK?IV.W4P0#7HETS#-I0SLXP:
M_5H(I\$@C5<'M'_H'AQ:NM.-A;:LIPG"7;A-OR!VJH7^X=S_-KO_ZOICW!-SS
M7W^+)GQ1MT>S/NAP@;(VF!;@*F^J*/X8N;^>?;%FP" _M.@&64'7H0MQ;Z
W,
MCKM" _ACB+T)G|K):Q86=:A6WD@AK75"?;E79\$/@A\$_'6#P7Z&NFM9_AV&6
MQ_\$ZM6+|""(|T&LKL>-4?Y^
09(SLB6N;6MVU->_JP;FR=0%A|@BIYDW7N2 MI#>#X?|3"+?+=3I+W::E?
V7ET^/|LRAL&|&MC-0|SJY7J?|@-B&H/AR?G7/% M1,(*S#|GM?NE
@Z?|HCE44Z@'NK,Z;,P;JYH)!QK;:O0C'I"\$MKH@%WK;W"D M,"-ZA*GJW-
D>\$|US\$1.F"XZ7D6UM+H>L;'F86'/SX^Y-BQ=-HA.UZ."K+D2
MLG+^F=JQ@?_7??-J>9NP5F.N+,-G5FJ*VF EW|48;K.K3O)L-,)#5

M: ^?::G&!4T-5A/D"+[5;9/3:JH/T;->V]T2^A=02P,\$% @ "HAL64||M|NA+!0
:B0|!E;&1N+65X,S)?,BYH=&WM6FUOVS80_MY?<601(@\$L M6|+CK)6|&
J|8 &*. (U=H/M(2Y3%E2(UDHKM_OH=*,^|B7L92;G1|^@EU&2X"?T#:#.
<'@T^>9UVL|UK58_(T%IR|'8R68 V"TY_M>YX3-64B!%(:^00+"ZD,\$28J2)
(P,0WA=3&./!4RRB;9B:\$('KNM"3LLA|C
MB|=\$0N>AUXER)FI.O_EKEXFHD)H9)D6H*">&75*4|H50VHU2U&.D4AA/LR
M#/S"1!4LS|@B|"-2TG.^"+(DA,PT)1;Z9(4:F;549,)\$^B&|B^"@>QS%AB
MLC!EQHN1DPJ+83#/V(09J\$)B1|@*6%!C:15W#4?
0_I:NVR,2HU;JMB0DOX.+M|>G)Z7%_?#H|@_./%Z./_.;QC(<00(:/S5'SN
FCP;&C!IVNW|CMN-V|C+8J M:/T1|+
S|>#=#^L1^QF9QS>|+I4W_B\$,3V#|^P!&_8NW_:/R!M^>C_X_K'
M8TMI^_Y.M\$#G:#NQ"1,>-+N=SLN;ZOZCKLAI>N|HZF&VGPK
!T%C.T'#C)D, M3\$;A0TD4)A9?P 6U"P)
XHE4.02^|P%D"@-.\$WQWGA&5(Z;2L)APW8!3\$3=A MSP|QZL6|
J0=Q="SS@HA%J9A\$^Y!*Y7045#&9 \$7_)C"BA:'YA"KH^ U,D/8! M\$
TI0S57J\$8T+A4N)= R(A(8S.,B"D%5)\$SK:T%^&LY\$V(H9%11A'H-367.
M"DS#<9<(06D,;!T:<\$Y*#N^9P253-XXS1E,X88*(F!\$.PS1E,8+\$8:W@TK:&
M4S59)(,2Q%? XI2Z1+746#D^FRR=+2;3:R%))%H>*-O6:R=;14-")J0@35
MWG#.Z0+ZL;\$46T?6 N+\$+-^\$:D?)F(:/0L|0?5,;/J36MJ&T#G>QLO:"?1>2
M90&E)<=JBC%AN,W?54XK^E?)%,U12-O(767('MD'+)6@NY?
LK_+@J@)6V5|E M0V^BCH(WG8/(EL8C!OPI1|Q=19P);'\$Y<6&T5(*;IP3?
7DL'PFQW1?7:1KYA
MR81S0#%LB|AID%!@*NB|J0Z6K#H0#)FXWY5H@Z4W,+R_|M+
(4>+^XWK31DPNGUW;5GT85VAQU-I,+9QL&PVVNTP;)
JG"QD:7#D.4VB2DO@ M^TW_92V MG!2:|H6A",-*V=X3:YU=AN7XX
5*W|DFG<=')F%F\$MOV1"KJ3F MJM1U7UM=<^L,"VQI'_IZ|O;K)KE%+KB?
&/: @_J58:?:/#B|BRA^43<=N3S1
M<#FR,8|F&"5OHBCY'+J_GGVQP=>7=HF:Z5EUF+*6|5;6!BW9?
L|3+T0SN1E MM5P+VM5R;:T&-L9@>9Q4%8+?#)B(=MX5|"VC=|
|"MXOPA|<1|A/&95.NX36| M!4*1G"4|9GQ+M|9W)L||,=J@'/,G&|R2-
W@X+_Y5-KUX\$AWZT&X8|('O_M.|SC%GN%|NG9_0,&>SLL_/Y-
;B=3|I;CZGL>-TI1W;(.WOGBJ%?"G3,E8OL M*5H_CF4I#-9R|;'|KTT3^&F/;!
|E1.M|G6'|HT;J"QXQ)UK;7C>EGI)K640 MU^;|'RFGJL=F;SK6E;:|J_^4_"N_

X'FZAI-MEJY+!\$SX2|M:\$/4|G3P
M.@\$=6;UVH:V6,"0U5(6\$S|A"NZ5,KV5O"AT|Z|7<':. 5!+ 0(4 Q0 (M J(:%G-
_)|T@K<" /N!(P 1 " 0 !E;&1N+3(P,C0P M.3,P+FAT;5!+ 0(4 Q0 (
J(:%EJ6)E?"3,!&KB\$@ 1 M " ;&W @!E;&1N+3(P,C0P.3,P+GAS9%!+ 0(4 Q0
(J(:%GX|7/W M0@@ (\$X / " >GJ P!E;&1N+65X,S%?,2YH=&U02P\$" M%,4 "
*B&Q9BKC+8\$\$(" #.0 #P @ %8|P, 96QD M;BUE>#,Q7S(N:'1M4\$L! A0#%
@ "HAL66@*FG%2!0 +"0 |M (!QOL# &5L9&XM97@S,E|Q+FAT;5!+ 0(4 Q0
(J(:%E/ M//;H2P4 &HD / " 44!! !E;&1N+65X,S)?,BYH=&U0 52P4& 8 !@!R 0
008\$ end

XML-75-eldn-20240930-htm.xml IDEA: XBRL DOCUMENT 0001404281
2023-09-30 0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2024-01-012024-09-30 0001404281 eldn:AccreditedInvestorMemberus-
gaap:PrivatePlacementMember 2023-04-28 0001404281 us-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementSecondCl
2024-07-082024-07-08 0001404281 us-
gaap:FairValueInputsLevel2Memberus-

gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-012023-09-30
0001404281 us-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementInitialClo
2023-05-052023-05-05 0001404281 2024-03-31 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2023-03-31
0001404281 us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgree
2024-05-09 0001404281 2023-04-012023-06-30 0001404281 us-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
srt:RestatementAdjustmentMember 2023-09-30 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2024-06-30
0001404281 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-
30 0001404281 srt:RestatementAdjustmentMember 2023-01-012023-09-30
0001404281
eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:SeriesX1NonVc
2023-05-162023-05-16 0001404281 eldn:PreFundedWarrantsMember
2024-09-30 0001404281 us-gaap:SubsequentEventMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClos
2024-10-012024-10-01 0001404281 us-
gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0001404281
us-gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2024-09-
30 0001404281 eldn:TwoThousandTwentyLongTermIncentivePlanMember
2024-09-30 0001404281 us-
gaap:CommonStockMembereldn:AllOtherWarrantsMember 2023-12-31
0001404281 us-
gaap:USGovernmentAgenciesShorttermDebtSecuritiesMember 2023-12-31
0001404281 eldn:LeerinkPartnersLlcMemberus-
gaap:SubsequentEventMembereldn:UnderwritingAgreementMember 2024-
10-292024-10-29 0001404281 us-gaap:CommonStockMember 2024-04-
012024-06-30 0001404281 srt:ScenarioPreviouslyReportedMember 2023-
01-012023-09-30 0001404281 eldn:LeerinkPartnersLlcMemberus-
gaap:WarrantMemberus-
gaap:SubsequentEventMembereldn:UnderwritingAgreementMember 2024-
10-29 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2024-03-31
0001404281 eldn:PreFundedWarrantsMember 2024-01-012024-09-30
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2017-12-31 0001404281 eldn:CommonStockWarrantsMember 2024-01-
012024-09-30 0001404281
srt:MaximumMembersrt:BoardOfDirectorsChairmanMemberus-
gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001404281
2022-12-31 0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2017-01-012017-12-31 0001404281 us-
gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel1Memberus-

gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember
2023-07-012023-09-30 0001404281 eldn:CommonStockWarrantsMember
2024-09-30 0001404281 us-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
eldn:TwoThousandTwentyLongTermIncentivePlanMember 2024-07-
102024-07-10 0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2023-01-012023-09-30 0001404281
eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:SeriesX1NonVc
gaap:CommonStockMembereldn:ConversionAgreementMember 2023-05-
162023-05-16 0001404281 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30
0001404281 srt:ScenarioPreviouslyReportedMemberus-
gaap:RetainedEarningsMember 2022-12-31 0001404281 us-
gaap:RetainedEarningsMember 2023-04-012023-06-30 0001404281
eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelo
2024-01-012024-09-30 0001404281 us-
gaap:StockCompensationPlanMember 2023-01-012023-09-30 0001404281
eldn:LeerinkPartnersLlcMemberus-gaap:CommonStockMemberus-
gaap:SubsequentEventMembereldn:UnderwritingAgreementMember 2024-
10-29 0001404281 us-gaap:RetainedEarningsMember 2023-07-012023-09-
30 0001404281 srt:RestatementAdjustmentMember 2023-04-012023-06-30
0001404281 us-gaap:AccountingStandardsUpdate202309Member 2024-09-
30 0001404281 us-gaap:CommonStockMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementInitialClo
2023-05-05 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2024-09-30
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2021-01-012021-12-31 0001404281
eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2024-06-30
0001404281 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-
012023-09-30 0001404281 us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember
2024-09-30 0001404281 2023-01-012023-03-31 0001404281 us-
gaap:CommonStockMembereldn:PreFundedWarrantsMember 2024-09-30
0001404281 stpr:MA 2024-09-04 0001404281 us-
gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001404281
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember
2023-04-012023-06-30 0001404281 us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember
2024-01-012024-09-30 0001404281
eldn:FiveHundredMillionAggregateNetSalesMembereldn:ALSTherapyDevelo
2024-09-30 0001404281 2024-09-30 0001404281
eldn:OticPharmaIncMember 2024-01-012024-09-30 0001404281 us-
gaap:CommonStockMember 2024-06-30 0001404281
eldn:AccreditedInvestorMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClos
2023-04-28 0001404281 srt:RestatementAdjustmentMember 2023-06-30
0001404281 eldn:AnelixisTherapeuticsIncorporationMember 2020-09-

142020-09-14 0001404281 us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberus-gaap:WarrantMember
2023-12-31 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgreeer
2023-11-06 0001404281 us-gaap:CommonStockMember 2023-03-31
0001404281 eldn:SeriesX1NonVotingConvertiblePreferredStockMember
2024-03-31 0001404281 us-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
srt:ScenarioPreviouslyReportedMember 2022-12-31 0001404281 us-
gaap:PreferredStockMember 2023-01-012023-09-30 0001404281 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2024-09-30
0001404281 us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:WarrantMember 2023-12-31 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2023-09-30
0001404281 us-gaap:CommonStockMember 2024-01-012024-03-31
0001404281 srt:ScenarioPreviouslyReportedMember 2023-01-012023-03-
31 0001404281 2023-07-012023-09-30 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgreeer
2023-07-14 0001404281 srt:ScenarioPreviouslyReportedMember 2023-06-
30 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgreeer
2024-07-11 0001404281
eldn:AnelixisTherapeuticsLlcAndOticPharmaLtdMember 2024-01-012024-
09-30 0001404281 srt:RestatementAdjustmentMember 2023-07-012023-
09-30 0001404281 us-gaap:AdditionalPaidInCapitalMember 2022-12-31
0001404281 us-gaap:CommonStockMembereldn:AllOtherWarrantsMember
2024-09-30 0001404281 us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
us-gaap:SubsequentEventMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClos
2024-10-01 0001404281
eldn:GuggenheimSecuritiesLlcMembereldn:EquityDistributionAgreementMc
2024-09-20 0001404281 us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
srt:ScenarioPreviouslyReportedMember 2023-03-31 0001404281
srt:ScenarioPreviouslyReportedMember 2023-07-012023-09-30
0001404281 us-gaap:CommonStockMember 2022-12-31 0001404281
stpr:CA 2024-04-19 0001404281 us-gaap:AdditionalPaidInCapitalMember
2024-03-31 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMemberus-
gaap:CommonStockMember 2024-09-30 0001404281 us-
gaap:CommonStockMember 2023-06-30 0001404281
eldn:AccreditedInvestorMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementSecondCh
2023-04-28 0001404281
eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:SeriesXNonVot
2023-05-162023-05-16 0001404281 us-

gaap:CommonStockMembereldn:PreFundedWarrantsMember 2023-12-31 0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember 2018-01-012018-12-31 0001404281 eldn:PreferredStockWarrantsMember 2023-12-31 0001404281 us-gaap:RetainedEarningsMember 2024-09-30 0001404281 eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2023-03-31 0001404281
eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMemberus-gaap:PrivatePlacementMember 2023-04-28 0001404281
eldn:TimeBasedAndPerformanceBasedVestingRequirementsMember 2023-05-012023-05-01 0001404281 eldn:PreferredStockWarrantsMember 2024-01-012024-09-30 0001404281 us-gaap:CommonStockMember 2023-09-30 0001404281 eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2023-09-30 0001404281 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281 stpr:CA 2024-04-192024-04-19 0001404281
eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMember 2023-04-282023-04-28 0001404281
eldn:CormorantGlobalHealthcareMasterFundLpMembereldn:SeriesXNonVot gaap:CommonStockMembereldn:ConversionAgreementMember 2023-05-162023-05-16 0001404281 us-
gaap:CommonStockMembereldn:PreFundedWarrantsMember 2024-01-012024-09-30 0001404281 eldn:PreFundedWarrantsMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementInitialClo 2023-05-05 0001404281 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001404281 eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2023-12-31 0001404281 us-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClos 2024-09-30 0001404281 us-gaap:CommonStockMember 2023-12-31 0001404281 us-gaap:AccountingStandardsUpdate202307Member 2024-09-30 0001404281
srt:MaximumMembereldn:AccreditedInvestorMembereldn:CommonStockWa 2023-04-282023-04-28 0001404281 eldn:CommonStockWarrantsMember 2023-12-31 0001404281 us-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001404281 us-gaap:CommonStockMember 2024-07-012024-09-30 0001404281
eldn:AccreditedInvestorMemberus-gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementInitialClo 2023-04-28 0001404281 us-
gaap:GeneralAndAdministrativeExpenseMember 2024-07-012024-09-30 0001404281 us-gaap:RetainedEarningsMember 2024-06-30 0001404281 eldn:CommonAndPreferredWarrantsOutstandingMember 2023-01-012023-09-30 0001404281 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-012024-09-30 0001404281 us-
gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0001404281 2024-11-08 0001404281 us-gaap:MoneyMarketFundsMemberus-

gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281 us-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementSecondCl
2024-07-08 0001404281 eldn:CommonStockWarrantsMember 2024-01-
012024-09-30 0001404281 stpr:CA 2022-08-122022-08-12 0001404281 us-
gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0001404281
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember
2023-06-30 0001404281 2024-01-012024-03-31 0001404281 us-
gaap:AdditionalPaidInCapitalMember 2024-06-30 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgree
2024-01-30 0001404281
srt:MaximumMembereldn:SeriesXNonVotingConvertiblePreferredStockMem
gaap:CommonStockMember 2024-01-012024-09-30 0001404281
srt:MinimumMembereldn:SeriesXNonVotingConvertiblePreferredStockMem
gaap:CommonStockMember 2024-01-012024-09-30 0001404281
srt:ScenarioPreviouslyReportedMember 2023-04-012023-06-30
0001404281 us-gaap:AccumulatedOtherComprehensiveIncomeMember
2024-09-30 0001404281
eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2023-06-30
0001404281
eldn:OneBillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFor
2024-09-30 0001404281 us-
gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-09-30
0001404281 eldn:SeriesXConvertiblePreferredStockMember 2024-09-30
0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgree
2024-05-07 0001404281
srt:MaximumMembereldn:AccreditedInvestorMembereldn:PreFundedWarra
2024-05-062024-05-06 0001404281 us-gaap:CommonStockMember 2023-
07-012023-09-30 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgree
2023-07-10 0001404281
eldn:GuggenheimSecuritiesLlcMembersrt:MaximumMembereldn:EquityDist
2024-09-202024-09-20 0001404281 2023-03-31 0001404281
srt:BoardOfDirectorsChairmanMemberus-
gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001404281 us-
gaap:StockCompensationPlanMember 2024-01-012024-09-30 0001404281
us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31
0001404281 srt:ScenarioPreviouslyReportedMember 2023-09-30
0001404281 us-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementThirdClos
2024-09-302024-09-30 0001404281
srt:MaximumMembereldn:AccreditedInvestorMembereldn:PreFundedWarra
2023-04-282023-04-28 0001404281 2024-04-012024-06-30 0001404281
srt:MaximumMember 2023-01-012023-12-31 0001404281
eldn:SeriesXConvertiblePreferredStockMember 2023-12-31 0001404281
stpr:MA 2024-09-042024-09-04 0001404281
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember
2023-09-30 0001404281 us-gaap:CommonStockMember 2024-03-31
0001404281
srt:MinimumMembereldn:AccreditedInvestorMembereldn:PreFundedWarrai

2024-05-062024-05-06 0001404281 srt:MinimumMember 2023-01-012023-12-31 0001404281 2024-01-012024-09-30 0001404281
srt:RestatementAdjustmentMemberus-gaap:RetainedEarningsMember
2023-09-30 0001404281 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30
0001404281 us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001404281
us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-09-30
0001404281 srt:RestatementAdjustmentMemberus-
gaap:RetainedEarningsMember 2023-07-012023-09-30 0001404281
eldn:SeriesXOnePreferredStockMember 2024-09-30 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2022-12-31
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2024-09-30 0001404281
eldn:AccreditedInvestorMembereldn:PreFundedWarrantsMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementMember
2024-05-06 0001404281 us-gaap:CommonStockMember 2024-09-30
0001404281 us-gaap:CommonStockMembereldn:AllOtherWarrantsMember
2024-01-012024-09-30 0001404281 us-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2023-04-012023-
06-30 0001404281 us-gaap:RetainedEarningsMember 2024-07-012024-09-
30 0001404281
srt:MaximumMembereldn:ALSTherapyDevelopmentFoundationIncLicenseAg
2024-09-30 0001404281 stpr:CA 2022-01-012022-12-31 0001404281 us-
gaap:CommonStockMember 2024-01-012024-09-30 0001404281
eldn:TwoThousandFourteenStockIncentivePlanMember 2024-09-30
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2022-01-012022-12-31 0001404281 eldn:PreFundedWarrantsMember
2023-01-012023-09-30 0001404281 us-gaap:RetainedEarningsMember
2022-12-31 0001404281 us-gaap:AdditionalPaidInCapitalMember 2023-09-
30 0001404281 2023-12-31 0001404281 us-gaap:RetainedEarningsMember
2023-03-31 0001404281 us-gaap:RetainedEarningsMember 2023-09-30
0001404281 2023-01-012023-09-30 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2023-06-30
0001404281 eldn:PreFundedWarrantsMember 2023-07-012023-09-30
0001404281 eldn:PreferredStockWarrantsMember 2024-01-012024-09-30
0001404281 us-gaap:FairValueMeasurementsRecurringMemberus-
gaap:WarrantMember 2024-09-30 0001404281 us-
gaap:AdditionalPaidInCapitalMember 2023-03-31 0001404281
eldn:OneBillionAggregateNetSalesMembereldn:ALSTherapyDevelopmentFoi
2024-01-012024-09-30 0001404281 2023-01-012023-12-31 0001404281
eldn:SeriesX1NonVotingConvertiblePreferredStockMember 2022-12-31
0001404281 2024-06-30 0001404281 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30
0001404281 us-gaap:AdditionalPaidInCapitalMember 2023-06-30
0001404281 us-gaap:RetainedEarningsMember 2024-01-012024-03-31
0001404281 us-gaap:MoneyMarketFundsMemberus-

gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
srt:MinimumMembersrt:BoardOfDirectorsChairmanMemberus-
gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0001404281 us-
gaap:RetainedEarningsMember 2023-06-30 0001404281
srt:MinimumMember 2024-01-012024-09-30 0001404281 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-
09-30 0001404281 us-gaap:AdditionalPaidInCapitalMember 2023-04-
012023-06-30 0001404281 us-gaap:AdditionalPaidInCapitalMember 2023-
12-31 0001404281 eldn:PreferredStockWarrantsMember 2024-09-30
0001404281 us-gaap:RetainedEarningsMember 2023-12-31 0001404281
eldn:PreFundedWarrantsMember 2024-07-012024-09-30 0001404281
eldn:TwoThousandFourteenEmployeeStockPurchasePlanMember 2024-09-
30 0001404281 us-gaap:RetainedEarningsMember 2023-01-012023-03-31
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2023-01-012023-12-31 0001404281
eldn:ArmisticeCapitalMasterFundLtdMembereldn:SecuritiesPurchaseAgree
2023-11-02 0001404281
eldn:AccreditedInvestorMembereldn:CommonStockWarrantsMember 2023-
04-282023-04-28 0001404281 srt:ScenarioPreviouslyReportedMemberus-
gaap:RetainedEarningsMember 2023-03-31 0001404281
srt:ScenarioPreviouslyReportedMemberus-gaap:RetainedEarningsMember
2023-01-012023-03-31 0001404281 srt:RestatementAdjustmentMemberus-
gaap:RetainedEarningsMember 2023-06-30 0001404281
eldn:TimeBasedVestingRequirementsMember 2023-05-012023-05-01
0001404281
eldn:ALSTherapyDevelopmentFoundationIncLicenseAgreementMember
2018-12-31 0001404281 2024-07-012024-09-30 0001404281 us-
gaap:PreferredStockMember 2024-01-012024-09-30 0001404281
srt:MaximumMember 2024-01-012024-09-30 0001404281
eldn:CommonAndPreferredWarrantsOutstandingMember 2024-01-012024-
09-30 0001404281 us-gaap:CommonStockMember 2023-04-012023-06-30
0001404281 srt:RestatementAdjustmentMemberus-
gaap:RetainedEarningsMember 2023-04-012023-06-30 0001404281
eldn:PerformanceBasedVestingRequirementsMember 2024-06-132024-06-
13 0001404281 eldn:SeriesX1NonVotingConvertiblePreferredStockMember
2023-04-012023-06-30 0001404281 2023-06-30 0001404281 us-
gaap:USGovernmentAgenciesDebtSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001404281
eldn:AccreditedInvestorMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementMember
2024-05-062024-05-06 0001404281
eldn:SeriesXNonVotingConvertiblePreferredStockMember 2023-12-31
0001404281 us-gaap:RetainedEarningsMember 2024-03-31 0001404281
eldn:AccreditedInvestorMemberus-
gaap:PrivatePlacementMembereldn:SecuritiesPurchaseAgreementMember
2024-05-06 0001404281 us-
gaap:USGovernmentCorporationsAndAgenciesSecuritiesMemberus-
gaap:FairValueInputsLevel2Memberus-

gaap:FairValueMeasurementsRecurringMember 2024-09-30 pure
iso4217:USD shares utr:sqft shares eldn:Milestone
iso4217:USD0001404281--12-31falseQ3
http://www.eledon.com/20240930#CommonStockWarrantsMemberhttp://ww
Qtrue2024-09-302024false001-36620ELEDON PHARMACEUTICALS,
INC.DE20-100096719800 MacArthur BlvdSuite
250IrvineCA92612(949)238-8090Common Stock, \$0.001 par
valueELDNNASDAQYesYesNon-accelerated
Filertruefalsefalse59739275675100046120007144000046490000331800056
310969000-
31940200076058000720800011457600089066000165200007931000340366
20510000-11198000-45881000-
32662000104200084900024850001962000-96439000-443000-
518290005573800076971000-99060008433000-8643800054429000-
99060005551000-864380001.05-0.330.13-
3.7951945920299744004144304922813085-17504000-9906000-61086000-
86438000-0.32-0.33-1.42-
3.795547834229974400431067462281308576971000-99060008433000-
8643800010200010200077073000-99060008535000-
8643800011008644222421313024000326586000-
31940200072080006000001000100016940001694000-23631000-
2363100011008644222481313025000328280000-343033000-
14728000131104841300048057000480700005830001000100030630003063
44907000-4490700011008644223850661439000379400000-387940000-
85010002436488200057010005703000240000178300017830001020001020
3109690007605800011797062041377678814000287034000-
2028650008418300013810001381000-10772000-
1077200011797062041377678814000288415000-
21363700074792000873016890003300800033017000-178299000-
7884437977-1000-100017200001720000-65760000-
6576000011008644222304393323000323142000-
279397000437680005011971000100017340001734000-9906000-
990600011008644222354513024000324876000-
289303000355970008433000-8643800010000271000280000-1916000-
57900065400004835000-5182900055738000-16850003560008791000-
3609000-249000-267000-28284000-
303960008335000060363000604180005000000-22932000-
55363000533550003301700053355000330170002139000-
52742000461200056409000675100036670001000102000377000420000

<p style="font-size:10pt;margin-top:12pt;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;white-space:pre-wrap;font-weight:bold;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 1.
Description of Business</p><p style="text-indent:5.333%;font-
size:10pt;margin-top:6pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-
content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology
company using its immunology expertise in targeting the CD40 Ligand
("CD40L") pathway to develop therapies to protect transplanted organs and
prevent rejection, and to treat amyotrophic lateral sclerosis ("ALS"). The

Company's lead compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that we believe has broad therapeutic potential. Unless otherwise indicated, references to the terms "Eledon," "our," "us," "we," or the "Company" refer to Eledon Pharmaceuticals, Inc. and its wholly owned subsidiaries, on a consolidated basis.

On September 14, 2020, Eledon acquired Anelixis Therapeutics, Inc. ("Anelixis"), a privately held clinical stage biotechnology company developing a next generation anti-CD40L antibody as a potential treatment for organ and cellular transplantation, autoimmune diseases, and neurodegenerative diseases. The Company maintains its corporate headquarters in Irvine, California and has research and development facilities in Burlington, Massachusetts.

Restatement of Previously Issued Financial Statements

During the preparation of the Company's Condensed Consolidated Financial Statements for the fiscal quarter ended June 30, 2024, the Company determined that the Common Warrants and the Subsequent Closing Warrants (each as defined in Note 8) do not meet the conditions to be classified as equity instruments under ASC 815-40, "Derivatives and Hedging — Contracts in Entity's Own Equity," ("ASC 815-40") and must instead be recorded as liabilities on the Company's consolidated balance sheet at their fair value and remeasured at fair value for each subsequent reporting period. As a result, the Company determined that a correction was necessary with respect to the Company's reporting and recording of the fair value of the Common Warrants and the Subsequent Closing Warrants. Certain prior period financial statements and financial information are presented herein as restated. See Note 12 for further information.

2020-09-14

Note 2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and Article 8 of Regulation S-X requirements as set forth by the Securities and Exchange Commission (“SEC”) for interim financial information and reflect all adjustments and disclosures, which are, in the opinion of management, of a normal and recurring nature, and considered necessary for a fair presentation of the financial information contained herein. Pursuant to these rules and regulations, the unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of results of operations and comprehensive loss, financial position, and cash flows in conformity with GAAP.

The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and accompanying notes of Eledon for the year ended December 31, 2023 included in the Company’s Annual Report on Form 10-K filed by the Company with the SEC on March 28, 2024, as amended on each of April 26, 2024 and August 19, 2024 (together, the “Amended Form 10-K”). The results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024

are not necessarily indicative of results expected for the full fiscal year or any other future period.

Principles of Consolidation

Eledon, a Delaware corporation, owns 100% of the issued and outstanding common stock or other

ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel ("Otic"). Otic owns

100% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc.

The functional currency of the Company's foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company's foreign subsidiary are not significant to the condensed consolidated financial statements.

All significant intercompany accounts and transactions among the entities have been eliminated from the condensed consolidated financial statements.

Liquidity and Financial Condition

The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company's assets and the satisfaction of the Company's liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company has

experienced recurring net losses and negative cash flows from operating activities since its inception. The Company recorded net income of \$77.0million and\$8.4million for the three and nine months ended September 30, 2024>, respectively. These results include a \$96.4million gain related to changes in the fair value of warrant liabilities and the fair value of financial instruments issued in excess of proceeds, recorded in the third quarter ending September 30, 2024. Excluding this gain, the Company would have recorded net losses of\$19.5million and\$43.4million for the>three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of\$78.2million, working capital of\$69.0million and an accumulated deficit of\$

family:Times New Roman;min-width:fit-content;">\$311.0 million. </p><p style="text-indent:5.391%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.065%;text-align:left;">On October 29, 2024, the Company entered into an underwriting agreement with Leerink Partners, LLC, as representative of the several underwriters named therein in connection with the underwritten offering, issuance and sale by the Company (the "Offering") of 18,356,173 shares of the Company's common stock, par value \$0.001 per share, at an offering price of \$3.65 per share, and pre-funded warrants at a price of \$3.649 per pre-funded warrant, which are exercisable to purchase 4,931,507 shares of the Company's common stock at an exercise price of \$0.001 per share. The Offering resulted in gross proceeds to the Company of \$85.0 million, or net proceeds of approximately \$79.5<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-

family:Times New Roman;min-width:fit-content;"> millionafter deducting underwriting discounts and commissions and offering expenses. See Note 11. Subsequent Events for additional </p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.065%;text-align:left;">information. The Company currently plans to use the net proceeds from the Offering to advance our pipeline and for working capital and general corporate purposes.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. In order to continue these activities, the Company will need to raise additional funds through public or private debt and equity financings or strategic collaboration and licensing arrangements. The Company's ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of risks and uncertainties, as well as uncertainty as to whether the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. If the Company issues equity or convertible debt securities to raise additional funding, its existing stockholders may experience dilution, it may incur significant financing costs, and the new equity or convertible debt securities may have rights, preferences and privileges senior to those of its existing stockholders. If the Company issues debt securities to raise additional funding, it would incur additional debt service obligations, it could become subject to additional restrictions limiting its ability to operate its business, and it may be required to further encumber its assets.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">At the time of issuance of the condensed consolidated financial statements for the three and nine months ended September 30, 2024, the Company's management performed an analysis and concluded that the Company had sufficient cash resources to meet its anticipated cash needs through at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements.</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The most significant estimates in the Company's consolidated financial statements relate to stock-based compensation expense, warrant liabilities, the fair value of right-of-use assets and liabilities, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates under different assumptions or conditions and the differences may be material to the consolidated financial statements.

Concentration of Credit Risk

Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.

Cash and Cash Equivalents

family:Times New Roman;min-width:fit-content;">The Company considers all highly liquid investments with original maturities of three months or lesswhen purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.</p></div><div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Risks and Uncertainties</p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024 and December 31, 2023, all of the Company's long-lived assets were located in the United States.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company's products will require approval from the U.S. Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company's business in the future. In</p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional

financing.

The Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages all its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.

<p style="font-size: 10pt; margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">In-Process Research and Development</p><p style="text-indent: 5.333%; font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">The fair values of in-process research and development ("IPR&D") projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development ("R&D") efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.</p><p style="text-indent: 5.333%; font-size: 10pt; margin-top: 12pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment,

including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets.

Research and Development Expenses

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the related goods are delivered or services are performed.

The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company's accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company's prior period accrued estimates for clinical trial activities during the three and nine months ended September 30, 2024

New Roman; margin-bottom: 0; text-align: left;">Recently Adopted Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments’ significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC

did not, or are not believed by management to, have a material impact on the Company's present or future financial position, results of operations or cash flows.

Warrant Liabilities

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 815-40, Derivatives and Hedging — Contracts in Entity's Own Equity ("ASC 815-40"). Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the condensed consolidated statements of operations and comprehensive loss as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with GAAP and Article 8 of Regulation S-X requirements as set forth by the Securities and Exchange Commission ("SEC") for interim financial information and reflect all adjustments and disclosures, which are, in the opinion of management, of a normal and recurring nature, and considered necessary for a fair presentation of the financial information contained herein. Pursuant to these rules and regulations, the unaudited condensed consolidated financial statements do not include all information and notes necessary for a complete presentation of results of operations and comprehensive loss, financial position, and cash flows in conformity with GAAP.

The accompanying unaudited condensed consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and accompanying notes of Eledon for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed by the Company with the SEC on March 28, 2024, as amended on each of April 26, 2024 and August 19, 2024 (together, the "Amended Form 10-K"). The results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2024

are not necessarily indicative of results expected for the full fiscal year or any other future period.

Principles of Consolidation

Eledon, a Delaware corporation, owns 100% of the issued and outstanding common stock or other ownership interest in Anelixis Therapeutics, LLC, a Delaware limited liability company, and Otic Pharma, Ltd., a private limited company organized under the laws of the State of Israel ("Otic"). Otic owns 100% of the issued and outstanding common stock or other ownership interest in its U.S. subsidiary, Otic Pharma, Inc.

The functional currency of the Company's foreign subsidiary is the U.S. Dollar; however, certain expenses, assets and liabilities are transacted at the local currency. These transactions are translated from the local currency into U.S. Dollars at exchange rates during or at the end of the reporting period. The activities of the Company's foreign subsidiary are not significant to the condensed consolidated financial statements.

All significant intercompany accounts and transactions among the entities have been eliminated from the condensed consolidated financial statements.

11

Liquidity and Financial Condition

The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company's assets and the satisfaction of the Company's liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company has experienced recurring net losses and negative cash flows from operating activities since its inception. The Company recorded net income of \$77.0 million and \$8.4 million for the three and nine months ended September 30, 2024, respectively. These results include a \$96.4 million gain related to changes in the fair value of warrant liabilities and

the fair value of financial instruments issued in excess of proceeds, recorded in the third quarter ending September 30, 2024. Excluding this gain, the Company would have recorded net losses of \$19.5 million and \$43.4 million for the three and nine months ended September 30, 2024, respectively. As of September 30, 2024, the Company had cash and cash equivalents and short-term investments of \$78.2 million, working capital of \$69.0 million and an accumulated deficit of \$311.0 million.

On October 29, 2024, the Company entered into an underwriting agreement with Leerink Partners, LLC, as representative of the several underwriters named therein in connection with the underwritten offering, issuance and sale by the Company (the "Offering") of 18,356,173 shares of the Company's common stock, par value \$0.001

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share, at an offering price of \$3.65 per share, and pre-funded warrants at a price of \$3.649 per pre-funded warrant, which are exercisable to purchase4,931,507 shares of the Company's common stock at an exercise price of \$0.001 per share. The Offering resulted in gross proceeds to the Company of \$85.0 million, or net proceeds of approximately \$79.5 million after deducting underwriting discounts and commissions and offering expenses. See Note 11. Subsequent Events for additional </p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.065%;text-align:left;">information.The Company currently plans to use the net proceeds from the Offering to advance our pipeline and for working capital and general corporate purposes.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Due to continuing research and development activities, the Company expects to continue to incur net losses into the foreseeable future. In order to continue these activities, the Company will need to raise additional funds through public

or private debt and equity financings or strategic collaboration and licensing arrangements. The Company's ability to raise additional capital in the equity and debt markets is dependent on a number of factors, including, but not limited to, the market demand for the Company's common stock, which itself is subject to a number of risks and uncertainties, as well as uncertainty as to whether the Company would be able to raise such additional capital at a price or on terms that are favorable to the Company. If the Company issues equity or convertible debt securities to raise additional funding, its existing stockholders may experience dilution, it may incur significant financing costs, and the new equity or convertible debt securities may have rights, preferences and privileges senior to those of its existing stockholders. If the Company issues debt securities to raise additional funding, it would incur additional debt service obligations, it could become subject to additional restrictions limiting its ability to operate its business, and it may be required to further encumber its assets.

At the time of issuance of the condensed consolidated financial statements for the three and nine months ended September 30, 2024, the Company's management performed an analysis and concluded that the Company had sufficient cash resources to meet its anticipated cash needs through at least the next 12 months from the date of issuance of the accompanying condensed consolidated financial statements.

770000008400000-96400000-19500000-434000007820000069000000-311000000183561730.0013.653.64949315070.0018500000079500000

Use of Estimates

The preparation of the Company's consolidated financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company's consolidated financial statements and accompanying notes. The most significant estimates in the Company's consolidated financial statements relate to stock-based compensation expense, warrant liabilities, the fair value of right-of-use assets and liabilities, accruals for liabilities, impairment of long-lived assets, and other matters that affect the consolidated financial statements and related disclosures. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates under different

assumptions or conditions and the differences may be material to the consolidated financial statements.

Concentration of Credit Risk

Financial instruments which potentially subject the Company to significant concentration of credit risk consists of cash, cash equivalents and short-term investments. The Company maintains deposits in federally insured institutions in excess of federally insured limits and invests in short-term investments with the primary objective of seeking to preserve principal, achieve liquidity requirements and safeguard invested funds. We believe that the Company is not exposed to significant credit risk due to the financial position of the depository institution in which those deposits are held and the nature, including the credit ratings, of our cash equivalents and short-term investments, but we have not eliminated all credit risk.

Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of
three months or less
when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts, money market funds, U.S. government securities and U.S. government agency securities. The carrying amounts reported in the unaudited condensed consolidated balance sheets for cash and cash equivalents are valued at cost, which approximates their fair value due to the short-term maturities of these investments.
three months or less

Risks and Uncertainties

As of September 30, 2024 and December 31, 2023, all of the Company's long-lived assets were

located in the United States.

The Company's products will require approval from the U.S. Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that its products will receive any of these required approvals. The denial or delay of such approvals may impact the Company's business in the future. In

addition, after the approval by the FDA, there is still an ongoing risk of adverse events that did not appear during the product approval process.

The Company is subject to risks common to companies in the pharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of its stock price and the need to obtain additional financing.

The Company's facilities and equipment, including those of the Company's suppliers and vendors, may be affected by natural or man-made disasters. The Company's administrative office is based in Irvine, California and the Company manages all its research and development activities through third parties that are located throughout the world. The Company has taken precautions to safeguard its facilities, equipment and systems, including insurance, health and safety protocols, and off-site storage of computer data. However, the Company's facilities and systems, as well as those of its third-party suppliers and vendors, may be vulnerable to earthquakes, fire, storm, public health or similar emergencies, power loss, telecommunications failures, physical and software break-ins, software viruses and similar events which could cause substantial delays in its operations, damage or destroy its equipment or inventory, and cause the Company to incur additional expenses and delay research and development activities. In addition, the insurance coverage the Company maintains may not be adequate to cover its losses in any circumstance and may not continue to be available to use on acceptable terms, or at all.

In-Process Research and Development

The fair values of in-process research and development ("IPR&D") projects acquired in a business combination that are not complete are capitalized and accounted for as indefinite-lived intangible assets until completion or abandonment of the related research and development ("R&D") efforts. Upon successful completion of the project, the capitalized amount is amortized over its estimated useful life. If a project is abandoned, all remaining capitalized amounts are written off immediately. Major risks and uncertainties are often associated with IPR&D projects because we are required to obtain regulatory approvals before marketing the resulting products. Such approvals require completing clinical trials that demonstrate a product candidate is safe and effective. Consequently, the eventual realized value of the acquired IPR&D project may vary from its fair value at the date of acquisition, and IPR&D impairment charges may occur in future periods.

Capitalized IPR&D projects are tested for impairment annually and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. We consider various factors for potential impairment, including the current legal and regulatory environment and the competitive landscape. Adverse clinical trial results, significant delays in obtaining marketing approval, the inability to bring a product to market and the introduction or advancement of competitors' products could result in partial or full impairment of the related intangible assets.

Research and Development Expenses

Research and development expenses include personnel and facility-related expenses, outside contracted services including clinical trial costs, manufacturing and process development costs, research costs and other consulting services and non-cash stock-based compensation. Research and development costs are expensed as incurred. Amounts due under contracts with third parties may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. Non-refundable advance payments under agreements are capitalized and expensed as the

related goods are delivered or services are performed.

The Company contracts with third parties to perform various clinical trial activities in the on-going development of potential products. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows to its vendors. Payments under the contracts depend on factors such as the achievement of certain events, successful enrollment of patients, and completion of portions of the clinical trial or similar conditions. The Company's accrual for clinical trials is based on estimates of the services received and efforts expended pursuant to contracts with clinical trial centers and clinical research organizations. These contracts may be terminated by the Company upon written notice and the Company is generally only liable for actual effort expended by the organizations to the date of termination, although in certain instances the Company may be further responsible for termination fees and penalties. The Company estimates its research and development expenses and the related accrual as of each balance sheet date based on the facts and circumstances known to the Company at that time. There have been no material adjustments to the Company's prior period accrued estimates for clinical trial activities during the three and nine months ended September 30, 2024

Recently Adopted Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-09 , Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. ASU No. 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires public entities to disclose information about their reportable segments' significant expenses and other segment items on an interim and annual basis. Public entities with a single reportable segment are required to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in ASC 280, on an interim and annual basis. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024, with early adoptions permitted. The Company is currently evaluating the impact of this guidance on its consolidated financial statements.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the SEC did not, or are not believed by management to, have a material impact on the Company's present or future financial position, results of operations or cash flows.

Warrant Liabilities

The Company accounts for issued warrants either as a liability or equity in accordance with ASC 815-40, Derivatives and Hedging — Contracts in Entity's Own Equity ("ASC 815-40"). Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the condensed consolidated statements of operations and comprehensive loss as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair

value recognized after the issuance date.

Note 3. Short-Term Investments

The objectives of the Company's investment policy are to preserve principal, meet the Company's liquidity requirements and safeguard invested funds. Short-term investments consist of U.S. government securities and U.S. government agency securities. The Company has classified these investments as available-for-sale securities, as the sale of such investments may be required prior to maturity to implement management strategies, and therefore has classified all investments with maturity dates beyond three months at the date of purchase as current assets in the accompanying unaudited condensed consolidated balance sheets. Any premium or discount arising at purchase is amortized and/or accreted to interest income as an adjustment to yield using the straight-line method over the life of the instrument. The amortized cost of available-for-sale securities is adjusted for amortization of premiums and accretion of discounts to maturity. Investments are reported at their estimated fair value. Unrealized gains and losses are included in accumulated other comprehensive loss as a component of stockholders' equity until realized.

The following is a summary of short-term investments, which were classified as available-for-sale securities as of

September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024	December 31, 2023	Cost	Unrealized gains	Unrealized losses	Net carrying amount
U.S. government securities	\$ 29.4%	\$ 1.28%	\$ 1%	\$ 8.8%	\$ 1%	\$ 1%
U.S. government agency securities	\$ 8.92%	\$ 8.1%	\$ 1%	\$ 1%	\$ 1%	\$ 1%

[illegible]

		Unrealized Gains	
		Unrealized Losses	
		Fair Value	
		Amortized Cost	

[illegible]

\$	3
)	\$
\$	67,847
\$	33,213
\$	\$

33,213	
U.S. government agency securities	
3,593	
—	

[illegible]

13,277	
Total short-term investments	
\$	
71,338	
\$	
105	

\$	
3	
)	
71,440	
46,490	
\$	

\$

All of the Company's available-for-sale securities have a stated maturity of less than one year.

The following is a summary of short-term investments, which were classified as available-for-sale securities as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024	December 31, 2023
U.S. government securities	\$1,234,567	\$987,654
Municipal securities	\$567,890	\$456,789
Corporate securities	\$345,678	\$234,567
Total	\$2,148,135	\$1,679,010

[illegible]

[illegible]

bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Fair Value</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cfff0c;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. government securities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">67,745</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">105</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-

$\frac{3}{67,847}$	$\frac{33,213}{33,213}$

space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. government agency securities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,593</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-

[illegible]

Roman; margin-bottom: 0; text-align: left; "></p></td></tr><tr style="height: 10pt; background-color: #c0c0c0; word-break: break-word;"><td style="white-space: pre-wrap; vertical-align: top;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Total short-term investments</p></td><td style="white-space: pre-wrap; vertical-align: bottom;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">71,338</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">105</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;"><span style="color: #000000; white-space: pre-

[illegible]

46,490	

Note 4. Fair Value Measurements

Financial assets and liabilities are recorded at fair value.

The Company classifies fair value measurements using a three-level hierarchy that prioritizes the inputs used to measure fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows:

- Level 1—Quoted market prices (unadjusted) in active markets for identical assets and liabilities.
- Level 2—Observable inputs other than quoted market prices included in Level 1, such as quoted market prices for markets that are not active or other inputs that are observable or can be corroborated by observable market data.
- Level 3—Unobservable inputs that are supported by little or no market activity.

•

Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. These fair values are obtained from independent pricing services which utilize Level 1 and Level 2 inputs.

Financial Assets

The following table summarizes the Company's financial asset instruments measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands). Included within cash and cash equivalents on the unaudited condensed consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.

	September 30, 2024	December 31, 2023	Level 1	Level 2	Level 3
Cash	\$12.245 billion	\$12.245 billion	\$12.245 billion	\$0.000 billion	\$0.000 billion
Time deposits	\$1.04 billion	\$1.04 billion	\$1.04 billion	\$0.000 billion	\$0.000 billion
Other financial assets	\$1.2 billion	\$1.2 billion	\$1.2 billion	\$0.000 billion	\$0.000 billion
Total	\$13.485 billion	\$13.485 billion	\$13.485 billion	\$0.000 billion	\$0.000 billion

[illegible]

[illegible]

colspan="2" style="vertical-align:bottom;"/> 	

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> —</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,741</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-

[illegible]

[illegible]

</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">67,847</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">67,847</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr><td style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">U.S. government agency securities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

[illegible]

Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">3,593</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> </tr> <tr style="height: 10pt; background-color: #ffffff; word-break: break-word; "> <td style="white-space: pre-wrap; vertical-align: top; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">Total short-term investments</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">\$</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">—</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">\$</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">71,440</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">\$</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-
align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—
</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;">
</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-
bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="white-space:pre-wrap;min-width:fit-content;"> </p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt
solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;min-width:fit-content;">\$</p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt
solid #000000;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
<span style="color:#000000;white-space:pre-wrap;min-width:fit-
content;">71,440</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> </tr> <tr style="background-
color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td
style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="white-space:pre-wrap;min-width:fit-content;"> </p></td>
<td style="vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p>
</td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt
solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:left;"><span style="white-
space:pre-wrap;min-width:fit-content;"> </p></td> <td
style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="vertical-
align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td colspan="2" style="vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-

[illegible]

bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p>
</td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
\$</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">71,440</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">77,181</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.095%;box-sizing:content-box;"></td><td style="width:1.641%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.245000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.245000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.2%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.245000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.04%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12.245000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 1</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p

[illegible]

[illegible]

[illegible]

[illegible]

4,246	
\$	
—	
\$	
—	

[illegible]

[illegible]

U.S. government securities	—	33,213	\$

[illegible]

[illegible]

bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,490</p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">46,490</p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
</tr>
<tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
<td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-

[illegible]

Total financial assets

\$	4,246	46,490	\$
\$	\$	\$	\$

bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,736</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant Liabilities</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;">The following table summarizes the Company's warrant liabilities (see Note 8) measured at fair value on a recurring basis as ofSeptember 30, 2024 and December 31, 2023 (in thousands) and was based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy.</p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.9%;box-sizing:content-box;"></td> <td style="width:4.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td

[illegible]

[illegible]

bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.9%;box-sizing:content-box;"></td> <td style="width:4.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td

[illegible]

[illegible]

\$

—	
\$	
76,211	
	\$
76,211	

The following table provides a roll-forward of the aggregate fair value of the warrant liability categorized with Level 3 inputs:

[illegible]

space:nowrap;vertical-align:bottom;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
min-width:fit-content;"/>	white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>	color:#000000;white-space:pre-wrap;min-width:fit-content;"/>
color:#000000;white-space:pre-wrap;min-width:fit-content;"/>	51,829
white-space:nowrap;vertical-align:bottom;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
color:#000000;min-width:fit-content;"/>	)
height:10pt;background-color:#cff0fc;word-break:break-word;"/>	text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"/>
margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>	color:#000000;white-space:pre-wrap;min-width:fit-content;"/>
Settlement of warrant liability	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
white-space:pre-wrap;vertical-align:bottom;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
white-space:pre-wrap;min-width:fit-content;"/>	white-space:pre-wrap;min-width:fit-content;"/>
white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>	min-width:fit-content;"/>
white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>
color:#000000;white-space:pre-wrap;min-width:fit-content;"/>	color:#000000;white-space:pre-wrap;min-width:fit-content;"/>
420	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>	color:#000000;min-width:fit-content;"/>
height:10pt;background-color:#ffffff;word-break:break-word;"/>	white-space:pre-wrap;vertical-align:top;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>	color:#000000;white-space:pre-wrap;min-width:fit-content;"/>
Balance as of September 30, 2024	
white-space:pre-wrap;vertical-align:bottom;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
white-space:pre-wrap;min-width:fit-content;"/>	white-space:pre-wrap;min-width:fit-content;"/>
white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>	color:#000000;min-width:fit-content;"/>
\$	white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"/>
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>

23,962

The change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds includes the reversal of \$58.7 million in warrant liabilities associated with the Subsequent Closing Warrants (as defined in Note 8), which expired during the quarter ended September 30, 2024.

The following table summarizes the Company's financial asset instruments measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands). Included within cash and cash equivalents on the unaudited condensed consolidated balance sheets, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions.

	September 30, 2024	December 31, 2023	Change	Change as a % of September 30, 2024
Cash and cash equivalents	12,245,000	12,245,000	0	0%
Accounts receivable	1,041	1,041	0	0%
Prepaid expenses	1,200	1,200	0	0%
Other current assets	1,200	1,200	0	0%
Investments	12,245,000	12,245,000	0	0%
Other non-current assets	1,041	1,041	0	0%
Other non-current liabilities	1,200	1,200	0	0%
Other non-current equity	1,200	1,200	0	0%
Other non-current debt	1,200	1,200	0	0%
Other non-current equity	1,200	1,200	0	0%
Other non-current debt	1,200	1,200	0	0%

[illegible]

align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Level 3</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr><tr style="height:10pt;background-color:#eff0fe;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Assets:</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></td></tr></table>

[illegible]

[illegible]

bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,741</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash equivalents</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,741</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #ffffff03;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-

5,741	

Short-term investments:	

[illegible]

—

		
\$	67,847	
		
—		
\$	\$	
—		
—		

| | | | |

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,593</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>			
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">			
<td style="white-space:pre-wrap;vertical-align:top;"> Total short-term investments </td>			
<td style="white-space:pre-wrap;vertical-align:bottom;"> </td>			
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> \$ </td>			
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td>			
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td>			
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td>			
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> \$ </td>			
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 71,440 </td>			
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-			

content;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">71,440</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="background-color:#fffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

content;">5,741</p></td>	<p ><="" ><span="" p="" p><="" span><="" style="min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><=""></p>	<p ><p="" ><span="" >71,440<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="min-width:fit-content;" td><=""></p>	<p >\$<="" ><p="" ><span="" p="" p><="" span><="" style="color:#000000;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >—<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="min-width:fit-content;" td><=""></p>
<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><=""></p>	<p ><="" ><p="" ><span="" p="" p><="" span><="" style="white-space:pre-wrap;min-width:fit-content;" td><=""></p>
<p ><p="" ><span="" >77,181<="" p="" p><="" span><="" style="color:#000000;white-space:pre-wrap;min-width:fit-content;" td><=""></p>	

#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:38.095%;box-sizing:content-box;"></td> <td style="width:1.641%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.245000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.245000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.2%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.245000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.245000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.04%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12.245000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">December 31, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td>

Level 1	
Level 2	
Level 3	
Total	
Assets:	

[illegible]

[illegible]

\$	
\$	
\$	
\$	
4,246	Total cash equivalents

[illegible]

[illegible]

[illegible]

U.S. government securities	
\$	
—	
\$	
33,213	
\$	
—	

[illegible]

[illegible]

—	\$
46,490	\$
46,490	\$
46,490	\$

[illegible]

[illegible]

New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,736</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p>5741000574100057410005741000678470006784700035930003593000The following table summarizes the Company's warrant liabilities (see Note 8) measured at fair value on a recurring basis as of September 30, 2024 and December 31, 2023 (in thousands) and was based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.9%;box-sizing:content-box;"></td> <td style="width:4.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.76%;box-sizing:content-box;"></td> <td>

[illegible]

[illegible]

bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,962</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"> <td style="width:47.9%;box-sizing:content-box;"></td> <td style="width:4.92%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.28%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.82%;box-sizing:content-box;"></td> <td

[illegible]

[illegible]

\$

\$	
76,211	
\$	
76,211	

23962000239620007621100076211000

The following table provides a roll-forward of the aggregate fair value of the warrant liability categorized with Level 3 inputs:

	Warrant Liabilities	
	76,211	
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds		

</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(51,829</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#cfffcc;word-break:break-word;"><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Settlement of warrant liability</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(420</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span

[illegible]

	December 31,	
	2024	
	2023	
Prepaid clinical		

\$	2,526
\$	4,128
Prepaid insurance	87

624	
Prepaid other	
263	
185	
Other current assets	

Total prepaid expenses and other current assets	90
Total	
\$3,318	

[illegible]

December 31,	
2024	2023
Prepaid clinical	\$

2,526	4,128
Prepaid insurance	87
624	

Prepaid other	263
	185
Other current assets	

[illegible]

bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,027</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr>

</table>2526000412800087000624000263000185000442000900003318000

||
| |

| |

[illegible]

\$	2,062
\$	2,003
Accrued clinical	3,798

451	Accrued professional services
475	Accrued other
47	Accrued other

	Total accrued expenses and other liabilities	
		6,443

Accrued expenses and other liabilities consisted of the following as of September 30, 2024 and December 31, 2023 (in thousands):

	September 30, 2024	December 31, 2023	September 30, 2022	December 31, 2021	September 30, 2020
Accounts payable	\$ 2,545	\$ 2,545	\$ 2,545	\$ 2,545	\$ 2,545
Accrued expenses and other liabilities	\$ 2,545	\$ 2,545	\$ 2,545	\$ 2,545	\$ 2,545
Total	\$ 5,090	\$ 5,090	\$ 5,090	\$ 5,090	\$ 5,090

	December 31,	
	2024	
	Accrued compensation and related expenses	

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> \$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,062</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical- align:bottom;text-align:center;"><p style="font-size:10pt;margin- top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> 2,003</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background- color:#ffffff;word-break:break-word;"> <td style="white-space:pre- wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;">Accrued clinical</p></td> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,798</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times

New Roman	
451	
Accrued professional services	
475	
47	
Accrued other	

[illegible]

\$	2,545

2062000200300037980004510004750004700010800044000644300

Note 7. Commitments and Contingencies

Operating Leases

The Company leases office space under various operating leases. Total rent expense for all operating leases in the accompanying condensed consolidated statements of operations and comprehensive income was \$0.1 million for each of the three months ended September 30, 2024 and 2023 and \$0.3 million for each of the nine months ended September 30, 2024 and 2023.

On April 19, 2024, the Company entered into a

38-month operating lease for 5,817 square feet of office space in Irvine, California, that expires on June 30, 2027 (the "Irvine Lease Agreement"). On April 19, 2024, in conjunction with the Irvine Lease Agreement, the Company terminated an existing operating lease for 5,197 square feet of office space in Irvine, California, that was set to expire on December 31, 2024. On April 19, 2024, the effective date of the Irvine Lease Agreement, the Company recognized additional net ROU assets and lease liabilities in the amount of \$0.5 million.

On September 4, 2024, the Company entered into a 36-month operating lease for 6,138 square feet of office space in Burlington, Massachusetts, that expires on November 21, 2027

(the "Burlington Lease Agreement"). The existing lease will expire on November 20, 2024. The Company will recognize additional net ROU assets and lease liabilities for the Burlington Lease Agreement beginning November 21, 2024.

The Company determines if a contract contains a lease at inception. Our office leases have a remaining term of approximately 3 years and do not include options to extend the leases for additional periods.

Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities as adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we estimate incremental secured borrowing rates corresponding to the maturities of the leases. As we have no outstanding debt nor committed credit facilities, secured or otherwise, we estimate this rate based on prevailing financial market conditions, comparable company and credit analysis, and management's judgment.

Our leases contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term. Additionally, tenant incentives used to fund leasehold improvements are recognized when earned and reduce our right-of-use asset related to the lease. These are amortized through the right-of-use asset as reductions of expense over the lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

While we do not currently have any lease agreement with lease and non-lease components, we elected to account for lease and non-lease components as separate

[illegible]

[illegible]

300

(a) Includes variable operating lease expenses, which are immaterial								
Other information related to leases was as follows (in thousands, except lease term and discount rate):								

[illegible]

[illegible]

bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">272</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">279</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Weighted-average remaining lease term</p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td></tr></table>

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cfff0f;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating leases</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9.60</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.48</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td></tr></table></div><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">All noncancelable operating leases have remaining terms of less than<span

one year

. Future payments for these noncancelable operating leases for the remainder of the current fiscal year are as follows (in thousands):

September 30,	2024			

2024

2024 (remainder of)	
	\$
83	
2025	
191	
2026	
197	

align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2027</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total minimum lease payments</p></td> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">571</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr>

70	Present value of lease liabilities
501	Less current portion of operating lease liabilities

186

Non-current operating lease liabilities	315

315

Grants and Licenses

ALS Therapy Development Foundation, Inc. License Agreement

In May 2015, Anelixis executed a License Agreement (the "Agreement"), which is an exclusive patent rights agreement with ALS Therapy Development Foundation, Inc. ("ALS TDI") for certain patents and "know-how" of ALS TDI. This Agreement continues until the licensee terminates the agreement with ninety days written notice. The Agreement requires license fees payable to ALS TDI, subject to the achievement of certain milestones and other conditions.

family:Times New Roman;min-width:fit-content;">The first and second milestones of the Agreement are the dosing of the first subjects in a first toxicity study in non-human primates and the dosing of the first patient in a Phase I Clinical Trial, respectively. Both of these milestones were achieved as of December 31, 2018 and 2017. The fee due for the achievement of these milestones was \$1.0 million each. During 2018 and 2017, Anelixis issued \$1.0 million worth of its common stock in lieu of making a cash payment. There were no milestones achieved during the nine months ended September 30, 2024 or 2023.

style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Agreement was amended and restated in February 2020, and a first amendment to the restated license agreement was executed in September 2020. As amended in September 2020, the remaining milestone payments for a first licensed product total \$6.0 million. In the event that the Company develops a second licensed product, the Company is obligated to pay up to \$2.5 million in additional milestone payments.

style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In addition to the milestone payments, the Company is required to pay ALS TDI an amended annual license maintenance fee of \$0.1 million beginning on the earlier of January 1, 2022, the Company's first sublicense, or change in control, as defined in the Agreement. The

Company has made a \$0.1 million annual license maintenance fee each year since 2022.

Furthermore, the Company is required to pay ALS TDI fees based on reaching certain levels of annual net sales of any product produced with the patent rights. A royalty in the low single digits will be due on aggregate net sales. Upon the first calendar year of reaching \$500.0 million in aggregate net sales, the Company will be required to pay ALS TDI a one-time milestone payment of \$15.0 million. Upon the first calendar year of reaching \$1.0 billion in aggregate net sales, the Company is obligated to pay ALS TDI a one-time milestone payment of \$30.0 million.

Lonza Sales AG Inc. License Agreement

In September 2018, Anelixis executed a License Agreement (the "Lonza Agreement"), which is a manufacturing know-how rights agreement with Lonza Sales AG Inc. ("Lonza") for the use of certain processes and know-how related to the manufacture of tegoprubart. The Lonza Agreement continues until the later of the last Valid Claim (as defined therein) or ten years from the First Commercial Sale of tegoprubart, as defined and subject to the conditions therein. A royalty in the low single digits will be due on aggregate net sales of tegoprubart that is manufactured by Lonza or any other third-party or licensee.

eGenesis, Inc. Collaboration Agreement

In September 2022, and subsequently amended in January 2023, Eledon executed a non-exclusive collaborative research agreement with eGenesis, Inc. (the “eGenesis Agreement”), under which eGenesis will gain access to tegoprubart for eGenesis’ ongoing preclinical research and development xenotransplant studies of human-compatible organs and cells for the treatment of organ failure. eGenesis will pay Eledon for supplies of tegoprubart based on the number of study days per animal needed for the eGenesis preclinical xenotransplant studies. The eGenesis agreement continues until September 2025, unless terminated earlier by either party.

Legal Matters

The Company and its subsidiaries are not a party to or the subject of any claim or lawsuit that individually or in the aggregate is anticipated to have a material effect on the Company’s results of operations, financial condition or cash flows.

Indemnifications

In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves future claims that may be made against the Company but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future because of these indemnification obligations.

No amounts associated with such indemnifications have been recorded to date.

Contingencies

From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made, and such expenditures can be reasonably estimated. Management is not aware of any contingent liabilities requiring accrual at September 30, 2024.

100000100000300000300000P38M58172027-06-3051972024-12-31500000P36M61382027-11-21P3Y0

The components of lease expense were as follows (in thousands):

For the Nine Months Ended September 30,

2024	2023
Operating lease cost	
(a)	
\$	306

New Roman

margin-bottom:0;text-align:left;	white-space:pre-wrap;min-width:fit-content;
white-space:nowrap;vertical-align:bottom;	font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;
color:#000000;min-width:fit-content;	white-space:pre-wrap;vertical-align:bottom;text-align:center;
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;	color:#000000;white-space:pre-wrap;min-width:fit-content;
300	white-space:nowrap;vertical-align:bottom;
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	min-width:fit-content;

height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;	vertical-align:bottom;
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;
(a)	color:#000000;white-space:pre-wrap;min-width:fit-content;
Includes variable operating lease expenses, which are immaterial	vertical-align:bottom;
font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	white-space:pre-wrap;min-width:fit-content;

306000300000

text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;

color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;

Other information related to leases was as follows (in thousands, except lease term and discount rate):

font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;	white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;
margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;	visibility:collapse;
width:69.534%;box-sizing:content-box;	width:1.68%;box-sizing:content-box;
width:1%;box-sizing:content-box;	width:9.942%;box-sizing:content-box;
width:1%;box-sizing:content-box;	width:2.3%;box-sizing:content-box;
width:1%;box-sizing:content-box;	width:12.542%;box-sizing:content-box;
width:1%;box-sizing:content-box;	width:1%;box-sizing:content-box;

height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;	vertical-align:bottom;text-align:left;
font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;	white-space:pre-wrap;min-width:fit-content;
vertical-align:bottom;	font-size:8pt;margin-top:0;font-family:Times New

For the Nine Months Ended September 30,					
2024					
2023					
Supplemental Cash Flows Information					

[illegible]

\$	272
\$	279
Weighted-average remaining lease term	
	
	
	
	
	

[illegible]

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:75.06%;box-sizing:content-box;"></td><td style="width:3.76%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:19.18%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">September 30,</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#c0c0c0;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024 (remainder of)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table></div>

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> \$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">83</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background- color:#ffffff;word-break:break-word;"> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;">2025</p></td> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">191</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background- color:#eff0fc;word-break:break-word;"> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;">2026</p></td> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font- size:10pt;margin-top:0;font-family:Times New Roman;margin- bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text- align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">197</p></td> <td style="white-space:nowrap;vertical- align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background- color:#ffffff;word-break:break-word;"> <td style="white-space:pre- wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font- family:Times New Roman;margin-bottom:0;text-align:left;"><span					

[illegible]

Present value of lease liabilities	501
Less current portion of operating lease liabilities	186

<td style="text-indent: 10pt; white-space: pre-wrap; vertical-align: bottom;">
<p style="margin-left: 10pt; text-indent: 0; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Non-current operating lease liabilities</p></td> <td style="text-indent: 10pt; white-space: pre-wrap; vertical-align: bottom;"><p style="margin-left: 10pt; text-indent: 0; font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td>
<td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">315</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> </tr>
</table>P1Y8300019100019700010000057100070000501000186000315000
style="font-size: 10pt; margin-top: 18pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Note 8. Stockholders' Equity </p><p style="font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Preferred Stock</p><p style="text-indent: 5.333%; font-size: 10pt; margin-top: 6pt; font-family: Times New Roman; margin-bottom: 0; text-align: left;">The Company has 5,000,000 authorized shares of preferred stock with a par value of \$0.001 per share:</p><div class="item-list-element-wrapper" style="margin-left: 4.528%; display: flex; margin-top: 6pt; justify-content: flex-start; align-items: baseline; margin-bottom: 0; min-width: 4.537%; text-align: left;"><span style="color: #000000; white-space: pre-wrap; font-

size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">•<div style="width:100%;display:inline;">Series X1 non-voting convertible preferred stock, 515,000 shares designated; 110,086 shares issued and outstanding, respectively, at each of September 30, 2024 and December 31, 2023; and </div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">Series X non-voting convertible preferred stock, 10,000 shares designated; 4,422 shares issued and outstanding, respectively, at each of September 30, 2024 and December 31, 2023. </div></div><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Each share of the Series X1

or X non-voting convertible preferred stock (the "Preferred Stock") is convertible into
55.5556
shares of common stock, at the option of the holder at any time, subject to certain limitations, including, that the holder will be prohibited from converting the Preferred Stock into common stock if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of shares of common stock above a conversion blocker, which is initially set at
9.99
% or
9.9
% of the total common stock then issued and outstanding immediately following the conversion of such shares of Series X Preferred Stock or Series X
1

Preferred Stock, respectively. The holder of the Preferred Stock is entitled to receive dividends on shares of the Preferred Stock equal (on an as-if-converted-to-common-stock basis and without regard to any beneficial ownership limitations) to and in the same form as dividends actually paid on shares of the common stock. No other dividends will be paid on shares of the Preferred Stock. In the event of any liquidation,

dissolution or winding up, the holder of the Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Preferred Stock were fully converted to common stock, which amounts shall be paid pari passu with all holders of common stock. Shares of the Preferred Stock will generally have no voting rights, except as required by law and except that consent of a majority of the holders of either series of outstanding Preferred Stock will be required to amend the terms of such series.

2023 Securities Purchase

Agreement

On April 28, 2023, the Company entered into the 2023 Securities Purchase Agreement with certain investors, pursuant to which the Company agreed to issue and sell to the investors in the 2023 Private Placement (i) in an initial closing, (a) an aggregate of 15,151,518 shares (the “Shares”) of the Company’s common stock, \$0.001 par value per share, or pre-funded warrants in lieu thereof (the “Pre-Funded Warrants”), and (b) common stock warrants exercisable into 15,151,518 shares of common stock (or Pre-Funded Warrants in lieu thereof) (the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”); (ii) in the Second Closing, , upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 20,202,024 shares of common stock (or Pre-Funded Warrants); and (iii) in the Third Closing, , upon the satisfaction or waiver of specified conditions set forth in the 2023 Securities Purchase Agreement, an aggregate of 25,252,530 shares of common stock (or Pre-Funded Warrants), in each case subject to customary adjustments as provided in the 2023 Securities Purchase Agreement, Pre-Funded Warrant or Common Warrant, as applicable. Each Common Warrant has an exercise price of \$3.00

*wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per share and expires five years after issuance. The Pre-Funded Warrants are exercisable immediately and until exercised in full, with an exercise price of \$** per share. </p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Pre-Funded Warrants and Common Warrants are subject to specified beneficial ownership limitations, which are generally set at 9.99% of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted. The Shares, the Warrants, and the shares of common stock issuable upon the exercise of the Warrants, have not been registered under the Securities Act of 1933, as amended, and were offered pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act of 1933, as amended, and Rule 506(b) promulgated thereunder.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">On May 5, 2023, the initial closing occurred and the Company received \$35.0 million, or net proceeds of approximately \$33.0 million after deducting offering costs, in exchange for 8,730,168 shares of common stock and Pre-Funded Warrants to purchase <span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-*

6,421,350 shares of common stock.

On July 8, 2024, the Second Closing occurred and the Company received gross proceeds of \$2.1 million, or net proceeds of approximately \$2.0 million after deducting offering costs, in exchange for 909,088 shares of common stock.

On September 30, 2024 and October 1, 2024, the Third Closing occurred and the Company received gross proceeds of \$4.0 million, or net proceeds of approximately \$3.8 million after deducting offering costs, in exchange for 1,727,400 shares of common stock.

In connection with the 2023 Private Placement, the Company filed on May 18, 2023, a registration statement on Form S-3 (the "2023 Registration Statement") with the SEC

to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2023 Registration Statement became effective on June 2, 2023.

In August 2024, the Company concluded that the Common Warrants, and the potential issuance of Pre-Funded Warrants in lieu of additional shares of common stock in the Second and Third Closings (the “Subsequent Closing Warrants”) do not meet the conditions to be classified as equity instruments under ASC 815-40 and must instead be recorded as liabilities on the Company’s consolidated balance sheets at their fair value and remeasured at fair value for each subsequent reporting period.

The valuation of the Common Warrants and the Subsequent Closing Warrants is adjusted to fair value (Level 3) at each balance sheet date until the Common Warrants and the Subsequent Closing Warrants are settled or expired.

The following table presents the assumptions used in the Black-Scholes option pricing model to determine the fair value of warrants as of September 30, 2024 as follows:

	Black-Scholes Assumptions	Warrant Assumptions	Warrant Assumptions	Warrant Assumptions	Warrant Assumptions	Warrant Assumptions
Exercise Price	\$1.00	\$1.00	\$1.00	\$1.00	\$1.00	\$1.00
Term	1.00	1.00	1.00	1.00	1.00	1.00
Volatility	20.00%	20.00%	20.00%	20.00%	20.00%	20.00%
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Interest Rate	5.00%	5.00%	5.00%	5.00%	5.00%	5.00%

September 30, 2024	
December 31, 2023	
Risk-free interest rate	
3.58	
%	
3.84	
%	
3.88	
%	

Expected volatility	93.46%	98.39%	%
Expected term (in years)	89.08%	94.28%	%
Expected term (in years)	3.75	5.25	

[illegible]

Agreement

On May 6, 2024, the Company entered into a Securities Purchase Agreement (the "2024 Securities Purchase Agreement") with certain institutional and accredited investors, pursuant to which the Company agreed to issue and sell to the investors in a private placement (the "2024 Private Placement") an aggregate of 13,110,484 shares (the "2024 Shares") of the Company's common stock, \$0.001 par value per share at a price of \$2.37 per share, and pre-funded warrants (the "2024 Pre-Funded Warrants") at a price of \$2.369 per underlying share, which are exercisable to purchase 7,989,516 shares of common stock at an exercise price of \$0.001 per share. The 2024 Pre-Funded Warrants were issued in lieu of shares of common stock and are exercisable immediately and until exercised in full. The 2024 Pre-Funded Warrants are subject to specified beneficial ownership limitations (equal to 4.99% or 9.99

content;">% as determined by holder of each such warrant) of the total common stock then issued and outstanding immediately following the exercise of such warrants, and provided that any beneficial ownership limitation may not exceed 19.99% unless otherwise permitted. </p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;">The 2024 Pre-Funded Warrants were classified as a component of permanent stockholders' equity within additional paid-in-capital. The 2024 Pre-Funded Warrants are equity classified because they are freestanding financial instruments that are legally detachable and separately exercisable from the equity instruments, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, permit the holders to receive a fixed number of common shares upon exercise, are indexed to the Company's common stock and meet the equity classification criteria. In addition, the 2024 Pre-Funded Warrants do not provide any guarantee of value or return.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The 2024 Private Placement resulted in gross proceeds to the Company of \$50.0 million, or net proceeds of approximately \$48.1 million after deducting offering costs. The Company intends to use the net proceeds from the 2024 Private Placement to fund pre-commercial activities for its products and general corporate purposes.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">In connection with the 2024 Private Placement, the Company filed on May 24, 2024, a registration statement on Form S-3 (the "2024 Registration Statement") with the SEC to register for resale the Shares and the shares of common stock issuable upon the exercise of the Warrants. The 2024 Registration Statement

became effective on June 5, 2024.

2024 Equity Distribution Agreement

On September 20, 2024, the Company entered into an Open Market Sale Agreement (the “Sales Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) to sell shares of the Company’s common stock, par value \$0.001 per share (the “Common Stock”), having aggregate sales proceeds of up to \$75.0 million, from time to time, through an “at the market” equity offering program under which Guggenheim Securities will act as sales agent. In connection with the Sales Agreement, the Company filed on September 20, 2024 a registration statement on Form S-3 containing a prospectus and prospectus supplement (the “ATM Registration Statement”) with the SEC. The ATM Registration Statement became effective on October 2, 2024. The Company has not sold any shares under the Sales Agreement.

2023 Conversion Agreement of Non-Voting Convertible Preferred Stock

On May 16, 2023, Cormorant Global Healthcare Master Fund LP provided notice to convert (i) 1,782 shares of Series X Non-Voting Convertible Preferred Stock for 99,000 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X Non-Voting

Convertible Preferred Stock, and (ii) 7,883.586 shares of Series X 1 Non-Voting Convertible Preferred Stock for 437,977 shares of common stock in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series X 1 Non-Voting Convertible Preferred Stock. The conversion was completed on May 23, 2023.

Exercise of Pre-Funded Warrants from 2023 Securities Purchase Agreement

On July 10, 2023, Armistice Capital Master Fund Ltd. (the “Exercising Stockholder”) exercised Pre-Funded Warrants to purchase 501,197 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On July 14, 2023, the Company issued 501,197 shares of common stock to the Exercising Stockholder in accordance with such exercise.

wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">
</p><p style="text-indent:5.333%;font-size:10pt;margin-
top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;">On November 2, 2023,
the Exercising Stockholder exercised Pre-Funded Warrants to purchase
<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;min-width:fit-
content;">653,000<span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">
shares of common stock at an exercise price of \$<span style="font-
size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-
wrap;min-width:fit-content;">0.001<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;"> per share, which were
issued in conjunction with the 2023 Securities Purchase Agreement. On
November 6, 2023, the Company issued <span style="font-
size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-
wrap;min-width:fit-content;">653,000<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;"> shares of common stock
to the Exercising Stockholder in accordance with such exercise.
</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;">On January 30, 2024, the
Exercising Stockholder exercised Pre-Funded Warrants to purchase
<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;min-width:fit-
content;">600,000<span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">
shares of common stock at an exercise price of \$<span style="font-
size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-
wrap;min-width:fit-content;">0.001<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;"> per share, which were
issued in conjunction with the 2023 Securities Purchase Agreement. On
January 30, 2024, the Company issued <span style="font-
size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-
wrap;min-width:fit-content;">600,000<span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;"> shares of common stock
to the Exercising Stockholder in accordance with such exercise.
</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-
family:Times New Roman;margin-bottom:0;text-align:left;"><span
style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;">On May 7, 2024, the
Exercising Stockholder exercised Pre-Funded Warrants to purchase
<span style="font-size:10pt;font-family:Times New
Roman;color:#000000;white-space:pre-wrap;min-width:fit-
content;">583,000<span style="color:#000000;white-space:pre-

shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On May 9, 2024, the Company issued 583,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.

On July 11, 2024, the Exercising Stockholder exercised Pre-Funded Warrants to purchase 240,000 shares of common stock at an exercise price of \$0.001 per share, which were issued in conjunction with the 2023 Securities Purchase Agreement. On July 11, 2024, the Company issued 240,000 shares of common stock to the Exercising Stockholder in accordance with such exercise.

Common Stock Warrants

As of September 30,

[illegible]

	Common Stock Warrants	
	Pre-Funded Warrants	All Other Warrants

Total	
Balance as of December 31, 2023	15,151,518
636,514	5,776,270

space:nowrap;vertical-align:bottom;"/> 			21,564,302								
<td style="white-space:pre-wrap;vertical-align:bottom;"></td> Issued											

[illegible]

[illegible]

[illegible]

(9,581)	
Balance as of September 30, 2024	
15,151,518	
12,342,786	

626,933	28,121,237
626,933	28,121,237

Preferred Stock Warrants

As of September 30, 2024, there were 50,207.419 warrants exercisable into Series X 1 Non-Voting Convertible Preferred Stock, which are convertible into

[illegible]

Total	
Balance as of December 31, 2023	
50,207.419	
Issued	
Exercised	

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">— </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,207.419</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div>50000000.001515000110086110086110086110086100004422442244 style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:8pt;text-align:left;">The following table presents the assumptions used in the Black-Scholes option pricing model to determine the fair value of warrants as of September 30, 2024 as follows:</p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:54.28%;box-

[illegible]

</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">3.84%3.88%</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Expected volatility</p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">93.46%98.39%</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">89.08%94.28%</p></td><td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:10pt;background-color:#eff0fc;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:top;"><p></p></td><td colspan="3"></td></tr></table>

Expected term (in years)		
3.75		
5.25		
4.5		
6.0		
Share price		
\$		
2.49		

space:pre-wrap;min-width:fit-content;"/>

style="white-space:nowrap;vertical-align:bottom;"/> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>color:#000000;min-width:fit-content;"/>\$	style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"/> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>color:#000000;white-space:pre-wrap;min-width:fit-content;"/>1.80	style="white-space:nowrap;vertical-align:bottom;"/> font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>min-width:fit-content;"/>

0.03580.03840.03880.93460.98390.89080.9428P3Y9MP5Y3MP4Y6

style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>**color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"/>**The following table shows the warrants to purchase common stock activity:

style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>**white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"/>**

visibility:collapse;"/>														
width:31.253%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.561%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>
width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:13.745%;box-sizing:content-box;"/>	width:1%;box-sizing:content-box;"/>	width:1.401%;box-sizing:content-box;"/>

height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"/>													
vertical-align:bottom;"/> **font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>****white-space:pre-wrap;min-width:fit-content;"/>**													
vertical-align:bottom;"/> **font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"/>****white-space:pre-wrap;min-width:fit-content;"/>**													
vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"/> **font-size:8pt;margin-top:0;font-family:Times New**													

Roll-Forward of Warrant Activity	
Common Stock Warrants	Pre-Funded Warrants
All Other Warrants	

[illegible]

[illegible]

content;">7,989,516</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,989,516</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Exercised</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

1,423,000	Cancelled/Expired

space:pre-wrap;vertical-align:bottom;"/>

bottom:0.5pt solid #000000;"/>

space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"/>

—

align:bottom;border-bottom:0.5pt solid #000000;"/>

bottom:0.5pt solid #ffffff03;"/>

td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>

td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"/>

—

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>

td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"/>

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>

td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"/>

(9,581)

td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>

td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"/>

[illegible]

align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">626,933</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">28,121,237</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr></table>151515185776270636514215643020798951607989516014230000<div style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As ofSeptember 30, 2024, there were50,207.419warrants exercisable into Series X1 Non-Voting Convertible Preferred Stock, which are convertible into<span style="font-

size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2,789,301 shares of common stock (after rounding for fractional shares and subject to beneficial ownership conversion limitations). </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:77%;box-sizing:content-box;"></td> <td style="width:1.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:19.48%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Roll-Forward of Series X1Non-Voting Convertible Preferred Warrant Activity</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr>

Total	
Balance as of December 31, 2023	
50,207.419	
Issued	
Exercised	

family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of September 30, 2024</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,207.419</p></td><td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p>50207.419278930150207.4190050207.419<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 9. Stock-based Compensation</p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value.</p><p style="text-indent:5.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-

The fair value of stock options is determined using the Black-Scholes option pricing model, using assumptions which are subjective and require significant judgment and estimation by management. The risk-free rate assumption was based on observed yields from governmental zero-coupon bonds with an equivalent term. The expected volatility assumption was based on historical volatilities of a group of comparable industry companies whose share prices are publicly available. The peer group was developed based on companies in the pharmaceutical industry. The expected term of stock options represents the weighted-average period that the stock options are expected to be outstanding. Because the Company does not have historical exercise behavior, the Company determined the expected life assumption using the simplified method for stock options granted to employees, which is an average of the options ordinary vesting period and the contractual term.

For stock options granted to the Company's board of directors (the "Board"), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination.

The expected dividend assumption was based on the Company's history and expectation of dividend payouts. The Company has not paid and does not expect to pay dividends at any time in the foreseeable future. The Company recognizes forfeitures on an actual basis and as such did not estimate forfeitures to calculate stock-based compensation.

Restricted Stock Units ("RSUs") are measured and recognized based on the quoted market price of our common stock on the date of grant.

On July 10, 2024, the Company held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved an

amendment to the Company's 2020 Long Term Incentive Plan (the "2020 Plan"). The 2020 Plan, as amended, (i) reflects an increase in the limit on the aggregate number of shares of the Company's common stock that may be delivered pursuant to all awards granted under the 2020 Incentive Plan by an additional 3,500,000 shares so that the new aggregate share limit under the 2020 Plan is 17,960,000 shares, and (ii) extends the date through which the Company may grant new awards under the 2020 Plan from November 15, 2030 to April 28, 2034.

On May 1, 2023, the Company issued stock option awards to its employees with both time-based and performance-based vesting requirements, totaling 7,381,857 stock options, with 1,476,372 of the granted stock options subject to the Company's customary time-based vesting schedule. The remaining 5,905,485 stock options granted are subject to both customary time-based vesting requirements and performance-based vesting requirements that are based on the same clinical development milestones applicable to the Second and Third Closings of the 2023 Private Placement as specified in the 2023 Securities Purchase Agreement.

In December 2023, the Company amended the performance-based vesting requirements with its named executive officers and other employees that upon the Second Closing and Third Closing, a full or prorated amount of each closing installment shall vest based on the percentage of funding received relative to the total funding opportunity represented by the investors' Second Closing and Third Closing subscription amounts. On June 13, 2024, the

performance-based vesting requirement based on the milestones applicable to the Second Closing were satisfied, and 1,980,952 stock options were issued.

The 2014 Plan was closed to new grants following the initial approval of the 2020 Plan, and therefore, there were no shares reserved for issuance under the 2014 Plan as of September 30, 2024. The number of shares reserved for issuance under the 2020 Plan and ESPP was 6,388,742 and 24,077 shares, respectively, as of September 30, 2024.

Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

[illegible]

2024	
2023	
2024	
2023	
2024	
2023	
2023	
Research and development	

\$	388
\$	321
\$	321
\$	1,552
\$	1,173

align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">General and administrative</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,395</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,413</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">4,988</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,662</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#eff0fe;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total stock-based compensation</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,783</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-

P12MP18M3500000179600007381857147637259054851980952063887422

For stock options granted to the Company's board of directors (the "Board"), the Company determined the expected life assumption using the simplified method as the starting point with an average period of twelve (12) months added to take into account the extended range of time of 12 to 18 months that vested stock options granted to Board members may be exercised upon termination.

Total stock-based compensation expense was recognized in our condensed consolidated statements of operations and comprehensive loss as follows (in thousands):

	2014	2013	2012	2011	2010
Cost of sales	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Operating expenses	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Other income	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Other expense	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Income before income taxes	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Income tax expense	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Net income	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000

For the Three Months Ended September 30,

	2014	2013	2012	2011	2010
Cost of sales	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Operating expenses	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Other income	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Other expense	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Income before income taxes	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Income tax expense	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000
Net income	\$1,000	\$1,000	\$1,000	\$1,000	\$1,000

wrap;font-weight:bold;min-width:fit-content;">For the Nine Months Ended September 30,</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"></p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid

#000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Research and development</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">388</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">321</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-

content;">1,552</p></td>	
<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
<td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
<td style="white-space:nowrap;vertical-align:bottom;"> \$ </td>	
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,173 </td>	
<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
</tr>	
<tr style="height:10pt;background-color:#ffffff;word-break:break-word;">	
<td style="white-space:pre-wrap;vertical-align:top;"> General and administrative </td>	
<td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
</td>	
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,395 </td>	
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
</td>	
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
</p></td>	
<td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,413 </td>	
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">	

4,988	3,662	Total stock-based compensation

1,783	
\$	
1,734	
\$	
6,540	
\$	
4,835	

388000321000155200011730001395000141300049880003662000178

Note 10. Net Income/Loss Per Share

Basic net income/loss per common share is calculated by dividing the net income/loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net income/loss per share is computed by dividing the net income/loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period determined using the treasury stock and if-converted methods. For purposes of the diluted net income/loss per share calculation, incentive stock options, restricted stock units, preferred stock and warrants are considered to be potentially dilutive securities and are excluded from the calculation of diluted net income/loss per share because their effect would be anti-dilutive. Basic weighted average shares outstanding for the three and nine months ended September 30, 2024 and 2023

include	12,342,786	and	6,429,270	, reflectively, shares underlying pre-funded warrants to purchase common shares. As the shares underlying these pre-funded warrants can be issued for little consideration (an exercise price per share equal to \$
	0.001			per share), these shares are deemed to be issued for purposes of basic earnings per share.

[illegible]

[illegible]

(In thousands, except share and per share data)		
		
		
	(As Restated)	
		
		
		
		
(As Restated)		
		
Net income (loss)		

	\$	76,971	(	9,906	)	\$	8,433	\$

86,438	Undistributed earnings allocated to participating securities
22,542	—

[illegible]

[illegible]

[illegible]

space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr><td style="height:9pt;background-color:#cfff0f;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(94,475</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td>

69,519	
Net loss attributable to common shares, basic	
17,504	

	\$	(9,906)	)	\$	(61,086)	)	\$	(86,438)	)

double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr>
<tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="text-indent:10pt;vertical-align:bottom;">
<p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td>
<td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
</p></td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
<td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td>
</tr><tr style="height:9pt;background-color:#cfff0f;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-

[illegible]

[illegible]

[illegible]

[illegible]

style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">29,974,400</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,106,746</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,813,085</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-

[illegible]

[illegible]

Diluted net loss per common share
\$0.32
\$0.33
\$1.42

bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3.79</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The computation of diluted earnings per share excludes incentive stock options, restricted stock units, preferred stock and warrants that are anti-dilutive. The following table provides a summary as of September 30, 2024 and 2023 of common share equivalents that were excluded because their inclusion would have been anti-dilutive. </p><p style="text-indent:5.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:63.247%;box-sizing:content-box;"></td><td style="width:1.44%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.937%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.44%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.937%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;">

For the Nine Months									
Ended September 30,									
2024									
2023									

[illegible]

16,543,376	
15,238,434	
Common and preferred warrants outstanding	
18,567,751	

align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,577,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,472,694</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">40,177,333</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> </table> <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></div>1234278612342786642927064292700.001 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.251%;box-

[illegible]

2024	
2023	
2024	
2023	
2024	
2023	

[illegible]

space:nowrap;vertical-align:bottom;"/>

\$

 76,971 | | | | (9,906 |) | | \$ | 8,433 | | | \$ | |

content;">(86,438</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:9pt;background-color:#ffffff;word-break:break-word;"><td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Undistributed earnings allocated to participating securities</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(22,542</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table>

[illegible]

	(9,906)
	5,551
	86,438
	Allocated undistributed earnings allocated to participating securities

[illegible]

Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, net of tax	94,475	—	

[illegible]

\$	9,906	
61,086		
\$	86,438	

[illegible]

[illegible]

[illegible]

~~size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common stock warrants</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,532,422</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,663,697</p></td><td style="white-~~

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"/>
<p style="font-size:9pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"/><span style="min-width:fit-
content;"/> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #ffffff03;"/><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"/><span style="white-space:pre-wrap;min-width:fit-
content;"/> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"/><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"/> </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt
solid #000000;text-align:center;"/><p style="font-size:9pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>

—</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"/><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"/> </p></td>
</tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-
word;"/> <td style="white-space:pre-wrap;vertical-align:bottom;"/><p
style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"/><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;"/>Weighted-average number of common shares
outstanding, diluted</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;"/><p style="font-size:9pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:left;"/><span
style="white-space:pre-wrap;min-width:fit-content;"/> </p></td>
<td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt
double #000000;"/><p style="font-size:9pt;margin-top:0;font-family:Times
New Roman;margin-bottom:0;text-align:left;"/><span style="min-width:fit-
content;"/> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;text-align:center;"/><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"/><span style="font-
size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;"/>55,478,342</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:2.25pt double
#000000;"/><p style="font-size:9pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"/><span style="min-width:fit-
content;"/> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:2.25pt double #ffffff03;"/><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"/><span style="white-space:pre-wrap;min-width:fit-
content;"/> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:2.25pt double #000000;"/><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"/> </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt
double #000000;text-align:center;"/><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"/>

[illegible]

[illegible]

	\$ (0.33) \$ 0.13 \$ (3.79)
	Diluted net loss per common share

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
\$</p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-
content;">(<span style="font-size:9pt;color:#000000;white-
space:pre-wrap;min-width:fit-content;">3.79</p></td> <td
style="white-space:nowrap;vertical-align:bottom;"><p style="font-
size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">)
</p></td> </tr> </table>76971000-99060008433000-
8643800022542000288200054429000-99060005551000-
86438000225420002882000-94475000-69519000-17504000-9906000-
61086000-
86438000519459202997440041443049228130853532422000166369700055
0.330.13-3.79-0.32-0.33-1.42-3.79<p style="text-indent:5.333%;font-
size:10pt;margin-top:6pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-
content;">The computation of diluted earnings per share exclude
<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-
family:Times New Roman;min-width:fit-content;">s incentive stock options,
restricted stock units, preferred stock and warrants that are anti-dilutive.
The following table provides a summary as of September 30, 2024 and 2023
of common share equivalents that were excluded because their inclusion
would have been anti-dilutive.<span style="color:#000000;white-
space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-
content;"> </p><p style="text-indent:5.333%;font-
size:10pt;margin-top:6pt;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-
size:10pt;font-family:Times New Roman;min-width:fit-content;">
</p> <table style="margin-left:auto;border-spacing:0;table-
layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
<tr style="visibility:collapse;"> <td style="width:63.247%;box-
sizing:content-box;"></td> <td style="width:1.44%;box-sizing:content-
box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td
style="width:14.937%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td
style="width:1.44%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> <td
style="width:14.937%;box-sizing:content-box;"></td> <td
style="width:1%;box-sizing:content-box;"></td> </tr> <tr
style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-
break:break-word;"> <td style="vertical-align:bottom;text-align:left;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="vertical-align:bottom;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td colspan="6">

For the Nine Months Ended September 30,											
			2024								
2023											

Preferred Stock	
6,361,567	
6,361,567	
Stock options outstanding and other equity awards	

wrap;min-width:fit-content;">16,543,376</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,238,434</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:10pt;background-color:#cff0fe;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common and preferred warrants outstanding</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">18,567,751</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-

18,577,332	
Total	
41,472,694	
40,177,333	

6361567636156716543376152384341856775118577332414726944017

Note 11. Subsequent Events

bottom:8pt;margin-right:1.111%;text-align:left;">On October 29, 2024, the Company entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners, LLC, as representative of the several underwriters named therein (the "Underwriters") in connection with the underwritten offering, issuance and sale by the Company (the "Offering") of 18,356,173 shares (the "Shares") of the Company's common stock, par value \$0.001 per share (the "Common Stock"), at an offering price of \$3.65 per share (the "Common Stock Purchase Price"), and pre-funded warrants (the "Pre-Funded Warrants") at a price of \$3.649 per Pre-Funded Warrant, which are exercisable to purchase 4,931,507 shares of Common Stock at an exercise price of \$0.001 per </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.111%;text-align:left;">share. The Offering resulted in gross proceeds to the Company of \$85.0 million, or net proceeds of approximately \$<span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-

content;">79.5
million after deducting underwriting discounts and commissions and offering expenses.
</p>183561730.0013.653.64949315070.0018500000079500000<p

Restatement of Previously Issued Consolidated Financial

Statements</p><p style="text-indent:5.393%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.111%;text-align:left;">In the course of

preparing the Company's Condensed Consolidated Financial Statements as of and for the three and six months ended June 30, 2024, the Company determined that a correction was necessary with respect to the Company's reporting and recording of the fair value of the Common Warrants and the Subsequent Closing Warrants, issuable by the Company in the Second and Third Closing contingent upon the satisfaction or waiver of certain specified conditions set forth therein (See Note 8).</p><p style="text-indent:5.393%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.111%;text-align:left;">The Company has

historically reported the Common Warrants and Subsequent Closing Warrants as equity instruments, because (i) of the respective holders' ability to settle the Common Warrants and Subsequent Closing Warrants by issuance of a fixed number of shares of common stock or Pre-funded Warrants and (ii) the Common Warrants and Subsequent Closing Warrants contain a fixed exercise price and contain no cash settlement obligation. However, in the course of preparing the Company's Condensed Consolidated Financial Statements as of and for the three and six months ended June 30, 2024, management of the Company concluded that the Common Warrants and the Subsequent Closing Warrants do not meet the conditions to be classified as equity instruments under ASC 815-40, and must instead be recorded as liabilities on the Company's balance sheet at their fair value and remeasured at fair value for each subsequent reporting period, with the initial fair value and fair value of financial instruments issued in excess of proceeds and any change in fair value recorded in the condensed consolidated statements of operations and comprehensive income as a gain or loss.</p><p style="text-indent:5.393%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:8pt;margin-right:1.111%;text-align:left;">Management prepared a

quantitative and qualitative analysis of the errors in accordance with the U.S. SEC Staff's Accounting Bulletin Nos. 99 and 108, Materiality, and concluded the impact of the errors are material to the Company's

previously reported interim unaudited condensed consolidated financial statements as of and for the three and nine months ended September 30, 2023. As a result, the Company has restated its Condensed Consolidated Balance Sheet, Condensed Consolidated Statement of Operations and Comprehensive Loss, Condensed Consolidated Statement of Stockholders' Equity, and Condensed Consolidated Statement of Cash Flows as of and for the three and nine months ended September 30, 2023. The restatement includes adjustments to Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds, Additional paid-in capital, and Accumulated Deficit.

The impact of the correction of the misstatements is summarized below (in thousands):

	As of September 30, 2023	For the Three Months Ended September 30, 2023	For the Nine Months Ended September 30, 2023	Total	Change from Previously Reported Financial Statements
Assets:	\$—	\$—	\$—	\$—	\$—
Liabilities:	\$—	\$—	\$—	\$—	\$—
Equity:	\$—	\$—	\$—	\$—	\$—
Cash flows:	\$—	\$—	\$—	\$—	\$—

As of September 30,
2023

Corrected Condensed

[illegible]

[illegible]

space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55,738</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">60,472</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr><td style="height:10pt;background-color:#eff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Common stock</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">24</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">—</p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">324,876</p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> </tr> <tr
style="height:10pt;background-color:#cff0fc;word-break:break-word;">
<td style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">Accumulated deficit</p></td> <td
style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">(<span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">233,565</p></td> <td
style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">)</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New

[illegible]

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(55,738</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,597</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.756%;box-sizing:content-box;"></td><td style="width:1.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.443%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.06%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.443%;box-sizing:content-box;"></td><td

[illegible]

Corrected Consolidated Consolidated Statements of Operations and Comprehensive Loss (Unaudited)	As Previously Reported	Impact
Restatement	As Restated	As Previously Reported

Restatement Impact	As Restated	Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds
As Restated	Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds	Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds

[illegible]

[illegible]

443	9,906	30,700

[illegible]

[illegible]

$$\frac{1.35}{2.44} = \frac{3.79}{10}$$

Roman;margin-bottom:0;text-align:left;"> </p></div><div style="font-size:10pt;font-family:Times New Roman;"> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:33.907%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.102%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.842%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.842%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.602%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.842%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="22" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">For the Nine Months Ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:6pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr>

Accumulated Deficit										
										
										
Total Stockholders' Equity										
										
Corrected Condensed Consolidated Statements of Stockholders' Equity (Unaudited)										
										
As Previously Reported										
										
										
Restatement Impact										
										

As Restated	
As Previously Reported	
As Restated	
As Restated	

word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of December 31, 2022</p></td>	<td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(202,865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(202,865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

[illegible]

[illegible]

[illegible]

Roman; margin-bottom: 0; text-align: left;"))</p></td> <td style="text-indent: 5pt; white-space: pre-wrap; vertical-align: top; border-bottom: 0.5pt solid #ffffff03;"><p style="margin-left: 5pt; text-indent: 0; font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">—</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">(10,772</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">)</p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #ffffff03;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"> </p></td> <td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: center;"><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">(10,772</p></td> <td style="white-space: nowrap; vertical-align: bottom; border-bottom: 0.5pt solid #000000;">

[illegible]

align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(**213,637</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)****</p></td><td style="white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(****213,637</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)****</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-**

74,792	Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs
74,792	

align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—
</p></td> <td style="white-space:nowrap;vertical-align:bottom;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="text-indent:5pt;white-space:pre-
wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—
</p></td> <td style="white-space:nowrap;vertical-align:bottom;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">—</p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">
<span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-
width:fit-content;">33,017</p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,017</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issuance of common stock in connection with conversion of X1non-voting convertible preferred stock</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span

1

[illegible]

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">— </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—
</p></td> <td style="white-space:nowrap;vertical-align:bottom;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">1,720</p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="text-indent:5pt;white-space:pre-
wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;"><span style="white-space:pre-wrap;min-width:fit-
content;"> </p></td> <td style="white-space:nowrap;vertical-
align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-
family:Times New Roman;margin-bottom:0;text-align:right;"><span
style="color:#000000;white-space:pre-wrap;min-width:fit-content;">—
</p></td> <td style="white-space:nowrap;vertical-align:bottom;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-

align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,720</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss and comprehensive loss</p></td><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,579</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(56,181</p></td><td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;"></p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;font-size:8pt;min-width:fit-content;">(<span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">65,760</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">)</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;font-size:8pt;min-width:fit-content;">(<span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">9,579</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">)
</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-
align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-
left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-

[illegible]

$\frac{56}{181}$	$\frac{279}{397}$
$\frac{99}{949}$	$\frac{99}{949}$

align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(56,181</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,768</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issuance of common stock in connection with exercise of pre-funded warrants</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-

[illegible]

<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">	
 </p></td>	
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1</p></td>	<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<tr style="height:8pt;background-color:#cfff00;word-break:break-word;">	
<td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Stock-based compensation</p></td>	<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td>
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td>
<p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>
<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	<td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>

align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,734</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,734</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-

[illegible]

align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,349</p></td>	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td>	text-indent:5pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">443</p></td>	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td>	white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,906</p></td>

align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:8pt;background-color:#cfff00;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of September 30, 2023</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(233,565</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(55,738</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times

New Roman; margin-bottom: 0; text-align: left; ">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">(289,303</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">)</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">91,335</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td><td style="white-space: pre-wrap; vertical-align: top; border-bottom: 2.25pt double #ffffff03; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "></p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">\$</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; text-align: center; "><p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right; ">(55,738</p></td><td style="white-space: nowrap; vertical-align: bottom; border-bottom: 2.25pt double #000000; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; ">)</p></td><td style="white-space: pre-wrap; vertical-align: bottom; border-bottom: 2.25pt double #ffffff03; "><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left; "><span style="white-space: pre-wrap; min-

\$	35,597											
For the Nine Months Ended September 30, 2023												

Corrected Condensed Consolidated Statements of Cash Flows (Unaudited)	
As Previously Reported	Restatement Impact
As Restated	Net loss

	\$			30,700			\$		55,738			\$		86,438		
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds																

[illegible]

Net cash used in operating activities	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()
	\$ 30,396
	()

New Roman; margin-bottom: 0; text-align: left;"></p></td></tr></table></div><p style="text-indent: 5.391%; font-size: 10pt; margin-top: 18pt; font-family: Times New Roman; margin-bottom: 8pt; margin-right: 1.065%; text-align: left;">The impact of the correction of the misstatements is summarized below (in thousands):</p><table style="margin-left: auto; border-spacing: 0; table-layout: fixed; width: 100.0%; border-collapse: separate; margin-right: auto;"><tr style="visibility: collapse;"><td style="width: 61.048%; box-sizing: content-box;"></td><td style="width: 1.58%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 9.498000000000001%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 1.44%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 9.498000000000001%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 1.44%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td><td style="width: 9.498000000000001%; box-sizing: content-box;"></td><td style="width: 1%; box-sizing: content-box;"></td></tr><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word; text-align: left;"><td style="vertical-align: bottom;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><td style="vertical-align: bottom;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><td colspan="10" style="vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;">As of September 30, 2023</p></td><td style="vertical-align: bottom; border-bottom: 0.5pt solid #000000;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td></tr><tr style="height: 8pt; background-color: #ffffff; white-space: pre-wrap; word-break: break-word;"><td style="vertical-align: bottom;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">Corrected Condensed Consolidated Balance Sheets (Unaudited)</p></td><td style="vertical-align: bottom; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: center;"></p></td><td colspan="2" style="vertical-align: bottom; border-bottom: 0.5pt solid #000000; text-align: left;"><p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-

bottom:0;text-align:center;">As Previously Reported</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Restatement Impact</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">As Restated</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Warrant liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td>

[illegible]

[illegible]

—	
24	
Additional paid-in capital	
324,876	
—	

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> <td
style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">324,876</p></td> <td style="white-
space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-
top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">
 </p></td> </tr> <tr
style="height:10pt;background-color:#c0c0c0;word-break:break-word;">
<td style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">Accumulated deficit</p></td> <td
style="white-space:pre-wrap;vertical-align:top;"><p style="font-
size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">(<span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">233,565</p></td> <td
style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid
#000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">)</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:10pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;min-width:fit-content;">(<span style="color:#000000;white-
space:pre-wrap;min-width:fit-content;">55,738</p></td> <td

[illegible]

[illegible]

[illegible]

As Previously Reported	Restatement Impact
As Previously Reported	As Restated
As Previously Reported	As Previously Reported

Restatement	Impact
As	Restated
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds	—

[illegible]

(	55,738
Net loss and comprehensive loss	\$
10,349	10,349

\$	
443	
9,906	
30,700	

\$	55,738
\$	86,438
Net loss per share, basic and diluted	0.35

[illegible]

align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(2.44</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(3.79</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr></table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:33.907%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-

[illegible]

[illegible]

		As Previously		
		Restatement Impact		
		As Restated		
				

space:nowrap;vertical-align:bottom;"/>\$

white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>

(202,865

white-space:nowrap;vertical-align:bottom;"/>

)

white-space:pre-wrap;vertical-align:top;"/>

white-space:nowrap;vertical-align:bottom;"/>

\$

white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>

—

white-space:nowrap;vertical-align:bottom;"/>

white-space:pre-wrap;vertical-align:bottom;"/>

white-space:nowrap;vertical-align:bottom;"/>

\$

white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>

(202,865

white-space:nowrap;vertical-align:bottom;"/>

)

white-space:pre-wrap;vertical-align:bottom;"/>

white-space:nowrap;vertical-align:bottom;"/>

\$

white-space:pre-wrap;vertical-align:bottom;text-align:center;"/>

(202,865

[illegible]

[illegible]

[illegible]

[illegible]

solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">—</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,772</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Balance as of March 31, 2023</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(213,637</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-

[illegible]

	74,792
Issuance of common stock and pre-funded warrants in connection with Securities Purchase Agreement, net of issuance costs	
margin-left: 5pt;	
text-align: left;	text-align: right;

[illegible]

[illegible]

[illegible]

space:nowrap;vertical-align:bottom;"/> | |)(1 |) || Stock-based compensation | | | — | | | | — | |

[illegible]

bottom:0;text-align:right;">1,720</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Net loss and comprehensive loss</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,579</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(56,181</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-

space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;font-size:8pt;min-width:fit-content;">(<span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">65,760</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">)</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p
style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-
width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;font-size:8pt;min-width:fit-content;">(<span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">9,579</p></td> <td style="white-space:nowrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-
size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-
align:left;">)
</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-
align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-
left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-
wrap;min-width:fit-content;"> </p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-
content;"> </p></td> <td style="white-space:pre-wrap;vertical-
align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p
style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-
bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-
wrap;font-size:8pt;min-width:fit-content;">(<span style="font-
size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-
content;">56,181</p></td> <td style="white-
space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;">
<p style="font-size:8pt;margin-top:0;font-family:Times New
Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-
width:fit-content;">)</p></td> <td style="white-space:pre-
wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p

[illegible]

[illegible]

bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(56,181</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,768</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Issuance of common stock in connection with exercise of pre-funded warrants</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"></p></td></tr></table>

[illegible]

[illegible]

1,734	
Net loss and comprehensive loss	

10,349	443	9,906

solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(10,349</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid #ffffff03;"><p style="margin-left:5pt;text-indent:0;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">443</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(9,906</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:8pt;background-color:#eff0fe;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-

content;">Balance as of September 30, 2023</p></td><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(233,565</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:top;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(55,738</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">\$</p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(<span style="font-size:8pt;color:#000000;white-space:pre-wrap;min-width:fit-

content;">289,303</p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">)</p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td>	<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">91,335</p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td>	<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;">(55,738</p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">)</p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;"></p></td>	<p style="font-size: 8pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: left;">\$</p></td>	<p style="font-size: 10pt; margin-top: 0; font-family: Times New Roman; margin-bottom: 0; text-align: right;"><span style="font-

35,597												
For the Nine Months Ended September 30, 2023												
Corrected Condensed Consolidated Statements of Cash Flows (Unaudited)												

[illegible]

30,700	
	\$
55,738	
	\$
86,438	
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds	

—	55,738
Net cash used in operating activities	

[illegible]

~~21363700074792000747920003301700033017000-1000-~~
~~100017200001720000-9579000-56181000-65760000-9579000-56181000-~~
~~65760000-223216000-56181000-27939700099949000-~~
~~56181000437680001000100017340001734000-10349000443000-9906000-~~
~~10349000443000-9906000-233565000-55738000-28930300091335000-~~
~~5573800035597000-30700000-55738000-864380005573800055738000-~~
~~30396000-30396000falsefalsefalsefalse~~